<SEC-DOCUMENT>0001513162-21-000112.txt : 20210827
<SEC-HEADER>0001513162-21-000112.hdr.sgml : 20210827
<ACCEPTANCE-DATETIME>20210827172347
ACCESSION NUMBER:		0001513162-21-000112
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20210531
FILED AS OF DATE:		20210827
DATE AS OF CHANGE:		20210827

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		211220140

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<head><title>Form 10-K</title> </head> <body vlink=purple link=blue style=WORD-WRAP:break-word bgcolor=white lang=EN-GB> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style=COLOR:black lang=EN-US>SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style=COLOR:black lang=EN-US>WASHINGTON, D.C. 20549</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FORM 10-K</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>[X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>For The Fiscal Year Ended May 31, 2021 </font></b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>or</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>[ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>For The Transition Period From ______ To ______</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Commission File Number: 001-37863</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><u><font style="FONT-SIZE:14pt; COLOR:black" lang=EN-US>BIOMERICA, INC.</font></u></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(Exact Name of registrant as specified in its charter)</font><font lang=EN-US>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <div align=center> <table width=600 style=WIDTH:450pt cellpadding=0> <tr style=HEIGHT:35.8pt> <td width=49% style="HEIGHT:35.8pt; WIDTH:49.5%; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Delaware</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(State or other jurisdiction of</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Incorporation of organization)</font></p></td> <td width=49% style="HEIGHT:35.8pt; WIDTH:49.5%; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm 0cm 0cm 1.5pt; TEXT-INDENT:-1.5pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>95-2645573</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm 0cm 0cm 1.5pt; TEXT-INDENT:-1.5pt' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(I.R.S. Employer <br>Identification No.)</font></p></td></tr> <tr style=HEIGHT:19.55pt> <td width=49% style="HEIGHT:19.55pt; WIDTH:49.5%; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>17571 Von Karman Avenue, Irvine, CA</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(Address of principal executive offices)</font></p></td> <td width=49% style="HEIGHT:19.55pt; WIDTH:49.5%; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>92614</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm 0cm 0cm 1.5pt; TEXT-INDENT:-1.5pt' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(Zip Code)</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>REGISTRANT'S TELEPHONE NUMBER:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(<b>949) 645-2111</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Securities registered under Section 12(b) of the Exchange Act:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>None</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Securities registered under Section 12(g) of the Exchange Act:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><u><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(Title of each class)</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>COMMON STOCK, PAR VALUE $0.08</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><u><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(Name of each exchange on which registered)</font></u></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style='FONT-FAMILY:"Times New Roman",serif' lang=EN-US>NASDAQ Capital Market</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style='FONT-FAMILY:"Times New Roman",serif' lang=EN-US>(Trading symbol)</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style='FONT-FAMILY:"Times New Roman",serif' lang=EN-US>BMRA</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act &nbsp;&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Yes [ &nbsp;&nbsp;]&nbsp; No [X]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Act. &nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Yes [&nbsp; ] &nbsp;No [X]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Yes [X]&nbsp; No [ &nbsp;]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Yes [X]&nbsp; No [ &nbsp;]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Indicate by check mark whether the registrant is a large accelerated, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. &nbsp;See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <table width=600 style="WIDTH:450pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=164 style="HEIGHT:15pt; WIDTH:122.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Large Accelerated Filer [ &nbsp;]</font></p></td> <td width=253 style="HEIGHT:15pt; WIDTH:189.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /> <td width=183 style="HEIGHT:15pt; WIDTH:137.5pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Accelerated Filer&nbsp;&nbsp;&nbsp;[ &nbsp;]</font></p></td></tr> <tr style=HEIGHT:15pt> <td style="HEIGHT:15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Non-Accelerated Filer &nbsp;&nbsp;[X]</font></p></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /> <td style="HEIGHT:15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Smaller Reporting Company [X]</font></p></td></tr> <tr style=HEIGHT:15pt> <td colspan=3 style="HEIGHT:15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Emerging Growth Company [&nbsp; ]</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:#333333" lang=EN-US>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided </font><font style=FONT-SIZE:10pt lang=EN-US>pursuant to </font><font lang=EN-US><font style="FONT-SIZE:10pt; TEXT-DECORATION:none; COLOR:windowtext">Section 13(a) of the Exchange Act</font></font><font style=FONT-SIZE:10pt lang=EN-US>. [&nbsp; <font style=COLOR:#333333>]</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:#333333" lang=EN-US>Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under </font><font lang=EN-US><font style="FONT-SIZE:10pt; TEXT-DECORATION:none; COLOR:windowtext">Section 404(b) of the Sarbanes-Oxley Act</font></font><font style=FONT-SIZE:10pt lang=EN-US> (</font><font lang=EN-US><font style="FONT-SIZE:10pt; TEXT-DECORATION:none; COLOR:windowtext">15 U.S.C. 7262(b)</font></font><font style=FONT-SIZE:10pt lang=EN-US>) <font style=COLOR:#333333>by the registered public accounting firm that prepared or issued its audit report.&nbsp; [ ]</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Yes [ &nbsp;]&nbsp; No [X]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter (based upon 9,631,507 shares held by non-affiliates and the closing price of $6.95 per share for Common Stock in the over-the-counter market as of November 30, 2020): $66,938,974. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The outstanding number of shares of common stock, par value $0.08, as of August 27, 2021 was 12,510,210. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>DOCUMENTS INCORPORATED BY REFERENCE: Part III contains information incorporated by reference to the Company's proxy statement for its 2021 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2021. The Exhibit Index incorporates by reference various documents previously filed with the Securities and Exchange Commission.<b> &nbsp;</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>2</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm' align=justify><i><font style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black" lang=EN-US>Except for historical financial information contained herein, the matters discussed in this Form 10-K may be considered forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, and subject to the safe harbor created by the Securities Litigation Reform Act of 1995. Such statements include declarations regarding our intent, belief, or current expectations and those of our management. </font></i><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology.&nbsp; <font style=BACKGROUND:white>Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our control; actual results could differ materially from those indicated by such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to, those risks and uncertainties identified under &#8220;Risk Factors,&#8221; and the other risks detailed from time-to-time in our reports and registration statements filed with the Securities and Exchange Commission, or SEC. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</font></font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>PART I</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 1. &nbsp;&nbsp;&nbsp;&nbsp; BUSINESS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>BUSINESS OVERVIEW</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>THE COMPANY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Biomerica, Inc. ("Biomerica", the "Company", "we", &#8220;us&#8221; or "our") was incorporated in Delaware in September 1971 as Nuclear Medical Systems, Inc., and later changed its name to Biomerica, Inc. The Company has two wholly owned subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing, and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk79659987 /><a name=_Hlk48290852><font style=FONT-SIZE:10pt lang=EN-US>We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Our products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk79659731 /><a name=_Hlk48290916><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our primary focus is the research and development of revolutionary, patented, diagnostic-guided therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome (&#8220;IBS&#8221;), and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), we believe the revenues potential to the Company is significant. </font></a><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We are currently finalizing an endpoint determination clinical study on it&#8217;s InFoods</font><font style=FONT-SIZE:10pt lang=EN-US>&reg;<font style=COLOR:black> IBS product. This trial is being conducted at </font>Mayo Clinics in Florida and Arizona, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, University of Texas Health Science Center at Houston, Houston Methodist, University of Michigan and other institutions<font style=COLOR:black>. We expect final patient enrollment in September 2021, and the trial completed by the end of our second fiscal quarter of 202</font></font><font style=FONT-SIZE:10pt lang=EN-US>2, with trial results reported shortly thereafter. During fiscal 2022, we also expect to be entertaining partnership/licensing discussions with pharmaceutical and technology companies that could help us commercialize the product, including obtaining FDA clearance. In order to file for final FDA clearance, we will need to conduct a pivotal trial that will be substantially similar to the endpoint trial that is currently nearing completion. The pivotal trial will focus on treating the specific endpoint(s) in IBS patients that show positive improvement under the current endpoint trial. We expect this final pivotal trial to be run at the same institutions that performed the endpoint trial, plus additional large gastrointestinal (GI) medical groups. If the endpoint trial shows positive results in IBS patients, we will also have the option to immediately seek regulatory clearance for the product to be sold outside of the US. &nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient&#8217;s body, within stools, or blood, often in extremely small concentrations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>3</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk79657334 /><a name=_Hlk48293512><font style=FONT-SIZE:10pt lang=EN-US>Due to the global 2019 SARS-CoV-2 novel coronavirus (&#8220;COVID-19&#8221;) pandemic, in March 2020 we began redirecting and focusing a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. During fiscal 2021, we sold two primary types of Covid 19 tests; 1) antibody diagnostic tests that use a patient&#8217;s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body&#8217;s immune response to a COVID-19 infection, even if the infection was asymptomatic, and 2) COVID-19 antigen tests that use a patient&#8217;s nasal fluid sample to detect if a patient is currently infected with the virus. </font></a><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;During the year, we sold these products outside of the U.S. under a CE Mark (European Conformity). Because individual orders for these tests have been large in size, this has created volatility and material fluctuations in our monthly and quarterly revenues. We continue to receive and fill orders for our COVID-19 test products. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Aside from the COVID-19 products we offer, the other products we sell are primarily focused on gastrointestinal diseases, food intolerances and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency.&nbsp; In addition, some products are cleared for sale in the U.S. by the FDA.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>While sales continue to occur in our COVID-19 products, </font><font style=FONT-SIZE:10pt lang=EN-US>by fiscal year end, the majority of our research and development efforts have returned to a focus on development and commercialization of non-Covid related products such as our Helicobacter pylori (&#8220;H. Pylori&#8221;) product, and our InFoods</font><font style=FONT-SIZE:10pt lang=EN-US>&reg;</font><font style=FONT-SIZE:10pt lang=EN-US> IBS diagnostic guided therapy product and our EZ Detect colon disease home screening test. As such, we expect to file for 510K clearance with the FDA for its H. Pylori laboratory diagnostic test during our second fiscal quarter of 2022. If approved by the FDA, we intend to commence sales of this product in the U.S. We also intend to sell this product internationally including in the European Union (&#8220;EU&#8221;) under a CE Mark which we will seek once we file 510K application with the FDA. International sales could commence earlier than U.S. sales. &nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We recently added several new employees in its sales and marketing department in order to increase sales of existing non-Covid products during fiscal 2022.&nbsp; Through these efforts, our EZ Detect colon disease home screening test is seeing a significant increased interest from retailers and distributors. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Technological advances in medical diagnostics have made it possible to perform diagnostic tests within the home and the physician's office (the point-of-care), rather than in the clinical laboratory. One of our objectives has also been to develop and market rapid diagnostic tests that are accurate, employ easily obtained specimens, and are simple to perform without instrumentation. &nbsp;Our over-the-counter (home use) and professional use (doctor&#8217;s office, clinics, etc.) rapid diagnostic products help to manage existing medical conditions and may save lives through early detection and prompt diagnosis. Typically, tests of this kind require the services of medical technologists and sophisticated instrumentation. &nbsp;Further, results are often not available until at least the following day. We believe that rapid point-of-care tests can be as accurate as laboratory tests when used properly, require limited to no instrumentation, give reliable results in minutes and can be performed with confidence in the home or the physician's office.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Biomerica maintains its headquarters in Irvine, California, where it houses administration, product development, sales and marketing, customer services and its primary manufacturing operations. &nbsp;Biomerica also maintains manufacturing and assembly operations in Mexicali, Mexico, in order to reduce the cost of manufacturing and compete more effectively worldwide. &nbsp; We expend considerable funds in research and development of certain new products that diagnose and, in certain cases, are designed to be used as a therapy for several major medical diseases. These products are both internally developed and licensed from others. &nbsp;We employ experienced and highly trained technical personnel (including Ph.D.&#8217;s and scientists) to develop new products and evaluate and implement technology technical transfer activities. Our technical staff, many of whom have been previously employed at large diagnostic manufacturing companies, has extensive industry experience. We also rely on our Scientific Advisory Board of leading medical doctors and clinicians to assist in guiding our clinical studies and product development.&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Additional information about Biomerica is available on our website at www.biomerica.com. The content on any website referred to in this Form 10-K is not a part of or incorporated by reference in this Form 10-K unless expressly noted. Our Annual Report on Form 10-K, Quarterly Reports on Forms 10-Q, Current Reports on Forms 8-K, Proxy Statements and all other filings we make with the Securities and Exchange Commission (&#8220;SEC&#8221;) are available on our website, free of charge, as soon as reasonably practical after we file them with or furnish them to the SEC and are also available online at the SEC&#8217;s website at www.sec.gov.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>4</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>PRODUCTION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Most of our diagnostic test kits are manufactured and/or assembled at our facilities in Irvine, California and in Mexicali, Mexico. We established our manufacturing facility in Mexicali, Mexico in fiscal 2003 and moved a significant portion of our diagnostic packaging and assembly to that facility. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Production of diagnostic tests can involve formulating component antibodies and antigens in specified concentrations, attaching a tracer to the antigen, filling components into vials, packaging and labeling. We continually engage in quality control procedures to assure the consistency and quality of our products and to comply with applicable FDA and international regulations. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our manufacturing operations and facilities are regulated by the FDA Good Manufacturing Practices for medical devices. We have an internal quality department that monitors and evaluates product quality and output. We also have an internal Quality Systems department whose goal is to ensure that our operating procedures are in compliance with current FDA, CE Mark and </font><font style=FONT-SIZE:10pt lang=EN-US>International Organization for Standardization</font><font style="FONT-SIZE:8pt; COLOR:black" lang=EN-US>&nbsp;</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(&#8220;ISO&#8221;) regulations. We either produce our own antibodies and antigens or purchase these materials from qualified vendors. We have alternate, approved sources for most critical raw materials and are working to procure alternate sources for the few that we do not have. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>RESEARCH AND DEVELOPMENT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>During most of the fiscal year, we focused much of our Research and Development (&#8220;R&amp;D&#8221;) resources on developing several COVID-19 diagnostic tests, as discussed in this section below, and pursuing the regulatory approval of two tests for the gastrointestinal market.&nbsp; Our increase in research and development spending is due to our focus on these tests and outside clinical studies intended to demonstrate the feasibility of FDA clearance for such tests. We also utilize technical personnel, with Ph.D. and other degrees and extensive experience in development and production of health diagnostic tests, to conduct other development activities and improve existing products, as well as explore potential new technologies that &nbsp;we may wish to develop and commercialize. Research and development expenses include the costs of materials, supplies, personnel, consultants, legal fees, facilities, outside clinical trial sites and equipment as well as outside contract services. Consolidated research and development expenses incurred by Biomerica for the years ended May 31, 2021 and 2020 aggregated $2,410,506, and $1,910,209, respectively. As Biomerica moves forward with development, validation and commercialize of additional key products that address diseases with large market opportunities, research and development expenses are expected to increase during upcoming quarters. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We developed a unique diagnostic-guided therapy that is designed to allow physicians to identify patient-specific foods (e.g. pork, milk, onions, sugar, chickpeas, etc.), that when removed from the diet, may alleviate or improve an individual's symptoms of Irritable Bowel Syndrome (IBS). This product is called <a name=_Hlk48896532>InFoods&reg; IBS </a>and is currently in clinical studies at the <a name=_Hlk79659402>Mayo Clinics in Florida and Arizona, Houston Methodist, the University of Michigan and other institutions</a>. The United States Patent and Trademark Office (&#8220;USPTO&#8221;) has issued the Company two patents with broad claims that protect the InFoods&reg; IBS product. Patents have also been allowed or issued in the countries of Japan, Korea, Mexico and Singapore. Additional patents for this product have been filed in the U.S. and in other countries. We are also developing, and have filed patents for other diseases that utilize the InFoods&reg; DGT technology platform which include:&nbsp; Functional Dyspepsia, Crohn&#8217;s Disease, Ulcerative Colitis, Gastroesophageal reflux disease (&#8220;GERD&#8221;), Migraine Headaches, and Osteoarthritis. Our first patent to be allowed for a disease/illness other than IBS was allowed in Japan in August, 2021. This patent covers the use of our InFoods&reg; technology to diagnose and treat persons suffering from depression. We are planning to pursue a de novo 510(k) clearance with the FDA rather than a Premarket Approval Application (&#8220;PMA&#8221;) for the InFoods&reg; IBS product. De novo clearance is typically faster and less expensive than the PMA route, which is the most stringent type of device marketing application required by the FDA for this type of product.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We are also in studies to evaluate the performance of our new and proprietary H. Pylori test.&nbsp; The clinical studies were conducted at the University of Southern California (&#8220;USC&#8221;), a European University and several other U.S. locations. We are working to complete the analytical studies needed to prepare for submission to the FDA and plans to utilize a 510(k) clearance pathway for this test. Biomerica&#8217;s test is designed to provide highly accurate sensitivity and specificity for H. pylori testing and for monitoring of treatment. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>5</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>During fiscal 2021, we dedicated much of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. Our COVID-19 R&amp;D efforts focused </font><font style=FONT-SIZE:10pt lang=EN-US>primarily on the following two types of tests: 1) antibody diagnostic tests that use a patient&#8217;s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body&#8217;s immune response to a COVID-19 infection, even if the infection was asymptomatic, and 2) antigen tests that use a patient&#8217;s nasal fluid sample to detect if a patient is currently infected with the virus. These tests were sold, and continue to be sold by us, in various markets outside of the US.</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US> We currently do not intend to offer either of these tests in the US.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>During </font><font style=FONT-SIZE:10pt lang=EN-US>the fiscal year we also submitted to the FDA an application under and Emergency Use Authorization (&#8220;EUA&#8221;) to sell in the U.S. a lab-scale, high throughput ELISA COVID-19 antibody test kit that would be sold to labs and hospitals to perform COVID-19 antibody testing. After the EUA was submitted to the FDA, on two separate occasions the FDA assigned reviewers to this EUA who each requested additional information and interacted with us on this submission, as is customary. However, we have not yet been issued clearance for this product to be sold. It appears that the FDA began redirecting and focusing its resources on reviewing applications for products that pertain to patients who are currently infected with the COVID-19 virus such as polymerase chain reaction tests and antigen tests, as the demand for antibody tests diminished in the second half of calendar year 2020.&nbsp; &nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Beginning in our fourth quarter of fiscal 2021, the focus of our R&amp;D resources returned to non-COVID-19 products such as our H. Pylori product, our InFoods&reg; IBS product and other products that we sell or would like to sell in the future. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>MARKETS AND METHODS OF DISTRIBUTION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk80101849><font style=FONT-SIZE:10pt lang=EN-US>Biomerica has approximately 400 current customers for its diagnostic business, of which approximately 75 are foreign distributors, 40 are domestic distributors and the balance are primarily domestic hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, physicians' offices and e-commerce customers.</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We employ a director of sales and marketing for Europe and South America who is headquartered in Germany.&nbsp; She has over 20 years of experience selling and marketing diagnostic and life science products across multiple diagnostics technologies and disciplines. She possesses broad international business experience, with communication skills in German, English, Spanish, French and Portuguese, and scientific and technical understanding of gastrointestinal diagnostic products. She also has strong relationships with key strategic entities in Europe, Eastern Europe, Latin America, Canada and the U.S. who is and will continue to help Biomerica add new distributors for existing products, and add new product-lines for future distribution by us. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We rely on affiliated and unaffiliated distributors, advertising in medical and trade journals, exhibitions at trade shows, direct mailings and an internal sales staff to market our diagnostic products. We target two main markets: (a) clinical laboratories and (b) point-of-care testing (physicians' offices and over-the-counter drug stores).&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Due to</font><b></b><font style=FONT-SIZE:10pt lang=EN-US> the Coronavirus global pandemic, our operations have been negatively impacted.<font style=COLOR:black> We have faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, loss of contracts and/or customers, closure of our manufacturing or distribution facilities or of the facilities of our suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where we make and/or sell our products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact our operations and financial performance and may continue to have significant material negative impacts on us.&nbsp;&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 11.7pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>For the fiscal years ended May 31, 2021 and 2020, the Company had two distributors and three distributors, respectively, which accounted for a total of 60% and 57% of our net consolidated sales, respectively. Of this, for the fiscal years ended May 31, 2021 and 2020, the largest of the distributors mentioned above accounted for 33% and 26%, respectively, of net consolidated sales.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN-LEFT:0cm; MARGIN-RIGHT:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>At May 31, 2021 and 2020, the Company had two distributors and three distributors, respectively, which accounted for a total of 73% and 80%, respectively, of gross accounts receivable. Of the 73% as of May 31, 2021, 41% was owed by a distributor in China. Total gross receivables at May 31, &nbsp;2021 and 2020 were $2,292,466 and $1,836,852, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>BACKLOG</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>At May 31, 2021 and 2020, Biomerica had a backlog of unshipped orders of approximately $85,000 and $727,000 respectively. At May 31, 2021, this consisted primarily of orders to our distributor in the Middle East.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>6</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>RAW MATERIALS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The principal raw materials utilized by Biomerica consist of various chemicals, serums, reagents and packaging supplies. Almost all of our raw materials are available from several sources, and we are not dependent upon any single source of supply or a few suppliers. &nbsp;&nbsp;However, due to the limited number of suppliers of some materials, especially those such as antibodies, there is always the possibility that we may encounter difficulty in the future obtaining key raw materials for its manufacturing processes or that such materials may be exceedingly costly. For the year ended May 31, 2021, one vendor accounted for 58% of our purchases of raw materials. For the year ended May 31, 2020, one vendor accounted for 59% of our purchases of raw materials. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our inventory consists of various types of materials including antibodies, antigens, bottles, boxes, various chemicals and reagents utilized in the manufacture of our test kits as well as products in various stages of completion.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our sourcing and receiving of raw materials have been negatively impacted due to the global COVID-19 pandemic. Many of our suppliers have been impacted by plant shut-downs, state or national mandated or recommended shut-downs, restrictions and constraints on distribution channels including ship freight, air freight and trucking, among other things. These suppliers are also experiencing their own disruptions in sourcing raw materials.&nbsp; It is unclear to what extent raw material availability will be impacted in the foreseeable future, and how that will impact our production and sales. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>COMPETITION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Immunodiagnostic products, including COVID-19 products are currently produced globally by hundreds of companies. Biomerica is not a significant player in the overall market for most of the product categories in which we compete. However, we do have certain proprietary products, such as our EZ Detect colon disease home test, that do not have significant competition from competitors with identical tests.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our competitors vary greatly in size. Many are divisions or subsidiaries of well-established medical and pharmaceutical companies which are much larger than Biomerica and expend substantially greater amounts than we do for research and development, manufacturing, advertising and marketing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The primary competitive factors affecting the sale of diagnostic products are uniqueness, technology, quality of product, performance, price, service and marketing. We believe we compete primarily on the basis of the uniqueness of our products, the quality of our products, the speed of our test results, our patent position, our pricing and our prompt shipment of orders. We offer a broad range of products, but have had limited marketing capability. However, during the past 18 months, we have expanded our sales and marketing capability, through marketing and strategic cooperation with larger companies and distributors and by hiring several new employees with marketing and sales expertise. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk79487021><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>GOVERNMENT REGULATION OF OUR DIAGNOSTIC BUSINESS </font></b></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our primary business consists of selling products that are generally legally defined to be in vitro diagnostic medical devices and medical devices. As a result, we are considered to be an in vitro diagnostic medical devices and medical device manufacturer, and as such are subject to the regulations of numerous governmental entities. These agencies include the FDA, Environmental Protection Agency, Federal Trade Commission, Occupational Safety and Health Administration, U.S. Department of Agriculture ("USDA"), and Consumer Product Safety Commission as wells as European Government agencies. These activities are also regulated by various agencies of the states and localities in which our products are sold. These regulations govern the introduction of new in vitro diagnostic medical devices and medical devices, the observance of certain standards with respect to the manufacture and labeling of medical devices, the maintenance of certain records, the reporting of potential product problems, and other matters.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Food, Drug &amp; Cosmetic Act of 1938 (the "FDCA") regulates medical devices in the United States by classifying them into one of three classes based on the extent of regulation believed necessary to ensure safety and effectiveness. Class I devices are those devices for which safety and effectiveness can reasonably be assured through general controls, such as device listing, adequate labeling, and adherence to the Quality System Regulation ("QSR") as well as Medical Device Reporting (&#8220;MDR&#8221;), labeling and other regulatory requirements. Some Class I medical devices are exempt from the requirement of Pre-Market Notification or clearance. Class II devices are those devices for which safety and effectiveness can reasonably be ensured through the use of special controls, such as performance standards, post-market surveillance and patient registries, as well as adherence to the general controls provisions applicable to Class I devices. Class III devices are devices that generally must receive clearance prior to marketing by the FDA pursuant to a pre-market approval to ensure their safety and effectiveness. Generally, Class III devices are limited to life-sustaining, life-supporting or implantable devices. However, this classification can also apply to novel technology or new intended uses or applications for existing devices. Our products are primarily either Class I or Class II medical devices. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>7</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Pursuant to FDA requirements, we have registered our manufacturing facility with the FDA as a medical device manufacturer, and listed the medical devices we manufacture. We are also subject to inspection on a routine basis for compliance with FDA regulations. This includes the QSR, which requires that we manufacture our products and maintain our documents in a prescribed manner with respect to issues such as design controls, manufacturing, testing and validation activities. Further, we are required to comply with other FDA requirements with respect to labeling and MDR regulation which requires that we provide information to the FDA on deaths or serious injuries alleged to have been associated with the use of our products, as well as product malfunctions that are likely to cause or contribute to death or serious injury if the malfunction were to recur. We believe that we are currently in material compliance with all relevant QSR and MDR requirements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In addition, our facility is required to have a California Medical Device Manufacturing License. The license is not transferable and must be renewed biannually. Our current license is valid until November 19, 2022. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Through compliance with FDA and California regulations, we can market some of our medical devices throughout the United States. International sales of medical devices are also subject to the regulatory requirements of each country. In Europe, the directives of the European Union (&#8220;EU&#8217;) require that a device have a CE Mark in order to be sold in EU countries. Our Company complies with In Vitro Diagnostic Medical Devices Directive (&#8220;IVDD&#8221;) 98/79/EC and Medical Devices Directive 93/42/EEC (&#8220;MDD&#8221;). We also comply with ISO 13485 2016 Medical Devices Quality Management Systems - Requirements for Regulatory Purposes. &nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>At present, outside the EU the regulatory international review process varies from country to country. We work with our distributors and sales representatives in the foreign countries in which we market our products to ensure that we comply with the regulatory laws of those countries. We believe that our international sales to date have been in compliance with the laws of all foreign countries in which we have made sales. Exports of most medical devices are also subject to certain FDA regulatory controls.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The designing, development, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of Biomerica&#8217;s immunoassay in vitro diagnostic (&#8220;IVD&#8221;) medical device products are subject to regulation in the United States by the Center for Devices and Radiological Health of the FDA and state agencies.&nbsp; FDA regulations require that some new products have pre-marketing clearance or approval by the FDA and require these products to be manufactured in accordance with the FDA&#8217;s &#8220;Current Good Manufacturing Practice&#8221; regulations, to be extensively tested and to be properly labeled to disclose test results and performance claims and limitations.&nbsp; After a product that is subject to FDA regulation is placed on the market, numerous regulatory requirements apply, including, for example, the requirement that we comply with recordkeeping and reporting requirements, such as the FDA&#8217;s medical device reporting regulations and reporting of corrections and removals.&nbsp; The FDA enforces these requirements by inspection and post -market surveillance. The last FDA announced inspection was in November 2019 and no observations were noted. We believe that all Biomerica products sold in the U.S. comply with the FDA and state regulations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Biomerica is an FDA regulated and ISO 13485:2016 certified In Vitro Diagnostic Medical Devices company. Our goal is to provide high quality medical diagnostic products that generally meet or exceed customer requirements and comply with all applicable regulatory requirements: FDA 21 CFR Part 820 Quality Management System, EN ISO 13485:2016, Medical Devices Quality Management Systems - Requirements for Regulatory Purposes, In Vitro Diagnostic Medical Devices Directive&nbsp; 98/79/EC &amp; and Medical Device Directive 93/42/EEC, Guidelines related to Medical Devices Directives and Guidance on CE Marking, etc.&nbsp; Biomerica involve its employees in a continuous improvement process to increase productivity, improve quality and maintain the suitability, adequacy, and effectiveness of our quality management system. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The new EU Medical Device Regulation (&#8220;MDR&#8221;) 2017/745 entered into force on May 25, 2017. The MDR transition period ends May 26, 2021 and will replace MDD 93/42/EEC. Manufacturers have less than one year to update their technical documentation and processes to meet the new, more stringent regulatory requirements of the European Union. Our Notified Body became designated under MDR in July 2020. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>8</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The new EU In Vitro Diagnostic Medical Device Regulation (&#8220;IVDR&#8221;) 2017/746 transition period ends May 26, 2022 and will replace IVDD 98/79/EC. Manufacturers have less than one year to update their technical documentation and processes to meet the new, more stringent regulatory requirements of the European Union. Notified Bodies can begin certifying devices to the new IVDR requirements once they have been designated under IVDR by their Competent Authority. While we are working to update our technical documentation to comply with these new and more stringent IVDR requirements, it is unclear which of our product will meet these new requirements prior to the May 26, 2022 deadline. If we are unable to complete the new technical documentation requirement, or have our updated documentation files approved by our Notified Body, prior to May 26, 2022, we will potentially be unable to sell these products in markets that require compliance with these EU IVDR regulations. In addition, our current Notified Body, which represents the regulatory bodies in the EU, may themselves not be able to meet all of the new IVDR requirements and become designated under IVDR. If this happens, we may need to transfer to a new Notified Body that does meet the new IVDR requirements and has been designated, or we may need to delay selling products in these regions until our Notified Body becomes designated under IVDR regulations. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>SEASONALITY OF BUSINESS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The businesses of our Company and its subsidiaries have not been subject to significant seasonal fluctuations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>INTERNATIONAL BUSINESS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The following table sets forth the dollar volume of revenue attributable to sales to domestic customers and foreign customers during the last two fiscal years for Biomerica:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=62% nowrap style="HEIGHT:15pt; WIDTH:62%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=4% colspan=7 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Year Ended</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=62% nowrap style="HEIGHT:15pt; WIDTH:62%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=4% colspan=3 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=4% colspan=3 nowrap style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=62% nowrap style="HEIGHT:15pt; WIDTH:62%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Revenues from sales to unaffiliated customers:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=62% nowrap style="HEIGHT:15pt; WIDTH:62%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Europe</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>4,301,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>60%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>2,434,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>36%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=62% nowrap style="HEIGHT:15pt; WIDTH:62%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Asia</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,908,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>26%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,867,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>28%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=62% nowrap style="HEIGHT:15pt; WIDTH:62%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>United States</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>548,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>8%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>445,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>7%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=62% nowrap style="HEIGHT:15pt; WIDTH:62%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>South America</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>250,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>3%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,615,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>24%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=62% nowrap style="HEIGHT:15pt; WIDTH:62%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Middle East</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>192,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>3%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>314,000</font></p></td> <td width=4% nowrap style="HEIGHT:15pt; WIDTH:4%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>5%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=62% nowrap style="HEIGHT:15pt; WIDTH:62%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Other</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=4% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>0%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>18,000</font></p></td> <td width=4% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>0%</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=62% nowrap style="HEIGHT:15.75pt; WIDTH:62%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total</font></b></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>7,199,000</font></b></p></td> <td width=4% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:4%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>&nbsp;100%</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>6,693,000</font></b></p></td> <td width=4% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:4%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>&nbsp;100%</font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We recognize that our foreign sales could be subject to some special or unusual risks, which are not present in the ordinary course of business in the United States. Changes in economic factors, government regulations, terrorism, tariffs, embargos, trade wars, import/export restrictions, disruptions in shipping and distribution channels and drop in demand for our products due to regional or national shut-downs from the COVID-19 pandemic, patients&#8217; fear or refusal to visit hospitals and healthcare providers due to the pandemic where our products are sold and used, the erosion of economic conditions in those countries, and many other factors all could impact sales within certain foreign countries. In addition, these factors could also impact our ability to collect foreign accounts receivable. Foreign countries have licensing requirements applicable to the sale of diagnostic products, which vary substantially from domestic requirements; depending upon the product and the foreign country, these may be more or less restrictive than requirements within the United States and may change without notice. Foreign diagnostic sales at Biomerica are made primarily through a network of approximately 75 independent distributors in approximately 65 countries.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The COVID-19 related factors mentioned above and in &#8220;Risk Factors&#8221; have also negatively impacted domestic sales of our non-COVID-19 products and may continue to negatively impact our domestic and international sales into the foreseeable future. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>INTELLECTUAL PROPERTY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We regard the protection of our methodologies, designs, product formulations, manufacturing processes, diagnostic procedures, copyrights, service marks, trademarks and trade secrets as important to our future success. We rely on a combination of copyright, trademark, patent, service mark and trade secret laws and contractual restrictions to establish and protect our proprietary rights in products and services. We have entered into confidentiality and invention assignment agreements with our employees and contractors, and nondisclosure agreements with most of our fulfillment partners and strategic partners to limit access to and disclosure of proprietary information. We cannot be certain that these contractual arrangements or the other steps taken by us to protect our intellectual property will prevent misappropriation of our technology. We have licensed in the past, and expect that we may license in the future, certain of our proprietary rights, such as trademarks, patents or copyrighted material, to third parties. While we attempt to ensure that the quality of our product brands is maintained by such licensees, we cannot be certain that such licensees will not take actions that might hurt the value of our proprietary rights or reputation.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>9</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>LICENSE OF THIRD-PARTY INTELLECTUAL PROPERTY</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On occasion, we in-licensed both exclusive and non-exclusive rights to intellectual property and patents owned by third parties. These license agreements typically require royalties and other payments. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We have a royalty agreement in which it has obtained rights to manufacture and market an ACTH test (used to detect chronic metabolic conditions). Royalty expense of approximately $11,000 and $15,000, respectively, is included in cost of sales for this agreement for the fiscal years ended May 31, 2021 and 2020. Sales of products manufactured under this agreement are non-material to total sales for the fiscal years ended May 31, 2021 and 2020, respectively. We may license other products or technology in the future as it deems necessary or opportunistic for conducting business.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In May, 2020, we signed an exclusive license agreement with</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US> The Regents of the University of California, to license patents pertaining to a CRISPR-based technology that we hope to use to produce a rapid test for the COVID-19 virus, that could be used to test individuals to determine if they are currently infected with the COVID-19 virus. This agreement requires the payment of certain milestone payments and a royalty on all sales that utilize the licensed technology. Collaboration efforts with the University on a CRISPR product that may be commercialized using this technology continues, however, there are no imminent plans to launch a product from this collaboration. &nbsp;&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Some of the products that we manufacture, sell or use may be covered by claims in issued patents held by other persons or entities, and as such, upon notice from such persons or entity we may be required to pay a license fee or may be required to cease all manufacture, sale or use of such products, which could negatively impact us. While we have not been notified of any such claims by third parties, we cannot guarantee that such claims will not be made in the future. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk79588310><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We are nearing completion of the endpoint determination clinical trial for our patented InFoods</font></a><font style=FONT-SIZE:10pt lang=EN-US>&reg;<font style=COLOR:black> IBS diagnostic guided therapy product. Our business model for this product includes the possible licensing of this product to a large international life sciences or technology company that would commercialize the product or assist us with the commercialization. &nbsp;</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>BRANDS AND TRADEMARKS</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We occasionally register our tradenames with the Office of Patents and Trademarks. Of note, we registered the tradename &#8220;InFoods&#8221; on December 24, 2016. Our unregistered tradenames are "EZ Detect", "EZ-H.P." and "EZ-PSA". A trademark for "Aware" was issued and assigned in November 2001 and renewed in 2011. On January 11, 2020, the USPTO renewed our &#8220;FORTEL&#8221; trademark for another ten years. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The laws of some foreign countries do not protect our proprietary rights to the same extent as do the laws of the U.S. Effective copyright, trademark and trade secret protection may not be available in such jurisdictions. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i></i>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>PATENTS AND INFOODS TECHNOLOGY</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We have filed over 100 international and Patent Corporation Treaty patents, and has 12 provisional and non-provisional patents currently filed with the USPTO. Some of these patent applications pertain to COVID-19 and other products, however, the majority of our patents that are pending, allowed or issued pertain to the <a name=_Hlk49356926>InFoods&reg; </a>technology platform.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our most important family of patent applications pertains to our</font><font style=FONT-SIZE:10pt lang=EN-US> InFoods&reg; technology platform, which is a new method of possibly diagnosing and treating symptoms of many different diseases. Our first planned product launch using this technology is the InFoods&reg; IBS product which is designed to diagnose and treat Irritable Bowel Syndrome. Using a patient blood sample, a physician or lab can run our test to identify specific foods (e.g. pork, milk, shrimp, broccoli, eggs) that, if eliminated from the patient&#8217;s diet, can alleviate or reduce the individual's IBS symptoms, including, but not limited to, constipation, diarrhea, bloating, cramping, severe pain and indigestion. <font style=COLOR:black>We have filed many patent applications with the USPTO and with other such similar agencies in other countries outside of the United States pertaining to this </font>InFoods&reg; <font style=COLOR:black>technology. These patent applications include claims that address the diagnosis and treatment of several disease states including IBS, functional dyspepsia, Crohn&#8217;s disease, ulcerative colitis, gastroesophageal reflux disease, osteoarthritis, psoriasis, migraine headaches and depression. These applications include the use of this technology in both humans and animals.&nbsp; The first patents filed by us pertained to IBS. Several of the patents pertaining to the</font> InFoods&reg; IBS<font style=COLOR:black> technology have been issued and many more are in active review and prosecution.&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>10</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk79479372><font style=FONT-SIZE:10pt lang=EN-US>In August 2018, the Korean Intellectual Property Office (&#8220;KIPO&#8221;) issued a Certificate of Patent (<font style=COLOR:black>#10-1887545) </font>covering our InFoods&reg; IBS product (entitled &#8220;COMPOSITIONS, DEVICES, AND METHODS OF IBS SENSIVITY TESTING&#8221;). This patent was the first for the InFoods&reg; patent portfolio, providing patent protection for InFoods&reg; IBS in Korea until November 13, 2035.</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In June 2019, we received our first issued patent from the USPTO </font><font style=FONT-SIZE:10pt lang=EN-US>(#10,309,970) <font style=COLOR:black>pertaining to our</font> InFoods&reg; IBS<font style=COLOR:black> product, with claims that covers the test kit that is used to determine patient food intolerances.&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In March 2020, the Japanese Patent Office issued our first</font><font style=FONT-SIZE:10pt lang=EN-US> InFoods&reg; IBS<font style=COLOR:black> patent in that country (6681907) which covers the compositions, devices and methods of IBS sensitivity testing.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><br>In September 2020, the USPTO issued our second</font><font style=FONT-SIZE:10pt lang=EN-US> InFoods&reg; IBS<font style=COLOR:black> patent in the U.S. (10,788,498) which covers IBS sensitivity testing.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In November 2020, the Singapore Patent Office issued our first</font><font style=FONT-SIZE:10pt lang=EN-US> InFoods&reg; IBS<font style=COLOR:black> patent in that country (11201705102Q) which covers the compositions, devices and methods of IBS sensitivity testing.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In March 2021, the Korean Patent Office issued a second </font><font style=FONT-SIZE:10pt lang=EN-US>InFoods&reg; IBS <font style=COLOR:black>patent in that country (10-2224649) which covers the compositions, devices and methods of IBS sensitivity testing.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In April 2021, the Japanese Patent Office issued a notice of allowance </font><font style=FONT-SIZE:10pt lang=EN-US>for an InFoods&reg; IBS<font style=COLOR:black> patent in that country (6876338) which covers the compositions, devices and methods of IBS sensitivity testing.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In May 2021, the Company received a notice of allowance for an </font><font style=FONT-SIZE:10pt lang=EN-US>InFoods&reg; IBS<font style=COLOR:black> patent in Mexico which covers the compositions, devices and methods of IBS sensitivity testing.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We believe the claims in these issued InFoods&reg; IBS patents, and claims in pending patents that protect the use of the </font><font style=FONT-SIZE:10pt lang=EN-US>InFoods&reg; IBS <font style=COLOR:black>&nbsp;technology to diagnose and treat other diseases, provide us with broad protections from other companies making or selling competing products in this highly disruptive new field of medicine.&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk48224651><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In addition to the use of our own patents, Biomerica has acquired from third parties the rights to manufacture and sell certain products that are protected by patents or intellectual property owned by these third parties. In some cases, royalties are paid on the sales of these products. Biomerica anticipates that it will license or purchase the rights to other products or technologies in the future.&nbsp;</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We are nearing completion of the endpoint determination clinical trial for our patented InFoods&reg; IBS diagnostic guided therapy product. Our business model for this product includes the possible out-licensing of this product and the related patents to a large international life sciences or technology company that would commercialize the product or assist us with the commercialization.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>EMPLOYEES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>As of May 31, 2021 and 2020, the Company employed 49 and 45 employees, respectively, in the U.S. and Europe. Various employees listed in the production department also perform research and development duties as a routine function of their job. The Company occasionally employs temporary employees when needed. The following is a breakdown of employees by departments:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>11</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=74% nowrap style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom><a name=RANGE!A1 /></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.16%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=74% nowrap style="HEIGHT:15pt; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Administrative</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>9</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>5</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=74% nowrap style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Research and Development</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>8</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.16%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>9</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=74% nowrap style="HEIGHT:15pt; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Marketing &amp; Sales</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>4</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>3</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=74% nowrap style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Production and Operations</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>28</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.16%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>28</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=74% nowrap style="HEIGHT:15.75pt; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>49</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>45</font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In addition, Biomerica de Mexico employs 17 people at its Mexico facility. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We also engage the services of many outside Ph.D.&#8217;s and M.D.&#8217;s and other types of industry expert consultants as well as medical institutions for technical support, regulatory advisors, marketing and public relations advisors, financial advisors, contract product development and manufacturing organization, and other advisors on a regular basis. We try to protect the Company with the use of confidentiality, intellectual property ownership and indemnifications agreements. However, we cannot guarantee that the use of such experts will fully protect the Company from third-party claims or from theft of our intellectual property.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 1A.&nbsp;&nbsp;&nbsp;RISK FACTORS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The risks described below are not the only ones we face. Additional risks and uncertainties we are not presently aware of or that we currently believe </font><font style=FONT-SIZE:10pt lang=EN-US>are immaterial may also impair our business operations. Our business could be harmed by any of these risks and uncertainties. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing these risks, you should also refer to the other information contained or incorporated by reference into this annual report on Form&nbsp;10-K, including our consolidated financial statements and related notes.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'><a name=s9B1D8344AA2ED028FBF5BF856A071139 /><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'><b><font style="FONT-SIZE:10pt; LINE-HEIGHT:120%" lang=EN-US>RISKS RELATED TO OUR BUSINESS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>Our business could be adversely affected by the effects of widespread public health epidemics<i>.</i></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:#222222" lang=EN-US>We are susceptible to ongoing outbreaks of an illness or other health issue, such as the recent COVID-19 Coronavirus outbreak, including outbreaks of variants of the COVID-19 virus such as the &#8220;Delta&#8221; variant. The outbreak of the COVID-19 virus caused the various governments, including the U.S., to implement quarantines, various restrictions on travel causing airlines to suspend international and certain domestic flights, shelter in place orders and other restrictions. Governments have also implemented work restrictions that prohibit many employees from going to work, and for businesses that are allowed to remain open, many employees are electing to remain at home to avoid spread of the disease. As a result of this COVID-19 virus outbreak and potential future pandemic outbreaks, the Company faces significant risks including, but not limited to: a) supply chain disruptions making it difficult for the Company to contract and receive materials needed for production of its products, and needed to ship finished products to our end customers, b) loss of contracts and customers from the financial strains or other disruptions they are experiencing as a result of the pandemic, c) financial risks pertaining to receivables due from customers that may fall into insolvency or otherwise be unable to pay their bills, d) government responses including orders that make it difficult to remain open for business, restrict imports of raw materials or exports of finished goods, refusal to allow the Company&#8217;s product to be licensed for sale in their countries, and other seen and unforeseen actions taken by government agencies, e) absenteeism or loss of employees at the Company, or at our partner&#8217;s companies, due to health reasons or government restrictions, that are needed to develop, validate, manufacture and perform other necessary functions for our operations, f) equipment failures, loss of utilities and other disruptions that could impact our operations or render them inoperable, g) litigation or government actions against the Company pertaining to existing products new products sold by the Company that are directed at limiting or treating the spread of the pandemic outbreak, h) a local or global recession or depression that could harm the international banking system, limit demand for all products including those made by the Company, &nbsp;i) a drop in demand for our products, that are all medical related, due to patients&#8217; reluctance or refusal to visit hospitals, labs, and doctors&#8217; offices where our products are used due to their fear of contracting a disease, and many other seen and unforeseen events and circumstances, all of which could negatively impact the Company. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm; LINE-HEIGHT:120%' align=center><font style="FONT-SIZE:10pt; LINE-HEIGHT:120%" lang=EN-US>12</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm; LINE-HEIGHT:120%' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We have a history of operating losses.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black" lang=EN-US>We have historically incurred net losses. There can be no assurance that we will generate net profits in future periods.&nbsp;Further, there can be no assurance that we will be cash flow positive in future periods.&nbsp;In the event that we fail to achieve profitability in future periods, the value of our common stock may decline.&nbsp;In addition, if we are unable to achieve or maintain positive cash flows, we would be required to seek additional funding, which may not be available on favorable terms, if at all.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:11pt lang=EN-US>Our operating results may fluctuate adversely as a result of many factors that are outside our control, which may negatively impact our stock price. </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our operating results are dependent upon many factors that are substantially outside of our control that could materially and adversely affect our business, results of operations and financial condition.&nbsp; Factors that are beyond our control and that could affect our operating results in the future include:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>regulatory clearance;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>changes in the level of competition, such as would occur if one of our competitors introduced a new, better performing or lower priced product to compete with one or more of our products;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>changes in the reimbursement systems or reimbursement amounts that end-users may rely upon in choosing to use our products;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>changes in economic conditions in our domestic and international markets, such as economic downturns, decreased healthcare spending, reduced consumer demand, inflation and currency fluctuations; changes in government laws and regulations affecting our business; reluctance for consumers to visit healthcare providers;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>lower than anticipated market penetration of our new or more recently introduced products;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>significant quantities of our product or that of our competitors in our distributors&#8217; inventories or distribution channels;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>changes in distributor buying patterns;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>government mandated shelter-in-place or other lock-down orders;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>continued spread of the COVID-19 virus or mutations of the virus; and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>changes in the healthcare market including consolidation in our customer base.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:11pt lang=EN-US>Fluctuations in our operating results, for any reason, could cause operating losses as a result of significant fixed expenses. </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We base the scope of our operations and related expenses on our estimates of future revenues. A significant portion of our operating expenses are fixed, and we may not be able to rapidly adjust our expenses if our revenues fall short of our expectations. Our revenue estimates for future periods are based, among other factors, on estimated end-user demand for our products. If end-user consumption is less than estimated, revenues from our distribution partners and other distribution channels would be expected to fall short of expectations, and because such a significant portion of our costs are fixed, could result in operating losses.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>To remain competitive, we must continue to develop, obtain and protect our proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling technologically superior products that compete with our products, or selling products at lower prices.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our ability to compete successfully in the diagnostic market depends on continued development and introduction of new products, technology and the improvement of existing technology. If we cannot continue to improve upon or develop, obtain and protect our technology, our operating results could be adversely affected.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our competitive position is heavily dependent on obtaining and protecting our own proprietary technology or obtaining licenses from others. Our ability to obtain patents and licenses, and their benefits, is uncertain.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>The Company is required to obtain government or regulatory certification in many countries and the European community to sell its products in those countries or regions.&nbsp; There is no assurance that the Company will be able to retain its certification in the future. This includes the possibility and risk that the Company&#8217;s products do not meet the new EU IVDR testing and documentation requirements in the future as described in the above &#8220;Research and Development&#8221; section of this document. </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Significant government regulation exists in countries in which we conduct business. </font><font style=FONT-SIZE:10pt lang=EN-US>A large part of the Company&#8217;s sales is to distributors in Europe, China and other countries, which require us to maintain certain certifications to sell our products.&nbsp; <font style=COLOR:black>Failure to comply with current governmental regulations and quality assurance guidelines could cause the loss of these certifications, which could materially adversely affect the results of the Company.&nbsp; Loss of certifications could lead to temporary manufacturing shutdowns, product recalls, product shortages or delays in product manufacturing and a decline in sales.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>13</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>The Company maintains a manufacturing plant in Mexico which presents risks to the Company including risks associated with doing business outside the United States.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The Company has a significant investment in its manufacturing facility in Mexico through its subsidiary, Biomerica de Mexico. In addition, the Company warehouses a significant amount of its inventory at the Mexico facility. </font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>There are a number of risks associated with doing business in Mexico, including, exposure to local economic and political conditions, social unrest, including risks of terrorism or other hostilities, export and import restrictions, the potential for shortages of trained labor, and the possible effects of currency exchange rate fluctuations.<b><i> </i></b></font><font style=FONT-SIZE:10pt lang=EN-US>These risks could lead to additional costs that we cannot foresee at this time and may materially adversely impact our business, results of operations and financial condition.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We use hazardous materials in our research and production that may result in unexpected and substantial claims against us relating to handling, storage or disposal. </font></b></p> <br><p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We use hazardous materials in our research and production. The risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held liable for any harm or damages that result and any such liability could exceed the resources of the Company.&nbsp; The Company may incur substantial costs to comply with environmental regulations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>If any governmental authorities were to impose new environmental regulations requiring compliance in addition to that required by existing regulations, or alter their interpretation of the requirements of such existing regulations, such environmental and safety regulations could impair our research, development or production efforts by imposing additional, and possibly substantial, costs, restrictions or compliance procedures on our business. In addition, because of the nature of the penalties provided for in some of these environmental and safety regulations, we could be required to pay sizable fines, penalties or damages in the event of noncompliance with regulations and environmental laws. Any environmental or safety violation or remediation requirement could also partially or completely shut down our research and manufacturing facilities and operations, which would have a material adverse effect on our business. The risk of accidental contamination or injury from these hazardous materials cannot be completely eliminated and exposure of individuals to these materials could result in substantial fines, penalties or damages that may not be covered by insurance.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>In order to remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there is no assurance our efforts to develop new technologies, products or markets will be successful or such technologies, products or markets will be commercially viable.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We devote a significant amount of financial and other resources to researching and developing new technologies, new products and new markets. The development, manufacture and sale of diagnostic products require a significant investment of resources. The development of new products and markets also requires a substantial investment of resources, such as new employees, offices and manufacturing facilities, consultants and clinical trials. No assurances can be given that our efforts to develop new technologies or products will be successful, that such technologies and products will be commercially viable, or our expansion into new markets will be profitable.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>There is also no guarantee that our new products, including our InFoods&reg; IBS products, will get approval and be well accepted into the marketplace.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our operations will be adversely affected if our operating results do not correspondingly increase with our increased expenditures or if our technology, product and market development efforts are unsuccessful or delayed. Furthermore, our failure to successfully introduce new technologies or products and develop new markets could have a material adverse effect on our business and prospects.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We rely on a limited number of key distributors that account for a substantial majority of our total revenue. The loss of any key distributor or an unsuccessful effort by us to directly distribute our products could lead to reduced sales.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>For the fiscal years ended May 31, 2021 and 2020, the Company had two distributors and three distributors, respectively, which accounted for a total of 60% and 57% of our net consolidated sales, respectively. Of this, for the fiscal years ended May 31, 2021 and 2020, the largest of the distributors mentioned above accounted for 33% and 26%, respectively, of net consolidated sales.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>14</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>At May 31, 2021 and 2020, the Company had two distributors and three distributors, respectively, which accounted for a total of 73% and 80%, respectively, of gross accounts receivable. Of the 73% as of May 31, 2021, 41% was owed by a distributor in China. Total gross receivables at May 31, 2021 and 2020 were $2,292,466 and $1,836,852, respectively. Adverse changes in our relationships with these distributors and other partners, or adverse developments in their financial condition, performance or purchasing patterns, could adversely affect our business and consolidated financial statements.&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We extend credit to customers outside the U.S. which can be difficult to collect.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We extend credit to many of our customers including those outside of the U.S. It is often difficult to obtain adequate credit information on these customers. Further, our ability to collect receivables from these customers through the court systems in those countries can be more difficult than here in the U.S.&nbsp; Our inability to collect on receivables from customers, in particular those outside of the U.S. could negatively impact the Company. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>If we are not able to manage our growth strategy our operating results may be adversely affected.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our business strategy contemplates further growth, which would likely result in expanding into larger facilities, expanding the scope of operating and financial systems and the geographical area of our operations, including further expansion outside the U.S., as new products and technologies are developed and commercialized or new geographical markets are entered. Because we have a small executive staff, acquisitions and other future growth may divert management&#8217;s attention from core aspects of our business, and place a strain on existing management and our operational, financial and management information systems. Furthermore, we may expand into markets in which we have less experience or incur higher costs. Any and all of these potential growth and expansion strategies and events could impose material risks and cause the Company to incur adverse operating and financial results.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Intellectual property risks and third-party claims of infringement, misappropriation of proprietary rights or other claims against us could adversely affect our ability to market our products, require us to redesign our products or attempt to seek licenses from third parties, result in significant costs, and materially adversely affect our operating results. </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Companies in or related to our industry often aggressively protect and pursue their intellectual property rights. There are often intellectual property risks associated with developing and producing new products and entering new markets, and we may not be able to obtain, at reasonable cost or upon commercially reasonable terms, if at all, licenses to intellectual property of others that is alleged to be part of such new or existing products. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We have hired and will continue to hire individuals or contractors who have experience in medical diagnostics and these individuals or contractors may have confidential trade secret or proprietary information of third parties. We cannot assure you that these individuals or contractors will not use this third-party information in connection with performing services for us or otherwise reveal this third-party information to us. Thus, we could be sued for misappropriation of proprietary information and trade secrets. Such claims are expensive to defend and could divert our attention and result in substantial damage awards and injunctions that could have a material adverse effect on our business, financial condition or results of operations. In addition, to the extent that individuals or contractors apply technical or scientific information independently developed by them to our projects, disputes may arise as to the proprietary rights to such data and may result in litigation.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The defense and prosecution of patent and trade secret claims are both costly and time consuming. We or our customers may be sued by other parties that claim that our products have infringed their patents or misappropriated their proprietary rights or that may seek to invalidate one or more of our patents. An adverse determination in any of these types of disputes could prevent us from manufacturing or selling some of our products, limit or restrict the type of work that employees involved with such products may perform for us, increase our costs and expose us to significant liability. In addition, the defense of such claims could result in significant costs and divert the attention of our management and other key employees.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>In addition to the foregoing, we may also be required to indemnify some customers, distributors and strategic partners under our agreements with such parties if a third party alleges or if a court finds that our products or activities have infringed upon, misappropriated or misused another person&#8217;s proprietary rights. Further, our products may contain technology provided to us by other parties such as contractors, suppliers or customers. We may have little or no ability to determine in advance whether such technology infringes the intellectual property rights of a third party. Our contractors, suppliers and licensors may not be required or financially able to indemnify us in the event that a claim of infringement is asserted against us, or they may be required to indemnify us only up to a maximum amount, above which we would be responsible for any further costs or damages.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>15</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Some of the products that we manufacture, sell or use may be covered by claims in issued patents held by other persons or entities, and as such, upon notice from such persons or entity, we may be required to pay a license fee or may be required to cease all manufacture, sale or use of such products, which could negatively impact our financial results or operations. We cannot guarantee that such claims will not be made in the future. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We need to continue to raise additional funds to finance our future capital or operating needs, which could have adverse consequences on our operations and the interests of our stockholders.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>As a company focused on research and development of new products that do not yet generate revenues, we need to continue to raise funds through public or private debt or sale of equity to achieve our business strategy. When we raise funds or acquire other technologies or businesses through issuance of equity, this dilutes the interests of our stockholders. Moreover, the availability of additional capital, whether debt or equity from private capital sources (including banks) or the public capital markets, fluctuates as our financial condition and industry or market conditions in general change. There may be times when the private capital markets and the public debt or equity markets lack sufficient liquidity or when our securities cannot be sold at attractive prices, in which case we would not be able to access capital from these sources on favorable terms, if at all. We can give no assurance as to the terms or availability of additional capital.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our inability to raise additional funds to finance our future capital or operating needs could force us to delay, reduce or eliminate our development programs or commercialization efforts.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Costs related to development projects and approvals are hard to estimate due to factors that are unknown to us at this time. These future costs could be much higher than anticipated and current operations are unlikely be able to cover these costs.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of studies and trials may not be predictive of future trial results.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Clinical trials are expensive, time consuming and difficult to design and implement. Regulatory agencies may analyze or interpret the results differently than we do. Even if the results of our clinical trials are favorable, the clinical trials for a number of our product candidates may take a significant amount of time to complete. Regulatory authorities, including state and local authorities, may suspend, delay or terminate our clinical trials at any time, require us to conduct additional clinical trials, require a particular clinical trial to continue for a longer duration than originally planned, or require a change to our development plans such that we conduct clinical trials for a product candidate in a different order.&nbsp; </font><font style=FONT-SIZE:10pt lang=EN-US>There is no assurance that the results of the clinical trials will be positive.&nbsp; A negative clinical trial could affect our ability to obtain regulatory clearances and/or potential licensing partners.&nbsp; There is also no assurance that our clinical trials will not be delayed or will be completed. &nbsp;<font style=COLOR:black>Any of the foregoing could have a material adverse effect on our business, results of operations and financial condition.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Our results of operations and financial conditions may be adversely affected by the financial soundness of our customers, distributors and suppliers.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>If our customers&#8217; or suppliers&#8217; operating and financial performance deteriorates, or if they are unable to make scheduled payments or obtain credit, our customers may not be able to pay, or may delay payment of, accounts receivable owed to us, and our suppliers may restrict credit or impose different payment terms or reduce or terminate production of products they supply to us, or may cease all operations. Any inability of customers to pay us for our products and services, or any demands by suppliers for different payment terms, or inability for such suppliers to continue operations may adversely affect our operating results and financial condition. Additionally, both state and federal government sponsored and private payers, as a result of budget deficits or reductions, may seek to reduce their healthcare expenditures by cutting or eliminating reimbursements for, or cutting purchase of our products. Any reduction in payments by such government sponsored or private payers may adversely affect our earnings and cash flow. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We may not achieve market acceptance of our new products among healthcare providers and physicians, and this would have a negative effect on future sales.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We believe our ability to introduce new products that gain acceptance among consumers, healthcare providers and physicians is an important part of our ability to grow our revenue in future periods. However, any new products we introduce may not gain market acceptance to the extent we anticipate or project. </font><font style=FONT-SIZE:10pt lang=EN-US>The acceptance in the medical community for any of our new products is unpredictable at this time. In addition, the Company will need to spend considerable funds in order to introduce new products into the marketplace. Sales, if any, of these products in the future are uncertain.<font style=COLOR:black>&nbsp; In addition, </font></font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>our competitors may offer different products and product formats at suggested prices that are lower than our products or whose products are more accurate than our products. We can provide no assurances that consumers and the medical community will purchase our products or that they will not prefer to purchase a competitive product.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>16</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>The industry and market segments in which we operate are highly competitive, and intense competition with other providers of diagnostic products may reduce our sales and margins.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our diagnostic tests compete with similar products made by our competitors. There are a large number of multinational and regional competitors making investments in competing technologies and products. We also face competition from our distributors as some have created, and others may decide to create, their own products to compete with ours. A number of our competitors have a potential competitive advantage because they have substantially greater financial, technical, research and other resources, larger, more established marketing, sales, distribution and service organizations; more established relationships with healthcare professionals; and </font><font style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black" lang=EN-US>greater experience in conducting research and development, manufacturing, clinical trials, and obtaining regulatory approval for products</font><font style=FONT-SIZE:10pt lang=EN-US>. Moreover, some competitors offer broader product lines and have greater name recognition than we have. If our competitors&#8217; products are more effective than ours or take market share from our products through more effective marketing or competitive pricing, our operating results could be materially and adversely affected.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>In addition, there has been a trend toward industry consolidation in our markets over the last few years. We may not be able to compete successfully in an increasingly consolidated industry. We expect this trend toward industry consolidation may continue as companies attempt to strengthen or hold their market positions in an evolving industry and as companies are acquired or are unable to continue operations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Our business and products are highly regulated by various governmental agencies. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals or clearances, the loss of previously received approvals or other changes to the existing laws and regulations that adversely impact our ability to manufacture and market our products.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The testing, manufacture and sale of our products are subject to regulation by numerous governmental authorities in the U.S., principally the FDA and corresponding state and foreign regulatory agencies. Our future performance depends on, among other matters, if, when and at what cost we will receive regulatory approval for new products, and if we can continue to comply with the many regulatory requirements that enable us to manufacture and sell medical related products and tests. Regulatory review can be a lengthy, expensive and uncertain process, making the timing and costs of clearances and approvals difficult to predict. Meeting all regulatory requirements, laws and mandates, and maintaining compliance with such in order to manufacture and sell medical products can be difficult and expensive. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals or clearances, the loss of previously received approvals or clearances, the placement of limits on the marketing and use of our products, and restrictions on our ability to manufacture our products. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Changes in government policy could adversely affect our business and potential profitability.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Changes in government policy could have a significant impact on our business by increasing the cost of doing business, affecting our ability to sell our products and negatively impacting our profitability. Such changes could include tariffs, embargos, trade wars or modifications to existing legislation, such as U.S. tax policy, or entirely new legislation, such as the Affordable Healthcare Act&nbsp; in the U.S. We cannot predict the many ways that healthcare reform in the U.S. and internationally, and changing trade legislation and policies could adversely affect our business. It is unclear whether and to what extent, if at all, other anticipated developments, including changes due to new presidential administration priorities, or changes resulting from healthcare reform, such as a change in the number of people with health insurance, may impact us. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We are subject to numerous government regulations in addition to FDA regulation, and compliance with laws, including changed or new laws, could increase our costs and adversely affect our operations.&nbsp; There is also the risk that our facilities could fail to get the proper licensing at our next inspection or renewal.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>In addition to FDA and other regulations referred to above, numerous laws relating to such matters as safe working conditions, manufacturing practices, data privacy, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances impact our business operations. If these laws or their interpretation change or new laws regulating any of our businesses are adopted, the costs of compliance with these laws could substantially increase our overall costs. Failure to comply with any laws, including laws regulating the manufacture and marketing of our products, could result in substantial costs and loss of sales or customers. Because of the number and extent of the laws and regulations affecting our industry, and the number of governmental agencies whose actions could affect our operations, it is impossible to reliably predict the full nature and impact of future legislation or regulatory developments relating to our industry and our products. To the extent the costs and procedures associated with meeting new or changing requirements are substantial, our business, results of operations and financial condition could be adversely affected.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>17</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Our total revenue could be affected by third-party reimbursement policies and potential cost constraints.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The end-users of our products are primarily physicians, labs and other healthcare providers. In the U.S., healthcare providers such as hospitals and physicians who purchase diagnostic products generally rely on third-party payers, principally private health insurance plans, federal Medicare and state Medicaid, to reimburse all or part of the cost of the procedure. Use of our products would be adversely impacted if physicians and other healthcare providers do not receive adequate reimbursement for the cost of our products by their patients&#8217; third-party payers both in the U.S. and in foreign markets. Our total revenue could also be adversely affected by changes or trends in reimbursement policies of governmental or private healthcare payers. We believe that the overall escalating cost of medical products and services has led to, and will continue to lead to, increased pressures on the healthcare industry, both foreign and domestic, to reduce the cost of products and services. Given the efforts to control and reduce healthcare costs in recent years, currently available levels of reimbursement may not continue to be available in the future for our existing products or products under development. Third-party reimbursement and coverage may not be available or adequate in either the U.S. or foreign markets, current reimbursement amounts may be decreased in the future and future legislation, regulation or reimbursement policies of third-party payers may reduce the demand for our products or adversely impact our ability to sell our products on a profitable basis.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Unexpected increases in, or inability to meet, demand for our products could require us to spend considerable resources to meet the demand or harm our reputation and customer relationships if we are unable to meet demand.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our inability to meet customer demand for our products, whether as a result of manufacturing problems or supply shortfalls, could harm our customer relationships and impair our reputation within the industry. In addition, our product manufacturing of certain product lines is concentrated in our two manufacturing sites. Weather, natural disasters (including pandemics), fires, terrorism, political change, governmental restrictions or stay-at-home orders in response to natural disasters (including pandemics), failure to follow specific internal protocols and procedures, equipment malfunction, environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products. This, in turn, could have a material adverse effect on our business.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>If we experience unexpected increases in the demand for our products, we may be required to expend additional capital resources or engage third-party manufacturers to meet these demands. These capital resources could involve the cost of new machinery or even the cost of new manufacturing facilities. In addition, engaging third-party manufacturers would increase manufacturing costs and reduce margins. This would increase our capital costs or third-party expenses, which could adversely affect our earnings and cash resources. If we are unable to develop or obtain necessary manufacturing capabilities in a timely manner or to engage third-party manufacturers to meet demand, our total revenue could be adversely affected. Failure to cost-effectively increase production volumes, if required, or lower than anticipated yields or production problems, including those encountered as a result of changes that we may make in our manufacturing processes to meet increased demand or changes in applicable laws and regulations, could result in shipment delays as well as increased manufacturing costs, which could also have a material adverse effect on our business, operating results and financial condition.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Unexpected increases in demand for our products could also require us to obtain additional raw materials in order to manufacture products to meet the demand. Some raw materials require significant ordering lead time and we may not be able to timely access sufficient raw materials in the event of an unexpected increase in demand, particularly those obtained from a sole supplier or a limited group of suppliers.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:24pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>If one or more of our products is claimed to be defective, or does not meet the performance criteria we claim in our marketing materials we could be subject to product recalls, claims of liability and harm to our reputation that could adversely affect our business.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>A claim of a defect in the design or manufacture of our products could have a material adverse effect on our reputation in the industry and subject us to claims of liability for injuries and otherwise. Further, a claim that one of our products is defective or does not actually meet the performance criteria we claim in our marketing materials, could require a product recall or otherwise have a substantial impact on our revenues and financial performance. Any substantial underinsured loss resulting from such a claim or defect would have a material adverse effect on our operating results and financial conditions and the damage to our reputation or product lines in the industry could have a material adverse effect on our business.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>18</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We are exposed to business risks which, if not covered by insurance, could have an adverse effect on our results of operations. We face potential product liability exposure, and, if claims brought against us are successful, we could incur substantial liabilities.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We face a number of business risks, including exposure to product liability claims, employment law claims, claims that the Company or its officers, directors or employees have engaged in illegal or wrongful acts, claims of violation of environmental laws and many other possible claims. Although we maintain insurance for a number of these risks, we may face claims for types of damages, or for amounts of damages, that are not covered by our insurance. For example, although we currently carry product liability insurance for liability losses, there is a risk that product liability or other claims may exceed the amount of our insurance coverage or may be excluded from coverage under the terms of our policy. Also, our existing insurance may not be renewed at the same cost and level of coverage as currently in effect, or may not be renewed at all. Further, we do not currently have insurance against many environmental risks we confront in our business. If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of product liability matters, cybersecurity matters, or from some other matter, that claim could have a material adverse effect on our results of operations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We may rely on third parties to conduct or be part of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to seek or obtain regulatory approval for or commercialize our product candidates.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We rely on third-party contract research organizations (&#8220;CROs&#8221;), universities or/clinical sites (&#8220;Vendors&#8221;), to coordinate, monitor and conduct of our clinical trials and to manage data for our clinical programs. We, our Vendors, and our clinical sites are required to comply with current Good Clinical Practices (&#8220;GCPs&#8221;), regulations and guidelines issued by the FDA and by similar governmental authorities in other countries where we are conducting clinical trials. We have an ongoing obligation to monitor the activities conducted by our Vendors and at our clinical sites to confirm compliance with these requirements. In the future, if we, our Vendors or our clinical sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. If our Vendors do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Failures in our information technology and storage systems could significantly disrupt our business or force us to expend excessive costs.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We utilize complex information technology systems&nbsp;to support our business and store information. We cannot be sure that our systems will meet our future business needs or that necessary upgrades will operate as designed, which could result in excessive costs or disruptions in portions of our business. In particular, any disruptions, delays or deficiencies caused by our enterprise resource planning system could adversely affect our ability to process orders, ship products, provide services and customer support, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. In addition, despite the implementation of security measures, information technology systems are vulnerable to damage from a variety of sources, including computer viruses, unauthorized access, telecommunications or network failures, malicious human acts, terrorism and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Cyber security is a great and growing risk to operating companies. Cyber-attacks may result in loss of vital Company documentation and data, or confidential third-party documents held by the Company, that are necessary for the Company to operate. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our systems, sustained or repeated system failures that interrupt our ability to generate and maintain data, could result in a material disruption in our operations and material adverse financial costs to the Company. Furthermore, to the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could face a variety of negative consequences, including regulatory actions or litigation, fines or penalties, adverse publicity, increased cybersecurity protection costs, and lost revenue.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>19</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>There is a risk that our measures to protect our systems from cyber-attack are not sufficient to avoid attacks by new sources and methods.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Our business could be negatively affected by the loss of or the inability to hire key personnel.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our future success depends in part on our ability to retain our key technical, sales, marketing and executive personnel and our ability to identify and hire additional qualified personnel. Competition for these personnel is intense, both in the industry in which we operate and where our operations are located. Further, we expect to grow our operations, and our needs for additional management and other key personnel are expected to increase. If we are not able to retain existing key personnel, or timely identify and hire replacement or additional qualified personnel to meet expected growth, our business could be adversely impacted. In addition, the loss of any of our key personnel, particularly key research and development personnel, could harm our business and prospects and could impede the achievement of our research and development, operation or strategic objectives.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>The Company&#8217;s lease obligations and growth expectations could create financial and operating risks.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Given the recent growth in the Company&#8217;s operations, it is uncertain the current leased facilities will be able to accommodate the Company&#8217;s operations in the future. As such, the Company may need to move to new facilities that would require the Company to seek to sublease its current facilities for the remainder of the lease(s) at a potential discount to the existing monthly lease obligation cost. Alternatively, the Company could be required to move a portion of its operations to a new facility which could be disruptive both short term and long term to the Company&#8217;s operations and create additional fixed costs. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We face risks relating to our international sales, including inherent economic, political and regulatory risks, which could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy. </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Our products are primarily sold internationally, with the majority of our international sales to our distributors in Asia, Europe and South America. We currently sell and market our products through distributor organizations and sales agents which creates foreign risks include, among others:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:24pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>compliance with multiple different registration requirements and new and changing registration requirements, our inability to benefit from registration for our products inasmuch as registrations may be controlled by a distributor, and the difficulty in transitioning our product registrations;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>compliance with complex foreign and U.S. laws and regulations that apply to our international operations, including U.S. laws such as import/export limitations, the Foreign Corrupt Practices Act, and local laws;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>tariffs or other barriers as we continue to expand into new countries and geographic regions, especially related to China as tariffs are changing constantly;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>exposure to currency exchange fluctuations against the U.S. dollar;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>longer payment cycles, generally lower average selling prices and greater difficulty in accounts receivable collection;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>lack of ability to enforce receivables collections contracts in foreign legal courts;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>reduced, or lack of, protection for, and enforcement of, intellectual property rights;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>political and economic instability in some of the regions where we currently sell our products or that we may expand into in the future;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>complex and potentially adverse tax consequences; and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>diversion to the U.S. of our products sold into international markets at lower prices.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Currently, most of our international sales are negotiated for and paid in U.S. dollars. Nonetheless, these sales are subject to currency risks, since changes in the values of foreign currencies relative to the value of the U.S. dollar can render our products comparatively more expensive. These exchange rate fluctuations could negatively impact international sales of our products, as could changes in the general economic conditions in those markets. In order to maintain a competitive price for our products internationally, we may have to continue to provide discounts or otherwise effectively reduce our prices, resulting in a lower margin on products sold internationally. Continued change in the values of the Euro, the Mexican peso and other foreign currencies could have a negative impact on our business, financial condition and results of operations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>In addition, we have certain supply agreements with foreign vendors whereby we share the foreign currency exchange fluctuation risk. We may, in the future, enter into similar arrangements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>20</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Sales of our common stock in the public market could lower the market price for our common stock and adversely impact the trading price of our securities.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Future sales by the Company of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the then prevailing market price of our common stock and could make it more difficult for us to raise funds in the future through a public offering of our securities.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On July 21, 2020, we filed with the SEC a &#8220;shelf&#8221; registration statement on Form S-3. The registration statement registers common shares that may be issued by the Company in a maximum aggregate amount of up to $90,000,000.&nbsp; Shares of our common stock may be sold from time to time under this registration statement for up to three years from the filing date. On January 22, 2021, we filed a prospectus supplement for the sale of up to $15,000,000 of shares of our common stock in an at-the-market offering under the shelf registration statement, of which $12,984,273, remains available for sale under the prospectus supplement.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The issuance of additional shares of our common stock, or issuances of additional securities, could dilute the ownership interest of our common stockholders and could depress the market price of shares of our common stock and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the size of future issuances or the effect, if any, that they may have on the market price for our common stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We also have a number of stockholders who own large blocks of our common stock. If one or more of these stockholders were to sell large portions of their holdings in a relatively short time, for liquidity or other reasons, the prevailing market price of shares of our common stock could be negatively affected.</font></p> <br><p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>The price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The stock market periodically experiences significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These broad market fluctuations may cause the market price of our common stock to drop. In particular, the market price of our common stock has been very volatile and unpredictable and may vary substantially in the future in response to:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; announcements by us or our competitors concerning technological innovations;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; introductions of new products;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FDA, SEC, Financial Industry Regulation Authority and foreign regulatory actions against the Company;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; developments or disputes relating to patents or proprietary rights;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure to meet the expectations of stock market analysts and investors;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in stock market analyst recommendations regarding our common stock;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in healthcare policy in the U.S. or other countries; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>lawsuits or liability claims from shareholders or other parties;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates, and the results of any proceedings or lawsuits, including patent or shareholder litigation;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>sales of our common stock or other securities by us or our stockholders in the future;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>trading volume of our common stock</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>actual or anticipated variations in quarterly operating results;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt; TEXT-INDENT:-18pt'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>effects of natural or man-made catastrophic events, including widespread public health epidemics like the pandemic related to COVID-19;</font><font style=FONT-SIZE:10pt lang=EN-US> and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt lang=EN-US>general stock market conditions and other factors unrelated to our operating performance.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Trading of our common stock is not significant, therefore sales of a larger volume of the stock could adversely affect the stock price. </font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>As of August 26, 2016, our Company's stock has been traded on the Nasdaq Capital Market. &nbsp;Trading of our stock is limited and liquidation of the Company&#8217;s stock may be difficult as there is a limited market for our stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>21</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'><b><font style="FONT-SIZE:10pt; LINE-HEIGHT:120%" lang=EN-US>Our ability to use our net operating loss carry forwards in the future may be subject to limitation.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Although&nbsp; we have Federal income tax net operating loss carryforwards of approximately $12,957,000 and California state income tax net operating loss carryforwards of approximately $6,768,000, use of these loss carryforwards will depend on future income in relationship to expirations dates of these carryforwards.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'><b><font style="FONT-SIZE:10pt; LINE-HEIGHT:120%" lang=EN-US>We do not anticipate declaring any cash dividends on our common stock.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p> <div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We have never declared or paid cash dividends on our common stock and do not plan to pay any cash dividends in the near future. Our current policy is to retain all </font><font style=FONT-SIZE:10pt lang=EN-US>funds and any earnings for use in the operation and expansion of our business. <font style=COLOR:black>As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future. Further, we may in the future become subject to contractual restrictions on, or prohibitions against, the payment of dividends. Consequently, in the foreseeable future, gains will likely only be experienced from investments in our common stock if the price of our common stock increases. There is no guarantee that our common stock will appreciate in value or even maintain the price at which shares were purchased, and returns may not be realized on investments in our common stock.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>We face risks related to our intellectual property including our patents (IP).</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We rely on IP for the current products we sell and for the new products in research, development and in clinical trials. While the Company tries to protect its IP with confidentiality agreements and internal policies, we still face risks that our IP will be stolen or otherwise misappropriated, by parties inside or outside of the U.S.&nbsp; Further, we have filed over 100 patents around the world on much of the research and development done by the Company, and the proposed products to come from this research. The vast majority of these filed patents are still under review and have not yet been allowed or issued. We may not be able to attain patent claims that adequately protect the company from competitors developing similar products or copying our products.&nbsp; Finally, there is a great number of issued patents owned by others that pertain to the product categories in which we operate. While we do not know of any patents with claims that we are violating by manufacturing or selling our current products, there is a risk that certain third party patents will emerge that prohibit us from selling our products or that require us to pay royalty payments. Such third party claims could have a material negative impact on the Company. Any of these IP related risks could cause material damage to future revenues and to the long term enterprise values of the Company.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 1B.&nbsp; UNRESOLVED STAFF COMMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>None.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 2.&nbsp; &nbsp;PROPERTIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><a name=_Hlk48056653 /><a name=_Hlk48148933><font style=FONT-SIZE:10pt lang=EN-US>The Company leases its office facilities. At May 31, 2021, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, 92614 which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. &nbsp;The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021. On April 9, 2021 the Company exercised its second option to extend its lease for an additional five years. &nbsp;When the Company extended its lease in April 2021, it was also granted an additional five year lease extension option. The initial base rent for the lease extension was $21,000 per month, increasing to $23,637 through August 31, 2021. The rent is currently $23,637 per month and will increase on September 1, 2021 to $25,213 per month.&nbsp; The security deposit of $22,080 remains the same.<font style=COLOR:black>&nbsp;</font> In November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space with initial base rent of $2,926 per month. The Company has one 10-year option to renew at the end of the initial lease period. The rent is currently $3,262 per month. &nbsp;Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.</font></font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm -9pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LEGAL PROCEEDINGS </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><a name=_Hlk48056653 /><a name=_Hlk48148933><font style=FONT-SIZE:10pt lang=EN-US>The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period.&nbsp; <font style=COLOR:black>We are not currently a party to any legal proceedings, not covered by insurance, that individually or in the aggregate, are deemed to be material to our financial condition or results of operations (see Note 9 to the consolidated financial statements).</font></font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm 2.7pt 0cm 0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>22</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm 2.7pt 0cm 0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>On July 2, 2020, the Company received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena requested information and documents related to events and circumstances leading up to the March 17, 2020 announcement that the Company had commenced shipping samples of the Company&#8217;s COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States.</font><font style=FONT-SIZE:10pt lang=EN-US> The subpoena also requested information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. <a name=_Hlk79495492>In addition, on December 15, 2020, the SEC sent a second subpoena related to this investigation to Zack Irani, the Company&#8217;s CEO, requesting documents held by Mr. Irani concerning his past purchases of Company stock, any past communications with certain persons and entities, and other personal and Company documents. The Company and Mr. Irani have cooperated fully with the SEC&#8217;s investigation and provided information as requested. At this time, the Company is unable to predict the duration, scope or outcome of these investigations. We can provide no assurances as to the outcome of the SEC investigation.</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 4.&nbsp; &nbsp;&nbsp;&nbsp; MINE SAFETY DISCLOSURES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Not applicable.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>PART II</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On August 2, 2016, the Company&#8217;s common stock became listed and began trading on the Nasdaq Capital Market stock exchange where it trades under the symbol BMRA. &nbsp;Previous to that date, the Company&#8217;s stock traded on the OTC Bulletin Board.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_aciFooter11 /><font style=FONT-SIZE:10pt lang=EN-US>As of May 31, 2021, the number of holders of record of Biomerica's common stock was approximately 800, excluding stock held in street name. The number of record holders does not bear any relationship to the number of beneficial owners of the common stock as most of the Company&#8217;s common stock is held in street name at securities brokerage firms. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company has not paid any cash dividends on its common stock in the past and does not plan to pay any cash dividends on its common stock in the foreseeable future. The Company's Board of Directors (&#8220;Board&#8221;) intends, for the foreseeable future, to retain any earnings to finance the continued operation and expansion of the Company's business.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We did not sell any unregistered equity securities during the year ended May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We did not purchase any of our shares of common stock or other securities during our fiscal year ended May 31, 2021. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The table below provides information relating to our equity compensation plans as of May 31 2021:&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=800 style="WIDTH:600pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:14.85pt> <td width=79% colspan=6 nowrap style="HEIGHT:14.85pt; WIDTH:79.84%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=20% style="BORDER-TOP:0px; HEIGHT:14.85pt; BORDER-RIGHT:0px; WIDTH:20.16%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" rowspan=4 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Securities Remaining</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Available for Future Issuance</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Under Compensation Plans</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(Excluding those Reflected in</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Second Column)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=25% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:25.28%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" rowspan=3 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Securities</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN> Plan</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Category</font></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=22% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:22.36%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" rowspan=3 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Number of Securities to be</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>&nbsp;Issued Upon Exercise of </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>&nbsp;Outstanding Options</font></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=22% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:22.36%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" rowspan=3 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Compensation Plans</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Weighted-Average <br>Exercise</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN> Price of <br>Outstanding Options</font></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=25% nowrap style="HEIGHT:15pt; WIDTH:25.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=20% style="HEIGHT:15pt; WIDTH:20.16%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=25% nowrap style="HEIGHT:15pt; WIDTH:25.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" rowspan=3> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Equity compensation </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>&nbsp; Plans approved</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN> by <br>&nbsp; Securities holders </font></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=20% style="HEIGHT:15pt; WIDTH:20.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15.75pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>2,081,366</font></p></td> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15.75pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$3.59</font></p></td> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>419,301</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=20% style="HEIGHT:15pt; WIDTH:20.16%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;SELECTED FINANCIAL DATA</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Not required.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>23</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 7.&nbsp; &nbsp;&nbsp;&nbsp; MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>You should read the following discussion and analysis in conjunction with our consolidated financial statements and the accompanying notes thereto included in Part II, Item 8 of this Report. This discussion and analysis contains forward-looking statements that are based on our management&#8217;s current beliefs and assumptions, which statements are subject to substantial risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those discussed in &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Report.&nbsp;</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>OVERVIEW</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH), is</font><font style=FONT-SIZE:10pt lang=EN-US> a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(physicians' offices and over-the-counter through drugstores and online)</font><font style=FONT-SIZE:10pt lang=EN-US> and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</font><font style=FONT-SIZE:10pt lang=EN-US> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our primary focus is the research and development of revolutionary, patented, diagnostic-guided therapy products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the U.S. Food and Drug Administration, we believe the revenues potential to the Company is significant.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company is currently finalizing an endpoint determination clinical trial on it&#8217;s InFoods</font><font style=FONT-SIZE:10pt lang=EN-US>&reg;<font style=COLOR:black> IBS product. This trial is and has been conducted at </font>Mayo Clinics in Florida and Arizona, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, University of Texas Health Science Center at Houston, Houston Methodist, the University of Michigan and other institutions<font style=COLOR:black>. We expect all patients to be either enrolled or completed by the end of our second fiscal quarter of 202</font></font><font style=FONT-SIZE:10pt lang=EN-US>2, with trial results reported shortly thereafter. During fiscal 2022, we also expect to be entertaining partnership/licensing discussions with pharmaceutical and technology companies that could help us commercialize the product, including obtaining FDA clearance. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic, in March 2020 we began redirecting and focusing a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. During fiscal 2021, we sold 2 primary types of COVID-19 tests; 1) antibody diagnostic tests that use a patient&#8217;s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body&#8217;s immune response to a COVID-19 infection, even if the infection was asymptomatic, and 2) COVID-19 antigen tests that use a patient&#8217;s nasal fluid sample to detect if a patient is currently infected with the virus. </font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;During the year, the Company sold these products outside of the U.S. under a CE Mark (European Conformity). Because individual orders for these tests have been large in size, this has created volatility and material fluctuations in our monthly and quarterly revenues. Although sales in these products have slowed, the company continues to receive and fill orders for our COVID-19 test products. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Aside from the COVID-19 products we offer, the other products we sell are primarily focused on gastrointestinal diseases, food intolerances and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency.&nbsp; In addition, some products are cleared for sale in the U.S. by the FDA.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>24</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>While sales continue to occur in our COVID-19 products, </font><font style=FONT-SIZE:10pt lang=EN-US>by fiscal year end, the majority of our research and development efforts have returned to a focus on development and commercialization of non-COVID related products such as our H. Pylori product, and our InFoods</font><font style=FONT-SIZE:10pt lang=EN-US>&reg;</font><font style=FONT-SIZE:10pt lang=EN-US> IBS product. As such, the Company expects to file for 510K clearance with the FDA for its H. Pylori laboratory diagnostic test during our second fiscal quarter of 2022. If approved by the FDA, we will commence sales of this product in the U.S. We also intend to sell this product internationally including in the European Union (&#8220;EU&#8221;) under a CE Mark. International sales could commence earlier than U.S. sales.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The Company has also recently added several new employees in its sales and marketing department in order to increase sales of existing non-COVID products during fiscal 2022.&nbsp; Through these efforts, our EZ Detect colon disease home screening test is seeing a significant increased interest from retailers and distributors. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN-LEFT:0cm; MARGIN-RIGHT:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>RESULTS OF OPERATIONS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Net Sales and Cost of Sales</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our consolidated net sales were $7,199,027 for fiscal 2021 compared to $6,692,711 for fiscal 2020. This represents an increase of $506,316, or </font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>8%</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>.&nbsp;<a name=_Hlk49411916>This increase in annual sales is primarily attributable to sales of COVID-19 tests, which offset decreases in other product lines that were negatively impacted by the COVID-19 pandemic and related national and international mandates affecting consumers. </a>Our consolidated net sales were $1,054,057 for the fiscal fourth quarter 2021, compared to $2,725,000 for fiscal fourth quarter of 2020. The lower sales in the fiscal fourth quarter 2021 were due to lower COVID-19 sales.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Consolidated cost of sales in fiscal 2021 as compared to fiscal 2020 increased from $4,910,935 to $6,702,046, or by $1,791,111. The percentage of cost of sales in 2020 was 73%. In 2021, this increased to 93%, due to various factors, primarily the establishment of an inventory reserve for slow moving COVID-19 antibody products. Our cost of goods sold for the fiscal fourth quarter 2021 were $1,062,943, or 101%, compared to $1,991,378, or 73%, for the fourth quarter of 2020.&nbsp; In fourth quarter 2021, the higher COGS was due to an approximate $100,000 increase in COVID-19 reserves and slower production in our factory.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Selling, General and Administrative Expenses</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Consolidated selling, general and administrative costs increased in fiscal 2021 as compared to fiscal 2020 from $2,274,415 to $4,608,950, or by $2,334,535, or 103%.&nbsp;The increase was due to an approximate increase of $766,000 in allowance for doubtful accounts, $884,000 in personnel costs as the Company is expanding its team, $520,000 in legal fees related to the SEC investigation, and $145,000 in consulting fees. Our consolidated selling, general and administrative expenses were $911,146 for the fiscal fourth quarter 2021, compared to $559,872 for the fourth quarter of 2020. The fourth quarter increase was primarily due to an approximate increase of $200,000 in allowance for doubtful accounts, and $100,000 in additional personnel costs as the Company is expanding its team. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Research and Development</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Consolidated research and development expense was $2,410,506 in fiscal 2021 as compared to $1,910,209 in fiscal 2020, an increase of $500,297, or 26%, primarily as a result of increases in costs related to the research, development and validation of COVID-19 tests, and increased costs related to our clinical trials and patents for our </font><font style=FONT-SIZE:10pt lang=EN-US>InFoods&reg; IBS<font style=COLOR:black> product.&nbsp; See &#8220;Research and Development&#8221; for a more extensive description of the research being conducted. Our consolidated research and development expenses were $586,194 for the fourth quarter of 2021, compared to $661,610 for the fourth quarter of 2020. </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Interest Expense</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Interest expense increased in fiscal 2021 to $367 as compared to $9 in fiscal 2020. Interest and dividend income for those same years decreased to $66,862 from $71,193, respectively. &nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>LIQUIDITY AND CAPITAL RESOURCES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>As of May 31, 2021, the Company had cash and cash equivalents in the amount of $4,199,311 as compared to $8,641,027 of cash and cash equivalents as of May 31, 2020. &nbsp;As of May 31, 2021 and 2020, the Company had working capital of $7,930,687 and $13,289,670, respectively. We believe that the aggregate of our existing cash and cash equivalents is sufficient to meet our operating cash requirements and strategic objectives for growth for at least the next year. To satisfy our capital requirements, including ongoing future operations, we may seek to raise additional financing through debt and equity financings.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>25</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Operating Activities</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>During fiscal 2021, cash used in operating activities was $5,251,748 as compared to $4,297,498 in fiscal 2020. The primary factors that contributed to this were a loss of $6,469,036, an increase in accounts receivable of $455,614, and an increase in inventories of $1,906,013, and paydown of accounts payable and accrued expenses of $403,331.&nbsp; These were primarily offset by a decrease in prepaid expenses of $1,138,793, which was a result of a refund of the prepayment from the prior year, a non-cash stock option expense of $377,391, an increase in inventory reserves of $1,550,594, and an increase in the allowance on accounts receivable of $766,434.&nbsp; During fiscal 2020, the Company had a net loss of $2,339,054, an increase in accounts receivable of $309,090, an increase in inventories of $717,460, and an increase in prepaid expenses of $1,306,681.&nbsp; These were offset by an increase in accrued compensation of $51,798, a non-cash stock option expense of $200,470 and depreciation and amortization of $129,172.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Investing Activities</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>During fiscal 2021, cash used in investing activities was $295,583 as compared to $118,927 in fiscal 2020. During fiscal 2021, the Company purchased $135,856 of property and equipment and had $159,727 in increased intangible assets related to patents. During fiscal 2020, the Company purchased $33,608 of property and equipment and $85,319 in increased intangible assets related to patents. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><i><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Financing Activities</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Cash provided by financing activities in fiscal 2021 was $1,113,730 as compared to $12,373,977 in fiscal 2020.&nbsp; In fiscal 2021 and 2020, the Company had proceeds from the exercise of stock options of $102,255 and $223,534, respectively. During fiscal 2021 and 2020, the Company received $1,011,475 and $10,232,857, respectively, in net proceeds from the sale of common stock through the two S-3 Registration Statements filed by the company, net of subscriptions receivable. In fiscal 2020, the Company also had proceeds from the sale of convertible preferred stock, net, in the amount of $1,917,586. <a name=_Hlk79675490>The common stock sold and issued in fiscal 2020 was issued under the S-3 &#8220;shelf&#8221; Registration Statement base prospectus filed with the Securities and Exchange Commission on June 30, 2017 and declared effective by the SEC on July 20, 2017, and under the prospectus supplement and At Market Issuance Sales Agreement, filed with the SEC on December 4, 2017, and the prospectus supplement filed with the SEC on March 20, 2020. The common stock sold and issued in fiscal 2021 was issued under the S-3 &#8220;shelf&#8221; Registration Statement base prospectus filed with the SEC on July 21, 2020 (the &#8220;2020 Shelf Registration Statement&#8221;) and declared effective by the SEC on September 30, 2020, and under the prospectus supplement and At Market Issuance Sales Agreement, filed with the SEC on January 22, 2021. (See Shareholders&#8217; Equity and Subsequent Events in the notes to the consolidated financial statements for further details about SEC registrations).</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-AUTOSPACE:'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The 2020 Shelf Registration Statement registers common shares that may be issued by the Company in a maximum aggregate amount of up to $90,000,000.&nbsp; On January 22, 2021, we filed a prospectus supplement (&#8220;2021 Prospectus Supplement&#8221;) for the sale of up to $15,000,000 of shares of our common stock in an at-the-market offering under the 2020 Shelf Registration Statement, of which $12,984,273 remains available for sale under the 2021 Prospectus Supplement.</font><font style=FONT-SIZE:10pt lang=EN-US>&nbsp; On August 27, 2021, the date on which this Annual Report on Form 10-K for the fiscal year ended May 31, 2021 is filed with the SEC, our 2020 Registration Statement became subject to the offering limits set forth in General Instruction I.B.6 of Form S-3 because our public float is less than $75 million.&nbsp; For so long as the Company's public float is less than $75 million, the aggregate market value of securities sold by the Company under the 2020 Shelf Registration Statement pursuant to Instruction I.B.6 to Form S-3 during any 12 consecutive months may not exceed one-third of the Company&#8217;s public float.&nbsp; We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 in the 12 calendar months preceding the date of filing this Annual Report on Form 10-K.&nbsp; For purposes of this limitation, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was $47,283,738, based on 11,151,825 shares of our outstanding common stock held by non-affiliates and a price of $4.24<u> </u>per share, which was the price at which our common stock was last sold on The Nasdaq Capital Market on August 23, 2021 (a date within 60 days of the date hereof), calculated in accordance with General Instruction I.B.6 of Form S-3. After giving effect to the $15,761,246 offering limit imposed by General Instruction I.B.6 of Form S-3, we may offer and sell from time to time up to the full amount of the $12,984,273 remaining under the 2021 Prospectus Supplement. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On February 24, 2020, Biomerica, Inc. entered into and closed on a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with </font><font style=FONT-SIZE:10pt lang=EN-US>Palm Global Small Cap Master Fund LP (&#8220;Palm&#8221;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&#8217;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2,000,000, or $3.50 per Series A Preferred Share. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#8217;s common stock. On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. The Company received approximately $1,917,586 in net proceeds from this sale. On September 30, 2020, these 250,000 unregistered shares became fully registered shares.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>26</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In January 2021, Palm Global Small Cap Master Fund LP converted 321,429 preferred shares into 321,429 fully registered common shares. Following this conversion, Palm Global Small Cap Master Fund LP no longer owns any preferred stock, and Biomerica currently has no preferred shares outstanding.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The Company intends to use the net proceeds from these offerings for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>SUBSEQUENT EVENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Subsequent to May 31, 2021, options to purchase 1,500 shares of Biomerica common stock were exercised at the exercise price of $2.68 per share.&nbsp; Proceeds to the Company were approximately $4,000.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Subsequent to May 31, 2021, the Company sold 201,553 shares of its common stock under its S-3 &#8220;shelf&#8221; Registration statement.&nbsp; The average sale price was $4.16 per share. Net proceeds to the Company were approximately $824,000.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On June 21, 2021, the Company signed an exclusive distribution and marketing agreement in Canada for its Helicobacter Pylori (H. Pylori) test.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In June 2021, the Company received a patent in Japan (#6902526) for the System and Method for a Digital Health System Providing a Food Recommendation Based on Food Sensitivity Testing. This technology is designed to allow for easier implementation of the dietary restrictions that result from InFoods&reg; diagnostic testing. This method describes using a smartphone or similar technology to identify prepared or packaged foods that contain restricted food ingredients, using barcodes or product labels.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In August 2021 the Company received a notice of allowance for a patent in Japan whose claims cover the use of the InFoods&reg; technology to diagnose and treat depression, and covers the compositions, devices and methods of depression sensitivity testing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>OFF BALANCE SHEET ITEMS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>There were no off-balance sheet arrangements as of May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>CRITICAL ACCOUNTING POLICIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The discussion and analysis of our financial condition and results of operations are based on the consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. Note 2 of the Consolidated Financial Statements describe the significant accounting policies essential to the consolidated financial statements. The preparation of these consolidated financial statements requires estimates and assumptions that affect the reported amounts and disclosures.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In general, the critical accounting policies that may require judgments or estimates relate specifically to Revenues, Allowance for Doubtful Accounts, Inventory Reserves, Stock-Based Compensation, Income Taxes, Right-of-Use Asset and Lease Liability.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We believe the following to be critical accounting policies as they require more significant judgments and estimates used in the preparation of our consolidated financial statements. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when transfer of control of goods has occurred and at which point title passes. An allowance is established, if necessary, for estimated returns as revenue is recognized. </font><font style=FONT-SIZE:10pt lang=EN-US>Services for some contract work are invoiced and recognized for work that has been performed as the project progresses.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>27</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>An allowance for doubtful accounts is established for estimated losses resulting from the inability of our customers to make required payments. The assessment of specific receivable balances and required reserves is performed by management and discussed with the audit committee. We have identified specific customers where collection is not probable and have established specific reserves, but to the extent collection is made, the allowance will be released. Additionally, if the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Reserves are provided for excess and obsolete inventory, which are estimated based on a comparison of the quantity and cost of inventory on hand to management's forecast of customer demand. Customer demand is dependent on many factors and requires us to use significant judgment in our forecasting process. We must also make assumptions regarding the rate at which new products will be accepted in the marketplace and at which customers will transition from older products to newer products. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of, even if in subsequent periods we forecast demand for the product.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We measure stock-based compensation costs at fair value, including estimated forfeitures, and recognize the expense over the period that the recipient is required to provide service in exchange for the award, which generally is the vesting period. We use the Black-Scholes option pricing model to measure the fair value of our stock options. In determining the amount of expense to be recorded, we also estimate forfeiture rates for all awards based on historical experience to reflect the probability that employees will complete the required service period. Employee retention patterns could vary in the future and result in a change to our estimated forfeiture rate which would directly impact stock-based compensation expense.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We follow authoritative guidance to evaluate whether a valuation allowance should be established against our deferred tax assets based on the consideration of all available evidence using a &#8220;more likely than not&#8221; standard.&nbsp; In making such judgments, significant weight is given to evidence that can be objectively verified.&nbsp;We assess our deferred tax assets annually under more likely than not scenarios in which they may be realized through future income.&nbsp;We have determined that although we believe our net deferred tax assets of $5,590,000 will be utilized at a future date, based on our recent losses and plans to continue our research and development, we have established a valuation allowance of $5,590,000, which fully covers the asset.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 13.55pt 0cm 0cm'><i><font style=FONT-SIZE:10pt lang=EN-US>Leases</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 13.55pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm -1.8pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>During the year ended May 31, 2020, the Company adopted ASC 842, Leases. As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm -1.8pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>REVENUE RECOGNITION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company has various contracts with customers.&nbsp; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2021 and 2020 and does not believe that any additional discounts will be given through the end of the contract periods. </font><font style=FONT-SIZE:10pt lang=EN-US>Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. <font style=COLOR:black>The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors.&nbsp; Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>RECENT ACCOUNTING PRONOUNCEMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>See Note 2 to our consolidated&nbsp;financial statements for a listing of adopted and soon to be adopted accounting pronouncements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 7A.&nbsp;&nbsp; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Not required.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Exhibit 99.3, "Biomerica, Inc. and Subsidiaries Consolidated Financial Statements" is incorporated herein by this reference.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>28</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>None.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 9A.&nbsp;&nbsp; CONTROLS AND PROCEDURES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Attached as exhibits to this Form 10-K are certifications of our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;) that are required in accordance with Rule 13a-14 of the Exchange Act. This &#8220;Disclosure Controls and Procedures&#8221; section includes information concerning the controls and controls evaluation referred to in the certifications.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>EVALUATION OF DISCLOSURE CONTROLS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our management evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act as of the end of the period covered by this report. &nbsp;Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. &nbsp;The disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives and the CEO and CFO have concluded that our disclosure controls and procedures are effective at the &#8220;reasonable assurance&#8221; level. Based on that evaluation the CEO and CFO concluded that information required to be disclosed in the reports that we file and submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms; and (2) accumulated and communicated to the Company&#8217;s management, including its CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>For the reasons discussed in "Management's Report on Internal Control over Financial Reporting" below, Company management, including the CEO and CFO concluded that, as of May 31, 2021, the Company's internal control over financial reporting was effective. Management has concluded that the consolidated financial statements included in this annual report present fairly, in all material respects, the Company's financial position, results of operations, and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>There have been no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during the last fiscal year that have materially affected, or that are reasonably likely to affect, our internal control over financial reporting.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Company management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company's internal control over financial reporting is designed to provide reasonable assurance to the Company's management and Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>A Company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>29</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The effectiveness of any system of internal control over financial reporting is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating and evaluating the controls and procedures. Because of these inherent limitations, internal control over financial reporting cannot provide absolute assurance regarding the reliability of financial reporting and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Company management, with the participation of the CEO and the CFO, evaluated the effectiveness of the Company's disclosure controls and procedures as defined in Rules 13(a)-15(e) and 15(d)-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. In making this assessment, Management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control - Integrated Framework (2013). Based on this assessment, management, with the participation of the CEO and CFO, believes that, as of May 31, 2021, the Company's internal control over financial reporting was effective based on those criteria.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Company management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures and its internal controls over financial reporting on an ongoing basis and are committed to taking further action and implementing improvements, as necessary and as funds allow.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Note: This 10-K does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this 10-K.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 9B.&nbsp;&nbsp; OTHER INFORMATION.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>None.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>PART III</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 10.&nbsp;&nbsp;&nbsp; DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</font></b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>.&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>This information is incorporated by reference to the Company's proxy statement for its 2021 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 11.&nbsp;&nbsp; &nbsp;EXECUTIVE COMPENSATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>This information is incorporated by reference to the Company's proxy statement for its 2021 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 12.&nbsp;&nbsp;&nbsp; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>This information is incorporated by reference to the Company's proxy statement for its 2021 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 13.&nbsp;&nbsp; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Other information regarding related transactions is incorporated by reference to the Company's proxy statement for its 2021 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ITEM 14.&nbsp;&nbsp; PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Please refer to the Company&#8217;s proxy statement for its 2021 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company&#8217;s fiscal year ended May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>30</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>PART IV</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <table width=720 style=WIDTH:540pt cellpadding=0 cellspacing=0> <tr> <td width=100% colspan=3 style="WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>ITEM 15. EXHIBITS LIST AND FINANCIAL SCHEDULES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The following documents are filed as part of this Annual Report on Form&nbsp;10-K: </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm 260pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1. <i>Consolidated Financial Statements</i></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reference is made to the Index to the consolidated financial statements as set forth on page&nbsp;FS-1 of this Annual &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Report on Form 10-K. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. <i>Consolidated Financial Statement Schedules</i></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All schedules have been omitted as the pertinent information is either not required, not applicable, or otherwise &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; included in the financial statements and notes thereto. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3. <i>Exhibits&nbsp;</i></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See below.</font></p></td></tr> <tr> <td width=100% colspan=3 style="WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=10% colspan=2 style="HEIGHT:15pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Exhibit No.</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Description</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% colspan=2 style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /></tr> <tr style=HEIGHT:25.2pt> <td width=10% colspan=2 style="HEIGHT:25.2pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3.1</font></p></td> <td width=89% style="HEIGHT:25.2pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>First Amended and Restated Certificate of Incorporation of Biomerica, Inc. filed with the Secretary of State of Delaware on August 1, 2000 (incorporated by reference to Exhibit 3.8 filed with the Registrant's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2000).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% colspan=2 style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% colspan=2 style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3.2</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 filed with Amendment No. 1 to Registration Statement on Form S-1, Commission File No. 2-83308).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% colspan=2 style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:25.5pt> <td width=10% colspan=2 style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>4.1</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Specimen Stock Certificate of Common Stock of Registrant (incorporated by reference to Exhibit 4.1 filed with Registrant's Registration Statement on Form SB-2, Commission No. 333-87231 filed on September 16, 1999).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% colspan=2 style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:25.5pt> <td width=10% colspan=2 style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=http://www.sec.gov/Archives/edgar/data/73290/000101968709003694/lease1.htm>10.1</a></font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=http://www.sec.gov/Archives/edgar/data/73290/000101968709003694/lease1.htm>Standard Industrial/Commercial Single-Tenant Lease for 17571 Von Karman Avenue, Irvine, CA 92614, incorporated by reference to Exhibit 10.1 of the Company's August 31, 2009 Form 10Q filed October 15, 2009.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% colspan=2 style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:25.5pt> <td width=10% colspan=2 style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>10.2</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2010 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on February 2, 2012).</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=10% colspan=2 style="HEIGHT:15pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:25.5pt> <td width=10% colspan=2 style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=http://www.sec.gov/Archives/edgar/data/73290/000151316215000284/forms8.htm>10.3</a></font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=http://www.sec.gov/Archives/edgar/data/73290/000151316215000284/forms8.htm>2014 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 22, 2015).</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% colspan=2 style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% colspan=2 style="HEIGHT:15.75pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>10.4</font></p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2017 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 10, 2018).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% colspan=2 style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=5% style="HEIGHT:15.75pt; WIDTH:5.26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>10.5</font></p></td> <td width=5% style="HEIGHT:15.75pt; WIDTH:5.26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2020 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 21, 2021).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=5% style="HEIGHT:15.75pt; WIDTH:5.26%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=5% style="HEIGHT:15.75pt; WIDTH:5.26%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=5% style="HEIGHT:15.75pt; WIDTH:5.26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit10_6.htm>10.6</a></font></p></td> <td width=5% style="HEIGHT:15.75pt; WIDTH:5.26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit10_6.htm>Form of Executive Stock Option Agreement (attached herein)</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=5% style="HEIGHT:15.75pt; WIDTH:5.26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=5% style="HEIGHT:15.75pt; WIDTH:5.26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% colspan=2 style="HEIGHT:15.75pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit21_1.htm>21.1</a></font></p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit21_1.htm>Listing of Subsidiaries (attached herein)</a></font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>31</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <table width=720 style="WIDTH:540pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit23_1.htm>23.1</a></font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit23_1.htm>Consent of Independent Registered Public Accounting Firm (PKF San Diego, LLP).</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit31_1.htm>31.1</a></font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit31_1.htm>Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit31_2.htm>31.2</a></font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit31_2.htm>Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit32_1.htm>32.1</a></font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit32_1.htm>Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit32_2.htm>32.2</a></font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=exhibit32_2.htm>Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>99.3</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Biomerica, Inc. and Subsidiaries Consolidated Financial Statements</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>101.INS</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>XBRL Instance Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>101.SCH</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>XBRL Taxonomy Extension Schema Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>101.CAL</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>XBRL Taxonomy Extension Calculation Linkbase Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>101.DEF</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>XBRL Taxonomy Extension Definition Linkbase Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>101.LAB</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>XBRL Taxonomy Extension Label Linkbase Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top /></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>101.PRE</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>XBRL Taxonomy Extension Presentation Linkbase Document.</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The certifications attached as Exhibits 32.1 and 32.2 accompany this Annual Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant&#8217;s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>32</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>SIGNATURES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=right><table width=600 style="WIDTH:450pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>BIOMERICA, INC.</font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Registrant</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=51% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:51.78%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>By /s/ Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Zackary S. Irani,</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Chief Executive Officer</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Dated: August 27, 2021</font></p></td></tr></table> </div><p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font lang=EN-US>&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Signature and Capacity</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <table width=600 style="WIDTH:450pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:14.35pt> <td width=45% style="BORDER-TOP:0px; HEIGHT:14.35pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>/s/ Zackary S. Irani &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% style="HEIGHT:14.35pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:14.35pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Date: August 27, 2021</font></p></td></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Zackary S. Irani</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Director, Chief Executive Officer</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:14.35pt> <td width=45% style="BORDER-TOP:0px; HEIGHT:14.35pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>/s/ Steve Sloan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% style="HEIGHT:14.35pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:14.35pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Date: August 27, 2021</font></p></td></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Steve Sloan,</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Chief Financial Officer</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:14.35pt> <td width=45% nowrap style="BORDER-TOP:0px; HEIGHT:14.35pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>/s/ Francis R. Cano, Ph.D. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% nowrap style="HEIGHT:14.35pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:14.35pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Date: August 27, 2021</font></p></td></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=ES>Francis R. Cano, Ph.D.</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Director</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:14.35pt> <td width=45% style="BORDER-TOP:0px; HEIGHT:14.35pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>/s/ Allen Barbieri &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% style="HEIGHT:14.35pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:14.35pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Date: August 27, 2021</font></p></td></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Allen Barbieri</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Director, Vice-Chairman</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:14.35pt> <td width=45% nowrap style="BORDER-TOP:0px; HEIGHT:14.35pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>/s/ Jane Emerson, M.D., Ph.D. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% nowrap style="HEIGHT:14.35pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:14.35pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Date: August 27, 2021</font></p></td></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Jane Emerson, M.D., Ph.D</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Director</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:14.35pt> <td width=45% nowrap style="HEIGHT:14.35pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=20% nowrap style="HEIGHT:14.35pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=34% style="HEIGHT:14.35pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:14.35pt> <td width=45% nowrap style="BORDER-TOP:0px; HEIGHT:14.35pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>/s/ Mark Sirgo,&nbsp; Pharm.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% nowrap style="HEIGHT:14.35pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:14.35pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Date: August 27, 2021</font></p></td></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Mark Sirgo, Pharm.D.</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="BORDER-TOP:0px; HEIGHT:15.1pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>/s/ Catherine Coste, CPA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Date: August 27, 2021</font></p></font></td></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="BORDER-TOP:0px; HEIGHT:15.1pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Catherine Coste, CPA </font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.1pt> <td width=45% style="HEIGHT:15.1pt; WIDTH:45.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Director</font></p></td> <td width=20% style="HEIGHT:15.1pt; WIDTH:20.28%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=34% style="HEIGHT:15.1pt; WIDTH:34.64%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr></table></div><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif' lang=EN-US><br clear=all style=PAGE-BREAK-BEFORE:none></font> <div style=page:WordSection2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>33</font></p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>BIOMERICA, INC. &nbsp;AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a name=TOC>TABLE OF CONTENTS</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=#Report>Report of Independent Registered Public Accounting Firm</a></font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FS-2</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>CONSOLIDATED FINANCIAL STATEMENTS</font></b></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=#BS>Consolidated Balance Sheets as of May 31, 2021 and 2020</a></font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FS-3</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=#IS>Consolidated Statements of Operations and Comprehensive Loss for the Years Ended May 31, 2021 and 2020</a></font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FS-4</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=#SHEQ>Consolidated Statements of Shareholders' Equity for the Years Ended May 31, 2021 and 2020</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FS-5</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=#CFS>Consolidated Statements of Cash Flows for the Years Ended May 31, 2021 and 2020</a></font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FS-6</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td nowrap style="HEIGHT:15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a href=#Notes>Notes to Consolidated Financial Statements</a></font></p></td> <td nowrap style="HEIGHT:15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td nowrap style="HEIGHT:15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FS-7 &#8211; FS-23</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div style="TEXT-ALIGN:center; MARGIN:0cm" align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:center; MARGIN:6pt 0cm' align=center><b></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:center; MARGIN:6pt 0cm' align=center><b><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US><a name=Report>REPORT</a> OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:center; MARGIN:6pt 0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:left; MARGIN:0cm' align=left><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>Board of Directors and Shareholders<br>Biomerica, Inc. and Subsidiaries</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:left; MARGIN:0cm' align=left><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>Irvine, California</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:left; MARGIN:0cm' align=left>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0cm'><u><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>Opinion on the Consolidated Financial Statements</font></u></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0cm'><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>We have audited the accompanying consolidated balance sheets of Biomerica, Inc. (a Delaware Corporation) and Subsidiaries (the &#8220;Company&#8221;) as of </font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>May 31, 2021 </font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>and </font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>2020</font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for each of the two years in the period ended </font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>May 31, 2021</font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).&nbsp; In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of </font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>May 31, 2021 </font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>and </font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>2020</font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>, and the results of its operations and its cash flows for each of the two years in the period ended </font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>May 31, 2021</font><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>, in conformity with accounting principles generally accepted in the United States of America.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0cm'><u><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>Basis for Opinion</font></u></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0cm'><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>These consolidated financial statements are the responsibility of the Company&#8217;s management.&nbsp; Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits.&nbsp; We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0cm'><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>We conducted our audits in accordance with the standards of the PCAOB.&nbsp; Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.&nbsp; The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.&nbsp; As part of our audits we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.&nbsp; Accordingly, we express no such opinion.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:6pt 0cm'><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.&nbsp; Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.&nbsp; Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.&nbsp; We believe that our audits provide a reasonable basis for our opinion.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk80257226><u><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>Critical Audit Matters</font></u></a></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments.&nbsp; The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</font></p><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US><br clear=all style=PAGE-BREAK-BEFORE:none></font> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk67406666><font style='FONT-FAMILY:"Times New Roman",serif; BACKGROUND:white; COLOR:black' lang=EN-US>Evaluation of Inventory and Accounts Receivable Allowances</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company recorded allowances for inventory and accounts receivable of approximately $1,600,000 and $840,000, respectively, as of May 31, 2021 primarily related to COVID-19 inventory items that have been slow moving and accounts receivable from foreign customers where collectability is questionable.&nbsp; As described in Note 2, these allowances are adjusted based on management&#8217;s ongoing evaluations and assessments based on current conditions.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Auditing the Company&#8217;s estimates for inventory and accounts receivable allowances was challenging due to the assumptions made by management based on anticipated future results of customers and marketplace developments.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>We obtained an understanding and evaluated the assumptions, criteria and process used by management to determine the allowances for inventory items and accounts receivable. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>To test the valuation and accuracy of allowances for inventory and accounts receivable, our <font size=+0>audit</font> procedures included, among others, observation and testing of the cost and the valuation allowance for inventory items on hand, examining recent sales of items, testing of aging of accounts receivable balances, confirmation and testing of subsequent cash receipts on accounts receivable, and discussions with management.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 6pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style='FONT-FAMILY:"Times New Roman",serif' lang=EN-US>/s/PKF San Diego, LLP</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 6pt'><font style='FONT-FAMILY:"Times New Roman",serif' lang=EN-US>(formerly PKF, LLP)</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style='FONT-FAMILY:"Times New Roman",serif' lang=EN-US>We have served as the Company&#8217;s auditor since 2004.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style='FONT-FAMILY:"Times New Roman",serif' lang=EN-US>San Diego, California</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>August 27, 2021</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>FS-2</font></p> <div style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=1000 style="WIDTH:750pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:30pt> <td width=100% colspan=6 nowrap style="HEIGHT:30pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;BIOMERICA, INC. AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a name=BS>CONSOLIDATED BALANCE SHEETS</a></font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=14% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=14% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Assets</font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Current Assets:</font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Cash and cash equivalents</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>4,199,311 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>8,641,027 </font></p></td></tr> <tr style=HEIGHT:26.25pt> <td width=70% style="HEIGHT:26.25pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accounts receivable, less allowance for doubtful accounts <br>&nbsp;&nbsp;&nbsp; of $837,415 and $70,981 as of May 31, 2021 and&nbsp; 2020, respectively</font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,455,051 </font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,765,871 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Inventories, net</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>3,206,255 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>2,850,836 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Prepaid expenses and other</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>370,290 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,509,083 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total current assets</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>9,230,907 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>14,766,817 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:26.25pt> <td width=70% style="HEIGHT:26.25pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Property and equipment, net of accumulated depreciation and amortization&nbsp; <br>&nbsp;&nbsp;&nbsp; of $1,972,357 and $1,867,643 as of May 31, 2021 and 2020, respectively</font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>310,520 </font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>279,379 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:26.25pt> <td width=70% style="HEIGHT:26.25pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Right of use assets, net of accumulated amortization of $469,077 and $231,489 <br>&nbsp;&nbsp;&nbsp; as of May 31, 2021 and 2020, respectively</font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,553,081 </font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,711,510 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Investments</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>165,324 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>165,324 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:26.25pt> <td width=70% style="HEIGHT:26.25pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Intangible assets, net of accumulated amortization of $126,769 and $496,124 as <br>&nbsp;&nbsp;&nbsp; of May 31, 2021 and 2020, respectively</font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>294,830 </font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>168,655 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Other assets</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>264,151 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>168,193 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total Assets</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>11,818,813 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>17,259,878 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Liabilities and Shareholders' Equity</font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Current Liabilities:</font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accounts payable and accrued expenses</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>583,380 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>986,711 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accrued compensation</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>388,896 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>278,627 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Lease liability, current portion</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>327,944 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>211,809 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total current liabilities</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,300,220 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,477,147 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Lease liability, net of current portion</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,291,570 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,569,678 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total Liabilities</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>2,591,790 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>3,046,825 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Commitments and contingencies (Notes 1 and 9)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Shareholders' Equity:</font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:26.25pt> <td width=70% style="HEIGHT:26.25pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Preferred stock, Series A 5% convertible, $0.08 par value, <br>&nbsp;&nbsp;&nbsp; 571,429 shares authorized, none issued and outstanding at May 31, 2021 and 321,429 <br>&nbsp;&nbsp;&nbsp; issued and outstanding at May 31, 2020</font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>25,714 </font></p></td></tr> <tr style=HEIGHT:26.25pt> <td width=70% style="HEIGHT:26.25pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Preferred stock, undesignated, no par value, <br>&nbsp;&nbsp;&nbsp; 4,428,571 shares authorized, none issued and outstanding at May 31, 2021 and 2020</font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td></tr> <tr style=HEIGHT:26.25pt> <td width=70% style="HEIGHT:26.25pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Common stock, $0.08 par value, <br>&nbsp;&nbsp;&nbsp; 25,000,000 shares authorized, 12,307,157 and 11,740,089 issued and outstanding at <br>&nbsp;&nbsp;&nbsp; May 31, 2021 and 2020, respectively</font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>984,571 </font></p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:26.25pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>939,205 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Additional paid-in-capital</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>36,685,176 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>35,213,707 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accumulated other comprehensive loss</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(47,956)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(39,841)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accumulated deficit</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(28,394,768)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(21,925,732)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total Shareholders' Equity</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>9,227,023 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>14,213,053 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total Liabilities and Shareholders' Equity</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>11,818,813 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>17,259,878 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=100% colspan=6 nowrap style="HEIGHT:15.75pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>See accompanying notes to consolidated financial statements</font></p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",sans-serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-3</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <div> <div align=center> <table width=1000 style="WIDTH:750pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:30pt> <td width=100% colspan=6 nowrap style="HEIGHT:30pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>BIOMERICA, INC. AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a name=IS>CONSOLIDATED STATEMENTS OF OPERATIONS</a> AND COMPREHENSIVE LOSS</font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=30% colspan=5 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:30%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>For The Years Ended</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=14% colspan=2 nowrap style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net sales </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>7,199,027 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>6,692,711 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Cost of sales </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(6,702,046)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(4,910,935)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Gross Profit </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>496,981 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,781,776 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Operating Expenses: </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Selling, general and administrative </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>4,608,950 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>2,274,415 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Research and development </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>2,410,506 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,910,209 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:20pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total operating expense </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>7,019,456 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>4,184,624 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Loss from operations </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(6,522,475)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(2,402,848)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Other Income: </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Dividend and interest income </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>66,863 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>71,193 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Interest expense </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(367)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(9)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:20pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total other income </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>66,496 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>71,184 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Loss before income taxes </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(6,455,979)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(2,331,664)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Provision for income taxes </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(13,057)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(7,390)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net loss </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(6,469,036)</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(2,339,054)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Basic net loss per common share </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(0.54)</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(0.23)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Diluted net loss per common share </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(0.54)</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(0.23)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:18pt> <td width=70% style="HEIGHT:18pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Weighted average number of common and <br>common equivalent shares: </font></p></td> <td width=2% nowrap style="HEIGHT:18pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:18pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:18pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:18pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:18pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Basic </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>11,928,941 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>10,166,296 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Diluted </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>11,928,941 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>10,166,296 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net loss </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(6,469,036)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(2,339,054)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Other comprehensive loss, net of tax: </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Foreign currency translation </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(8,115)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(3,310)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Comprehensive loss </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(6,477,151)</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(2,342,364)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=100% colspan=6 nowrap style="HEIGHT:15.75pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>See accompanying notes to consolidated financial statements&nbsp; </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-4</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=1033 style="WIDTH:775pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:45pt> <td width=6% colspan=22 nowrap style="HEIGHT:45pt; WIDTH:6%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>BIOMERICA, INC. AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a name=SHEQ>CONSOLIDATED STATEMENTS OF SHAREHOLDERS</a>' EQUITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FOR THE YEARS ENDED MAY 31, 2021 AND 2020</font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=6% colspan=22 nowrap style="HEIGHT:15pt; WIDTH:6%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:41.25pt> <td width=26% nowrap style="HEIGHT:41.25pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p></td> <td width=6% colspan=4 nowrap style="BORDER-TOP:0px; HEIGHT:41.25pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Common Stock</font></p></td> <td width=2% nowrap style="HEIGHT:41.25pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% colspan=4 nowrap style="BORDER-TOP:0px; HEIGHT:41.25pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Series A 5% Convertible <br>Preferred Stock</font></p></td> <td width=2% nowrap style="HEIGHT:41.25pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:41.25pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" rowspan=2 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Additional </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>&nbsp;Paid-in Capital</font></p></td> <td width=2% nowrap style="HEIGHT:41.25pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:41.25pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% style="BORDER-TOP:0px; HEIGHT:41.25pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" rowspan=2 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accumulated <br>Other <br>Comprehensive</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Loss</font></p></td> <td width=2% nowrap style="HEIGHT:41.25pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:41.25pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" rowspan=2 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accumulated</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Deficit</font></p></td> <td width=2% nowrap style="HEIGHT:41.25pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:41.25pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:41.25pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Shares</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% colspan=2 nowrap style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Amount</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Shares</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% colspan=2 nowrap style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Amount </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Total</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Balances, May 31, 2019</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>9,677,188 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>774,173 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>22,830,006 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(36,531)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(19,586,678)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>3,980,970 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Exercise of stock options</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>137,958 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>11,037 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>212,497 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>223,534 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net proceeds from ATM</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,674,943 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>133,995 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>10,098,862 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>10,232,857 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Issuance of preferred stock</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>571,429 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>45,714 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,871,872 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,917,586 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Foreign currency translation</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(3,310)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(3,310)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Conversion of preferred to common stock</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>250,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>20,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(250,000)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(20,000)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Compensation expense in connection with options granted</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>200,470 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>200,470 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net loss</font></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(2,339,054)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(2,339,054)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Balances, May 31, 2020</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>11,740,089 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>939,205 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>321,429 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>25,714 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>35,213,707 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(39,841)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(21,925,732)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>14,213,053 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Exercise of stock options</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>86,750 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>6,940 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>95,315 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>102,255 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net proceeds from ATM</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>158,889 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>12,712 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>998,763 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,011,475 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Foreign currency translation</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(8,115)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(8,115)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Conversion of preferred to common stock</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>321,429 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>25,714 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(321,429)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(25,714)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Compensation expense in connection with options granted</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>377,391</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>377,391 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=26% nowrap style="HEIGHT:15pt; WIDTH:26%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net loss</font></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(6,469,036)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(6,469,036)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=26% nowrap style="HEIGHT:15.75pt; WIDTH:26%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Balances, May 31, 2021</font></b></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>12,307,157 </font></b></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></b></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>984,571 </font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></b></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></b></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>-</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></b></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>36,685,176 </font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></b></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(47,956)</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></b></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(28,394,768)</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></b></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>9,227,023 </font></b></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=6% colspan=22 nowrap style="HEIGHT:15.75pt; WIDTH:6%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=6% colspan=22 nowrap style="HEIGHT:15pt; WIDTH:6%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>See accompanying notes to consolidated financial statements.&nbsp;</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><a name=_aciHeader26><font style=FONT-SIZE:10pt lang=EN-US>FS-5</font></a></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <div align=center> <table width=1000 style="WIDTH:750pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:30pt> <td width=100% colspan=6 nowrap style="HEIGHT:30pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>BIOMERICA, INC. AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a name=CFS>CONSOLIDATED STATEMENTS OF CASH FLOWS</a></font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=30% colspan=5 nowrap style="HEIGHT:15pt; WIDTH:30%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>For The Years Ended</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p></td> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>May 31, 2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Cash flows from operating activities: </font></b></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net loss </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(6,469,036)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(2,339,054)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Adjustments to reconcile net loss to net cash used in operating activities: </font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Depreciation and amortization </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>138,267 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>129,172 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Change in allowance on accounts receivable </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>766,434 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(2,129)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Inventory reserve </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,550,594 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>17,714 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Stock option expense </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>377,391 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>200,470 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Reduction in deferred rent liability </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(37,971)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Amortization of right-of-use asset </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>237,588 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>269,460 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Changes in assets and liabilities: </font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accounts receivable </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(455,614)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(309,090)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Inventories </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(1,906,013)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(717,460)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Prepaid expenses </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,138,793 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(1,306,681)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Reduction in lease liability </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(241,132)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(199,483)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Other assets </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(95,958)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(41,361)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accounts payable and accrued expenses </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(403,331)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(12,883)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Accrued compensation </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>110,269 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>51,798 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net cash used in operating activities </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(5,251,748)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(4,297,498)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Cash flows from investing activities: </font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Increase in intangibles </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(159,727)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(85,319)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Purchases of property and equipment </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(135,856)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(33,608)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net cash used in investing activities </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(295,583)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(118,927)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Cash flows from financing activities: </font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Proceeds from sale of common stock, net </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,011,475 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>10,232,857 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Proceeds from sale of convertible preferred stock, net </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,917,586 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Proceeds from exercise of stock options </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>102,255 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>223,534 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net cash provided by financing activities </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,113,730 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>12,373,977 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Effect of exchange rate changes in cash </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(8,115)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(3,310)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Net (decrease) increase in cash and cash equivalents </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>(4,441,716)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>7,954,242 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Cash and cash equivalents at beginning of year </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>8,641,027 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>686,785 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Cash and cash equivalents at end of year </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>4,199,311 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>8,641,027 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Supplemental Disclosure of Cash-Flow Information: </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Cash paid during the year for: </font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Interest </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>367 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>9 </font></p></td></tr> <tr style=HEIGHT:16.5pt> <td width=70% nowrap style="HEIGHT:16.5pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Income taxes </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>27,171 </font></p></td> <td width=2% nowrap style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>7,390 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Non-cash investing and financing activities: </font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Increase in right of use asset due to lease extension or establishment </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>79,159 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,942,999 </font></p></td></tr> <tr style=HEIGHT:16.5pt> <td width=70% nowrap style="HEIGHT:16.5pt; WIDTH:70%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>Increase in lease liability due to lease extension or establishment </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>79,159 </font></p></td> <td width=2% nowrap style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>$ </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-IN>1,980,970 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=100% colspan=6 nowrap style="HEIGHT:15.75pt; WIDTH:100%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The accompanying notes are an integral part of these statements </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-6</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>BIOMERICA, INC. AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US><a name=Notes>NOTES</a> TO CONSOLIDATED FINANCIAL STATEMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>YEARS ENDED MAY 31, 2021 AND 2020</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 1: &nbsp;&nbsp;&nbsp;ORGANIZATION </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Biomerica Inc. and Subsidiaries (collectively the &#8220;Company&#8221;, &#8220;Biomerica&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;) develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(physicians' offices and over-the-counter through drugstores and online)</font><font style=FONT-SIZE:10pt lang=EN-US> and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. </font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</font><font style=FONT-SIZE:10pt lang=EN-US> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our primary focus is the research and development of revolutionary, patented, diagnostic-guided therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Our medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic, in March 2020 we began redirecting and focusing a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. During fiscal 2021, we sold 2 primary types of Covid 19 tests; 1) antibody diagnostic tests that use a patient&#8217;s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body&#8217;s immune response to a COVID-19 infection, even if the infection was asymptomatic, and 2) antigen tests that use a patient&#8217;s nasal fluid sample to detect if a patient is currently infected with the virus. </font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Aside from the COVID-19 products we offer, the other products we sell are primarily focused on gastrointestinal diseases, food intolerances, diabetes and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency.&nbsp; In addition, some products are cleared for sale in the U.S. by the FDA.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 2: &nbsp;&nbsp;&nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>PRINCIPLES OF CONSOLIDATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The enclosed consolidated financial statements for the years ended May 31, 2021 and 2020 include the accounts of Biomerica, Inc. ("Biomerica") as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ACCOUNTING ESTIMATES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-7</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>MARKETS AND METHODS OF DISTRIBUTION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Due to</font><b></b><font style=FONT-SIZE:10pt lang=EN-US> the Coronavirus global pandemic, the Company&#8217;s operations have been negatively impacted.<font style=COLOR:black> The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, loss of contracts and/or customers, closure of the Company&#8217;s manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&#8217;s operations and financial performance and may continue to have significant material negative impacts on the Company.&nbsp;&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>LIQUIDITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $28.4 million as of May 31, 2021.&nbsp; Management expects to continue to incur significant costs as it advances its trials and development activities.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020 and declared effective by the SEC on September 30, 2020 and an ATM Agreement. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Under an ATM Agreement, sales of the Placement Shares are deemed to be &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act.&nbsp; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#8217;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement (</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>File No. 333-239980) </font><font style=FONT-SIZE:10pt lang=EN-US>and ATM Agreement which resulted in gross proceeds of $1,177,394 and net proceeds to the Company of $1,011,475 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>As a result of cash and cash equivalents on hand at May 31, 2021, management believes the Company has sufficient funds to operate through August 2022 and the ability to raise additional funds through the ATM noted above.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FAIR VALUE OF FINANCIAL INSTRUMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&nbsp;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>CONCENTRATION OF CREDIT RISK</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&nbsp; As of May 31, 2021, the Company had approximately $3,767,000 of uninsured cash. </font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company does not believe it is exposed to any significant credit risks.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&nbsp; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-8</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>For the years ended May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 60% and 57% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2021 and 2020 one of the distributors mentioned above accounted for 33% and 26%, respectively, of net consolidated sales.&nbsp; At May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 73% and 80%, respectively, of gross accounts receivable. <a name=_Hlk48558057>Of the 73% as of May 31, 2021, 41% was owed by a distributor in China. Total gross receivables at May 31, 2021 and 2020 were </a></font><font style=FONT-SIZE:10pt lang=EN-US>$2,292,466</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US> and $1,836,852, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; TEXT-ALIGN:justify;FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>For the year ended May 31, 2021, one vendor accounted for 58% of the purchases of raw materials. For the year ended May 31, 2020, one vendor accounted for a total of 59% of the purchases of raw materials.</font><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>GEOGRAPHIC CONCENTRATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>As of May 31, 2021 and 2020, approximately $803,000 and $613,000 of Biomerica's gross inventory and approximately $25,000 and $31,000, of Biomerica's property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>CASH AND</font></b><font style=FONT-SIZE:10pt lang=EN-US><b><font style=COLOR:black> CASH EQUIVALENTS</font></b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ACCOUNTS RECEIVABLE</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company extends unsecured credit to its customers on a regular basis. &nbsp;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &nbsp;Based on various criteria,&nbsp;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &nbsp;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &nbsp;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &nbsp; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>The Company has established a reserve of $837,415 for doubtful accounts as of May 31, 2021. The majority of this reserve has been established to cover 100% of outstanding accounts receivable from an international distributor.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>PREPAIDS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>The Company occasionally prepays for items such as inventory, insurance and other items.&nbsp; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>As of May 31, 2021, the prepaids were approximately $370,000, composed of prepayments to insurance and various other suppliers. As of May 31, 2020, approximately $1 million of the prepaids was an advance payment to one of our suppliers, which was subsequently refunded by the supplier when the Company determined it no longer needed the materials that had been ordered.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>INVENTORIES, NET</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black" lang=EN-US>The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-9</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Inventories approximate the following at May 31:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=119 nowrap style="HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>May 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>May 31, 2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=119 nowrap style="HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Raw materials</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,583,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,635,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=119 nowrap style="HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Work in progress</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,006,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>988,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=119 nowrap style="HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Finished products</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>617,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>228,000 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=119 nowrap style="HEIGHT:15.75pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3,206,000 </font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2,851,000 </font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2021 and 2020, inventory reserves were approximately $1,617,000 and $67,000, respectively. </font><font style=FONT-SIZE:9pt lang=EN-US>Of the inventory reserve, </font><font style=FONT-SIZE:9pt lang=EN-US>$1,502,675 was related to a market downturn in our COVID-19 antibody test and materials, as the market shifted to&nbsp; COVID-19 PCR viral tests and antigen tests.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>PROPERTY AND EQUIPMENT, NET</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $104,715 and $105,299 for the years ended May 31, 2021 and 2020, respectively. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>INTANGIBLE ASSETS, NET</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $33,552 and $23,873 for the years ended May 31, 2021 and 2020, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2021 or 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>INVESTMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>From time-to-time, the Company makes investments in privately-held companies. &nbsp;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&#8217;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&#8217;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &nbsp;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>SHARE-BASED COMPENSATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company follows the guidance of the accounting provisions of ASC 718<a name=_Hlk17621381>, </a>Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-10</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In applying the Black-Scholes options-pricing model, assumptions used were as follows: &nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=143 nowrap style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=143 nowrap style="HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Dividend yield</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>0%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>0%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=143 nowrap style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Expected volatility</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;71.19-107.53% </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;55.52-72.62% </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=143 nowrap style="HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Risk free interest rate</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;0.34-1.18% </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;0.43-1.80% </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=143 nowrap style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Expected Term</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;5.50-6.25 Years </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;3.75-6.25 Years </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>REVENUE RECOGNITION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company has various contracts with customers.&nbsp; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2021 and 2020 and does not believe that any additional discounts will be given through the end of the contract periods. </font><font style=FONT-SIZE:10pt lang=EN-US>Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. <font style=COLOR:black>The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &nbsp;Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </font><a name=_Hlk49511094 /></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Disaggregation of revenue:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The following is a breakdown of revenues according to markets to which the products are sold:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=155 nowrap style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=5 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Year Ended</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=155 nowrap style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>May 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>May 31, 2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=155 nowrap style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Clinical lab</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3,077,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2,922,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=155 nowrap style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Physician's office</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2,801,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2,195,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=155 nowrap style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Over-the-counter</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>766,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,270,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=155 nowrap style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Contract manufacturing</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>552,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>306,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=155 nowrap style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Lab supplies</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=155 nowrap style="HEIGHT:15.75pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>7,199,000 </font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>6,693,000 </font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>See Note 8 for additional information regarding revenue concentrations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>SHIPPING AND HANDLING FEES </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company includes shipping and handling fees billed to customers in net sales. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>RESEARCH AND DEVELOPMENT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Research and development costs are expensed as incurred. The Company expensed $2,410,506 and $1,910,209 of research and development costs during the years ended May 31, 2021 and 2020, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-11</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>INCOME TAXES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2021 and 2020, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&nbsp;&nbsp; During the fiscal year ended May 31, 2021, this valuation allowance was increased to $5,590,000, which fully covers the tax asset of $5,590,000</font><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#8217;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#8220;Interest expense&#8221; line and penalties related to liabilities for income taxes within the &#8220;Other expense&#8221; line of the consolidated statements of operations and comprehensive loss. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ADVERTISING COSTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <font style=BACKGROUND:white>$10,070</font> and $<font style=BACKGROUND:white>174</font> for the years ended May 31, 2021 and 2020, respectively. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>FOREIGN CURRENCY TRANSLATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2021 and 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>RIGHT-OF-USE ASSETS AND LEASE LIABILITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.<font style=COLOR:black>&nbsp;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&nbsp; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&nbsp; Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&nbsp; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&nbsp; Leases are classified as financing or operating which will drive the expense recognition pattern.&nbsp; The Company has elected to exclude short-term leases.&nbsp; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&nbsp; An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&nbsp; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&#8217;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not book the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&nbsp; Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&nbsp; The leases do not include the options to purchase the leased property.&nbsp; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-12</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NET LOSS PER SHARE </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2021 and 2020 were 2,081,366 and 1,789,251, respectively. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company also had 0 and 321,429 of Series A 5% Convertible Preferred Stock outstanding for the years ended May 31, 2021 and 2020, respectively. &nbsp;The 321,429 shares outstanding at May 31, 2020 were converted to common stock during the year ended May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>SEGMENT REPORTING</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>ASC 280, Segment Reporting (&#8220;ASC 280&#8221;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#8217;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>REPORTING COMPREHENSIVE LOSS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#8217; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>RECENT ACCOUNTING PRONOUNCEMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 7.2pt 0cm 0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#8217;s present or future consolidated financial statements. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 3: &nbsp;&nbsp;&nbsp;PROPERTY AND EQUIPMENT, NET</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Property and equipment, net of accumulated depreciation, consist of the following at May 31:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=312 nowrap style="HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=312 nowrap style="HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Equipment </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,849,888 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,921,833 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=312 nowrap style="HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Furniture, fixtures and leasehold improvements</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>432,989 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>225,189 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=312 nowrap style="HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Less accumulated depreciation</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(1,972,357)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(1,867,643)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=312 nowrap style="HEIGHT:15.75pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Net property and equipment</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>310,520 </font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>279,379 </font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 4: &nbsp;&nbsp;&nbsp;INTANGIBLE ASSETS, NET</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Intangible assets, net of accumulated amortization, consist of the following at May 31:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=72% nowrap style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=72% nowrap style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Licenses</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>182,176 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>551,397 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=72% nowrap style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Patents</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>239,423 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>113,382 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=72% nowrap style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Less accumulated amortization-licenses</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(107,194)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(487,989)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=72% nowrap style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Less accumulated amortization-patents</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(19,575)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(8,135)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=72% nowrap style="HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Intangible asssets, net</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>294,830 </font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>168,655 </font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-13</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Expected amortization of intangible assets for the years ending May 31:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=147 nowrap style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2022</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>21,846 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=147 nowrap style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2023</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>20,058 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=147 nowrap style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2024</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>20,058 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=147 nowrap style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2025</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>19,071 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=147 nowrap style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2026</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>18,975 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=147 nowrap style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Thereafter</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>194,822 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=147 nowrap style="HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>294,830 </font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 5:&nbsp;&nbsp;&nbsp; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company&#8217;s accounts payable and accrued expense balances consist of the following at May 31:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=175 nowrap style="HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=175 nowrap style="HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=175 nowrap style="HEIGHT:15pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Accounts payable</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>431,621 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>833,412 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=175 nowrap style="HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Accrued expense</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>151,759 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>153,299 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=175 nowrap style="HEIGHT:15.75pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>583,380 </font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>986,711 </font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>As of May 31, 2021 and 2020 the Company had one vendor and two vendors which accounted for 17% and 27%, respectively, of accounts payable.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 6: &nbsp;&nbsp;&nbsp;SHAREHOLDERS' EQUITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On February 24, 2020, the Company filed with the Secretary of State of Delaware a certificate of designation to authorize for issuance 571,429 shares of Series A 5% Convertible Preferred Stock.&nbsp; On February 26, 2020, the Company filed with the Secretary of State of Delaware a certificate of correction, correcting certain language defects in the previously filed certificate of designation.&nbsp; Please see below a description of the Series A 5% Convertible Preferred Stock shares that were issued in February 2020, and subsequently converted into registered common shares.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>STOCK OPTION AND RESTRICTED STOCK PLANS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In August 2010, the Company adopted a stock option and restricted stock plan (the "2010 Plan") which provided that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock could be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2010. &nbsp;The 2010 Plan expired in December 2020. Options granted under the 2010 Plan were granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2014. &nbsp;The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-14</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In December 2017, the Company adopted a stock option and restricted stock plan (the &#8220;2017 Plan&#8221;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company&#8217;s unissued common stock may be granted to affiliates, employees or consultants of the Company.&nbsp; This plan was approved by shareholders in December 2017.&nbsp; The 2017 Plan expires in December 2027.&nbsp; Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) and on December 11, 2020 the shareholders of the Company approved The Plan. The 2020 Plan authorizes the issuance of an</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US> aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000. &nbsp;The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Stock option expense during fiscal 2021 was $377,391.&nbsp; This included, by department, $64,491 for research and development, $221,052 for administrative, $18,035 for sales and marketing and $73,813 for production.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Stock option expense during fiscal 2020 was $200,470. This included, by department, $17,892 for research and development, $156,750 in administrative, $2,933 in sales and marketing and $22,895 for production.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Activity as to aggregate stock options outstanding is as follows: </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=734 style="WIDTH:550.7pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=400 nowrap style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=90 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NUMBER OF STOCK OPTIONS</font></p></td> <td width=17 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>EXCERCISE PRICE <br>RANGE PER SHARE</font></p></td> <td width=17 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=106 colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:79.4pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>WEIGHTED AVERAGE EXERCISE <br>PRICE</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=400 nowrap style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Options outstanding at May 31, 2019</font></b></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=90 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,476,209 </font></b></p></td> <td width=17 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$0.82-$3.90</font></b></p></td> <td width=17 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=16 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=90 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2.07 </font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=400 nowrap style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Options granted</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>517,500 </font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=88 nowrap style="HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$2.68-$8.18</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=16 nowrap style="HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>4.47 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=400 nowrap style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Options excercised</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(137,958)</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=88 nowrap style="HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$0.82-$3.90</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=16 nowrap style="HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1.64 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=400 nowrap style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Options canceled or expired</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=90 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(66,500)</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$0.85-$8.18</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=16 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=90 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3.43 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=400 nowrap style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Options outstanding at May 31, 2020</font></b></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,789,251 </font></b></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=88 nowrap style="HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$0.82-$8.18</font></b></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=16 nowrap style="HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2.75 </font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=400 nowrap style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Options granted</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>430,616 </font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=88 nowrap style="HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$5.14-$8.70</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=16 nowrap style="HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>6.73 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=400 nowrap style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Options excercised</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(86,750)</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=88 nowrap style="HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$0.82-$3.62</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=16 nowrap style="HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=90 nowrap style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1.20 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=400 nowrap style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Options canceled or expired</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=90 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(51,751)</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$2.35-$8.18</font></p></td> <td width=17 nowrap style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=16 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=90 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>4.77 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=400 nowrap style="HEIGHT:15.75pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Options outstanding at May 31, 2021</font></b></p></td> <td width=17 nowrap style="HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=90 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2,081,366 </font></b></p></td> <td width=17 nowrap style="HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$0.82-$8.70</font></b></p></td> <td width=17 nowrap style="HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=16 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom /> <td width=90 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$1.20 - $6.73</font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The weighted average fair value of options granted during 2021 and 2020 was $6.73 and $4.47, respectively. The aggregate intrinsic value of options exercised during 2021 and 2020 was approximately $501,000 and $589,000, respectively. The aggregate intrinsic value of options outstanding at May 31, 2021 and 2020 was approximately $2,132,000 and $6,923,000, respectively. The aggregate intrinsic value of options vested and exercisable at May 31, 2021 and 2020 was approximately $1,872,000 and $4,442,000, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The number of non-vested stock options included in the table above is as follows:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font lang=EN-US>&nbsp;&nbsp; </font></p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:54.75pt> <td width=230 nowrap style="HEIGHT:54.75pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Number of<br>&nbsp;shares</font></p></td> <td width=2% nowrap style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Stock options<br>weighted<br>average grant <br>date fair value</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=230 nowrap style="HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Non-vested shares at May 31, 2020 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>822,584 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3.78 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=230 nowrap style="HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Granted </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>430,616 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>6.73</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=230 nowrap style="HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Vested&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(409,459)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3.36</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=230 nowrap style="HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Forfeited </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(50,500)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>4.80</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=230 nowrap style="HEIGHT:15.75pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Non-vested shares at May 31, 2021 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>793,241 </font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>5.54 </font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-15</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>At May 31, 2021, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $1,208,000. The weighted-average period over which this amount is expected to be recognized is 2.59 years. The weighted average remaining contractual term of options that were exercisable at May 31, 2021 was 6.07 years.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The following summarizes information about all of the Company's stock options outstanding at May 31, 2021. These options are comprised of those granted under the 2010, 2014, 2017 and 2020 plans.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>RANGE OF <br>EXERCISE PRICES</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NUMBER <br>OUTSTANDING <br>MAY 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>WEIGHTED <br>AVERAGE <br>REMAINING <br>CONTRACTUAL <br>LIFE IN YEARS</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>WEIGHTED<br>&nbsp;AVERAGE <br>EXERCISE PRICE</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NUMBER <br>EXCERCISABLE <br>AT MAY 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>WEIGHTED <br>AVERAGE <br>EXERCISE PRICE</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$0.82-$1.04</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>216,000</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3.75</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$0.82 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>216,000</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$0.82 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$1.20-$2.81</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,024,500</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>6.45</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$2.17 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>795,250</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$2.02 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$3.62-$8.70</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>840,866</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>8.00</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$6.03 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>276,875</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$4.54 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>COMMON STOCK ACTIVITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk17185589><font style=FONT-SIZE:10pt lang=EN-US>During the year ended May 31, 2020, options to purchase 137,958 shares of common stock were exercised at prices ranging from $0.82 to $3.90.&nbsp; Total net proceeds to the Company were $223,534.</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On December 1, 2017, the Company entered into an At Market Issuance Sales Agreement (or &#8220;ATM Agreement&#8221;) with an agent, and filed a prospectus supplement with the SEC pursuant under which the Company could offer and sell from time to time up to an aggregate of $7,000,000 of shares of the Company&#8217;s common stock, par value $0.08 per share (the &#8220;Placement Shares&#8221;), through the agent. From December 1, 2017 to March 19, 2020, the Company sold common stock resulting in $6,997,935 of gross proceeds under this ATM Agreement, of which $3,771,048 were sold during the year ended May 31, 2020. </font><font style=FONT-SIZE:10pt lang=EN-US>This At Market Issuance Agreement expired on July 20, 2020 upon the expiration of the Company&#8217;s Form S-3 registration statement base prospectus dated July 20, 2017. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:40.5pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 12pt'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Placement Shares sold and issued under this ATM Agreement have been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to the Registration Statement on Form S-3 (File No. 333-219130) (the &#8220;Registration Statement&#8221;), which was originally filed with the SEC on June 30, 2017 and declared effective by the SEC on July 20, 2017, the base prospectus contained within the Registration Statement, and the prospectus supplement related to the sale of shares under the ATM Agreement was filed with the SEC on December 1, 2017.&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On March 20, 2020, the Company filed a new prospectus supplement to the S-3 registration statement base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the ATM Agreement. </font><a name=_Hlk47966232><font style=FONT-SIZE:10pt lang=EN-US>This ATM Agreement expired on July 20, 2020 upon the expiration of the Company&#8217;s Form S-3 registration statement base prospectus dated July 20, 2017. Gross proceeds for the year ended May 31, 2020 were $6,817,330. There were no proceeds for the year ended May 31, 2021, for this July 20, 2017 Form S-3 registration statement.</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Combined Placement Shares sold under the ATM Agreements during the year ended May 31, 2020 under the two prospectus supplements dated December 1, 2017 and March 20, 2020 totaled 1,674,943 shares. Total net proceeds from the sale of Placement Shares under the two prospectus supplements during the year ended May 31, 2020 were $10,232,857 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&nbsp; These shares were sold at prices ranging from $2.33 to $9.08 per share. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On September 11, 2020, the Company filed a Pre-Effective Amendment No. 1 to the Form S-3 to register 571,429 shares of Biomerica common stock in connection with the Stock Purchase Agreement dated February 21, 2020, wherein the Company entered into a registration rights agreement with the selling stockholder, pursuant to which we agreed to file a registration statement registering the resale of the shares of our common stock issuable upon conversion of our Series A Preferred Stock issued to the selling stockholder under the Stock Purchase Agreement.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-16</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><a name=_Hlk79676889><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for the Form S-3 &#8220;shelf&#8221; </font></a><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Registration Statement filed on July 21, 2020 and amended on September 11, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>During the year ended May 31, 2020, 250,000 shares of common stock were converted from Preferred Stock as described below in &#8220;Preferred Stock Activity&#8221;.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>During the year ended May 31, 2021, options to purchase 86,750 shares of common stock were exercised at prices ranging from $0.82 to $3.62.&nbsp; Total net proceeds to the Company were $102,255.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020 and declared effective by the SEC on September 30, and an ATM Agreement. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On May 21, 2021, in conjunction with the Company&#8217;s 2020 Stock Incentive Plan, that was approved by shareholders at the Company&#8217;s annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to 900,000 shares of the Company&#8217;s common stock that could be issued under this Plan.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Under an ATM Agreements, sales of the Placement Shares are deemed to be &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act.&nbsp; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#8217;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>During the year ended May 31, 2021, 321,429 shares of common stock were converted from Preferred Stock as described below in &#8220;Preferred Stock Activity&#8221;.</font><a name=_Hlk49188299 /></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement <a name=_Aci_Pg1>(</a></font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>File No. 333-239980</font><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>) </font><font style=FONT-SIZE:10pt lang=EN-US>and ATM Agreement which resulted in gross proceeds of $1,177,394 and net proceeds to the Company of $1,011,475 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>PREFERRED STOCK ACTIVITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><u><font style=FONT-SIZE:10pt lang=EN-US></font></u></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with </font><font style=FONT-SIZE:10pt lang=EN-US>Palm Global Small Cap Master Fund LP (&#8220;Palm&#8221;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&#8217;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#8217;s common stock, subject to certain adjustments. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay such accruing dividends. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered 571,429 common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. <font style=COLOR:black>On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares.&nbsp; On January 21, 2021 Palm Converted their remaining 321,429 Convertible Preferred Shares into registered common shares. At May 30, 2021, the Company had no shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative Dividends were paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past cumulative dividends. </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-17</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 7: &nbsp;&nbsp;&nbsp;INCOME TAXES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Provision for income taxes for the years ended May 31 consists of the following:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;Years ended May 31,</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Current:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>U.S. Federal</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Foreign Taxes Subsidiaries</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(12,257)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(6,590)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>State and local</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(800)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(800)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total current</font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(13,057)</font></b></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(7,390)</font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Deferred:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>U.S. Federal&nbsp;</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>State and local</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=200 nowrap style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total deferred</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=200 nowrap style="HEIGHT:15.75pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Income tax expense</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(13,057)</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(7,390)</font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Provision for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (</font><font style=FONT-SIZE:10pt lang=EN-US>21<font style=COLOR:black>% for 2021 and 2020) to pretax income as a result of the following:</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Years ended May 31,</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Computed "expected" tax benefit </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,355,756 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>489,651 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Increase (reduction) in income taxes resulting from:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Change in valuation allowance</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(2,102,000)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(1,029,000)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>State income taxes, net of federal benefit</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>190,233 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>154,254 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Research and development tax credits</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>456,388 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>49,770 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Permanent tax differences and other</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>98,823 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>334,525 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Foreign taxes of subsidiaries</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(12,257)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(6,590)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=68% nowrap style="HEIGHT:15.75pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Income tax expense</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(13,057)</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(7,390)</font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The tax effect of significant temporary differences&nbsp;is presented below:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>As of May 31,</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Deferred tax assets:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Accounts receivable, principally due to allowance for doubtful accounts</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>200,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>17,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Inventory valuation&nbsp;&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp; </font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>387,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>16,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Compensated absences</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>85,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>64,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Net operating loss carryforwards&nbsp;&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3,195,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2,286,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Tax credit carryforwards</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,055,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>599,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Deferred rent expense/Capitalized leases</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>14,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>17,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Stock Options</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>299,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>181,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Losses of foreign subsidiaries &amp; Other, net</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>370,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>303,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Accumulated depreciation and amortization</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(15,000)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>5,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total deferred tax assets&nbsp;&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>5,590,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3,488,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=68% nowrap style="HEIGHT:15pt; WIDTH:68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Less valuation allowance</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(5,590,000)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>(3,488,000)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=68% nowrap style="HEIGHT:15.75pt; WIDTH:68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Net deferred tax asset</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-18</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company has provided a valuation allowance of approximately $5,590,000 and $3,488,000 as of May 31, 2021 and 2020, respectively. The net change in the valuation allowance for the years ended May 31, 2021 and 2020 was an increase of $2,102,000 and $1,029,000, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company increased the deferred tax asset and the valuation allowance by $313,000 as of May 31, 2020 based on the outstanding stock options as of May 31, 2020. This change had no impact on the Company&#8217;s consolidated financial statements as our deferred tax asset is fully offset by our valuation allowance. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>At May 31, 2021, the Company has Federal income tax net operating loss carryforwards of approximately $12,957,000. &nbsp;At May 31, 2021, the Company has California state income tax net operating loss carryforwards of approximately $6,768,000. For tax reporting purposes, operating loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in 2022 and 2037 for federal and state purposes, respectively.&nbsp; Federal net operating losses beginning in 2018 have no expiration date. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>At May 31, 2021, the Company has Federal research and development tax credit carryforward of approximately $715,000. &nbsp;The Federal credits begin to expire in 2027. &nbsp;The Company also had similar credit carryforwards for state purposes of $341,000 at May 31, 2021, which don&#8217;t expire.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company's net operating loss ("NOL") and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company's NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>For the year ended May 31, 2021, the Company did an analysis of its ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740. Should such position be identified in the future and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal year 2017.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 8: &nbsp;&nbsp;&nbsp;GEOGRAPHIC INFORMATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company operates as one segment. Geographic information regarding net sales is approximately as follows: </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=306 nowrap style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% colspan=7 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Year Ended</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=306 nowrap style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% colspan=3 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>May 31, 2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% colspan=3 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>May 31, 2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=306 nowrap style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Revenues from sales to unaffiliated customers:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=306 nowrap style="HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Europe</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>4,301,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>60%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2,434,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>36%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=306 nowrap style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Asia</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,908,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>26%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,867,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>28%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=306 nowrap style="HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>United States</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>548,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>8%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>445,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>7%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=306 nowrap style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>South America</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>250,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,615,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>24%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=306 nowrap style="HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Middle East</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>192,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>3%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>314,000 </font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>5%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=306 nowrap style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Other</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>0%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>18,000 </font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>0%</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=306 nowrap style="HEIGHT:15.75pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>7,199,000 </font></b></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>100%</font></b></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></b></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>6,693,000 </font></b></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>100%</font></b></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 9: &nbsp;&nbsp;&nbsp;COMMITMENTS AND CONTINGENCIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>OPERATING LEASES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. </font><font style=FONT-SIZE:10pt lang=EN-US>&nbsp;On November 30, 2015, the Company entered into the First Amendment to Lease wherein it exercised its option to extend its lease until August 31, 2021. The initial base rent for the lease extension was $21,000 per month, increasing to $23,637 through August 31, 2021. On April 9, 2021 the Company exercised its second option to extend its lease for an additional five years through August 2026.&nbsp; The Company was also granted an additional five years lease extension option through August 2031. The rent is currently $23,637 per month and will increase on September 1, 2021 to $25,970 per month and be increased 3% each year thereafter. The security deposit of $22,080 remains the same.<font style=COLOR:black>&nbsp;</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>In November 2016, the Company&#8217;s subsidiary, Biomerica de Mexico, entered into a ten-year lease for approximately 8,104 square feet at a monthly rent of $2,926. The Company has one 10-year option to renew at the end of the initial lease period. The yearly rate is subject to an annual adjustment for inflation according to the United States Bureau of Labor Statistics Consumer Price Index for All Urban Consumers. The monthly rate is currently $3,262. &nbsp;Biomerica, Inc. is not a guarantor of such lease. &nbsp;Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-19</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total gross rent expense in the U.S. for fiscal 2021 was $294,759 and 2020 was $300,267.&nbsp; Rent expense for the Mexico facility for fiscal 2021 and 2020 was $25,351 and $43,481, respectively. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0.9pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#8217;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&nbsp; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred.&nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; MARGIN:0cm'><font style='FONT-FAMILY:"Times New Roman",serif' lang=EN-US>Supplemental cash flow information related to leases for the year ended May 31: </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=396 nowrap style="HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2020</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=396 nowrap style="HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Operating cash flows from operating leases&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>320,606 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>311,742 </font></p></td></tr> <tr style=HEIGHT:14.4pt> <td width=396 style="HEIGHT:14.4pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Right-of-use assets obtained in exchange for<br>&nbsp;&nbsp;&nbsp; &nbsp;new operating lease liabilities</font></p></td> <td width=2% nowrap style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=10% nowrap style="HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>79,159 </font></p></td> <td width=2% nowrap style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=10% nowrap style="HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>&nbsp;- </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=396 nowrap style="HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Weighted average remaining lease term (in years)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>5.27</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>6.27</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=396 nowrap style="HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Weighted average discount rate</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>6.50%</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>6.50%</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Future minimum lease payments under the operating lease as of May 31, 2021 are as follows:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=733 style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=271 nowrap style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2022</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>337,630 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=271 nowrap style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2023</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>350,311 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=271 nowrap style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2024</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>360,769 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=271 nowrap style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2025</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>371,539 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=271 nowrap style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>2026</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>382,631 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=271 nowrap style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Thereafter</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>103,927 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=271 nowrap style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total undiscounted lease payments</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,906,807 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=271 nowrap style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Less imputed interest</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>287,293 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=271 nowrap style="HEIGHT:15.75pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Total operating lease liabilities</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:right; MARGIN:0cm' align=right><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>1,619,514 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company also has various insignificant leases for office equipment.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>RETIREMENT SAVINGS PLAN</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan's inception.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-20</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>LITIGATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. There were no legal proceedings pending as of May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>On July 2, 2020, we received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena requested information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also requested information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. In addition, on December 15, 2020, the SEC sent a second subpoena related to this investigation to Zack Irani, the Company&#8217;s CEO, requesting documents held by Mr. Irani concerning his past purchases of Company stock, his past communications with certain persons and entities, and other personal and Company documents. The Company and Mr. Irani have cooperated fully with the SEC&#8217;s investigation and provided information as requested. At this time, the Company is unable to predict the duration, scope or outcome of these investigations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>CONTRACTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Contracts and Licensing Agreements</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $11,000 and $15,000 is included in cost of sales for the agreement for each of the years ended May 31, 2021 and 2020, respectively. Sales of products manufactured under these agreements comprise approximately 1.5% and 1.8% of total sales for the years ended May 31, 2021 and 2020, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business.&nbsp; The Company has other royalty agreements, however they are not considered material.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (&#8220;Telcon Agreement&#8221;) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (&#8220;Telcon&#8221;), a medical company in South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica&#8217;s new InFoods&reg; IBS products (&#8220;IBS Products&#8221;) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. We are working with Telcon management to extend the term of the Telcon Agreement. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica&#8217;s starting clinical trials in the United States, receipt of U.S. FDA clearance and Telcon&#8217;s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common stock in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>Additionally, the Telcon Agreement provides for&nbsp;a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.&nbsp; In order to retain the exclusivity within South Korea, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon&#8217;s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019.<b> </b>&nbsp;&nbsp;In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. &nbsp;During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On May 29, 2019, the Company entered into an exclusive distribution agreement which contained certain annual minimum sales requirements, with MaxHealth Medical International Limited (a Chinese company) for the distribution of the Company&#8217;s EZ Detect Product in China.&nbsp; On March 15, 2021, the Company terminated this agreement due to MaxHealth&#8217;s failure to meet the minimum sales requirements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-21</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the &#8220;Mount Sinai License Agreements&#8221;) with the Mount Sinai Icahn School of Medicine in New York (&#8220;Mount Sinai&#8221;) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&nbsp; This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States.&nbsp; The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for Emergency Use Authorization with the FDA based on this on this technology. The Company purchased materials in the amount of $5,100 during fiscal 2020 and subsequently to that another $2,850.&nbsp; No royalty fees have been paid yet on these agreements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On May 7, 2020, the Company entered into an exclusive license agreement (the &#8220;UC License Agreements&#8221;) with The Regents of the University of California (&#8220;UC&#8221;) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at the University by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus.&nbsp;If this technology development is successful, the Company will work with the University to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated and cleared with regulatory agencies for commercial sale into the market.&nbsp; The exclusive UC License Agreements provide for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $5,000 with the execution of the agreement. An additional $5,000 was paid in September 2020.&nbsp; No royalties have been paid yet on this agreement. A license maintenance fee of $10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 16.2pt 0cm 0cm'><b><font style=FONT-SIZE:10pt lang=EN-US>Clinical Trial Agreements</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 16.2pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.&nbsp; The initial budget was estimated to be $82,472. The work started in October 2017 with charges for work performed being invoiced and paid monthly.&nbsp; This study ended in February 2020. The Company incurred $2,200 in fiscal 2020 and $12,567 in expenses previously invoiced for a total of $14,767. In addition, $17,064 in fees has been accrued for unbilled charges as of May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In November 2017, the Company entered into a Clinical Trial Agreement with the University of Michigan to perform an InFoods</font><font style=FONT-SIZE:10pt lang=EN-US>&reg;<font style=COLOR:black> 24 Endpoint Determination Study.&nbsp; The Company will be invoiced monthly for work performed the previous month. The maximum budget for the study is $181,015. The Company incurred $20,550 and $30,900 in expenses for this study during fiscal 2021 and 2020, respectively. This commitment is approximately 56% billed.&nbsp; The Company has accrued $2,050 in charges as of May 31, 2021.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In January 2018, the Company entered into a Clinical Trial Agreement with Beth Israel Deaconess Medical Center for the purposes of conducting an Antibody Guided Restriction Trial Using Biomerica InFoods</font><font style=FONT-SIZE:10pt lang=EN-US>&reg;<font style=COLOR:black> 24G Test in patients with a previous diagnosis of Irritable Bowel Syndrome.&nbsp; The study began in the first quarter of fiscal 2019. The Company was invoiced monthly for work performed the previous month.&nbsp; The total cost of the study was initially estimated to be $142,000, however the study was expanded and total costs of the trial was approximately $305,000. The Company incurred $0 and $141,640 in expenses for this study during fiscal 2021 and 2020, respectively. This study was closed in February 2020 and no additional costs are expected.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>On July 12, 2019, the Company entered into a Clinical Trial Agreement with a research management institution for the purpose of conducting a clinical trial of the Biomerica HP Stool Antigen test.&nbsp; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&nbsp; The maximum budgeted costs were approximately $117,200.&nbsp; During fiscal 2021 and 2020, $13,111 and $13,355 in charges were billed, respectively. This study is now closed so no further charges will be incurred.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>On July 22, 2019, the Company entered into a Clinical Trial Agreement with a research institution, for the purpose of conducting a clinical trial of the Biomerica InFoods&reg; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000.&nbsp; The Company incurred $20,875 in charges during fiscal 2020. This commitment is approximately 31% billed. In addition, the Company was billed $12,675 in fiscal 2021 and accrued $19,600 in unbilled charges as of May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>On September 25, 2019, the Company entered into a Clinical Trial Agreement with a medical practice for the purpose of conducting a clinical trial of the Biomerica InFoods&reg; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $136,000. During fiscal 2021 and 2020, the Company was invoiced $11,725 and $45,250 respectively in expenses. This commitment is approximately 42% billed. In addition, the Company accrued $5,975 in unbilled charges as of May 31, 2020. No charges were accrued at May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-22</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style=FONT-SIZE:10pt color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>On September 25, 2019, the Company entered into a Clinical Trial Agreement with a research institution for the purpose of conducting a clinical trial of the Biomerica H. pylori product.&nbsp; The term of the agreement shall be until completion of the work outlined and the charges were invoiced monthly for work performed in the previous month.&nbsp; The maximum budgeted costs will be approximately $57,800. The Company was invoiced $41,845 in charges during the year ended May 31, 2020. At May 31, 2020, the commitment was approximately 72% billed and the study was closed so no further charges will be incurred.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>In December 2019, the Company entered into a Clinical Trial Agreement with Houston Methodist Research Institute for the purpose of conducting a clinical trial of the Biomerica InFoods&reg; product.&nbsp; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&nbsp; The maximum budgeted costs will be approximately $133,000. During the years ended May 31, 2021 and 2020, the Company was invoiced $0 and $4,000 in charges, respectively. This commitment is approximately 3% billed. The Company accrued $3,550 in charges at May 31, 2021.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 16.2pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Arizona for the purpose of participating in the ongoing end point clinical trial of the Biomerica InFoods&reg; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. &nbsp;At May 31, 2021 and 2020, $0 and $17,390 had been invoiced to the Company. The Company has accrued $3,750 in expenses as of May 31, 2021. This commitment is approximately 13% billed.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Jacksonville for the purpose of participating in the ongoing end point clinical trial of the Biomerica InFoods&reg; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. The Company has not received any billings as of May 31, 2020, however accrued $17,390 in charges as of that date. The Company received $22,827 in billings in fiscal 2021 and did not accrue any charges as of May 31, 2021. As of May 31, 2021, approximately 17% of the commitment had been invoiced.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm'><font style=FONT-SIZE:10pt lang=EN-US>On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica InFoods&reg; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850. As of May 31, 2021, $4,850 had been billed and $3,750 in accruals remained. As of May 31, 2021, approximately 4% of the commitment had been invoiced.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>The addition of both Mayo Clinic sites and other major medical centers were brought into the InFoods&reg; IBS clinicals studies in order to accelerate patient enrollment.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 16.2pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 16.2pt 0cm 0cm'><b><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>NOTE 10:&nbsp;&nbsp;&nbsp; SUBSEQUENT EVENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Subsequent to May 31, 2021, options to purchase 1,500 shares of Biomerica common stock were exercised at the exercise price of $2.68 per share.&nbsp; Proceeds to the Company were approximately $4,000.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style=FONT-SIZE:10pt lang=EN-US>Subsequent to May 31, 2021, the Company sold 201,553 shares of its common stock under its Form S-3 &#8220;shelf&#8221; Registration statement. The average sale price was $4.16 per share. Net proceeds to the Company were approximately $824,000.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>On June 21, 2021, the Company signed an exclusive distribution and marketing agreement in Canada for its Helicobacter Pylori (H. Pylori) test.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In June 2021, the Company received a patent in Japan (#6902526) for the System and Method for a Digital Health System Providing a Food Recommendation Based on Food Sensitivity Testing. This technology is designed to allow for easier implementation of the dietary restrictions that result from InFoods&reg; diagnostic testing. This method describes using a smartphone or similar technology to identify prepared or packaged foods that contain restricted food ingredients, using barcodes or product labels.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>In August 2021, the Company received a notice of allowance for a patent in Japan whose claims cover the use of the InFoods&reg; technology to diagnose and treat depression, and covers the compositions, devices and methods of depression sensitivity testing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p></div> <div style=page:WordSection3> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>FS-23</font></p></div></body>
<!-- EDGAR Validation Code: 98D9D5DD -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>exhibit10_6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<head><title>Exhibit 10.6</title> </head> <body style=WORD-WRAP:break-word lang=EN-GB> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; FONT-WEIGHT:bold; TEXT-ALIGN:center; MARGIN:0cm'><font lang=EN-US>FORM OF</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font lang=EN-US>BIOMERICA, INC.</font></b></p> <h1 style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:0cm'><font lang=EN-US>NON-STATUTORY</font><font lang=EN-US> STOCK OPTION AGREEMENT</font></h1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; MARGIN:0cm'><b><font lang=EN-US>Optionee Name:</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; MARGIN:0cm'><b><font lang=EN-US>No. of Option Shares: </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; MARGIN:0cm'><b><font lang=EN-US>Issue Date:&nbsp; </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; MARGIN:0cm'><b><font lang=EN-US>Expiration Date: </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; MARGIN:0cm'><b><font lang=EN-US>Exercise Price: </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; MARGIN:0cm'><b><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>This Stock Option Agreement (the &#147;Agreement&#148;) is made and entered into effective as of the date set forth on the Signature Page attached hereto by and between Biomerica, Inc., a Delaware corporation (the &#147;Corporation&#148;), and that person identified on the Signature Page below and attached hereto (the &#147;Optionee&#148;).&nbsp; This option is not intended to qualify and will not be treated as an &#147;incentive stock option&#148; with the meaning of Section 422 of the Internal Revenue Code (the &#147;Code.&#148;)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>The grant hereunder is in connection with and in furtherance of the Corporation&#146;s compensatory benefit plan for participation of the Corporation&#146;s employees. This Agreement and the stock option granted hereunder are subject to the terms and conditions found in the Biomerica, Inc. 2020 Stock Incentive Plan (the &#147;Plan&#148;). All defined terms not explicitly defined in this Agreement but defined in the Plan shall have the same definitions as in the Plan.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Grant of Option</u>.&nbsp; Subject to the vesting provisions of Section 3 and/or as set forth on the Signature Page attached hereto, the Corporation hereby grants to Optionee, as of the date hereof the right and option to purchase, on the terms and conditions hereinafter set forth, all or any part of the aggregate number of shares of Common Stock set forth on the Signature Page attached hereto (the &#147;Option&#148;), subject to adjustment in accordance with the provisions of The Plan and Section 18 below. It is understood and acknowledged that the Option is designated as a Nonstatutory Stock Option which will not qualify as an Incentive Stock Option under Section 422 of the Code.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Exercise Price</u>.&nbsp; The price to be paid for the shares of Common Stock to be issued upon exercise of the Option or any part thereof shall be as set forth on the Signature Page below (the &#147;Exercise Price.&#148;)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Right to Exercise</u>.&nbsp; The option shall vest 25% on <a name=_Hlk80692899><i>[DATE &#150; one year anniversary]</i></a><i>,</i> 25% on <i>[DATE &#150; two year anniversary]</i>, 25% on <i>[DATE &#150; three year anniversary]</i> and 25% on <i>[DATE &#150; four year anniversary]</i>. Subject to the provisions of the 2020 Stock Incentive Plan, and the terms of this Agreement, all vested options shall be exercisable in full or in part at any time until <i>[DATE &#150; ten year anniversary]</i>.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Securities Law Requirements</u>.&nbsp; <b>No part of the Option shall be exercised if counsel to the Corporation determines that any applicable registration requirement under the Securities Act of 1933, as amended (the &#147;1933 Act&#148;), or any other applicable requirement of </b>from grant date</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>1</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Term of Option</u>.&nbsp; The Option shall terminate in any event on the earliest of (a) the date set forth on the Signature Page, (b) the expiration of the period described in Section 6 below, or (c) the expiration of the period described in Section 7 below. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Exercise Following Termination of Employment, Except By Death, Disability or for Cause</u>.&nbsp; If the Optionee&#146;s employment at the company is terminated for reasons other than by death, disability or for Cause, all vested Options shall remain exercisable for a period of 90 days following termination of employment. If the Optionee&#146;s employment with the company is terminated for Cause, the Options shall remain exercisable for 7 days. &nbsp;&nbsp;&nbsp;For this purpose, &#147;Cause&#148; shall mean conviction of a felony, misappropriation of assets of the Corporation or any subsidiary, gross negligence in carrying out the duties of a Member and acts of malfeasance toward the Company. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Exercise Following Death</u>.&nbsp; If the Optionee&#146;s service with the Corporation terminates by reason of the Optionee&#146;s death or disability, or if the Optionee dies after termination of service but while the Option would have been exercisable hereunder, the vested portion of the Option (to the extent it has not previously been exercised and is then exercisable) may be exercised within twelve (12) months after the date of Optionee&#146;s death or disability (but not later than the Expiration date set forth on the signature page below). &nbsp;&nbsp;The exercise may be made by the disabled Optionee, or by the Optionee&#146;s representative or by the person entitled thereto under Optionee&#146;s will or the laws of descent and distribution; provided that such representative or such person consents in writing to abide by and be subject to the terms of this Agreement and such writing is delivered to the President of the Corporation.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Nontransferability</u>.&nbsp; Unless the Corporation otherwise consents in writing, the &nbsp;Option and all rights and privileges granted hereunder shall be non-assignable and non-transferable by the Optionee, either voluntarily or by operation of law, except by will, by operation of the laws of descent and distribution, by instrument to an inter vivos or testamentary trust in which the Option is to be passed to beneficiaries upon the death of the trustor, or by gift to the Optionee&#146;s immediate family, shall not be pledged or hypothecated in any way, and shall be exercisable during lifetime only by the Optionee.&nbsp; Except as otherwise provided herein, any attempted alienation, assignment, pledge, hypothecation, attachment, execution or similar process, whether voluntary or involuntary, with respect to all or any part of the Option or any right thereunder, shall be null and void and, at the Corporation&#146;s option, shall cause all of Optionee&#146;s rights under this Agreement to terminate.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Effect of Exercise</u>.&nbsp; Upon exercise of all or any part of the Option, the number of shares of Common Stock subject to option under this Agreement shall be reduced by the number of shares with respect to which such exercise is made.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Partial Exercise</u>.&nbsp; Any exercisable portion of the Option or the entire Option, if then wholly vested and exercisable, may be exercised in whole or in part at any time prior to the time when the Option or portion thereof becomes unexercisable under Section 5; provided, however, that each partial exercise shall be for not less than one hundred (100) shares and shall be for whole shares only.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Method of Exercise</u>.&nbsp; Each exercise of the Option shall be by means of a written notice of exercise in substantially the form attached as Exhibit A delivered to the Secretary of the Corporation at its principal office and accompanied by payment in full of the Exercise Price for each share of Common Stock purchased under the Option.&nbsp; Such notice shall specify the number of shares of Common Stock with respect to which the Option is exercised and shall be signed by the person exercising the Option.&nbsp; If the Option is exercised by a person other than the Optionee, such notice shall be accompanied by proof, reasonably satisfactory to the Corporation, of such person&#146;s right to exercise the Option. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>2</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>The Exercise Price specified in Section 2 above shall be paid in full upon the exercise of the Option (i) by cash, in United States dollars.&nbsp; The Board of Directors may, but is not obligated to, accept a secured recourse promissory note of Optionee (bearing such rate of interest and such other terms as they may reasonably determine) as payment of the Exercise Price; <u>provided</u>, <u>however</u>, no stock certificate representing the shares be released until the note shall have been paid in full.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Withholding Taxes</u>.&nbsp; If the Optionee is an employee or former employee of the Corporation when all or part of the Option is exercised, the Corporation may require the Optionee to deliver payment of any withholding taxes (in addition to the Exercise Price) in cash with respect to the difference between the Exercise Price and the Fair Market Value of the Common Stock acquired upon exercise.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Issuance of Shares</u>.&nbsp; Subject to the foregoing conditions, the Corporation, as soon as reasonably practicable after receipt of a proper notice of exercise and without transfer or issue tax or other incidental expense to the person exercising the Option, shall deliver to such person at the principal office of the Corporation, or such other location as may be acceptable to the Corporation and such person, one or more certificates for the shares of Common Stock with respect to which the Option has been exercised.&nbsp; Such shares shall be fully paid and nonassessable and shall be issued in the name of such person.&nbsp; However, at the request of the Optionee, such shares may be issued in the names of the Optionee and his or her spouse (a) as joint tenants with right of survivorship, (b) as community property or (c) as tenants in common without right of survivorship.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Limitation of Optionee&#146;s Rights</u>.&nbsp; Neither Optionee nor any person entitled to exercise the Option shall be or have any of the rights of a shareholder of the Corporation in respect of any share issuable upon the exercise of the Option unless and until a certificate or certificates representing shares of Common Stock shall have been issued and delivered upon exercise of the Option in full or in part.&nbsp; No adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificates are issued.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>15.&nbsp; <u>Consent Required to Transfer</u>.&nbsp; In connection with any underwritten public offering by the Corporation of its equity securities pursuant to an effective registration statement filed under the 1933 Act, Optionee shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to, any shares of Common Stock purchased under the Option without the prior written consent of the Corporation or its underwriters.&nbsp; Such limitations shall be in effect for such period of time from and after the effective date of such registration statement as may be requested by the Corporation or such underwriters.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>3</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Recapitalizations</u>.&nbsp; Subject to the provision of the Plan, if the outstanding shares of the class then subject to this Option are adjusted for any increase or decrease in the number of issued shares of Common Stock resulting from a subdivision or consolidation of Common Stock or the payment of a stock dividend (but only of Common Stock) or any other increase or decrease in the number of issued shares of Common Stock effected without receipt of consideration by the Corporation for the issuance of such shares, appropriate adjustments shall be made in the number and /or kind of shares or securities for which the unexercised portions of this Option may thereafter be exercised, all without any change in the aggregated Exercise Price applicable to the unexercised portions of this Option, but with a corresponding adjustment in the Exercise Price per share and/or an adjustment in the number of shares available under this Option agreement.&nbsp; Subject to the provisions of the Plan, if the Corporation is the surviving corporation in any merger or consolidation, this Option shall pertain and apply to the securities to which a holder of the number of Common Stock subject to the Option would have been entitled.&nbsp; In the event of a merger or consolidation in which the Corporation is not the surviving corporation, the date of exercisability of this Option shall be accelerated to a date prior to such merger or consolidation, unless, in order to qualify for &#147;pooling-of-interest&#148; treatment, the agreement of merger or consolidation provides for the assumption of the Option by the successor to the Corporation.&nbsp; To the extent that the foregoing adjustments relate to securities of the Corporation, such adjustments shall be made by the Board, whose determination shall be conclusive and binding on all persons.&nbsp; Except as expressly provided in this Section 16, the Optionee shall have no rights by reason of subdivision or consolidation of shares of Common Stock of any class, the payment of any Common Stock dividend or any other increase or decrease in the number of shares of Common Stock of any class or by reason of any dissolution, liquidation, merger or consolidation or spin-off of assets or common stock of another corporation, and any issue by the Corporation of shares of Common Stock of any class, or securities convertible into shares of Common Stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the Exercise Price or the number or Common Stock subject to this Option.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Restricted Stock Provisions</u>.&nbsp; In addition to certain Federal and state securities laws<u> </u>restrictions, the shares of Common Stock issued on exercise of this Option shall upon issuance be subject to the following restrictions (and, as used herein, &#147;restricted stock&#148; means shares issued on exercise of this Option which are still subject to the restrictions imposed under this Section that have not yet expired or terminated):</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:72pt'><font lang=EN-US>(a)&nbsp; Such shares of restricted stock may not be sold or otherwise transferred or hypothecated;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:72pt'><font lang=EN-US>(b)&nbsp; The restrictions imposed under Section 17 shall apply as well to all shares or other securities issued in respect of restricted stock in connection with any stock split, reverse stock split, stock dividend, recapitalization, reclassification, spin-off, split-off merger, consolidation or reorganization, but such restrictions imposed under Section 17 shall expire or terminate on the earliest to occur of the following:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:108pt'><font lang=EN-US>(i) The ninetieth (90th) day after the date on which shares of the same class of Common Stock as such restricted stock first become registered pursuant to the Exchange Act (which term for this purpose has the same meaning as set forth in the Plan);</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:108pt'><font lang=EN-US>(ii) The fifth (5th) anniversary of the date of grant hereof; or</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>4</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:108pt'><font lang=EN-US>(iii) The occurrence of any event or transaction upon which this Option terminated by reason of the provisions of Section 19 hereof.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:72pt'><font lang=EN-US>(c) <b>Unless the shares to be acquired by the Optionee have been registered under the 1933 Act and any other applicable securities laws of any state</b>, all certificates representing shares of Common Stock purchased upon the exercise of the Option shall bear the following legends:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 36pt 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 36pt 0pt'><b><font lang=EN-US>&#147;THE SALE OF THE SECURITIES REPRESENTED HEREBY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &#147;ACT&#148;).&nbsp; ANY TRANSFER OF SUCH SECURITIES WILL BE INVALID UNLESS A REGISTRATION STATEMENT UNDER THE ACT IS IN EFFECT AS TO SUCH TRANSFER OR IN THE OPINION OF COUNSEL FOR THE ISSUER SUCH REGISTRATION IS UNNECESSARY IN ORDER FOR SUCH TRANSFER TO COMPLY WITH THE ACT.&#148;</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Stock Incentive Plan</u>.&nbsp; This Agreement is subject to, and the Corporation and the Optionee agree to be bound by, all of the terms and conditions of the Plan under which this Option was granted, as the same shall have been amended from time to time in accordance with the terms thereof, provided that no such amendment shall deprive the Optionee, without his or her consent, of this Option or any of his or her rights hereunder.&nbsp; Pursuant to said Plan, the Board of Directors of the Corporation or its Committee established for such purposes is vested with final authority to interpret and construe the Plan and this Option, and is authorized to adopt rules and regulations for carrying out the Plan.&nbsp; A copy of the Plan in its present form is available for inspection during business hours by the Optionee or other persons entitled to exercise this Option at the Corporation&#146;s principal office.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Notices</u>.&nbsp; Any notice to the Corporation contemplated by this Agreement shall be addressed to it in care of its CEO; any notice to the Optionee shall be addressed to him or her at the address on file with the Corporation on the date hereof or at such other address as Optionee may hereafter designate in a writing delivered to the Corporation as provided herein.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Interpretation</u>.&nbsp; The interpretation, construction, performance and enforcement of this Agreement shall lie within the sole discretion of the Board, and the Board&#146;s determinations shall be conclusive and binding on all interested persons.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Governing Law</u>.&nbsp; This Agreement has been made, executed and delivered in, and the interpretation, performance and enforcement hereof shall be governed by and construed under the laws of the State of California.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><u><font lang=EN-US></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Information to Optionee</u>.&nbsp; The Corporation hereby agrees to provide the Optionee with the Corporation&#146;s audited annual financial statements.</font></p></div><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line' lang=EN-US><br clear=all style=PAGE-BREAK-BEFORE:always></font> <div style=page:WordSection2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>5</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>SIGNATURE PAGE</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>NON-STATUTORY STOCK OPTION AGREEMENT</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>PURSUANT TO</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>BIOMERICA, INC.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>2020 STOCK INCENTIVE PLAN</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 0cm 6pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 0cm 6pt'><font lang=EN-US>Date of Grant: <i>[DATE]</i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 0cm 6pt'><font lang=EN-US>Exercise Price<i>:&nbsp; [Price]</i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 0cm 6pt'><font lang=EN-US>Shares Vesting:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt'><i><font lang=EN-US>[Number - 25% of issued options] on [DATE &#150; one year anniversary <a name=_Hlk80693274>from grant date</a>]</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt'><i><font lang=EN-US>[Number - 25% of issued options] on [DATE &#150; one year anniversary from grant date]</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt'><i><font lang=EN-US>[Number - 25% of issued options] on [DATE &#150; one year anniversary from grant date]</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 18pt'><i><font lang=EN-US>[Number - 25% of issued options] on [DATE &#150; one year anniversary from grant date]</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>Total number of shares: <i>[Number]</i> shares</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm 0cm 6pt'><font lang=EN-US>Expiration Date: <i>[DATE &#150; ten year anniversary from grant date]</i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>I have reviewed this Non-Statutory Stock Option Agreement, which was adopted for use in connection with the 2020 Stock Incentive Plan.&nbsp; I have also received and reviewed a copy of the 2020 Stock Incentive Plan.&nbsp; As Optionee, I hereby acknowledge that as of the date of grant of this Option, it sets forth the entire understanding between the undersigned Optionee and the Corporation and its Affiliates regarding the acquisition of stock in the Corporation and supersedes all prior oral and written agreements on that subject with the exception of any other option awards previously granted and delivered in writing to the undersigned Optionee under the stock incentive plans of the Corporation.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>IN WITNESS WHEREOF, this Non-Statutory Stock Option Agreement has been delivered, adopted and accepted in full by the Parties hereto.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>Date: &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; By: _______________________________</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:216pt'><font style=COLOR:red lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <i>&nbsp;</i></font><i><font lang=EN-US>[Officer Name]</font></i><font lang=EN-US>, &#147;Optionee&#148;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:216pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>The Corporation hereby agrees to all the terms of the Agreement.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>Biomerica, Inc.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>By:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allen Barbieri, Secretary</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>By:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zackary Irani, Chief Executive Officer</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; LAYOUT-GRID-MODE:line; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>6</font></p></div></body>
<!-- EDGAR Validation Code: B53D14E7 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>exhibit21_1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<head> <title>Exhibit 21.1 </title></head> <body style=WORD-WRAP:break-word lang=EN-GB> <div style=page:WordSection1> <table width=100% style="WIDTH:100%; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; TEXT-ALIGN:right; MARGIN:0cm; LINE-HEIGHT:normal' align=right><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black' lang=EN-IN>EXHIBIT 21.1</font></b></p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=907 colspan=3 nowrap style="HEIGHT:12.75pt; WIDTH:680pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; TEXT-ALIGN:center; MARGIN:0cm; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black' lang=EN-IN>LIST OF SUBSIDIARIES</font></b></p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:13.5pt> <td width=436 nowrap style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:327pt; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black' lang=EN-IN>NAME OF SUBSIDIARY</font></p></td> <td width=35 nowrap style="HEIGHT:13.5pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:327pt; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black' lang=EN-IN>COUNTRY OF INCORPORATION</font></p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black' lang=EN-IN>BioEurope GmbH</font></p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black' lang=EN-IN>Germany</font></p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black' lang=EN-IN>Biomerica de Mexico</font></p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black' lang=EN-IN>Mexico</font></p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; BACKGROUND:white; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:12.75pt> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom /> <td width=35 nowrap style="HEIGHT:12.75pt; WIDTH:26pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom /> <td width=436 nowrap style="HEIGHT:12.75pt; WIDTH:327pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom /></tr></table> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri",sans-serif; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:115%'>&nbsp;</p></div></body>
<!-- EDGAR Validation Code: 5E3A5320 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit23_1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<head> <title>Exhibit 23.1</title></head> <body> <div style="page:WordSection1"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">EXHIBIT 23.1</font></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><b><font style="FONT-SIZE:10pt; COLOR:black">CONSENT OF INDEPENDENT</font></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><b><font style="FONT-SIZE:10pt; COLOR:black">REGISTERED PUBLIC ACCOUNTING FIRM</font></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. and Subsidiaries</font></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Irvine, California</font></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">We hereby consent to the incorporation by reference in, the previously
filed Registration Statements on Form S-8 (Nos. 333-179443, 333-204410, 333-224836 and 333-256377) and Form S-3 (No. 333-239980) of
Biomerica, Inc. and Subsidiaries, of our report dated August 27, 2021,
relating to the consolidated financial statements as of May 31, 2021 and 2020 and for the years ended May 31,  2021 and 2020, which appears in
this Form 10-K. </font></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt">&nbsp;</p> <table style="WIDTH:166pt; BORDER-COLLAPSE:collapse" width="221" cellspacing="0" cellpadding="0" bordercolor="transparent"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:166pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" width="221" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt" lang="DE">/s/ PKF San Diego, LLP</font></p></td></tr> <tr style="HEIGHT:9.4pt"> <td style="HEIGHT:9.4pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt" lang="DE">PKF San Diego, LLP<br>(formerly PKF, LLP)</font></p></td></tr> <tr style="HEIGHT:9.9pt"> <td style="HEIGHT:9.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="HEIGHT:30pt"> <td style="HEIGHT:30pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">San Diego, CA</font></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">August 27, 2021</font></p></td></tr></table> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt">&nbsp;</p></div></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exhibit31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<head> <title>Exhibit 31.1</title></head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="left"><b>EXHIBIT 31.1</b></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER <br>PURSUANT TO</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">18 U.S.C. SECTION 1350,</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">AS ADOPTED PURSUANT TO</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">I, Zackary S. Irani, certify that:</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">1. I have reviewed this Annual Report on Form 10-K of Biomerica, Inc.;</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">2.
 Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">3.
 Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects, the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">4.
 The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">a)
 designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this
report is being prepared;</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">b)
 designed such internal control over financial reporting, or caused such
 internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">c)
 evaluated the effectiveness of the registrant's disclosure controls and
 procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">d)
 disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth quarter in the case
of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over
financial reporting; and</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px">5.
 The registrant's other certifying officer and I have disclosed, based
on our most recent evaluation of our internal control over financial
reporting, to the registrant's auditors and the audit committee of the
registrant's board of directors (or other persons performing the
equivalent functions):</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">a)
 all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information; and</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">b)
 any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control over financial reporting.</p> <p style="MARGIN:0px">&nbsp;</p> <table style="WIDTH:210.75pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" width="281" cellspacing="0" cellpadding="0" bordercolor="transparent"> <tr style="HEIGHT:22pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black"></font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="BORDER-TOP:0px; HEIGHT:14.75pt; BORDER-RIGHT:0px; WIDTH:210.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">/s/ Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">Chief Executive Officer</font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">Date: August 27, 2021</font></p></td></tr></table> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px">&nbsp;</p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exhibit31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<head><title>Exhibit 31.2</title> </head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="left"><font style="FONT-SIZE:9pt"><b>EXHIBIT 31.2</b></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt"><b>CERTIFICATION OF CHIEF FINANCIAL OFFICER<br> PURSUANT TO</font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt">18 U.S.C. SECTION 1350,</font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt">AS ADOPTED PURSUANT TO</font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><font style="FONT-SIZE:9pt">I, Steve Sloan, certify that:</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><font style="FONT-SIZE:9pt">1. I have reviewed this Annual Report on Form 10-K of Biomerica, Inc.;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">2.
 Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">3.
 Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects, the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">4.
 The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)
 designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this
report is being prepared;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)
 designed such internal control over financial reporting, or caused such
 internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)
 evaluated the effectiveness of the registrant's disclosure controls and
 procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)
 disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth quarter in the case
of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over
financial reporting; and</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">5.
 The registrant's other certifying officer and I have disclosed, based
on our most recent evaluation of our internal control over financial
reporting, to the registrant's auditors and the audit committee of the
registrant's board of directors (or other persons performing the
equivalent functions):</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)
 all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information; and</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)
 any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control over financial reporting.</font></p> <p style="MARGIN:0px">&nbsp;</p> <table style="WIDTH:179pt; BORDER-COLLAPSE:collapse" width="239" cellspacing="0" cellpadding="0" bordercolor="transparent"><tr style="HEIGHT:15pt"> <td style="HEIGHT:22pt; WIDTH:179pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" width="239"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;"></font></font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">/s/ Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Chief Financial Officer</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Date: August 27, 2021</font></p></td></tr></table> <p style="MARGIN:0px"><br><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exhibit32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<head> <title>Exhibit 32.1</title></head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><b>EXHIBIT 32.1</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER<br> PURSUANT TO</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">18 U.S.C. SECTION 1350,</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">AS ADOPTED PURSUANT TO</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify;MARGIN:0px">In
 connection with the Annual Report of Biomerica, Inc. (the "Company")
 on Form 10-K for the year ended May 31, 2021, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
 Zackary Irani, Chief Executive Officer of the Company, certify, to the
best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18
U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes
Oxley Act of 2002,</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">i. &nbsp;&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">ii. &nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The
 information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company.</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p> <table style="WIDTH:167pt; BORDER-COLLAPSE:collapse" width="223" cellspacing="0" cellpadding="0" bordercolor="transparent"><tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:167pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" width="223"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">/s/ Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Chief Executive Officer</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Date: August 27, 2021</font></p></td></tr></table> <p style="MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p> <p style="MARGIN:0px"><br><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>exhibit32_2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<head> <title>Exhibit 32.2</title></head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><b>EXHIBIT 32.2</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>CERTIFICATION OF CHIEF FINANCIAL OFFICER<br> PURSUANT TO</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">18 U.S.C. SECTION 1350</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">AS ADOPTED PURSUANT TO</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify;MARGIN:0px">In
 connection with the Annual Report of Biomerica, Inc. (the "Company")
 on Form 10-K for the year ended May 31, 2021, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
 Steve Sloan, Chief Financial Officer of the Company, certify, to the
best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18
U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes
Oxley Act of 2002,</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">i. &nbsp;&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">ii. &nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The
 information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company.</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p>  <table style="WIDTH:179pt; BORDER-COLLAPSE:collapse" width="239" cellspacing="0" cellpadding="0" bordercolor="transparent"><tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:179pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" width="239" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">/s/ Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Chief Financial Officer</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Date: August 27, 2021</font></p></td></tr></table><p style="MARGIN:0px"><br></p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px"><br></p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px"><br><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>bmra-20210531.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 27 21:08:32 UTC 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:compsci="http://compsciresources.com" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:bmra="http://www.biomerica.com/20210531" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="bmra-20210531.xsd"/>
  <context id="c0_From1Jun2020To31May2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf27Aug2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2021-08-27</instant>
    </period>
  </context>
  <context id="c2_AsOf30Nov2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2020-11-30</instant>
    </period>
  </context>
  <context id="c3_AsOf31May2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c4_AsOf31May2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c5_AsOf31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c6_AsOf31May2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31May2021_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31May2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c9_From1Jun2019To31May2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c10_AsOf31May2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c11_AsOf31May2019_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c12_AsOf31May2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c13_AsOf31May2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c14_AsOf31May2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c15_AsOf31May2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c16_From1Jun2019To31May2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c17_From1Jun2019To31May2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c18_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c19_From1Jun2019To31May2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c20_From1Jun2019To31May2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c21_AsOf31May2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c22_AsOf31May2020_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c23_AsOf31May2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31May2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c25_AsOf31May2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c26_From1Jun2020To31May2021_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c27_From1Jun2020To31May2021_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c28_From1Jun2020To31May2021_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c29_From1Jun2020To31May2021_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c30_From1Jun2020To31May2021_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c31_AsOf31May2021_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c32_AsOf31May2021_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c33_AsOf31May2021_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c34_AsOf31May2021_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c35_AsOf31May2021_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c36_AsOf22Jan2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2021-01-22</instant>
    </period>
  </context>
  <context id="c37_AsOf31May2021_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c38_AsOf31May2021_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c39_From1Jun2020To31May2021_ATMAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c40_From1Jun2020To31May2021_SalesRevenueNetMember_CustomerConcentrationRiskMember_TwoDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c41_From1Jun2019To31May2020_SalesRevenueNetMember_CustomerConcentrationRiskMember_ThreeDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:ThreeDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c42_From1Jun2020To31May2021_SalesRevenueNetMember_CustomerConcentrationRiskMember_OneDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c43_From1Jun2019To31May2020_SalesRevenueNetMember_CustomerConcentrationRiskMember_OneDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c44_From1Jun2020To31May2021_AccountsReceivableMember_CustomerConcentrationRiskMember_TwoDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c45_From1Jun2019To31May2020_AccountsReceivableMember_CustomerConcentrationRiskMember_ThreeDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:ThreeDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c46_From1Jun2020To31May2021_AccountsReceivableMember_CustomerConcentrationRiskMember_DistributorsInChinaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:DistributorsInChinaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c47_From1Jun2020To31May2021_CostOfGoodsProductLineMember_SupplierConcentrationRiskMember_OneVendorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c48_From1Jun2019To31May2020_CostOfGoodsProductLineMember_SupplierConcentrationRiskMember_OneVendorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c49_AsOf31May2021_MX">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c50_AsOf31May2020_MX">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c51_From1Jun2020To31May2021_AccountsReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c52_From1Jun2020To31May2021_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c53_From1Jun2020To31May2021_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c54_From1Jun2020To31May2021_DistributionRightsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c55_From1Jun2020To31May2021_PurchasedTechnologyRightsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmra:PurchasedTechnologyRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c56_From1Jun2020To31May2021_PatentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c57_AsOf31May2021_AccountingStandardsUpdate201602Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c58_AsOf31May2021_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c59_From1Jun2019To31May2020_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c60_From1Jun2019To31May2020_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c61_From1Jun2020To31May2021_ClinicalLabMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c62_From1Jun2019To31May2020_ClinicalLabMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c63_From1Jun2020To31May2021_PhysiciansOfficeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c64_From1Jun2019To31May2020_PhysiciansOfficeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c65_From1Jun2020To31May2021_OverthecounterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c66_From1Jun2019To31May2020_OverthecounterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c67_From1Jun2020To31May2021_ContractManufacturingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c68_From1Jun2019To31May2020_ContractManufacturingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c69_From1Jun2020To31May2021_LabSuppliesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:LabSuppliesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c70_From1Jun2020To31May2021_AccountsPayableMember_CustomerConcentrationRiskMember_OneVendorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c71_From1Jun2019To31May2020_AccountsPayableMember_CustomerConcentrationRiskMember_TwoVendorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoVendorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c72_AsOf24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-02-24</instant>
    </period>
  </context>
  <context id="c73_AsOf31Aug2010_EmployeeStockOptionMember_A2010PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2010PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-08-31</instant>
    </period>
  </context>
  <context id="c74_From31Aug2010To31Aug2010_EmployeeStockOptionMember_A2010PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2010PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-08-31</startDate>
      <endDate>2010-08-31</endDate>
    </period>
  </context>
  <context id="c75_AsOf31Dec2014_EmployeeStockOptionMember_A2014PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2014PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c76_From31Dec2014To31Dec2014_EmployeeStockOptionMember_A2014PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2014PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-12-31</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="c77_AsOf31Dec2017_EmployeeStockOptionMember_A2017PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2017PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c78_From31Dec2017To31Dec2017_EmployeeStockOptionMember_A2017PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2017PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-31</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="c79_AsOf29Feb2020_EmployeeStockOptionMember_A2020PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2020PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-02-29</instant>
    </period>
  </context>
  <context id="c80_From1Jun2020To31May2021_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c81_From1Jun2020To31May2021_EmployeeStockOptionMember_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c82_From1Jun2020To31May2021_EmployeeStockOptionMember_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c83_From1Jun2020To31May2021_EmployeeStockOptionMember_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c84_From1Jun2020To31May2021_EmployeeStockOptionMember_CostOfSalesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c85_From1Jun2019To31May2020_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c86_From1Jun2019To31May2020_EmployeeStockOptionMember_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c87_From1Jun2019To31May2020_EmployeeStockOptionMember_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c88_From1Jun2019To31May2020_EmployeeStockOptionMember_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c89_From1Jun2019To31May2020_EmployeeStockOptionMember_CostOfSalesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c90_AsOf31May2021_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c91_AsOf31May2020_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c92_From1Jun2019To31May2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c93_From1Jun2019To31May2020_MinimumMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c94_From1Jun2019To31May2020_MaximumMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c95_From1Dec2017To1Dec2017_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-01</startDate>
      <endDate>2017-12-01</endDate>
    </period>
  </context>
  <context id="c96_AsOf1Dec2017_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-01</instant>
    </period>
  </context>
  <context id="c97_From1Dec2017To19Mar2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-01</startDate>
      <endDate>2020-03-19</endDate>
    </period>
  </context>
  <context id="c98_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c99_From20Mar2020To20Mar2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember_RegistrationRightsAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">bmra:RegistrationRightsAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-20</startDate>
      <endDate>2020-03-20</endDate>
    </period>
  </context>
  <context id="c100_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember_RegistrationRightsAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">bmra:RegistrationRightsAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c101_AsOf31May2020_MinimumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c102_AsOf31May2020_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c103_AsOf11Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-02-11</instant>
    </period>
  </context>
  <context id="c104_From1Jun2019To31May2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c105_From1Jun2020To31May2021_EmployeeStockOptionMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c106_From1Jun2020To31May2021_MinimumMember_EmployeeStockOptionMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c107_From1Jun2020To31May2021_MaximumMember_EmployeeStockOptionMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c108_From22Jan2021To22Jan2021_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember_RegistrationRightsAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">bmra:RegistrationRightsAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-22</startDate>
      <endDate>2021-01-22</endDate>
    </period>
  </context>
  <context id="c109_AsOf21May2021_EmployeeStockOptionMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-21</instant>
    </period>
  </context>
  <context id="c110_From1Jun2020To31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c111_From1Jun2020To31May2021_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c112_AsOf31May2021_MinimumMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c113_AsOf31May2021_MaximumMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c114_From24Feb2020To24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-02-24</startDate>
      <endDate>2020-02-24</endDate>
    </period>
  </context>
  <context id="c115_AsOf24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-02-24</instant>
    </period>
  </context>
  <context id="c116_From1Jun2020To31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c117_From24Feb2020To24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-02-24</startDate>
      <endDate>2020-02-24</endDate>
    </period>
  </context>
  <context id="c118_From21Jul2020To21Jul2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-21</startDate>
      <endDate>2020-07-21</endDate>
    </period>
  </context>
  <context id="c119_From21Jan2021To21Jan2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-21</startDate>
      <endDate>2021-01-21</endDate>
    </period>
  </context>
  <context id="c120_AsOf31May2019_ExercisePriceRangePerShare082390Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082390Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c121_From1Jun2019To31May2020_ExercisePriceRangePerShare268818Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare268818Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c122_From1Jun2019To31May2020_ExercisePriceRangePerShare082390Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082390Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c123_From1Jun2019To31May2020_ExercisePriceRangePerShare085818Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare085818Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c124_AsOf31May2020_ExercisePriceRangePerShare082818Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082818Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c125_From1Jun2020To31May2021_ExercisePriceRangePerShare514870Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare514870Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c126_From1Jun2020To31May2021_ExercisePriceRangePerShare082362Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082362Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c127_From1Jun2020To31May2021_ExercisePriceRangePerShare235818Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare235818Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c128_AsOf31May2021_ExercisePriceRangePerShare082870Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082870Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c129_AsOf31May2021_MinimumMember_ExercisePriceRangePerShare082870Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082870Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c130_AsOf31May2021_MaximumMember_ExercisePriceRangePerShare082870Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082870Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c131_From1Jun2020To31May2021_RangeOfExercisePrice082104Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice082104Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c132_AsOf31May2021_RangeOfExercisePrice082104Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice082104Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c133_From1Jun2020To31May2021_RangeOfExercisePrice120281Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice120281Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c134_AsOf31May2021_RangeOfExercisePrice120281Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice120281Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c135_From1Jun2020To31May2021_RangeOfExercisePrice362870Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice362870Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c136_AsOf31May2021_RangeOfExercisePrice362870Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice362870Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c137_From1Jun2019To31May2020_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c138_AsOf31May2021_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c139_AsOf31May2021_CaliforniaStateIncomeTaxMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bmra:CaliforniaStateIncomeTaxMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c140_AsOf31May2021_DomesticCountryMember_ResearchMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c141_AsOf31May2021_StateAndLocalJurisdictionMember_ResearchMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c142_From1Jun2020To31May2021_EuropeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c143_From1Jun2020To31May2021_EuropeMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c144_From1Jun2019To31May2020_EuropeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c145_From1Jun2019To31May2020_EuropeMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c146_From1Jun2020To31May2021_AsiaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c147_From1Jun2020To31May2021_AsiaMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c148_From1Jun2019To31May2020_AsiaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c149_From1Jun2019To31May2020_AsiaMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c150_From1Jun2020To31May2021_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c151_From1Jun2020To31May2021_US_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c152_From1Jun2019To31May2020_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c153_From1Jun2019To31May2020_US_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c154_From1Jun2020To31May2021_SouthAmericaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c155_From1Jun2020To31May2021_SouthAmericaMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c156_From1Jun2019To31May2020_SouthAmericaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c157_From1Jun2019To31May2020_SouthAmericaMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c158_From1Jun2020To31May2021_MiddleEastMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c159_From1Jun2020To31May2021_MiddleEastMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c160_From1Jun2019To31May2020_MiddleEastMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c161_From1Jun2019To31May2020_MiddleEastMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c162_From1Jun2020To31May2021_OtherMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:OtherMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c163_From1Jun2020To31May2021_OtherMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:OtherMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c164_From1Jun2019To31May2020_OtherMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:OtherMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c165_From1Jun2019To31May2020_OtherMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:OtherMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c166_From1Jun2020To31May2021_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c167_From1Jun2019To31May2020_SalesRevenueSegmentMember_GeographicConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c168_From30Nov2015To30Nov2015_BuildingInIrvineCaliforniaMember_FirstAmendmentToLeaseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:FirstAmendmentToLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-30</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="c169_From1Jun2020To31May2021_BuildingInIrvineCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c170_From1Sep2021To1Sep2021_BuildingInIrvineCaliforniaMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-09-01</startDate>
      <endDate>2021-09-01</endDate>
    </period>
  </context>
  <context id="c171_AsOf1Sep2021_BuildingInIrvineCaliforniaMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-09-01</instant>
    </period>
  </context>
  <context id="c172_From30Nov2016To30Nov2016_MX_PropertyAvailableForOperatingLeaseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-30</startDate>
      <endDate>2016-11-30</endDate>
    </period>
  </context>
  <context id="c173_From1Jun2020To31May2021_MX">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c174_From1Jun2019To31May2020_MX">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c175_From1Jun2020To31May2021_RoyaltyAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c176_From1Jun2019To31May2020_RoyaltyAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c177_From1Jun2020To31May2021_SalesRevenueNetMember_RoyaltyAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c178_From1Jun2019To31May2020_SalesRevenueNetMember_RoyaltyAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c179_AsOf25May2016_TelconAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavKWZZQpVGPQgLzjYAjvzt1lMb3ldQptVWNNbJwjkia1PUcr18sUX/6/CBQxCu0zoFpf9ty/fXA1UJHl1DDNUMKOhjgQRktncUxc9RKHmOZ3h2pC3DDMRBD+L4CIpLjq8k=] CSR-->
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:TelconAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-05-25</instant>
    </period>
  </context>
  <context id="c180_From25May2016To25May2016_TelconAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:TelconAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-05-25</startDate>
      <endDate>2016-05-25</endDate>
    </period>
  </context>
  <context id="c181_From1Jun2019To31May2020_MountSinaiLicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:MountSinaiLicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c182_From1Jun2021To26Aug2021_MountSinaiLicenseAgreementsMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:MountSinaiLicenseAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-06-01</startDate>
      <endDate>2021-08-26</endDate>
    </period>
  </context>
  <context id="c183_From7May2020To7May2020_UCLicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UCLicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-07</startDate>
      <endDate>2020-05-07</endDate>
    </period>
  </context>
  <context id="c184_From1Jun2021To26Aug2021_UCLicenseAgreementsMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UCLicenseAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-06-01</startDate>
      <endDate>2021-08-26</endDate>
    </period>
  </context>
  <context id="c185_AsOf30Sep2017_UniversityOFSouthernCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="c186_From1Jun2019To31May2020_UniversityOFSouthernCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c187_From30Sep2017To30Sep2017_UniversityOFSouthernCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-09-30</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="c188_AsOf31May2021_UniversityOFSouthernCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFSouthernCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c189_AsOf30Nov2017_UniversityOFMichiganMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFMichiganMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-30</instant>
    </period>
  </context>
  <context id="c190_From1Jun2020To31May2021_UniversityOFMichiganMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFMichiganMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c191_From1Jun2019To31May2020_UniversityOFMichiganMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFMichiganMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c192_AsOf31May2021_UniversityOFMichiganMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFMichiganMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c193_AsOf31Jan2018_UniversityOFBethIsraelDeaconessMedicalCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFBethIsraelDeaconessMedicalCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-01-31</instant>
    </period>
  </context>
  <context id="c194_AsOf31May2021_UniversityOFBethIsraelDeaconessMedicalCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFBethIsraelDeaconessMedicalCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c195_From1Jun2020To31May2021_UniversityOFBethIsraelDeaconessMedicalCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFBethIsraelDeaconessMedicalCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c196_From1Jun2019To31May2020_UniversityOFBethIsraelDeaconessMedicalCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFBethIsraelDeaconessMedicalCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c197_AsOf12Jul2019_BiomericaHPStoolAntigenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaHPStoolAntigenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-12</instant>
    </period>
  </context>
  <context id="c198_From1Jun2020To31May2021_BiomericaHPStoolAntigenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaHPStoolAntigenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c199_From1Jun2019To31May2020_BiomericaHPStoolAntigenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaHPStoolAntigenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c200_AsOf22Jul2019_BiomericaInFoodsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInFoodsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-22</instant>
    </period>
  </context>
  <context id="c201_From1Jun2019To31May2020_BiomericaInFoodsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInFoodsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c202_From1Jun2020To31May2021_BiomericaInFoodsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInFoodsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c203_AsOf31May2021_BiomericaInFoodsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInFoodsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c204_AsOf25Sep2019_MedicalPracticeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MedicalPracticeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-25</instant>
    </period>
  </context>
  <context id="c205_From1Jun2020To31May2021_MedicalPracticeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MedicalPracticeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c206_From1Jun2019To31May2020_MedicalPracticeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MedicalPracticeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c207_AsOf31May2020_MedicalPracticeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MedicalPracticeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c208_AsOf25Sep2019_BiomericaHPyloriProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaHPyloriProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-25</instant>
    </period>
  </context>
  <context id="c209_From1Jun2019To31May2020_BiomericaHPyloriProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaHPyloriProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c210_AsOf31Dec2019_HousetonMethodistResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:HousetonMethodistResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c211_From1Jun2020To31May2021_HousetonMethodistResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:HousetonMethodistResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c212_From1Jun2019To31May2020_HousetonMethodistResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:HousetonMethodistResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c213_AsOf31May2021_HousetonMethodistResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:HousetonMethodistResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c214_AsOf31May2020_MayoClinicArizonaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicArizonaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c215_From1Jun2020To31May2021_MayoClinicArizonaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicArizonaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c216_From1Jun2019To31May2020_MayoClinicArizonaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicArizonaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c217_AsOf31May2021_MayoClinicArizonaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicArizonaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c218_AsOf28May2020_MayoClinicJacksonvilleMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicJacksonvilleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-28</instant>
    </period>
  </context>
  <context id="c219_AsOf31May2020_MayoClinicJacksonvilleMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicJacksonvilleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c220_From1Jun2020To31May2021_MayoClinicJacksonvilleMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicJacksonvilleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c221_AsOf25Jun2020_UniversityOfTexasHealthScienceCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOfTexasHealthScienceCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-25</instant>
    </period>
  </context>
  <context id="c222_From1Jun2020To31May2021_UniversityOfTexasHealthScienceCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOfTexasHealthScienceCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2021-05-31</endDate>
    </period>
  </context>
  <context id="c223_AsOf31May2021_UniversityOfTexasHealthScienceCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOfTexasHealthScienceCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-05-31</instant>
    </period>
  </context>
  <context id="c224_From1Jun2021To31Aug2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-06-01</startDate>
      <endDate>2021-08-31</endDate>
    </period>
  </context>
  <context id="c225_AsOf31Aug2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-08-31</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jun2020To31May2021">2021-05-31</dei:DocumentPeriodEndDate>
  <dei:EntityRegistrantName contextRef="c0_From1Jun2020To31May2021">BIOMERICA INC</dei:EntityRegistrantName>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c0_From1Jun2020To31May2021">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jun2020To31May2021">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jun2020To31May2021">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityFilerCategory contextRef="c0_From1Jun2020To31May2021">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness contextRef="c0_From1Jun2020To31May2021">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jun2020To31May2021">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityShellCompany contextRef="c0_From1Jun2020To31May2021">false</dei:EntityShellCompany>
  <dei:AmendmentFlag contextRef="c0_From1Jun2020To31May2021">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jun2020To31May2021">--05-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jun2020To31May2021">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jun2020To31May2021">2021</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="c0_From1Jun2020To31May2021">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jun2020To31May2021">0000073290</dei:EntityCentralIndexKey>
  <dei:EntityVoluntaryFilers contextRef="c0_From1Jun2020To31May2021">Yes</dei:EntityVoluntaryFilers>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf27Aug2021" decimals="INF">12510210</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat unitRef="usd" contextRef="c2_AsOf30Nov2020" decimals="0">66938974</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">4199311</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">8641027</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">1455051</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">1765871</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">837415</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">70981</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">3206255</us-gaap:InventoryNet>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">2850836</us-gaap:InventoryNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">370290</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">1509083</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">9230907</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">14766817</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">310520</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">279379</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">1972357</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">1867643</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">1553081</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">1711510</us-gaap:OperatingLeaseRightOfUseAsset>
  <bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">469077</bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
  <bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">231489</bmra:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
  <us-gaap:Investments unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">165324</us-gaap:Investments>
  <us-gaap:Investments unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">165324</us-gaap:Investments>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">294830</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">168655</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">126769</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">496124</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">264151</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">168193</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">11818813</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">17259878</us-gaap:Assets>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">583380</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">986711</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">388896</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">278627</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">327944</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">211809</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">1300220</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">1477147</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">1291570</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">1569678</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:Liabilities unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">2591790</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">3046825</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c3_AsOf31May2021" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c4_AsOf31May2020" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">25714</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c5_AsOf31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c6_AsOf31May2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">25714</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c5_AsOf31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c6_AsOf31May2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c5_AsOf31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">571429</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c6_AsOf31May2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">571429</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c5_AsOf31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c6_AsOf31May2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">321429</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c5_AsOf31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c6_AsOf31May2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">321429</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c7_AsOf31May2021_PreferredStockMember" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c8_AsOf31May2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:PreferredStockNoParValue unitRef="usdPershares" contextRef="c7_AsOf31May2021_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <us-gaap:PreferredStockNoParValue unitRef="usdPershares" contextRef="c8_AsOf31May2020_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c7_AsOf31May2021_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c8_AsOf31May2020_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c7_AsOf31May2021_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c8_AsOf31May2020_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <bmra:PreferredStockUndesignatedShares unitRef="shares" contextRef="c7_AsOf31May2021_PreferredStockMember" decimals="INF">4428571</bmra:PreferredStockUndesignatedShares>
  <bmra:PreferredStockUndesignatedShares unitRef="shares" contextRef="c8_AsOf31May2020_PreferredStockMember" decimals="INF">4428571</bmra:PreferredStockUndesignatedShares>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">984571</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">939205</us-gaap:CommonStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31May2021" decimals="INF">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c4_AsOf31May2020" decimals="INF">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31May2021" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c4_AsOf31May2020" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c3_AsOf31May2021" decimals="INF">12307157</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c4_AsOf31May2020" decimals="INF">11740089</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31May2021" decimals="INF">12307157</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c4_AsOf31May2020" decimals="INF">11740089</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">36685176</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">35213707</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">-47956</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">-39841</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">-28394768</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">-21925732</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">9227023</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">14213053</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">11818813</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">17259878</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:Revenues unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">7199027</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">6692711</us-gaap:Revenues>
  <us-gaap:CostOfRevenue unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">6702046</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">4910935</us-gaap:CostOfRevenue>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">496981</us-gaap:GrossProfit>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">1781776</us-gaap:GrossProfit>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">4608950</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">2274415</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">2410506</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">1910209</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">7019456</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">4184624</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-6522475</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-2402848</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterestAndDividend unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">66863</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:InvestmentIncomeInterestAndDividend unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">71193</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">367</us-gaap:InterestExpense>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">9</us-gaap:InterestExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">66496</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">71184</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-6455979</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-2331664</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">13057</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">7390</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-6469036</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-2339054</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasic unitRef="usdPershares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-0.54</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic unitRef="usdPershares" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-0.23</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted unitRef="usdPershares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-0.54</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted unitRef="usdPershares" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-0.23</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">11928941</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c9_From1Jun2019To31May2020" decimals="INF">10166296</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding unitRef="shares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">11928941</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding unitRef="shares" contextRef="c9_From1Jun2019To31May2020" decimals="INF">10166296</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-8115</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-3310</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-6477151</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-2342364</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c10_AsOf31May2019_CommonStockMember" decimals="INF">9677188</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c10_AsOf31May2019_CommonStockMember" decimals="INF">774173</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c11_AsOf31May2019_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c11_AsOf31May2019_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c12_AsOf31May2019_AdditionalPaidInCapitalMember" decimals="INF">22830006</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c13_AsOf31May2019_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-36531</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c14_AsOf31May2019_RetainedEarningsMember" decimals="INF">-19586678</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c15_AsOf31May2019" decimals="INF">3980970</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c16_From1Jun2019To31May2020_CommonStockMember" decimals="INF">137958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c16_From1Jun2019To31May2020_CommonStockMember" decimals="INF">11037</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c17_From1Jun2019To31May2020_AdditionalPaidInCapitalMember" decimals="INF">212497</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">223534</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c16_From1Jun2019To31May2020_CommonStockMember" decimals="INF">1674943</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c16_From1Jun2019To31May2020_CommonStockMember" decimals="INF">133995</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c17_From1Jun2019To31May2020_AdditionalPaidInCapitalMember" decimals="INF">10098862</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">10232857</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <bmra:StockIssuedDuringPeriodSharesPreferredStock unitRef="shares" contextRef="c18_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">571429</bmra:StockIssuedDuringPeriodSharesPreferredStock>
  <bmra:StockIssuedDuringPeriodValuePreferredStock unitRef="usd" contextRef="c18_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">45714</bmra:StockIssuedDuringPeriodValuePreferredStock>
  <bmra:StockIssuedDuringPeriodValuePreferredStock unitRef="usd" contextRef="c17_From1Jun2019To31May2020_AdditionalPaidInCapitalMember" decimals="INF">1871872</bmra:StockIssuedDuringPeriodValuePreferredStock>
  <bmra:StockIssuedDuringPeriodValuePreferredStock unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">1917586</bmra:StockIssuedDuringPeriodValuePreferredStock>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c19_From1Jun2019To31May2020_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-3310</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c16_From1Jun2019To31May2020_CommonStockMember" decimals="INF">250000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 unitRef="usd" contextRef="c16_From1Jun2019To31May2020_CommonStockMember" decimals="INF">20000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c18_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">-250000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 unitRef="usd" contextRef="c18_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">-20000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c17_From1Jun2019To31May2020_AdditionalPaidInCapitalMember" decimals="INF">200470</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">200470</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c20_From1Jun2019To31May2020_RetainedEarningsMember" decimals="INF">-2339054</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c21_AsOf31May2020_CommonStockMember" decimals="INF">11740089</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c21_AsOf31May2020_CommonStockMember" decimals="INF">939205</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c22_AsOf31May2020_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">321429</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c22_AsOf31May2020_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">25714</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c23_AsOf31May2020_AdditionalPaidInCapitalMember" decimals="INF">35213707</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c24_AsOf31May2020_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-39841</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c25_AsOf31May2020_RetainedEarningsMember" decimals="INF">-21925732</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c26_From1Jun2020To31May2021_CommonStockMember" decimals="INF">86750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c26_From1Jun2020To31May2021_CommonStockMember" decimals="INF">6940</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c27_From1Jun2020To31May2021_AdditionalPaidInCapitalMember" decimals="INF">95315</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">102255</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c26_From1Jun2020To31May2021_CommonStockMember" decimals="INF">158889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c26_From1Jun2020To31May2021_CommonStockMember" decimals="INF">12712</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c27_From1Jun2020To31May2021_AdditionalPaidInCapitalMember" decimals="INF">998763</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">1011475</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c28_From1Jun2020To31May2021_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-8115</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c26_From1Jun2020To31May2021_CommonStockMember" decimals="INF">321429</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 unitRef="usd" contextRef="c26_From1Jun2020To31May2021_CommonStockMember" decimals="INF">25714</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c29_From1Jun2020To31May2021_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">-321429</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 unitRef="usd" contextRef="c29_From1Jun2020To31May2021_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">-25714</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c27_From1Jun2020To31May2021_AdditionalPaidInCapitalMember" decimals="INF">377391</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">377391</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c30_From1Jun2020To31May2021_RetainedEarningsMember" decimals="INF">-6469036</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c31_AsOf31May2021_CommonStockMember" decimals="INF">12307157</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c31_AsOf31May2021_CommonStockMember" decimals="INF">984571</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c32_AsOf31May2021_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c32_AsOf31May2021_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c33_AsOf31May2021_AdditionalPaidInCapitalMember" decimals="INF">36685176</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c34_AsOf31May2021_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-47956</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c35_AsOf31May2021_RetainedEarningsMember" decimals="INF">-28394768</us-gaap:StockholdersEquity>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">138267</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">129172</us-gaap:DepreciationAndAmortization>
  <us-gaap:ProvisionForDoubtfulAccounts unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">766434</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ProvisionForDoubtfulAccounts unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-2129</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:InventoryLIFOReservePeriodCharge unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">1550594</us-gaap:InventoryLIFOReservePeriodCharge>
  <us-gaap:InventoryLIFOReservePeriodCharge unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">17714</us-gaap:InventoryLIFOReservePeriodCharge>
  <us-gaap:StockOptionPlanExpense unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">377391</us-gaap:StockOptionPlanExpense>
  <us-gaap:StockOptionPlanExpense unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">200470</us-gaap:StockOptionPlanExpense>
  <bmra:IncreaseDecreaseInDeferredRentLiability unitRef="usd" contextRef="c0_From1Jun2020To31May2021" xs:nil="true"/>
  <bmra:IncreaseDecreaseInDeferredRentLiability unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-37971</bmra:IncreaseDecreaseInDeferredRentLiability>
  <bmra:OperatingLeaseRightofUseAssetAmortization unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">237588</bmra:OperatingLeaseRightofUseAssetAmortization>
  <bmra:OperatingLeaseRightofUseAssetAmortization unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">269460</bmra:OperatingLeaseRightofUseAssetAmortization>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">455614</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">309090</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">1906013</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">717460</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-1138793</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">1306681</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <bmra:IncreaseDecreaseInLeaseLiability unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-241132</bmra:IncreaseDecreaseInLeaseLiability>
  <bmra:IncreaseDecreaseInLeaseLiability unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-199483</bmra:IncreaseDecreaseInLeaseLiability>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">95958</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">41361</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-403331</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-12883</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">110269</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">51798</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-5251748</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-4297498</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquireIntangibleAssets unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">159727</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireIntangibleAssets unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">85319</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">135856</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">33608</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-295583</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-118927</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">1011475</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">10232857</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock unitRef="usd" contextRef="c0_From1Jun2020To31May2021" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">1917586</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">102255</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">223534</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">1113730</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">12373977</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-8115</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-3310</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-4441716</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">7954242</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c15_AsOf31May2019" decimals="INF">686785</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InterestPaidNet unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">367</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">9</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">27171</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">7390</us-gaap:IncomeTaxesPaid>
  <bmra:IncreaseInRightOfUseAsset unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">79159</bmra:IncreaseInRightOfUseAsset>
  <bmra:IncreaseInRightOfUseAsset unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">1942999</bmra:IncreaseInRightOfUseAsset>
  <bmra:IncreaseInLeaseLiability unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">79159</bmra:IncreaseInLeaseLiability>
  <bmra:IncreaseInLeaseLiability unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">1980970</bmra:IncreaseInLeaseLiability>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 1: &amp;#xa0;&amp;#xa0;&amp;#xa0;ORGANIZATION &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Biomerica Inc. and Subsidiaries (collectively the &amp;#x201c;Company&amp;#x201d;, &amp;#x201c;Biomerica&amp;#x201d;, &amp;#x201c;we&amp;#x201d;, &amp;#x201c;us&amp;#x201d;, or &amp;#x201c;our&amp;#x201d;) develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(physicians&apos; offices and over-the-counter through drugstores and online)&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Company&apos;s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians&apos; offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company&apos;s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Our primary focus is the research and development of revolutionary, patented, diagnostic-guided therapy (&amp;#x201c;DGT&amp;#x201d;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Our medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians&apos; offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient&amp;#x2019;s body, stools, or blood, often in extremely small concentrations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic, in March 2020 we began redirecting and focusing a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. During fiscal 2021, we sold 2 primary types of Covid 19 tests; 1) antibody diagnostic tests that use a patient&amp;#x2019;s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body&amp;#x2019;s immune response to a COVID-19 infection, even if the infection was asymptomatic, and 2) antigen tests that use a patient&amp;#x2019;s nasal fluid sample to detect if a patient is currently infected with the virus. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Aside from the COVID-19 products we offer, the other products we sell are primarily focused on gastrointestinal diseases, food intolerances, diabetes and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&amp;#x2019;s regulatory agency.&amp;#xa0; In addition, some products are cleared for sale in the U.S. by the FDA.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 2: &amp;#xa0;&amp;#xa0;&amp;#xa0;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;PRINCIPLES OF CONSOLIDATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The enclosed consolidated financial statements for the years ended May 31, 2021 and 2020 include the accounts of Biomerica, Inc. (&quot;Biomerica&quot;) as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ACCOUNTING ESTIMATES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#x201c;GAAP&amp;#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;MARKETS AND METHODS OF DISTRIBUTION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;Due to &lt;/font&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;the Coronavirus global pandemic, the Company&amp;#x2019;s operations have been negatively impacted. &lt;font style=&quot;color: black;&quot;&gt;The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, loss of contracts and/or customers, closure of the Company&amp;#x2019;s manufacturing or distribution facilities or of the facilities of the Company&amp;#x2019;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&amp;#x2019;s operations and financial performance and may continue to have significant material negative impacts on the Company.&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;LIQUIDITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $28.4 million as of May 31, 2021.&amp;#xa0; Management expects to continue to incur significant costs as it advances its trials and development activities.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020 and declared effective by the SEC on September 30, 2020 and an ATM Agreement. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Under an ATM Agreement, sales of the Placement Shares are deemed to be &amp;#x201c;at the market offering&amp;#x201d; as defined in Rule 415 promulgated under the Securities Act.&amp;#xa0; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&amp;#x2019;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement (&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;File No. 333-239980) &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;and ATM Agreement which resulted in gross proceeds of $1,177,394 and net proceeds to the Company of $1,011,475 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 12pt 0cm 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;As a result of cash and cash equivalents on hand at May 31, 2021, management believes the Company has sufficient funds to operate through August 2022 and the ability to raise additional funds through the ATM noted above.&lt;br/&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company&apos;s financial instruments consist of its cash and cash equivalents, accounts receivable,&amp;#xa0;and accounts payable. The carrying amounts of the Company&apos;s financial instruments approximate their fair values.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;CONCENTRATION OF CREDIT RISK&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&amp;#xa0; As of May 31, 2021, the Company had approximately $3,767,000 of uninsured cash. &lt;/font&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;The Company does not believe it is exposed to any significant credit risks.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&amp;#xa0; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;For the years ended May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 60% and 57% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2021 and 2020 one of the distributors mentioned above accounted for 33% and 26%, respectively, of net consolidated sales.&amp;#xa0; At May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 73% and 80%, respectively, of gross accounts receivable. &lt;a name=&quot;_Hlk48558057&quot;&gt;&lt;/a&gt;Of the 73% as of May 31, 2021, 41% was owed by a distributor in China. Total gross receivables at May 31, 2021 and 2020 were &lt;/font&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;$2,292,466 &lt;/font&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;and $1,836,852, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;For the year ended May 31, 2021, one vendor accounted for 58% of the purchases of raw materials. For the year ended May 31, 2020, one vendor accounted for a total of 59% of the purchases of raw materials.&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;GEOGRAPHIC CONCENTRATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;As of May 31, 2021 and 2020, approximately $803,000 and $613,000 of Biomerica&apos;s gross inventory and approximately $25,000 and $31,000, of Biomerica&apos;s property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;CASH AND &lt;/font&gt;&lt;/strong&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;color: black;&quot;&gt;CASH EQUIVALENTS&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ACCOUNTS RECEIVABLE&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company extends unsecured credit to its customers on a regular basis. &amp;#xa0;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &amp;#xa0;Based on various criteria,&amp;#xa0;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &amp;#xa0;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &amp;#xa0;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &amp;#xa0; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The Company has established a reserve of $837,415 for doubtful accounts as of May 31, 2021. The majority of this reserve has been established to cover 100% of outstanding accounts receivable from an international distributor.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;PREPAIDS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The Company occasionally prepays for items such as inventory, insurance and other items.&amp;#xa0; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;As of May 31, 2021, the prepaids were approximately $370,000, composed of prepayments to insurance and various other suppliers. As of May 31, 2020, approximately $1 million of the prepaids was an advance payment to one of our suppliers, which was subsequently refunded by the supplier when the Company determined it no longer needed the materials that had been ordered.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INVENTORIES, NET&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:white; COLOR:black&quot;&gt;The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Inventories approximate the following at May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,583,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,635,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Work in progress&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,006,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;988,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Finished products&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;617,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;228,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,206,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,851,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2021 and 2020, inventory reserves were approximately $1,617,000 and $67,000, respectively. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:9pt&quot;&gt;Of the inventory reserve, &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:9pt&quot;&gt;$1,502,675 was related to a market downturn in our COVID-19 antibody test and materials, as the market shifted to&amp;#xa0; COVID-19 PCR viral tests and antigen tests.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;PROPERTY AND EQUIPMENT, NET&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $104,715 and $105,299 for the years ended May 31, 2021 and 2020, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INTANGIBLE ASSETS, NET&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;), ASC 350 Intangibles &amp;#x2013; Goodwill and Other (&amp;#x201c;ASC 350&amp;#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $33,552 and $23,873 for the years ended May 31, 2021 and 2020, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&apos;s balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2021 or 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INVESTMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;From time-to-time, the Company makes investments in privately-held companies. &amp;#xa0;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&amp;#x2019;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&amp;#x2019;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &amp;#xa0;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SHARE-BASED COMPENSATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company follows the guidance of the accounting provisions of ASC 718&lt;a name=&quot;_Hlk17621381&quot;&gt;, &lt;/a&gt;Share-based Compensation (&amp;#x201c;ASC 718&amp;#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&amp;#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &amp;#x201c;simplified method&amp;#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In applying the Black-Scholes options-pricing model, assumptions used were as follows: &amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;71.19-107.53% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;55.52-72.62% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;0.34-1.18% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;0.43-1.80% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected Term&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;5.50-6.25 Years &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;3.75-6.25 Years &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;REVENUE RECOGNITION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has various contracts with customers.&amp;#xa0; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2021 and 2020 and does not believe that any additional discounts will be given through the end of the contract periods. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. &lt;font style=&quot;COLOR:black&quot;&gt;The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &amp;#xa0;Physicians&amp;#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. &lt;/font&gt;&lt;a name=&quot;_Hlk49511094&quot;&gt;&lt;/a&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Disaggregation of revenue:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The following is a breakdown of revenues according to markets to which the products are sold:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;5&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Year Ended&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Clinical lab&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,077,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,922,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Physician&apos;s office&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,801,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,195,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Over-the-counter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;766,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,270,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Contract manufacturing&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;552,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;306,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Lab supplies&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;7,199,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,693,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;See Note 8 for additional information regarding revenue concentrations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SHIPPING AND HANDLING FEES &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company includes shipping and handling fees billed to customers in net sales. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RESEARCH AND DEVELOPMENT&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Research and development costs are expensed as incurred. The Company expensed $2,410,506 and $1,910,209 of research and development costs during the years ended May 31, 2021 and 2020, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&amp;#x201c;ASC 740&amp;#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2021 and 2020, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&amp;#xa0;&amp;#xa0; During the fiscal year ended May 31, 2021, this valuation allowance was increased to $5,590,000, which fully covers the tax asset of $5,590,000&lt;/font&gt;&lt;font style=&quot;font-size: 9pt; color: black;&quot;&gt;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&amp;#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &amp;#x201c;Interest expense&amp;#x201d; line and penalties related to liabilities for income taxes within the &amp;#x201c;Other expense&amp;#x201d; line of the consolidated statements of operations and comprehensive loss. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ADVERTISING COSTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately &lt;font style=&quot;BACKGROUND:white&quot;&gt;$10,070&lt;/font&gt; and $&lt;font style=&quot;BACKGROUND:white&quot;&gt;174&lt;/font&gt; for the years ended May 31, 2021 and 2020, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;FOREIGN CURRENCY TRANSLATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2021 and 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RIGHT-OF-USE ASSETS AND LEASE LIABILITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.&lt;font style=&quot;COLOR:black&quot;&gt;&amp;#xa0;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&amp;#xa0; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;In February 2016, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&amp;#xa0; Right-of-use assets represent the Company&amp;#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&amp;#xa0; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&amp;#xa0; Leases are classified as financing or operating which will drive the expense recognition pattern.&amp;#xa0; The Company has elected to exclude short-term leases.&amp;#xa0; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&amp;#xa0; An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&amp;#xa0; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&amp;#x2019;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not book the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&amp;#xa0; Most leases include the option to renew and the exercise of the renewal options is at the Company&amp;#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&amp;#xa0; The leases do not include the options to purchase the leased property.&amp;#xa0; The depreciable life of assets and leasehold improvements are limited by the expected lease term.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NET LOSS PER SHARE &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2021 and 2020 were 2,081,366 and 1,789,251, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company also had 0 and 321,429 of Series A 5% Convertible Preferred Stock outstanding for the years ended May 31, 2021 and 2020, respectively. &amp;#xa0;The 321,429 shares outstanding at May 31, 2020 were converted to common stock during the year ended May 31, 2021.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SEGMENT REPORTING&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ASC 280, Segment Reporting (&amp;#x201c;ASC 280&amp;#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&amp;#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;REPORTING COMPREHENSIVE LOSS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&amp;#x2019; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 7.2pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Recent ASU&apos;s issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&amp;#x2019;s present or future consolidated financial statements. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;PRINCIPLES OF CONSOLIDATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The enclosed consolidated financial statements for the years ended May 31, 2021 and 2020 include the accounts of Biomerica, Inc. (&quot;Biomerica&quot;) as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ACCOUNTING ESTIMATES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#x201c;GAAP&amp;#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <bmra:MarketsAndMethodsOfDistributionPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;MARKETS AND METHODS OF DISTRIBUTION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;Due to &lt;/font&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;the Coronavirus global pandemic, the Company&amp;#x2019;s operations have been negatively impacted. &lt;font style=&quot;color: black;&quot;&gt;The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, loss of contracts and/or customers, closure of the Company&amp;#x2019;s manufacturing or distribution facilities or of the facilities of the Company&amp;#x2019;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&amp;#x2019;s operations and financial performance and may continue to have significant material negative impacts on the Company.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</bmra:MarketsAndMethodsOfDistributionPolicyTextBlock>
  <bmra:LiquidityPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;LIQUIDITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $28.4 million as of May 31, 2021.&amp;#xa0; Management expects to continue to incur significant costs as it advances its trials and development activities.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020 and declared effective by the SEC on September 30, 2020 and an ATM Agreement. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Under an ATM Agreement, sales of the Placement Shares are deemed to be &amp;#x201c;at the market offering&amp;#x201d; as defined in Rule 415 promulgated under the Securities Act.&amp;#xa0; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&amp;#x2019;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement (&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;File No. 333-239980) &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;and ATM Agreement which resulted in gross proceeds of $1,177,394 and net proceeds to the Company of $1,011,475 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 12pt 0cm 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;As a result of cash and cash equivalents on hand at May 31, 2021, management believes the Company has sufficient funds to operate through August 2022 and the ability to raise additional funds through the ATM noted above.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</bmra:LiquidityPolicyTextBlock>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c35_AsOf31May2021_RetainedEarningsMember" decimals="-5">28400000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue unitRef="usd" contextRef="c36_AsOf22Jan2021" decimals="0">15000000</bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">158889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c37_AsOf31May2021_MinimumMember" decimals="2">7.06</us-gaap:SharePrice>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c38_AsOf31May2021_MaximumMember" decimals="2">7.79</us-gaap:SharePrice>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c39_From1Jun2020To31May2021_ATMAgreementMember" decimals="0">1177394</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c39_From1Jun2020To31May2021_ATMAgreementMember" decimals="0">1011475</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company&apos;s financial instruments consist of its cash and cash equivalents, accounts receivable,&amp;#xa0;and accounts payable. The carrying amounts of the Company&apos;s financial instruments approximate their fair values.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;CONCENTRATION OF CREDIT RISK&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&amp;#xa0; As of May 31, 2021, the Company had approximately $3,767,000 of uninsured cash. &lt;/font&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;The Company does not believe it is exposed to any significant credit risks.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&amp;#xa0; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;For the years ended May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 60% and 57% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2021 and 2020 one of the distributors mentioned above accounted for 33% and 26%, respectively, of net consolidated sales.&amp;#xa0; At May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 73% and 80%, respectively, of gross accounts receivable. &lt;a name=&quot;_Hlk48558057&quot;&gt;&lt;/a&gt;Of the 73% as of May 31, 2021, 41% was owed by a distributor in China. Total gross receivables at May 31, 2021 and 2020 were &lt;/font&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;$2,292,466 &lt;/font&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;and $1,836,852, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;For the year ended May 31, 2021, one vendor accounted for 58% of the purchases of raw materials. For the year ended May 31, 2020, one vendor accounted for a total of 59% of the purchases of raw materials.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:CashUninsuredAmount unitRef="usd" contextRef="c3_AsOf31May2021" decimals="0">3767000</us-gaap:CashUninsuredAmount>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c40_From1Jun2020To31May2021_SalesRevenueNetMember_CustomerConcentrationRiskMember_TwoDistributorsMember" decimals="2">0.60</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c41_From1Jun2019To31May2020_SalesRevenueNetMember_CustomerConcentrationRiskMember_ThreeDistributorsMember" decimals="2">0.57</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c42_From1Jun2020To31May2021_SalesRevenueNetMember_CustomerConcentrationRiskMember_OneDistributorsMember" decimals="2">0.33</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c43_From1Jun2019To31May2020_SalesRevenueNetMember_CustomerConcentrationRiskMember_OneDistributorsMember" decimals="2">0.26</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c44_From1Jun2020To31May2021_AccountsReceivableMember_CustomerConcentrationRiskMember_TwoDistributorsMember" decimals="2">0.73</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c45_From1Jun2019To31May2020_AccountsReceivableMember_CustomerConcentrationRiskMember_ThreeDistributorsMember" decimals="2">0.80</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c46_From1Jun2020To31May2021_AccountsReceivableMember_CustomerConcentrationRiskMember_DistributorsInChinaMember" decimals="2">0.41</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:OtherReceivablesGrossCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="0">2292466</us-gaap:OtherReceivablesGrossCurrent>
  <us-gaap:OtherReceivablesGrossCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="0">1836852</us-gaap:OtherReceivablesGrossCurrent>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c47_From1Jun2020To31May2021_CostOfGoodsProductLineMember_SupplierConcentrationRiskMember_OneVendorMember" decimals="2">0.58</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c48_From1Jun2019To31May2020_CostOfGoodsProductLineMember_SupplierConcentrationRiskMember_OneVendorMember" decimals="2">0.59</us-gaap:ConcentrationRiskPercentage1>
  <bmra:ConcentrationRiskGeographicPolicyPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;GEOGRAPHIC CONCENTRATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;As of May 31, 2021 and 2020, approximately $803,000 and $613,000 of Biomerica&apos;s gross inventory and approximately $25,000 and $31,000, of Biomerica&apos;s property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</bmra:ConcentrationRiskGeographicPolicyPolicyTextBlock>
  <us-gaap:InventoryGross unitRef="usd" contextRef="c49_AsOf31May2021_MX" decimals="0">803000</us-gaap:InventoryGross>
  <us-gaap:InventoryGross unitRef="usd" contextRef="c50_AsOf31May2020_MX" decimals="0">613000</us-gaap:InventoryGross>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c49_AsOf31May2021_MX" decimals="0">25000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c50_AsOf31May2020_MX" decimals="0">31000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;CASH AND &lt;/font&gt;&lt;/strong&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;color: black;&quot;&gt;CASH EQUIVALENTS&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ACCOUNTS RECEIVABLE&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company extends unsecured credit to its customers on a regular basis. &amp;#xa0;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &amp;#xa0;Based on various criteria,&amp;#xa0;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &amp;#xa0;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &amp;#xa0;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &amp;#xa0; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The Company has established a reserve of $837,415 for doubtful accounts as of May 31, 2021. The majority of this reserve has been established to cover 100% of outstanding accounts receivable from an international distributor.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable contextRef="c0_From1Jun2020To31May2021">P90D</us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable>
  <us-gaap:ProvisionForDoubtfulAccounts unitRef="usd" contextRef="c51_From1Jun2020To31May2021_AccountsReceivableMember" decimals="0">837415</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c0_From1Jun2020To31May2021" decimals="2">1.00</us-gaap:ConcentrationRiskPercentage1>
  <bmra:PrepaidsPolicyPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;PREPAIDS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The Company occasionally prepays for items such as inventory, insurance and other items.&amp;#xa0; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;As of May 31, 2021, the prepaids were approximately $370,000, composed of prepayments to insurance and various other suppliers. As of May 31, 2020, approximately $1 million of the prepaids was an advance payment to one of our suppliers, which was subsequently refunded by the supplier when the Company determined it no longer needed the materials that had been ordered.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</bmra:PrepaidsPolicyPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInPrepaidSupplies unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="0">370000</us-gaap:IncreaseDecreaseInPrepaidSupplies>
  <us-gaap:IncreaseDecreaseInPrepaidSupplies unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="-6">1000000</us-gaap:IncreaseDecreaseInPrepaidSupplies>
  <us-gaap:InventoryPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INVENTORIES, NET&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:white; COLOR:black&quot;&gt;The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Inventories approximate the following at May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,583,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,635,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Work in progress&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,006,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;988,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Finished products&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;617,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;228,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,206,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,851,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2021 and 2020, inventory reserves were approximately $1,617,000 and $67,000, respectively. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:9pt&quot;&gt;Of the inventory reserve, &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:9pt&quot;&gt;$1,502,675 was related to a market downturn in our COVID-19 antibody test and materials, as the market shifted to&amp;#xa0; COVID-19 PCR viral tests and antigen tests.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryValuationReserves unitRef="usd" contextRef="c3_AsOf31May2021" decimals="0">1617000</us-gaap:InventoryValuationReserves>
  <us-gaap:InventoryValuationReserves unitRef="usd" contextRef="c4_AsOf31May2020" decimals="0">67000</us-gaap:InventoryValuationReserves>
  <us-gaap:InventoryLIFOReserve unitRef="usd" contextRef="c3_AsOf31May2021" decimals="0">1502675</us-gaap:InventoryLIFOReserve>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;PROPERTY AND EQUIPMENT, NET&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $104,715 and $105,299 for the years ended May 31, 2021 and 2020, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c52_From1Jun2020To31May2021_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c53_From1Jun2020To31May2021_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="0">104715</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="0">105299</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INTANGIBLE ASSETS, NET&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;), ASC 350 Intangibles &amp;#x2013; Goodwill and Other (&amp;#x201c;ASC 350&amp;#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $33,552 and $23,873 for the years ended May 31, 2021 and 2020, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&apos;s balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2021 or 2020.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c54_From1Jun2020To31May2021_DistributionRightsMember">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c55_From1Jun2020To31May2021_PurchasedTechnologyRightsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c56_From1Jun2020To31May2021_PatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:AmortizationOfIntangibleAssets unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="0">33552</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="0">23873</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:InvestmentPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INVESTMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;From time-to-time, the Company makes investments in privately-held companies. &amp;#xa0;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&amp;#x2019;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&amp;#x2019;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &amp;#xa0;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c3_AsOf31May2021" decimals="2">0.06</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SHARE-BASED COMPENSATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company follows the guidance of the accounting provisions of ASC 718&lt;a name=&quot;_Hlk17621381&quot;&gt;, &lt;/a&gt;Share-based Compensation (&amp;#x201c;ASC 718&amp;#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&amp;#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &amp;#x201c;simplified method&amp;#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In applying the Black-Scholes options-pricing model, assumptions used were as follows: &amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;71.19-107.53% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;55.52-72.62% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;0.34-1.18% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;0.43-1.80% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected Term&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;5.50-6.25 Years &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;3.75-6.25 Years &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;REVENUE RECOGNITION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has various contracts with customers.&amp;#xa0; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2021 and 2020 and does not believe that any additional discounts will be given through the end of the contract periods. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. &lt;font style=&quot;COLOR:black&quot;&gt;The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &amp;#xa0;Physicians&amp;#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. &lt;/font&gt;&lt;a name=&quot;_Hlk49511094&quot;&gt;&lt;/a&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Disaggregation of revenue:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The following is a breakdown of revenues according to markets to which the products are sold:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;5&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Year Ended&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Clinical lab&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,077,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,922,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Physician&apos;s office&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,801,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,195,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Over-the-counter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;766,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,270,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Contract manufacturing&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;552,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;306,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Lab supplies&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;7,199,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,693,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;See Note 8 for additional information regarding revenue concentrations.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SHIPPING AND HANDLING FEES &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company includes shipping and handling fees billed to customers in net sales.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RESEARCH AND DEVELOPMENT&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Research and development costs are expensed as incurred. The Company expensed $2,410,506 and $1,910,209 of research and development costs during the years ended May 31, 2021 and 2020, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&amp;#x201c;ASC 740&amp;#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2021 and 2020, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&amp;#xa0;&amp;#xa0; During the fiscal year ended May 31, 2021, this valuation allowance was increased to $5,590,000, which fully covers the tax asset of $5,590,000&lt;/font&gt;&lt;font style=&quot;font-size: 9pt; color: black;&quot;&gt;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&amp;#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &amp;#x201c;Interest expense&amp;#x201d; line and penalties related to liabilities for income taxes within the &amp;#x201c;Other expense&amp;#x201d; line of the consolidated statements of operations and comprehensive loss.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ADVERTISING COSTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately &lt;font style=&quot;BACKGROUND:white&quot;&gt;$10,070&lt;/font&gt; and $&lt;font style=&quot;BACKGROUND:white&quot;&gt;174&lt;/font&gt; for the years ended May 31, 2021 and 2020, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
  <us-gaap:AdvertisingExpense unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="0">10070</us-gaap:AdvertisingExpense>
  <us-gaap:AdvertisingExpense unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="0">174</us-gaap:AdvertisingExpense>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;FOREIGN CURRENCY TRANSLATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2021 and 2020.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RIGHT-OF-USE ASSETS AND LEASE LIABILITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.&lt;font style=&quot;COLOR:black&quot;&gt;&amp;#xa0;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&amp;#xa0; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;In February 2016, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&amp;#xa0; Right-of-use assets represent the Company&amp;#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&amp;#xa0; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&amp;#xa0; Leases are classified as financing or operating which will drive the expense recognition pattern.&amp;#xa0; The Company has elected to exclude short-term leases.&amp;#xa0; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&amp;#xa0; An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&amp;#xa0; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&amp;#x2019;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not book the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&amp;#xa0; Most leases include the option to renew and the exercise of the renewal options is at the Company&amp;#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&amp;#xa0; The leases do not include the options to purchase the leased property.&amp;#xa0; The depreciable life of assets and leasehold improvements are limited by the expected lease term.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c57_AsOf31May2021_AccountingStandardsUpdate201602Member" decimals="0">1942999</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseLiability unitRef="usd" contextRef="c57_AsOf31May2021_AccountingStandardsUpdate201602Member" decimals="0">1980970</us-gaap:OperatingLeaseLiability>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NET LOSS PER SHARE &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2021 and 2020 were 2,081,366 and 1,789,251, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company also had 0 and 321,429 of Series A 5% Convertible Preferred Stock outstanding for the years ended May 31, 2021 and 2020, respectively. &amp;#xa0;The 321,429 shares outstanding at May 31, 2020 were converted to common stock during the year ended May 31, 2021.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">2081366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c9_From1Jun2019To31May2020" decimals="INF">1789251</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c32_AsOf31May2021_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c22_AsOf31May2020_SeriesAPreferredStockMember_A5ConvertiblePreferredStockMember" decimals="INF">321429</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion unitRef="shares" contextRef="c58_AsOf31May2021_SeriesAPreferredStockMember" decimals="INF">321429</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SEGMENT REPORTING&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ASC 280, Segment Reporting (&amp;#x201c;ASC 280&amp;#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&amp;#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;REPORTING COMPREHENSIVE LOSS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&amp;#x2019; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 7.2pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Recent ASU&apos;s issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&amp;#x2019;s present or future consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,583,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,635,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Work in progress&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,006,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;988,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Finished products&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;617,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;228,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,206,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,851,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:InventoryRawMaterialsNetOfReserves unitRef="usd" contextRef="c3_AsOf31May2021" decimals="-3">1583000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves unitRef="usd" contextRef="c4_AsOf31May2020" decimals="-3">1635000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves unitRef="usd" contextRef="c3_AsOf31May2021" decimals="-3">1006000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves unitRef="usd" contextRef="c4_AsOf31May2020" decimals="-3">988000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves unitRef="usd" contextRef="c3_AsOf31May2021" decimals="-3">617000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves unitRef="usd" contextRef="c4_AsOf31May2020" decimals="-3">228000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;71.19-107.53% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;55.52-72.62% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;0.34-1.18% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;0.43-1.80% &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected Term&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;5.50-6.25 Years &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;3.75-6.25 Years &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c0_From1Jun2020To31May2021" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c9_From1Jun2019To31May2020" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c52_From1Jun2020To31May2021_MinimumMember" decimals="4">0.7119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c53_From1Jun2020To31May2021_MaximumMember" decimals="4">1.0753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c59_From1Jun2019To31May2020_MinimumMember" decimals="4">0.5552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c60_From1Jun2019To31May2020_MaximumMember" decimals="4">0.7262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c52_From1Jun2020To31May2021_MinimumMember" decimals="4">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c53_From1Jun2020To31May2021_MaximumMember" decimals="4">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c59_From1Jun2019To31May2020_MinimumMember" decimals="4">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c60_From1Jun2019To31May2020_MaximumMember" decimals="4">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c52_From1Jun2020To31May2021_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c53_From1Jun2020To31May2021_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c59_From1Jun2019To31May2020_MinimumMember">P3Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c60_From1Jun2019To31May2020_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;5&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Year Ended&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Clinical lab&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,077,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,922,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Physician&apos;s office&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,801,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,195,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Over-the-counter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;766,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,270,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Contract manufacturing&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;552,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;306,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Lab supplies&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;7,199,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,693,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c61_From1Jun2020To31May2021_ClinicalLabMember" decimals="INF">3077000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c62_From1Jun2019To31May2020_ClinicalLabMember" decimals="INF">2922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c63_From1Jun2020To31May2021_PhysiciansOfficeMember" decimals="INF">2801000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c64_From1Jun2019To31May2020_PhysiciansOfficeMember" decimals="INF">2195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c65_From1Jun2020To31May2021_OverthecounterMember" decimals="INF">766000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c66_From1Jun2019To31May2020_OverthecounterMember" decimals="INF">1270000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c67_From1Jun2020To31May2021_ContractManufacturingMember" decimals="INF">552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c68_From1Jun2019To31May2020_ContractManufacturingMember" decimals="INF">306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c69_From1Jun2020To31May2021_LabSuppliesMember" decimals="INF">3000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">7199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">6693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 3: &amp;#xa0;&amp;#xa0;&amp;#xa0;PROPERTY AND EQUIPMENT, NET&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Property and equipment, net of accumulated depreciation, consist of the following at May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Equipment &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,849,888 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,921,833 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Furniture, fixtures and leasehold improvements&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;432,989 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;225,189 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated depreciation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(1,972,357)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(1,867,643)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Net property and equipment&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;310,520 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;279,379 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Equipment &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,849,888 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,921,833 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Furniture, fixtures and leasehold improvements&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;432,989 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;225,189 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated depreciation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(1,972,357)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(1,867,643)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Net property and equipment&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;310,520 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;279,379 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <bmra:Equipment unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">1849888</bmra:Equipment>
  <bmra:Equipment unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">1921833</bmra:Equipment>
  <bmra:FurnitureFixturesAndLeaseholdImprovements unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">432989</bmra:FurnitureFixturesAndLeaseholdImprovements>
  <bmra:FurnitureFixturesAndLeaseholdImprovements unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">225189</bmra:FurnitureFixturesAndLeaseholdImprovements>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 4: &amp;#xa0;&amp;#xa0;&amp;#xa0;INTANGIBLE ASSETS, NET&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets, net of accumulated amortization, consist of the following at May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Licenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;182,176 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;551,397 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Patents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;239,423 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;113,382 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated amortization-licenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(107,194)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(487,989)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated amortization-patents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(19,575)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(8,135)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible asssets, net&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;294,830 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;168,655 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected amortization of intangible assets for the years ending May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2022&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;21,846 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2023&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;20,058 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;20,058 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2025&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;19,071 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2026&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;18,975 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;194,822 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;294,830 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Licenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;182,176 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;551,397 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Patents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;239,423 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;113,382 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated amortization-licenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(107,194)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(487,989)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated amortization-patents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(19,575)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(8,135)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible asssets, net&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;294,830 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;168,655 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:FiniteLivedLicenseAgreementsGross unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">182176</us-gaap:FiniteLivedLicenseAgreementsGross>
  <us-gaap:FiniteLivedLicenseAgreementsGross unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">551397</us-gaap:FiniteLivedLicenseAgreementsGross>
  <us-gaap:FiniteLivedPatentsGross unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">239423</us-gaap:FiniteLivedPatentsGross>
  <us-gaap:FiniteLivedPatentsGross unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">113382</us-gaap:FiniteLivedPatentsGross>
  <bmra:FiniteLivedLicenseAccumulatedAmortization unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">107194</bmra:FiniteLivedLicenseAccumulatedAmortization>
  <bmra:FiniteLivedLicenseAccumulatedAmortization unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">487989</bmra:FiniteLivedLicenseAccumulatedAmortization>
  <bmra:FiniteLivedPatentsAccumulatedAmortization unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">19575</bmra:FiniteLivedPatentsAccumulatedAmortization>
  <bmra:FiniteLivedPatentsAccumulatedAmortization unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">8135</bmra:FiniteLivedPatentsAccumulatedAmortization>
  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2022&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;21,846 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2023&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;20,058 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;20,058 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2025&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;19,071 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2026&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;18,975 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;194,822 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;294,830 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">21846</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">20058</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">20058</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">19071</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">18975</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">194822</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsNet unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">294830</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 5:&amp;#xa0;&amp;#xa0;&amp;#xa0; ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company&amp;#x2019;s accounts payable and accrued expense balances consist of the following at May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Accounts payable&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;431,621 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;833,412 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Accrued expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;151,759 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;153,299 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;583,380 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;986,711 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;As of May 31, 2021 and 2020 the Company had one vendor and two vendors which accounted for 17% and 27%, respectively, of accounts payable.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c70_From1Jun2020To31May2021_AccountsPayableMember_CustomerConcentrationRiskMember_OneVendorMember" decimals="2">0.17</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c71_From1Jun2019To31May2020_AccountsPayableMember_CustomerConcentrationRiskMember_TwoVendorsMember" decimals="2">0.27</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Accounts payable&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;431,621 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;833,412 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Accrued expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;151,759 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;153,299 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;583,380 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;986,711 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">431621</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">833412</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">151759</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">153299</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 6: &amp;#xa0;&amp;#xa0;&amp;#xa0;SHAREHOLDERS&apos; EQUITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On February 24, 2020, the Company filed with the Secretary of State of Delaware a certificate of designation to authorize for issuance 571,429 shares of Series A 5% Convertible Preferred Stock.&amp;#xa0; On February 26, 2020, the Company filed with the Secretary of State of Delaware a certificate of correction, correcting certain language defects in the previously filed certificate of designation.&amp;#xa0; Please see below a description of the Series A 5% Convertible Preferred Stock shares that were issued in February 2020, and subsequently converted into registered common shares.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;STOCK OPTION AND RESTRICTED STOCK PLANS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In August 2010, the Company adopted a stock option and restricted stock plan (the &quot;2010 Plan&quot;) which provided that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company&apos;s unissued common stock could be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2010. &amp;#xa0;The 2010 Plan expired in December 2020. Options granted under the 2010 Plan were granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In December 2014, the Company adopted a stock option and restricted stock plan (the &quot;2014 Plan&quot;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company&apos;s unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2014. &amp;#xa0;The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In December 2017, the Company adopted a stock option and restricted stock plan (the &amp;#x201c;2017 Plan&amp;#x201d;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company&amp;#x2019;s unissued common stock may be granted to affiliates, employees or consultants of the Company.&amp;#xa0; This plan was approved by shareholders in December 2017.&amp;#xa0; The 2017 Plan expires in December 2027.&amp;#xa0; Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;In February 2020, the Board approved the 2020 Stock Incentive Plan (the &amp;#x201c;2020 Plan&amp;#x201d;) and on December 11, 2020 the shareholders of the Company approved The Plan. The 2020 Plan authorizes the issuance of an &lt;/font&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000. &amp;#xa0;The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Stock option expense during fiscal 2021 was $377,391.&amp;#xa0; This included, by department, $64,491 for research and development, $221,052 for administrative, $18,035 for sales and marketing and $73,813 for production.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Stock option expense during fiscal 2020 was $200,470. This included, by department, $17,892 for research and development, $156,750 in administrative, $2,933 in sales and marketing and $22,895 for production.&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Activity as to aggregate stock options outstanding is as follows: &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;734&quot; style=&quot;WIDTH:550.7pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER OF STOCK OPTIONS&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;EXCERCISE PRICE &lt;br/&gt;RANGE PER SHARE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:79.4pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED AVERAGE EXERCISE &lt;br/&gt;PRICE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2019&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,476,209 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.90&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.07 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;517,500 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.68-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.47 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options excercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(137,958)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1.64 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options canceled or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(66,500)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.85-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.43 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2020&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,789,251 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$8.18&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.75 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;430,616 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$5.14-$8.70&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.73 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options excercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(86,750)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.62&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1.20 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options canceled or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(51,751)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.35-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.77 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2021&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,081,366 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$8.70&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$1.20 - $6.73&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The weighted average fair value of options granted during 2021 and 2020 was $6.73 and $4.47, respectively. The aggregate intrinsic value of options exercised during 2021 and 2020 was approximately $501,000 and $589,000, respectively. The aggregate intrinsic value of options outstanding at May 31, 2021 and 2020 was approximately $2,132,000 and $6,923,000, respectively. The aggregate intrinsic value of options vested and exercisable at May 31, 2021 and 2020 was approximately $1,872,000 and $4,442,000, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The number of non-vested stock options included in the table above is as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:54.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:54.75pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Number of&lt;br/&gt;&amp;#xa0;shares&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Stock options&lt;br/&gt;weighted&lt;br/&gt;average grant &lt;br/&gt;date fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Non-vested shares at May 31, 2020 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;822,584 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.78 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Granted &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;430,616 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.73&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Vested&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(409,459)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.36&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Forfeited &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(50,500)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.80&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Non-vested shares at May 31, 2021 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;793,241 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5.54 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;At May 31, 2021, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $1,208,000. The weighted-average period over which this amount is expected to be recognized is 2.59 years. The weighted average remaining contractual term of options that were exercisable at May 31, 2021 was 6.07 years.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The following summarizes information about all of the Company&apos;s stock options outstanding at May 31, 2021. These options are comprised of those granted under the 2010, 2014, 2017 and 2020 plans.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RANGE OF &lt;br/&gt;EXERCISE PRICES&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER &lt;br/&gt;OUTSTANDING &lt;br/&gt;MAY 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED &lt;br/&gt;AVERAGE &lt;br/&gt;REMAINING &lt;br/&gt;CONTRACTUAL &lt;br/&gt;LIFE IN YEARS&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED&lt;br/&gt;&amp;#xa0;AVERAGE &lt;br/&gt;EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER &lt;br/&gt;EXCERCISABLE &lt;br/&gt;AT MAY 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED &lt;br/&gt;AVERAGE &lt;br/&gt;EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$1.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;216,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.75&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;216,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$1.20-$2.81&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,024,500&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.45&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.17 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;795,250&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.02 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$3.62-$8.70&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;840,866&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;8.00&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$6.03 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;276,875&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$4.54 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;COMMON STOCK ACTIVITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;a name=&quot;_Hlk17185589&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;During the year ended May 31, 2020, options to purchase 137,958 shares of common stock were exercised at prices ranging from $0.82 to $3.90.&amp;#xa0; Total net proceeds to the Company were $223,534.&lt;/font&gt;&lt;/a&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On December 1, 2017, the Company entered into an At Market Issuance Sales Agreement (or &amp;#x201c;ATM Agreement&amp;#x201d;) with an agent, and filed a prospectus supplement with the SEC pursuant under which the Company could offer and sell from time to time up to an aggregate of $7,000,000 of shares of the Company&amp;#x2019;s common stock, par value $0.08 per share (the &amp;#x201c;Placement Shares&amp;#x201d;), through the agent. From December 1, 2017 to March 19, 2020, the Company sold common stock resulting in $6,997,935 of gross proceeds under this ATM Agreement, of which $3,771,048 were sold during the year ended May 31, 2020. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;This At Market Issuance Agreement expired on July 20, 2020 upon the expiration of the Company&amp;#x2019;s Form S-3 registration statement base prospectus dated July 20, 2017. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 12pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Placement Shares sold and issued under this ATM Agreement have been registered under the Securities Act of 1933, as amended (the &amp;#x201c;Securities Act&amp;#x201d;), pursuant to the Registration Statement on Form S-3 (File No. 333-219130) (the &amp;#x201c;Registration Statement&amp;#x201d;), which was originally filed with the SEC on June 30, 2017 and declared effective by the SEC on July 20, 2017, the base prospectus contained within the Registration Statement, and the prospectus supplement related to the sale of shares under the ATM Agreement was filed with the SEC on December 1, 2017.&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On March 20, 2020, the Company filed a new prospectus supplement to the S-3 registration statement base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the ATM Agreement. &lt;/font&gt;&lt;a name=&quot;_Hlk47966232&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;This ATM Agreement expired on July 20, 2020 upon the expiration of the Company&amp;#x2019;s Form S-3 registration statement base prospectus dated July 20, 2017. Gross proceeds for the year ended May 31, 2020 were $6,817,330. There were no proceeds for the year ended May 31, 2021, for this July 20, 2017 Form S-3 registration statement.&lt;/font&gt;&lt;/a&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Combined Placement Shares sold under the ATM Agreements during the year ended May 31, 2020 under the two prospectus supplements dated December 1, 2017 and March 20, 2020 totaled 1,674,943 shares. Total net proceeds from the sale of Placement Shares under the two prospectus supplements during the year ended May 31, 2020 were $10,232,857 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&amp;#xa0; These shares were sold at prices ranging from $2.33 to $9.08 per share. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On September 11, 2020, the Company filed a Pre-Effective Amendment No. 1 to the Form S-3 to register 571,429 shares of Biomerica common stock in connection with the Stock Purchase Agreement dated February 21, 2020, wherein the Company entered into a registration rights agreement with the selling stockholder, pursuant to which we agreed to file a registration statement registering the resale of the shares of our common stock issuable upon conversion of our Series A Preferred Stock issued to the selling stockholder under the Stock Purchase Agreement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;a name=&quot;_Hlk79676889&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for the Form S-3 &amp;#x201c;shelf&amp;#x201d; &lt;/font&gt;&lt;/a&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Registration Statement filed on July 21, 2020 and amended on September 11, 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;During the year ended May 31, 2020, 250,000 shares of common stock were converted from Preferred Stock as described below in &amp;#x201c;Preferred Stock Activity&amp;#x201d;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;During the year ended May 31, 2021, options to purchase 86,750 shares of common stock were exercised at prices ranging from $0.82 to $3.62.&amp;#xa0; Total net proceeds to the Company were $102,255.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020 and declared effective by the SEC on September 30, and an ATM Agreement. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On May 21, 2021, in conjunction with the Company&amp;#x2019;s 2020 Stock Incentive Plan, that was approved by shareholders at the Company&amp;#x2019;s annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to 900,000 shares of the Company&amp;#x2019;s common stock that could be issued under this Plan.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Under an ATM Agreements, sales of the Placement Shares are deemed to be &amp;#x201c;at the market offering&amp;#x201d; as defined in Rule 415 promulgated under the Securities Act.&amp;#xa0; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&amp;#x2019;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;During the year ended May 31, 2021, 321,429 shares of common stock were converted from Preferred Stock as described below in &amp;#x201c;Preferred Stock Activity&amp;#x201d;.&lt;/font&gt;&lt;a name=&quot;_Hlk49188299&quot;&gt;&lt;/a&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement &lt;a name=&quot;_Aci_Pg1&quot;&gt;(&lt;/a&gt;&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;File No. 333-239980&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;) &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;and ATM Agreement which resulted in gross proceeds of $1,177,394 and net proceeds to the Company of $1,011,475 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;PREFERRED STOCK ACTIVITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &amp;#x201c;Stock Purchase Agreement&amp;#x201d;) with &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Palm Global Small Cap Master Fund LP (&amp;#x201c;Palm&amp;#x201d;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&amp;#x2019;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&amp;#x2019;s common stock, subject to certain adjustments. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay such accruing dividends. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered 571,429 common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. &lt;font style=&quot;COLOR:black&quot;&gt;On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares.&amp;#xa0; On January 21, 2021 Palm Converted their remaining 321,429 Convertible Preferred Shares into registered common shares. At May 30, 2021, the Company had no shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative Dividends were paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past cumulative dividends. &lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c72_AsOf24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">571429</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c73_AsOf31Aug2010_EmployeeStockOptionMember_A2010PlanMember" decimals="INF">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent unitRef="pure" contextRef="c74_From31Aug2010To31Aug2010_EmployeeStockOptionMember_A2010PlanMember" decimals="2">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c74_From31Aug2010To31Aug2010_EmployeeStockOptionMember_A2010PlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c75_AsOf31Dec2014_EmployeeStockOptionMember_A2014PlanMember" decimals="INF">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent unitRef="pure" contextRef="c76_From31Dec2014To31Dec2014_EmployeeStockOptionMember_A2014PlanMember" decimals="2">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c76_From31Dec2014To31Dec2014_EmployeeStockOptionMember_A2014PlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c77_AsOf31Dec2017_EmployeeStockOptionMember_A2017PlanMember" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent unitRef="pure" contextRef="c78_From31Dec2017To31Dec2017_EmployeeStockOptionMember_A2017PlanMember" decimals="2">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c78_From31Dec2017To31Dec2017_EmployeeStockOptionMember_A2017PlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c79_AsOf29Feb2020_EmployeeStockOptionMember_A2020PlanMember" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c80_From1Jun2020To31May2021_EmployeeStockOptionMember" decimals="0">377391</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c81_From1Jun2020To31May2021_EmployeeStockOptionMember_ResearchAndDevelopmentExpenseMember" decimals="0">64491</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c82_From1Jun2020To31May2021_EmployeeStockOptionMember_GeneralAndAdministrativeExpenseMember" decimals="0">221052</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c83_From1Jun2020To31May2021_EmployeeStockOptionMember_SellingAndMarketingExpenseMember" decimals="0">18035</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c84_From1Jun2020To31May2021_EmployeeStockOptionMember_CostOfSalesMember" decimals="0">73813</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c85_From1Jun2019To31May2020_EmployeeStockOptionMember" decimals="0">200470</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c86_From1Jun2019To31May2020_EmployeeStockOptionMember_ResearchAndDevelopmentExpenseMember" decimals="0">17892</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c87_From1Jun2019To31May2020_EmployeeStockOptionMember_GeneralAndAdministrativeExpenseMember" decimals="0">156750</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c88_From1Jun2019To31May2020_EmployeeStockOptionMember_SellingAndMarketingExpenseMember" decimals="0">2933</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c89_From1Jun2019To31May2020_EmployeeStockOptionMember_CostOfSalesMember" decimals="0">22895</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c80_From1Jun2020To31May2021_EmployeeStockOptionMember" decimals="2">6.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c85_From1Jun2019To31May2020_EmployeeStockOptionMember" decimals="2">4.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue unitRef="usd" contextRef="c80_From1Jun2020To31May2021_EmployeeStockOptionMember" decimals="0">501000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue unitRef="usd" contextRef="c85_From1Jun2019To31May2020_EmployeeStockOptionMember" decimals="0">589000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c90_AsOf31May2021_EmployeeStockOptionMember" decimals="0">2132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c91_AsOf31May2020_EmployeeStockOptionMember" decimals="0">6923000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 unitRef="usd" contextRef="c90_AsOf31May2021_EmployeeStockOptionMember" decimals="0">1872000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 unitRef="usd" contextRef="c91_AsOf31May2020_EmployeeStockOptionMember" decimals="0">4442000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions unitRef="usd" contextRef="c90_AsOf31May2021_EmployeeStockOptionMember" decimals="0">1208000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c80_From1Jun2020To31May2021_EmployeeStockOptionMember">P2Y215D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c80_From1Jun2020To31May2021_EmployeeStockOptionMember">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c92_From1Jun2019To31May2020_CommonStockMember" decimals="INF">137958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c93_From1Jun2019To31May2020_MinimumMember_CommonStockMember" decimals="2">0.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c94_From1Jun2019To31May2020_MaximumMember_CommonStockMember" decimals="2">3.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c92_From1Jun2019To31May2020_CommonStockMember" decimals="0">223534</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c95_From1Dec2017To1Dec2017_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="0">7000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c96_AsOf1Dec2017_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="2">0.08</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c97_From1Dec2017To19Mar2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="0">6997935</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c98_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="0">3771048</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c99_From20Mar2020To20Mar2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember_RegistrationRightsAgreementMember" decimals="0">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c100_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember_RegistrationRightsAgreementMember" decimals="0">6817330</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c98_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="INF">1674943</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c98_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="0">10232857</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c101_AsOf31May2020_MinimumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="2">2.33</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c102_AsOf31May2020_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="2">9.08</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c103_AsOf11Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">571429</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c104_From1Jun2019To31May2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="INF">250000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c105_From1Jun2020To31May2021_EmployeeStockOptionMember_CommonStockMember" decimals="0">86750</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c106_From1Jun2020To31May2021_MinimumMember_EmployeeStockOptionMember_CommonStockMember" decimals="2">0.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c107_From1Jun2020To31May2021_MaximumMember_EmployeeStockOptionMember_CommonStockMember" decimals="2">3.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c105_From1Jun2020To31May2021_EmployeeStockOptionMember_CommonStockMember" decimals="0">102255</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c108_From22Jan2021To22Jan2021_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember_RegistrationRightsAgreementMember" decimals="0">15000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c109_AsOf21May2021_EmployeeStockOptionMember_CommonStockMember" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c110_From1Jun2020To31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="INF">321429</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c111_From1Jun2020To31May2021_CommonStockMember" decimals="INF">158889</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c112_AsOf31May2021_MinimumMember_CommonStockMember" decimals="2">7.06</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c113_AsOf31May2021_MaximumMember_CommonStockMember" decimals="2">7.79</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c111_From1Jun2020To31May2021_CommonStockMember" decimals="0">1177394</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c111_From1Jun2020To31May2021_CommonStockMember" decimals="0">1011475</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c114_From24Feb2020To24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="INF">571429</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c115_AsOf24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="2">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ConversionOfStockAmountIssued1 unitRef="usd" contextRef="c114_From24Feb2020To24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="-6">2000000</us-gaap:ConversionOfStockAmountIssued1>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c115_AsOf24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="2">3.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:PreferredStockDividendsPerShareDeclared unitRef="usdPershares" contextRef="c116_From1Jun2020To31May2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="3">0.175</us-gaap:PreferredStockDividendsPerShareDeclared>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c117_From24Feb2020To24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">250000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesIssued1 unitRef="shares" contextRef="c114_From24Feb2020To24Feb2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="INF">250000</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits unitRef="shares" contextRef="c118_From21Jul2020To21Jul2020_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="INF">571429</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c119_From21Jan2021To21Jan2021_A5ConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="INF">321429</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;734&quot; style=&quot;WIDTH:550.7pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER OF STOCK OPTIONS&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;EXCERCISE PRICE &lt;br/&gt;RANGE PER SHARE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:79.4pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED AVERAGE EXERCISE &lt;br/&gt;PRICE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2019&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,476,209 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.90&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.07 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;517,500 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.68-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.47 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options excercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(137,958)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1.64 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options canceled or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(66,500)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.85-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.43 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2020&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,789,251 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$8.18&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.75 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;430,616 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$5.14-$8.70&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.73 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options excercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(86,750)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.62&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1.20 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options canceled or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(51,751)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.35-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.77 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2021&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,081,366 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$8.70&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$1.20 - $6.73&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c120_AsOf31May2019_ExercisePriceRangePerShare082390Member" decimals="INF">1476209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c120_AsOf31May2019_ExercisePriceRangePerShare082390Member" decimals="INF">2.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c121_From1Jun2019To31May2020_ExercisePriceRangePerShare268818Member" decimals="INF">517500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c121_From1Jun2019To31May2020_ExercisePriceRangePerShare268818Member" decimals="INF">4.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c122_From1Jun2019To31May2020_ExercisePriceRangePerShare082390Member" decimals="INF">137958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c122_From1Jun2019To31May2020_ExercisePriceRangePerShare082390Member" decimals="INF">1.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c123_From1Jun2019To31May2020_ExercisePriceRangePerShare085818Member" decimals="INF">66500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c123_From1Jun2019To31May2020_ExercisePriceRangePerShare085818Member" decimals="INF">3.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c124_AsOf31May2020_ExercisePriceRangePerShare082818Member" decimals="INF">1789251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c124_AsOf31May2020_ExercisePriceRangePerShare082818Member" decimals="INF">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c125_From1Jun2020To31May2021_ExercisePriceRangePerShare514870Member" decimals="INF">430616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c125_From1Jun2020To31May2021_ExercisePriceRangePerShare514870Member" decimals="INF">6.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c126_From1Jun2020To31May2021_ExercisePriceRangePerShare082362Member" decimals="INF">86750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c126_From1Jun2020To31May2021_ExercisePriceRangePerShare082362Member" decimals="INF">1.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c127_From1Jun2020To31May2021_ExercisePriceRangePerShare235818Member" decimals="INF">51751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c127_From1Jun2020To31May2021_ExercisePriceRangePerShare235818Member" decimals="INF">4.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c128_AsOf31May2021_ExercisePriceRangePerShare082870Member" decimals="INF">2081366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c129_AsOf31May2021_MinimumMember_ExercisePriceRangePerShare082870Member" decimals="INF">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c130_AsOf31May2021_MaximumMember_ExercisePriceRangePerShare082870Member" decimals="INF">6.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:54.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:54.75pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Number of&lt;br/&gt;&amp;#xa0;shares&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Stock options&lt;br/&gt;weighted&lt;br/&gt;average grant &lt;br/&gt;date fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Non-vested shares at May 31, 2020 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;822,584 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.78 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Granted &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;430,616 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.73&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Vested&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(409,459)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.36&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Forfeited &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(50,500)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.80&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Non-vested shares at May 31, 2021 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;793,241 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5.54 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares unitRef="shares" contextRef="c4_AsOf31May2020" decimals="INF">822584</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c4_AsOf31May2020" decimals="INF">3.78</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">430616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">6.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares unitRef="shares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">409459</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">3.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares unitRef="shares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">50500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c0_From1Jun2020To31May2021" decimals="INF">4.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares unitRef="shares" contextRef="c3_AsOf31May2021" decimals="INF">793241</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c3_AsOf31May2021" decimals="INF">5.54</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RANGE OF &lt;br/&gt;EXERCISE PRICES&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER &lt;br/&gt;OUTSTANDING &lt;br/&gt;MAY 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED &lt;br/&gt;AVERAGE &lt;br/&gt;REMAINING &lt;br/&gt;CONTRACTUAL &lt;br/&gt;LIFE IN YEARS&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED&lt;br/&gt;&amp;#xa0;AVERAGE &lt;br/&gt;EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER &lt;br/&gt;EXCERCISABLE &lt;br/&gt;AT MAY 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED &lt;br/&gt;AVERAGE &lt;br/&gt;EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$1.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;216,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.75&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;216,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$1.20-$2.81&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,024,500&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.45&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.17 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;795,250&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.02 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$3.62-$8.70&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;840,866&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;8.00&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$6.03 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;276,875&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$4.54 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c131_From1Jun2020To31May2021_RangeOfExercisePrice082104Member" decimals="INF">0.82</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c131_From1Jun2020To31May2021_RangeOfExercisePrice082104Member" decimals="INF">1.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c132_AsOf31May2021_RangeOfExercisePrice082104Member" decimals="INF">216000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c131_From1Jun2020To31May2021_RangeOfExercisePrice082104Member">P3Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c132_AsOf31May2021_RangeOfExercisePrice082104Member" decimals="INF">0.82</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c132_AsOf31May2021_RangeOfExercisePrice082104Member" decimals="INF">216000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 unitRef="usdPershares" contextRef="c132_AsOf31May2021_RangeOfExercisePrice082104Member" decimals="INF">0.82</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c133_From1Jun2020To31May2021_RangeOfExercisePrice120281Member" decimals="INF">1.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c133_From1Jun2020To31May2021_RangeOfExercisePrice120281Member" decimals="INF">2.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c134_AsOf31May2021_RangeOfExercisePrice120281Member" decimals="INF">1024500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c133_From1Jun2020To31May2021_RangeOfExercisePrice120281Member">P6Y164D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c134_AsOf31May2021_RangeOfExercisePrice120281Member" decimals="INF">2.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c134_AsOf31May2021_RangeOfExercisePrice120281Member" decimals="INF">795250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 unitRef="usdPershares" contextRef="c134_AsOf31May2021_RangeOfExercisePrice120281Member" decimals="INF">2.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c135_From1Jun2020To31May2021_RangeOfExercisePrice362870Member" decimals="INF">3.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c135_From1Jun2020To31May2021_RangeOfExercisePrice362870Member" decimals="INF">8.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c136_AsOf31May2021_RangeOfExercisePrice362870Member" decimals="INF">840866</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c135_From1Jun2020To31May2021_RangeOfExercisePrice362870Member">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c136_AsOf31May2021_RangeOfExercisePrice362870Member" decimals="INF">6.03</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c136_AsOf31May2021_RangeOfExercisePrice362870Member" decimals="INF">276875</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 unitRef="usdPershares" contextRef="c136_AsOf31May2021_RangeOfExercisePrice362870Member" decimals="INF">4.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 7: &amp;#xa0;&amp;#xa0;&amp;#xa0;INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Provision for income taxes for the years ended May 31 consists of the following:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;Years ended May 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Current:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;U.S. Federal&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Foreign Taxes Subsidiaries&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(12,257)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(6,590)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;State and local&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(800)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(800)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total current&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(13,057)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(7,390)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Deferred:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;U.S. Federal&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;State and local&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total deferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Income tax expense&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(13,057)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(7,390)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Provision for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;21&lt;font style=&quot;COLOR:black&quot;&gt;% for 2021 and 2020) to pretax income as a result of the following:&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto; height: 135px;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Years ended May 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 101.383px; white-space: nowrap; padding: 0cm;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: center; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 101.383px; white-space: nowrap; padding: 0cm;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: center; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Computed &quot;expected&quot; tax benefit &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;1,355,756 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;489,651 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Increase (reduction) in income taxes resulting from:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(2,102,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(1,029,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;State income taxes, net of federal benefit&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;190,233 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;154,254 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;456,388 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;49,770 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Permanent tax differences and other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;98,823 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;334,525 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Foreign taxes of subsidiaries&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 14.6333px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(12,257)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 14.6333px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(6,590)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15.75pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Income tax expense&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 14.6333px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(13,057)&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 14.6333px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(7,390)&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The tax effect of significant temporary differences&amp;#xa0;is presented below:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;width: 550.1pt; border-collapse: collapse; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;As of May 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: center; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: center; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm 0cm 0cm 10.8pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Accounts receivable, principally due to allowance for doubtful accounts&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;200,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;17,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Inventory valuation&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;387,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;16,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Compensated absences&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;85,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;64,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Net operating loss carryforwards&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;3,195,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2,286,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Tax credit carryforwards&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;1,055,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;599,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Deferred rent expense/Capitalized leases&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;14,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;17,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Stock Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;299,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;181,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Losses of foreign subsidiaries &amp;amp; Other, net&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;370,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;303,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm 0cm 0cm 10.8pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(15,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;5,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Total deferred tax assets&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;5,590,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;3,488,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Less valuation allowance&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(5,590,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(3,488,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15.75pt;&quot;&gt;
&lt;td style=&quot;height: 15.75pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Net deferred tax asset&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;The Company has provided a valuation allowance of approximately $5,590,000 and $3,488,000 as of May 31, 2021 and 2020, respectively. The net change in the valuation allowance for the years ended May 31, 2021 and 2020 was an increase of $2,102,000 and $1,029,000, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;The Company increased the deferred tax asset and the valuation allowance by $313,000 as of May 31, 2020 based on the outstanding stock options as of May 31, 2020. This change had no impact on the Company&amp;#x2019;s consolidated financial statements as our deferred tax asset is fully offset by our valuation allowance. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;At May 31, 2021, the Company has Federal income tax net operating loss carryforwards of approximately $12,957,000. &amp;#xa0;At May 31, 2021, the Company has California state income tax net operating loss carryforwards of approximately $6,768,000. For tax reporting purposes, operating loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in 2022 and 2037 for federal and state purposes, respectively.&amp;#xa0; Federal net operating losses beginning in 2018 have no expiration date. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;At May 31, 2021, the Company has Federal research and development tax credit carryforward of approximately $715,000. &amp;#xa0;The Federal credits begin to expire in 2027. &amp;#xa0;The Company also had similar credit carryforwards for state purposes of $341,000 at May 31, 2021, which don&amp;#x2019;t expire.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Pursuant to Internal Revenue Code (&amp;#x201c;IRC&amp;#x201d;) Sections 382 and 383, annual use of the Company&apos;s net operating loss (&quot;NOL&quot;) and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company&apos;s NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;For the year ended May 31, 2021, the Company did an analysis of its ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740. Should such position be identified in the future and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal year 2017.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c0_From1Jun2020To31May2021" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c9_From1Jun2019To31May2020" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="0">2102000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="0">1029000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount unitRef="usd" contextRef="c137_From1Jun2019To31May2020_StockOptionMember" decimals="0">313000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c138_AsOf31May2021_DomesticCountryMember" decimals="0">12957000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c139_AsOf31May2021_CaliforniaStateIncomeTaxMember" decimals="0">6768000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:TaxCreditCarryforwardAmount unitRef="usd" contextRef="c140_AsOf31May2021_DomesticCountryMember_ResearchMember" decimals="0">715000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount unitRef="usd" contextRef="c141_AsOf31May2021_StateAndLocalJurisdictionMember_ResearchMember" decimals="0">341000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;Years ended May 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Current:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;U.S. Federal&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Foreign Taxes Subsidiaries&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(12,257)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(6,590)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;State and local&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(800)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(800)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total current&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(13,057)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(7,390)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Deferred:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;U.S. Federal&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;State and local&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total deferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Income tax expense&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(13,057)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(7,390)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2020To31May2021" xs:nil="true"/>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:CurrentForeignTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-12257</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-6590</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-800</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-800</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-13057</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-7390</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2020To31May2021" xs:nil="true"/>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2020To31May2021" xs:nil="true"/>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2020To31May2021" xs:nil="true"/>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table style=&quot;width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto; height: 135px;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Years ended May 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 101.383px; white-space: nowrap; padding: 0cm;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: center; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 101.383px; white-space: nowrap; padding: 0cm;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: center; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Computed &quot;expected&quot; tax benefit &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;1,355,756 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;489,651 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Increase (reduction) in income taxes resulting from:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(2,102,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(1,029,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;State income taxes, net of federal benefit&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;190,233 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;154,254 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;456,388 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;49,770 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Permanent tax differences and other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;98,823 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;334,525 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Foreign taxes of subsidiaries&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 14.6333px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(12,257)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 14.6333px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(6,590)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15.75pt;&quot;&gt;
&lt;td style=&quot;height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Income tax expense&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 14.6333px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(13,057)&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 14.6333px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(7,390)&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">1355756</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">489651</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-2102000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-1029000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">190233</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">154254</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">456388</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">49770</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">98823</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">334525</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">-12257</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">-6590</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table style=&quot;width: 550.1pt; border-collapse: collapse; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;As of May 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: center; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: center; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm 0cm 0cm 10.8pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Accounts receivable, principally due to allowance for doubtful accounts&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;200,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;17,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Inventory valuation&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;387,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;16,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Compensated absences&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;85,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;64,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Net operating loss carryforwards&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;3,195,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2,286,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Tax credit carryforwards&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;1,055,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;599,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Deferred rent expense/Capitalized leases&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;14,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;17,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Stock Options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;299,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;181,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Losses of foreign subsidiaries &amp;amp; Other, net&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;370,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;303,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm 0cm 0cm 10.8pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(15,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;5,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Total deferred tax assets&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;5,590,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;3,488,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Less valuation allowance&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(5,590,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(3,488,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15.75pt;&quot;&gt;
&lt;td style=&quot;height: 15.75pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Net deferred tax asset&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: right; margin: 0cm;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">17000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
  <us-gaap:DeferredTaxAssetsInventory unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">387000</us-gaap:DeferredTaxAssetsInventory>
  <us-gaap:DeferredTaxAssetsInventory unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">16000</us-gaap:DeferredTaxAssetsInventory>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">85000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">64000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">3195000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">2286000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">1055000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">599000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">14000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">17000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <bmra:DefferedTaxAssetsStockOptions unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">299000</bmra:DefferedTaxAssetsStockOptions>
  <bmra:DefferedTaxAssetsStockOptions unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">181000</bmra:DefferedTaxAssetsStockOptions>
  <bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">370000</bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet>
  <bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">303000</bmra:DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet>
  <bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">-15000</bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization>
  <bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">5000</bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">5590000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">3488000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">5590000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c4_AsOf31May2020" decimals="INF">3488000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c3_AsOf31May2021" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c4_AsOf31May2020" xs:nil="true"/>
  <bmra:GeographicInformationDisclosureTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 8: &amp;#xa0;&amp;#xa0;&amp;#xa0;GEOGRAPHIC INFORMATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company operates as one segment. Geographic information regarding net sales is approximately as follows: &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;7&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Year Ended&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Revenues from sales to unaffiliated customers:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Europe&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4,301,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;60%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,434,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;36%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Asia&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,908,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;26%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,867,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;28%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;United States&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;548,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;8%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;445,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;7%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;South America&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;250,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,615,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;24%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Middle East&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;192,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;314,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;18,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;7,199,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;100%&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,693,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;100%&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;/div&gt;</bmra:GeographicInformationDisclosureTextBlock>
  <us-gaap:NumberOfOperatingSegments unitRef="pure" contextRef="c0_From1Jun2020To31May2021" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;7&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Year Ended&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;3&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Revenues from sales to unaffiliated customers:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Europe&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4,301,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;60%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,434,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;36%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Asia&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,908,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;26%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,867,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;28%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;United States&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;548,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;8%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;445,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;7%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;South America&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;250,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,615,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;24%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Middle East&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;192,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;314,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;18,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;7,199,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;100%&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,693,000 &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;100%&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
  <us-gaap:Revenues unitRef="usd" contextRef="c142_From1Jun2020To31May2021_EuropeMember" decimals="-3">4301000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c143_From1Jun2020To31May2021_EuropeMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.60</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c144_From1Jun2019To31May2020_EuropeMember" decimals="-3">2434000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c145_From1Jun2019To31May2020_EuropeMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.36</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c146_From1Jun2020To31May2021_AsiaMember" decimals="-3">1908000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c147_From1Jun2020To31May2021_AsiaMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.26</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c148_From1Jun2019To31May2020_AsiaMember" decimals="-3">1867000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c149_From1Jun2019To31May2020_AsiaMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.28</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c150_From1Jun2020To31May2021_US" decimals="-3">548000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c151_From1Jun2020To31May2021_US_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.08</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c152_From1Jun2019To31May2020_US" decimals="-3">445000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c153_From1Jun2019To31May2020_US_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.07</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c154_From1Jun2020To31May2021_SouthAmericaMember" decimals="-4">250000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c155_From1Jun2020To31May2021_SouthAmericaMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.03</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c156_From1Jun2019To31May2020_SouthAmericaMember" decimals="-3">1615000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c157_From1Jun2019To31May2020_SouthAmericaMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.24</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c158_From1Jun2020To31May2021_MiddleEastMember" decimals="-3">192000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c159_From1Jun2020To31May2021_MiddleEastMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.03</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c160_From1Jun2019To31May2020_MiddleEastMember" decimals="-3">314000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c161_From1Jun2019To31May2020_MiddleEastMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.05</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c162_From1Jun2020To31May2021_OtherMember" xs:nil="true"/>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c163_From1Jun2020To31May2021_OtherMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.00</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues unitRef="usd" contextRef="c164_From1Jun2019To31May2020_OtherMember" decimals="-3">18000</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c165_From1Jun2019To31May2020_OtherMember_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">0.00</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c166_From1Jun2020To31May2021_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">1.00</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c167_From1Jun2019To31May2020_SalesRevenueSegmentMember_GeographicConcentrationRiskMember" decimals="2">1.00</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 9: &amp;#xa0;&amp;#xa0;&amp;#xa0;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;OPERATING LEASES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;On November 30, 2015, the Company entered into the First Amendment to Lease wherein it exercised its option to extend its lease until August 31, 2021. The initial base rent for the lease extension was $21,000 per month, increasing to $23,637 through August 31, 2021. On April 9, 2021 the Company exercised its second option to extend its lease for an additional five years through August 2026.&amp;#xa0; The Company was also granted an additional five years lease extension option through August 2031. The rent is currently $23,637 per month and will increase on September 1, 2021 to $25,970 per month and be increased 3% each year thereafter. The security deposit of $22,080 remains the same.&lt;font style=&quot;COLOR:black&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;In November 2016, the Company&amp;#x2019;s subsidiary, Biomerica de Mexico, entered into a ten-year lease for approximately 8,104 square feet at a monthly rent of $2,926. The Company has one 10-year option to renew at the end of the initial lease period. The yearly rate is subject to an annual adjustment for inflation according to the United States Bureau of Labor Statistics Consumer Price Index for All Urban Consumers. The monthly rate is currently $3,262. &amp;#xa0;Biomerica, Inc. is not a guarantor of such lease. &amp;#xa0;Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total gross rent expense in the U.S. for fiscal 2021 was $294,759 and 2020 was $300,267.&amp;#xa0; Rent expense for the Mexico facility for fiscal 2021 and 2020 was $25,351 and $43,481, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 0.9pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&amp;#x2019;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&amp;#xa0; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred.&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Courier New&amp;quot;; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif&quot;&gt;Supplemental cash flow information related to leases for the year ended May 31: &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Operating cash flows from operating leases&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;320,606 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;311,742 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:14.4pt&quot;&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Right-of-use assets obtained in exchange for&lt;br/&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0; &amp;#xa0;new operating lease liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;79,159 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Weighted average remaining lease term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5.27&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.27&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Weighted average discount rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.50%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.50%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Future minimum lease payments under the operating lease as of May 31, 2021 are as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2022&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;337,630 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2023&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;350,311 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;360,769 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2025&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;371,539 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2026&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;382,631 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;103,927 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total undiscounted lease payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,906,807 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less imputed interest&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;287,293 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total operating lease liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,619,514 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company also has various insignificant leases for office equipment.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RETIREMENT SAVINGS PLAN&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan&apos;s inception.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;LITIGATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company&apos;s consolidated financial position, results of operations or cash flows. There were no legal proceedings pending as of May 31, 2021.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On July 2, 2020, we received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena requested information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also requested information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. In addition, on December 15, 2020, the SEC sent a second subpoena related to this investigation to Zack Irani, the Company&amp;#x2019;s CEO, requesting documents held by Mr. Irani concerning his past purchases of Company stock, his past communications with certain persons and entities, and other personal and Company documents. The Company and Mr. Irani have cooperated fully with the SEC&amp;#x2019;s investigation and provided information as requested. At this time, the Company is unable to predict the duration, scope or outcome of these investigations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;CONTRACTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Contracts and Licensing Agreements&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $11,000 and $15,000 is included in cost of sales for the agreement for each of the years ended May 31, 2021 and 2020, respectively. Sales of products manufactured under these agreements comprise approximately 1.5% and 1.8% of total sales for the years ended May 31, 2021 and 2020, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business.&amp;#xa0; The Company has other royalty agreements, however they are not considered material.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (&amp;#x201c;Telcon Agreement&amp;#x201d;) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (&amp;#x201c;Telcon&amp;#x201d;), a medical company in South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica&amp;#x2019;s new InFoods&amp;#xae; IBS products (&amp;#x201c;IBS Products&amp;#x201d;) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. We are working with Telcon management to extend the term of the Telcon Agreement. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica&amp;#x2019;s starting clinical trials in the United States, receipt of U.S. FDA clearance and Telcon&amp;#x2019;s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common stock in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Additionally, the Telcon Agreement provides for&amp;#xa0;a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.&amp;#xa0; In order to retain the exclusivity within South Korea, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon&amp;#x2019;s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019.&lt;b&gt; &lt;/b&gt;&amp;#xa0;&amp;#xa0;In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. &amp;#xa0;During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On May 29, 2019, the Company entered into an exclusive distribution agreement which contained certain annual minimum sales requirements, with MaxHealth Medical International Limited (a Chinese company) for the distribution of the Company&amp;#x2019;s EZ Detect Product in China.&amp;#xa0; On March 15, 2021, the Company terminated this agreement due to MaxHealth&amp;#x2019;s failure to meet the minimum sales requirements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the &amp;#x201c;Mount Sinai License Agreements&amp;#x201d;) with the Mount Sinai Icahn School of Medicine in New York (&amp;#x201c;Mount Sinai&amp;#x201d;) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&amp;#xa0; This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States.&amp;#xa0; The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for Emergency Use Authorization with the FDA based on this on this technology. The Company purchased materials in the amount of $5,100 during fiscal 2020 and subsequently to that another $2,850.&amp;#xa0; No royalty fees have been paid yet on these agreements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On May 7, 2020, the Company entered into an exclusive license agreement (the &amp;#x201c;UC License Agreements&amp;#x201d;) with The Regents of the University of California (&amp;#x201c;UC&amp;#x201d;) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at the University by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus.&amp;#xa0;If this technology development is successful, the Company will work with the University to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated and cleared with regulatory agencies for commercial sale into the market.&amp;#xa0; The exclusive UC License Agreements provide for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $5,000 with the execution of the agreement. An additional $5,000 was paid in September 2020.&amp;#xa0; No royalties have been paid yet on this agreement. A license maintenance fee of $10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 16.2pt 0cm 0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Clinical Trial Agreements&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.&amp;#xa0; The initial budget was estimated to be $82,472. The work started in October 2017 with charges for work performed being invoiced and paid monthly.&amp;#xa0; This study ended in February 2020. The Company incurred $2,200 in fiscal 2020 and $12,567 in expenses previously invoiced for a total of $14,767. In addition, $17,064 in fees has been accrued for unbilled charges as of May 31, 2021.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;In November 2017, the Company entered into a Clinical Trial Agreement with the University of Michigan to perform an InFoods&lt;/font&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;&amp;#xae; &lt;font style=&quot;color: black;&quot;&gt;24 Endpoint Determination Study.&amp;#xa0; The Company will be invoiced monthly for work performed the previous month. The maximum budget for the study is $181,015. The Company incurred $20,550 and $30,900 in expenses for this study during fiscal 2021 and 2020, respectively. This commitment is approximately 56% billed.&amp;#xa0; The Company has accrued $2,050 in charges as of May 31, 2021.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,serif; text-align: justify; margin: 0cm;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;In January 2018, the Company entered into a Clinical Trial Agreement with Beth Israel Deaconess Medical Center for the purposes of conducting an Antibody Guided Restriction Trial Using Biomerica InFoods&lt;/font&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;&amp;#xae; &lt;font style=&quot;color: black;&quot;&gt;24G Test in patients with a previous diagnosis of Irritable Bowel Syndrome.&amp;#xa0; The study began in the first quarter of fiscal 2019. The Company was invoiced monthly for work performed the previous month.&amp;#xa0; The total cost of the study was initially estimated to be $142,000, however the study was expanded and total costs of the trial was approximately $305,000. The Company incurred $0 and $141,640 in expenses for this study during fiscal 2021 and 2020, respectively. This study was closed in February 2020 and no additional costs are expected.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On July 12, 2019, the Company entered into a Clinical Trial Agreement with a research management institution for the purpose of conducting a clinical trial of the Biomerica HP Stool Antigen test.&amp;#xa0; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&amp;#xa0; The maximum budgeted costs were approximately $117,200.&amp;#xa0; During fiscal 2021 and 2020, $13,111 and $13,355 in charges were billed, respectively. This study is now closed so no further charges will be incurred.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On July 22, 2019, the Company entered into a Clinical Trial Agreement with a research institution, for the purpose of conducting a clinical trial of the Biomerica InFoods&amp;#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000.&amp;#xa0; The Company incurred $20,875 in charges during fiscal 2020. This commitment is approximately 31% billed. In addition, the Company was billed $12,675 in fiscal 2021 and accrued $19,600 in unbilled charges as of May 31, 2021.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On September 25, 2019, the Company entered into a Clinical Trial Agreement with a medical practice for the purpose of conducting a clinical trial of the Biomerica InFoods&amp;#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $136,000. During fiscal 2021 and 2020, the Company was invoiced $11,725 and $45,250 respectively in expenses. This commitment is approximately 42% billed. In addition, the Company accrued $5,975 in unbilled charges as of May 31, 2020. No charges were accrued at May 31, 2021.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On September 25, 2019, the Company entered into a Clinical Trial Agreement with a research institution for the purpose of conducting a clinical trial of the Biomerica H. pylori product.&amp;#xa0; The term of the agreement shall be until completion of the work outlined and the charges were invoiced monthly for work performed in the previous month.&amp;#xa0; The maximum budgeted costs will be approximately $57,800. The Company was invoiced $41,845 in charges during the year ended May 31, 2020. At May 31, 2020, the commitment was approximately 72% billed and the study was closed so no further charges will be incurred.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;In December 2019, the Company entered into a Clinical Trial Agreement with Houston Methodist Research Institute for the purpose of conducting a clinical trial of the Biomerica InFoods&amp;#xae; product.&amp;#xa0; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&amp;#xa0; The maximum budgeted costs will be approximately $133,000. During the years ended May 31, 2021 and 2020, the Company was invoiced $0 and $4,000 in charges, respectively. This commitment is approximately 3% billed. The Company accrued $3,550 in charges at May 31, 2021.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Arizona for the purpose of participating in the ongoing end point clinical trial of the Biomerica InFoods&amp;#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. &amp;#xa0;At May 31, 2021 and 2020, $0 and $17,390 had been invoiced to the Company. The Company has accrued $3,750 in expenses as of May 31, 2021. This commitment is approximately 13% billed.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Jacksonville for the purpose of participating in the ongoing end point clinical trial of the Biomerica InFoods&amp;#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. The Company has not received any billings as of May 31, 2020, however accrued $17,390 in charges as of that date. The Company received $22,827 in billings in fiscal 2021 and did not accrue any charges as of May 31, 2021. As of May 31, 2021, approximately 17% of the commitment had been invoiced.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica InFoods&amp;#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850. As of May 31, 2021, $4,850 had been billed and $3,750 in accruals remained. As of May 31, 2021, approximately 4% of the commitment had been invoiced.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The addition of both Mayo Clinic sites and other major medical centers were brought into the InFoods&amp;#xae; IBS clinicals studies in order to accelerate patient enrollment.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <bmra:OperatingLeasesRentExpensesMinimumRentals unitRef="usd" contextRef="c168_From30Nov2015To30Nov2015_BuildingInIrvineCaliforniaMember_FirstAmendmentToLeaseMember" decimals="0">21000</bmra:OperatingLeasesRentExpensesMinimumRentals>
  <bmra:RentalExpenseIncreaseDuringPeriod unitRef="usd" contextRef="c168_From30Nov2015To30Nov2015_BuildingInIrvineCaliforniaMember_FirstAmendmentToLeaseMember" decimals="0">23637</bmra:RentalExpenseIncreaseDuringPeriod>
  <us-gaap:LeaseExpirationDate1 contextRef="c168_From30Nov2015To30Nov2015_BuildingInIrvineCaliforniaMember_FirstAmendmentToLeaseMember">2021-08-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:OperatingLeaseExpense unitRef="usd" contextRef="c169_From1Jun2020To31May2021_BuildingInIrvineCaliforniaMember" decimals="0">23637</us-gaap:OperatingLeaseExpense>
  <bmra:RentalExpenseIncreaseDuringPeriod unitRef="usd" contextRef="c170_From1Sep2021To1Sep2021_BuildingInIrvineCaliforniaMember_SubsequentEventMember" decimals="0">25970</bmra:RentalExpenseIncreaseDuringPeriod>
  <bmra:RentalExpenseIncreaseDuringThePeriodPercentage unitRef="pure" contextRef="c170_From1Sep2021To1Sep2021_BuildingInIrvineCaliforniaMember_SubsequentEventMember" decimals="2">0.03</bmra:RentalExpenseIncreaseDuringThePeriodPercentage>
  <us-gaap:LeaseDepositLiability unitRef="usd" contextRef="c171_AsOf1Sep2021_BuildingInIrvineCaliforniaMember_SubsequentEventMember" decimals="0">22080</us-gaap:LeaseDepositLiability>
  <bmra:OperatingLeasesRentExpensesMinimumRentals unitRef="usd" contextRef="c172_From30Nov2016To30Nov2016_MX_PropertyAvailableForOperatingLeaseMember" decimals="0">2926</bmra:OperatingLeasesRentExpensesMinimumRentals>
  <bmra:LeaseExpirationPeriod contextRef="c172_From30Nov2016To30Nov2016_MX_PropertyAvailableForOperatingLeaseMember">P10Y</bmra:LeaseExpirationPeriod>
  <us-gaap:OperatingLeaseExpense unitRef="usd" contextRef="c172_From30Nov2016To30Nov2016_MX_PropertyAvailableForOperatingLeaseMember" decimals="0">3262</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense unitRef="usd" contextRef="c150_From1Jun2020To31May2021_US" decimals="0">294759</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense unitRef="usd" contextRef="c152_From1Jun2019To31May2020_US" decimals="0">300267</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense unitRef="usd" contextRef="c173_From1Jun2020To31May2021_MX" decimals="0">25351</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense unitRef="usd" contextRef="c174_From1Jun2019To31May2020_MX" decimals="0">43481</us-gaap:OperatingLeaseExpense>
  <us-gaap:RoyaltyExpense unitRef="usd" contextRef="c175_From1Jun2020To31May2021_RoyaltyAgreementsMember" decimals="0">11000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense unitRef="usd" contextRef="c176_From1Jun2019To31May2020_RoyaltyAgreementsMember" decimals="0">15000</us-gaap:RoyaltyExpense>
  <bmra:RoyaltyExpensePercentageOfSales unitRef="pure" contextRef="c177_From1Jun2020To31May2021_SalesRevenueNetMember_RoyaltyAgreementsMember" decimals="3">0.015</bmra:RoyaltyExpensePercentageOfSales>
  <bmra:RoyaltyExpensePercentageOfSales unitRef="pure" contextRef="c178_From1Jun2019To31May2020_SalesRevenueNetMember_RoyaltyAgreementsMember" decimals="3">0.018</bmra:RoyaltyExpensePercentageOfSales>
  <us-gaap:AccruedFeesAndOtherRevenueReceivable unitRef="usd" contextRef="c179_AsOf25May2016_TelconAgreementMember" decimals="-4">1250000</us-gaap:AccruedFeesAndOtherRevenueReceivable>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c180_From25May2016To25May2016_TelconAgreementMember" decimals="INF">83333</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:ProceedsFromFeesReceived unitRef="usd" contextRef="c180_From25May2016To25May2016_TelconAgreementMember" decimals="0">250000</us-gaap:ProceedsFromFeesReceived>
  <bmra:RoyaltyPercentage unitRef="pure" contextRef="c180_From25May2016To25May2016_TelconAgreementMember" decimals="2">0.15</bmra:RoyaltyPercentage>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty unitRef="usd" contextRef="c181_From1Jun2019To31May2020_MountSinaiLicenseAgreementsMember" decimals="0">5100</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty unitRef="usd" contextRef="c182_From1Jun2021To26Aug2021_MountSinaiLicenseAgreementsMember_SubsequentEventMember" decimals="0">2850</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:PaymentsForFees unitRef="usd" contextRef="c183_From7May2020To7May2020_UCLicenseAgreementsMember" decimals="0">5000</us-gaap:PaymentsForFees>
  <us-gaap:PaymentsForFees unitRef="usd" contextRef="c184_From1Jun2021To26Aug2021_UCLicenseAgreementsMember_SubsequentEventMember" decimals="0">5000</us-gaap:PaymentsForFees>
  <bmra:LicenseMaintenanceFeePayable unitRef="usd" contextRef="c183_From7May2020To7May2020_UCLicenseAgreementsMember" decimals="0">10000</bmra:LicenseMaintenanceFeePayable>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c185_AsOf30Sep2017_UniversityOFSouthernCaliforniaMember" decimals="0">82472</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c186_From1Jun2019To31May2020_UniversityOFSouthernCaliforniaMember" decimals="0">2200</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c187_From30Sep2017To30Sep2017_UniversityOFSouthernCaliforniaMember" decimals="0">12567</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c187_From30Sep2017To30Sep2017_UniversityOFSouthernCaliforniaMember" decimals="0">14767</us-gaap:OtherExpenses>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c188_AsOf31May2021_UniversityOFSouthernCaliforniaMember" decimals="0">17064</us-gaap:AccruedLiabilitiesCurrent>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c189_AsOf30Nov2017_UniversityOFMichiganMember" decimals="0">181015</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c190_From1Jun2020To31May2021_UniversityOFMichiganMember" decimals="0">20550</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c191_From1Jun2019To31May2020_UniversityOFMichiganMember" decimals="0">30900</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c190_From1Jun2020To31May2021_UniversityOFMichiganMember" decimals="2">0.56</bmra:BilledCommitmentPercentage>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c192_AsOf31May2021_UniversityOFMichiganMember" decimals="0">2050</us-gaap:AccruedLiabilitiesCurrent>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c193_AsOf31Jan2018_UniversityOFBethIsraelDeaconessMedicalCenterMember" decimals="0">142000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c194_AsOf31May2021_UniversityOFBethIsraelDeaconessMedicalCenterMember" decimals="0">305000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c195_From1Jun2020To31May2021_UniversityOFBethIsraelDeaconessMedicalCenterMember" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c196_From1Jun2019To31May2020_UniversityOFBethIsraelDeaconessMedicalCenterMember" decimals="0">141640</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c197_AsOf12Jul2019_BiomericaHPStoolAntigenMember" decimals="0">117200</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c198_From1Jun2020To31May2021_BiomericaHPStoolAntigenMember" decimals="0">13111</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c199_From1Jun2019To31May2020_BiomericaHPStoolAntigenMember" decimals="0">13355</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c200_AsOf22Jul2019_BiomericaInFoodsMember" decimals="0">107000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c201_From1Jun2019To31May2020_BiomericaInFoodsMember" decimals="0">20875</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c202_From1Jun2020To31May2021_BiomericaInFoodsMember" decimals="2">0.31</bmra:BilledCommitmentPercentage>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c202_From1Jun2020To31May2021_BiomericaInFoodsMember" decimals="0">12675</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c203_AsOf31May2021_BiomericaInFoodsMember" decimals="0">19600</us-gaap:AccruedLiabilitiesCurrent>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c204_AsOf25Sep2019_MedicalPracticeMember" decimals="0">136000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c205_From1Jun2020To31May2021_MedicalPracticeMember" decimals="0">11725</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c206_From1Jun2019To31May2020_MedicalPracticeMember" decimals="0">45250</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c205_From1Jun2020To31May2021_MedicalPracticeMember" decimals="2">0.42</bmra:BilledCommitmentPercentage>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c207_AsOf31May2020_MedicalPracticeMember" decimals="0">5975</us-gaap:AccruedLiabilitiesCurrent>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c208_AsOf25Sep2019_BiomericaHPyloriProductMember" decimals="0">57800</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c209_From1Jun2019To31May2020_BiomericaHPyloriProductMember" decimals="0">41845</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c209_From1Jun2019To31May2020_BiomericaHPyloriProductMember" decimals="2">0.72</bmra:BilledCommitmentPercentage>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c210_AsOf31Dec2019_HousetonMethodistResearchInstituteMember" decimals="0">133000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c211_From1Jun2020To31May2021_HousetonMethodistResearchInstituteMember" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c212_From1Jun2019To31May2020_HousetonMethodistResearchInstituteMember" decimals="0">4000</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c212_From1Jun2019To31May2020_HousetonMethodistResearchInstituteMember" decimals="2">0.03</bmra:BilledCommitmentPercentage>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c213_AsOf31May2021_HousetonMethodistResearchInstituteMember" decimals="0">3550</us-gaap:AccruedLiabilitiesCurrent>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c214_AsOf31May2020_MayoClinicArizonaMember" decimals="0">135515</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c215_From1Jun2020To31May2021_MayoClinicArizonaMember" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c216_From1Jun2019To31May2020_MayoClinicArizonaMember" decimals="0">17390</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c217_AsOf31May2021_MayoClinicArizonaMember" decimals="0">3750</us-gaap:AccruedLiabilitiesCurrent>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c215_From1Jun2020To31May2021_MayoClinicArizonaMember" decimals="2">0.13</bmra:BilledCommitmentPercentage>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c218_AsOf28May2020_MayoClinicJacksonvilleMember" decimals="0">135515</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c219_AsOf31May2020_MayoClinicJacksonvilleMember" decimals="0">17390</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c220_From1Jun2020To31May2021_MayoClinicJacksonvilleMember" decimals="0">22827</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c220_From1Jun2020To31May2021_MayoClinicJacksonvilleMember" decimals="2">0.17</bmra:BilledCommitmentPercentage>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c221_AsOf25Jun2020_UniversityOfTexasHealthScienceCenterMember" decimals="0">139850</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c222_From1Jun2020To31May2021_UniversityOfTexasHealthScienceCenterMember" decimals="0">4850</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c223_AsOf31May2021_UniversityOfTexasHealthScienceCenterMember" decimals="0">3750</us-gaap:AccruedLiabilitiesCurrent>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c222_From1Jun2020To31May2021_UniversityOfTexasHealthScienceCenterMember" decimals="2">0.04</bmra:BilledCommitmentPercentage>
  <bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Operating cash flows from operating leases&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;320,606 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;311,742 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:14.4pt&quot;&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Right-of-use assets obtained in exchange for&lt;br/&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0; &amp;#xa0;new operating lease liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;79,159 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Weighted average remaining lease term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5.27&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.27&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Weighted average discount rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.50%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6.50%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock>
  <us-gaap:OperatingLeasePayments unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">320606</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeasePayments unitRef="usd" contextRef="c9_From1Jun2019To31May2020" decimals="INF">311742</us-gaap:OperatingLeasePayments>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability unitRef="usd" contextRef="c0_From1Jun2020To31May2021" decimals="INF">79159</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3_AsOf31May2021">P5Y98D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4_AsOf31May2020">P6Y98D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent unitRef="pure" contextRef="c3_AsOf31May2021" decimals="4">0.0650</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent unitRef="pure" contextRef="c4_AsOf31May2020" decimals="4">0.0650</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2022&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;337,630 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2023&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;350,311 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;360,769 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2025&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;371,539 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2026&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;382,631 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;103,927 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total undiscounted lease payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,906,807 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less imputed interest&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;287,293 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total operating lease liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,619,514 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">337630</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">350311</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">360769</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">371539</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">382631</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">103927</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">1906807</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">287293</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:OperatingLeaseLiability unitRef="usd" contextRef="c3_AsOf31May2021" decimals="INF">1619514</us-gaap:OperatingLeaseLiability>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jun2020To31May2021">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,serif; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 16.2pt 0cm 0cm&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NOTE 10:&amp;#xa0;&amp;#xa0;&amp;#xa0; SUBSEQUENT EVENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Subsequent to May 31, 2021, options to purchase 1,500 shares of Biomerica common stock were exercised at the exercise price of $2.68 per share.&amp;#xa0; Proceeds to the Company were approximately $4,000.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Subsequent to May 31, 2021, the Company sold 201,553 shares of its common stock under its Form S-3 &amp;#x201c;shelf&amp;#x201d; Registration statement. The average sale price was $4.16 per share. Net proceeds to the Company were approximately $824,000.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On June 21, 2021, the Company signed an exclusive distribution and marketing agreement in Canada for its Helicobacter Pylori (H. Pylori) test.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In June 2021, the Company received a patent in Japan (#6902526) for the System and Method for a Digital Health System Providing a Food Recommendation Based on Food Sensitivity Testing. This technology is designed to allow for easier implementation of the dietary restrictions that result from InFoods&amp;#xae; diagnostic testing. This method describes using a smartphone or similar technology to identify prepared or packaged foods that contain restricted food ingredients, using barcodes or product labels.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In August 2021, the Company received a notice of allowance for a patent in Japan whose claims cover the use of the InFoods&amp;#xae; technology to diagnose and treat depression, and covers the compositions, devices and methods of depression sensitivity testing.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c224_From1Jun2021To31Aug2021_SubsequentEventMember" decimals="INF">1500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 unitRef="usdPershares" contextRef="c225_AsOf31Aug2021_SubsequentEventMember" decimals="2">2.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c224_From1Jun2021To31Aug2021_SubsequentEventMember" decimals="0">4000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c224_From1Jun2021To31Aug2021_SubsequentEventMember" decimals="INF">201553</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c225_AsOf31Aug2021_SubsequentEventMember" decimals="2">4.16</us-gaap:SharePrice>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c224_From1Jun2021To31Aug2021_SubsequentEventMember" decimals="0">824000</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>bmra-20210531.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 27 21:08:32 UTC 2021 -->
<xs:schema xmlns:bmra="http://www.biomerica.com/20210531" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" targetNamespace="http://www.biomerica.com/20210531" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20210531_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20210531_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20210531_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20210531_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet" id="bmra_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals" id="bmra_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement" id="bmra_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatementAlt0" id="bmra_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3" id="bmra_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow" id="bmra_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ORGANIZATION" id="bmra_r_ORGANIZATION">
        <link:definition>006 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" id="bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET" id="bmra_r_PROPERTYANDEQUIPMENTNET">
        <link:definition>008 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNET" id="bmra_r_INTANGIBLEASSETSNET">
        <link:definition>009 - Disclosure - INTANGIBLE ASSETS, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES" id="bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
        <link:definition>010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY" id="bmra_r_SHAREHOLDERSEQUITY">
        <link:definition>011 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INCOMETAXES" id="bmra_r_INCOMETAXES">
        <link:definition>012 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION" id="bmra_r_GEOGRAPHICINFORMATION">
        <link:definition>013 - Disclosure - GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES" id="bmra_r_COMMITMENTSANDCONTINGENCIES">
        <link:definition>014 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS" id="bmra_r_SUBSEQUENTEVENTS">
        <link:definition>015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy" id="bmra_r_AccountingPoliciesByPolicy">
        <link:definition>016 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" id="bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables" id="bmra_r_PROPERTYANDEQUIPMENTNETTables">
        <link:definition>018 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables" id="bmra_r_INTANGIBLEASSETSNETTables">
        <link:definition>019 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" id="bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
        <link:definition>020 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables" id="bmra_r_SHAREHOLDERSEQUITYTables">
        <link:definition>021 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INCOMETAXESTables" id="bmra_r_INCOMETAXESTables">
        <link:definition>022 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables" id="bmra_r_GEOGRAPHICINFORMATIONTables">
        <link:definition>023 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables" id="bmra_r_COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" id="bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/InventoriesTable" id="bmra_r_InventoriesTable">
        <link:definition>026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable" id="bmra_r_SharebasedcompensationassumptionsTable">
        <link:definition>027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable" id="bmra_r_RevenuefromcontractswithcustomersTable">
        <link:definition>028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/PropertyandequipmentnetTable" id="bmra_r_PropertyandequipmentnetTable">
        <link:definition>029 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable" id="bmra_r_IntangibleassetsnetTable">
        <link:definition>030 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Intangible assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable" id="bmra_r_ExpectedamortizationofintangibleassetsTable">
        <link:definition>031 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" id="bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
        <link:definition>032 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable" id="bmra_r_AccountspayableandaccruedexpensebalancesTable">
        <link:definition>033 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails" id="bmra_r_SHAREHOLDERSEQUITYDetails">
        <link:definition>034 - Disclosure - SHAREHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavKWZZQpVGPQgLzjYAjvzt1lMb3ldQptVWNNbJwjkia1PUcr18sUX/6/CBQxCu0zoFpf9ty/fXA1UJHl1DDNUMKOhjgQRktncUegIxnB0eiwqCWGCro0FUTrH6nNiCFTKM=] CSR-->
      <link:roleType roleURI="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable" id="bmra_r_OutstandingStockOptionsActivityTable">
        <link:definition>035 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable" id="bmra_r_NonvestedStockOptionsActivityTable">
        <link:definition>036 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/StockOptionsSummaryTable" id="bmra_r_StockOptionsSummaryTable">
        <link:definition>037 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Stock Options Summary</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INCOMETAXESDetails" id="bmra_r_INCOMETAXESDetails">
        <link:definition>038 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/IncometaxexpenseTable" id="bmra_r_IncometaxexpenseTable">
        <link:definition>039 - Disclosure - INCOME TAXES (Details) - Income tax expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable" id="bmra_r_IncomeTaxRateReconciliationTable">
        <link:definition>040 - Disclosure - INCOME TAXES (Details) - Income Tax Rate Reconciliation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/DeferredTaxTable" id="bmra_r_DeferredTaxTable">
        <link:definition>041 - Disclosure - INCOME TAXES (Details) - Deferred Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails" id="bmra_r_GEOGRAPHICINFORMATIONDetails">
        <link:definition>042 - Disclosure - GEOGRAPHIC INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable" id="bmra_r_GeographicinformationregardingnetsalesTable">
        <link:definition>043 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails" id="bmra_r_COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable" id="bmra_r_SupplementalcashflowinformationrelatedtoleasesTable">
        <link:definition>045 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable" id="bmra_r_ThematurityofleaseliabilitiesTable">
        <link:definition>046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - The maturity of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails" id="bmra_r_SUBSEQUENTEVENTSDetails">
        <link:definition>047 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xs:element name="InventoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_InventoriesAbstract"/>
  <xs:element name="ShareBasedCompensationAssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ShareBasedCompensationAssumptionsAbstract"/>
  <xs:element name="RevenueFromContractsWithCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RevenueFromContractsWithCustomersAbstract"/>
  <xs:element name="PropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PropertyAndEquipmentNetAbstract"/>
  <xs:element name="IntangibleAssetsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IntangibleAssetsNetAbstract"/>
  <xs:element name="ExpectedAmortizationOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
  <xs:element name="AccountsPayableAndAccruedExpenseBalancesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
  <xs:element name="OutstandingStockOptionsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OutstandingStockOptionsActivityAbstract"/>
  <xs:element name="NonVestedStockOptionsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_NonVestedStockOptionsActivityAbstract"/>
  <xs:element name="StockOptionsSummaryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_StockOptionsSummaryAbstract"/>
  <xs:element name="IncomeTaxExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncomeTaxExpenseAbstract"/>
  <xs:element name="IncomeTaxRateReconciliationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncomeTaxRateReconciliationAbstract"/>
  <xs:element name="DeferredTaxAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAbstract"/>
  <xs:element name="GeographicInformationDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationDisclosureAbstract"/>
  <xs:element name="GeographicInformationRegardingNetSalesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationRegardingNetSalesAbstract"/>
  <xs:element name="SupplementalCashFlowInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
  <xs:element name="TheMaturityOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00"/>
  <xs:element name="SupplementalDisclosureOfCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SupplementalDisclosureOfCashFlowInformationAbstract"/>
  <xs:element name="CashPaidDuringTheYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_CashPaidDuringTheYearForAbstract"/>
  <xs:element name="TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract"/>
  <xs:element name="IncreaseReductionInIncomeTaxesResultingFromAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAssetsAbstract"/>
  <xs:element name="RevenuesFromSalesToUnaffiliatedCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract"/>
  <xs:element name="OperatingLeaseRightOfUseAssetAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
  <xs:element name="PreferredStockUndesignatedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bmra_PreferredStockUndesignatedShares"/>
  <xs:element name="StockIssuedDuringPeriodValuePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_StockIssuedDuringPeriodValuePreferredStock"/>
  <xs:element name="StockIssuedDuringPeriodSharesPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_StockIssuedDuringPeriodSharesPreferredStock"/>
  <xs:element name="IncreaseDecreaseInDeferredRentLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseDecreaseInDeferredRentLiability"/>
  <xs:element name="OperatingLeaseRightofUseAssetAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_OperatingLeaseRightofUseAssetAmortization"/>
  <xs:element name="IncreaseDecreaseInLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseDecreaseInLeaseLiability"/>
  <xs:element name="IncreaseInRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseInRightOfUseAsset"/>
  <xs:element name="IncreaseInLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseInLeaseLiability"/>
  <xs:element name="GeographicInformationDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationDisclosureTextBlock"/>
  <xs:element name="MarketsAndMethodsOfDistributionPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock"/>
  <xs:element name="LiquidityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_LiquidityPolicyTextBlock"/>
  <xs:element name="ConcentrationRiskGeographicPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
  <xs:element name="PrepaidsPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PrepaidsPolicyPolicyTextBlock"/>
  <xs:element name="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
  <xs:element name="Equipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_Equipment"/>
  <xs:element name="FurnitureFixturesAndLeaseholdImprovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_FurnitureFixturesAndLeaseholdImprovements"/>
  <xs:element name="FiniteLivedLicenseAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_FiniteLivedLicenseAccumulatedAmortization"/>
  <xs:element name="FiniteLivedPatentsAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_FiniteLivedPatentsAccumulatedAmortization"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems"/>
  <xs:element name="DefferedTaxAssetsStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_DefferedTaxAssetsStockOptions"/>
  <xs:element name="DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
  <xs:element name="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
  <xs:element name="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
  <xs:element name="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
  <xs:element name="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SHAREHOLDERSEQUITYDetailsTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
  <xs:element name="INCOMETAXESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_INCOMETAXESDetailsTable"/>
  <xs:element name="INCOMETAXESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_INCOMETAXESDetailsLineItems"/>
  <xs:element name="PropertySubjectToOrAvailableForOperatingLease_Domain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
  <xs:element name="COMMITMENTSANDCONTINGENCIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
  <xs:element name="COMMITMENTSANDCONTINGENCIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems"/>
  <xs:element name="OperatingLeasesRentExpensesMinimumRentals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_OperatingLeasesRentExpensesMinimumRentals"/>
  <xs:element name="RentalExpenseIncreaseDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_RentalExpenseIncreaseDuringPeriod"/>
  <xs:element name="RentalExpenseIncreaseDuringThePeriodPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RentalExpenseIncreaseDuringThePeriodPercentage"/>
  <xs:element name="LeaseExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_LeaseExpirationPeriod"/>
  <xs:element name="RoyaltyExpensePercentageOfSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RoyaltyExpensePercentageOfSales"/>
  <xs:element name="RoyaltyPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RoyaltyPercentage"/>
  <xs:element name="LicenseMaintenanceFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_LicenseMaintenanceFeePayable"/>
  <xs:element name="ClinicalTrialAgreementMaximumBudgetedCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
  <xs:element name="BilledCommitmentPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BilledCommitmentPercentage"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SUBSEQUENTEVENTSDetailsTable"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
  <xs:element name="A2010PlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2010PlanMember"/>
  <xs:element name="A2014PlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2014PlanMember"/>
  <xs:element name="A2017PlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2017PlanMember"/>
  <xs:element name="A2020PlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2020PlanMember"/>
  <xs:element name="A5ConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A5ConvertiblePreferredStockMember"/>
  <xs:element name="ATMAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ATMAgreementMember"/>
  <xs:element name="AtMarketIssuanceSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_AtMarketIssuanceSalesAgreementMember"/>
  <xs:element name="BiomericaHPStoolAntigenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BiomericaHPStoolAntigenMember"/>
  <xs:element name="BiomericaHPyloriProductMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BiomericaHPyloriProductMember"/>
  <xs:element name="BiomericaInFoodsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BiomericaInFoodsMember"/>
  <xs:element name="BuildingInIrvineCaliforniaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BuildingInIrvineCaliforniaMember"/>
  <xs:element name="CaliforniaStateIncomeTaxMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_CaliforniaStateIncomeTaxMember"/>
  <xs:element name="ClinicalLabMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ClinicalLabMember"/>
  <xs:element name="ContractManufacturingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ContractManufacturingMember"/>
  <xs:element name="DistributorsInChinaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DistributorsInChinaMember"/>
  <xs:element name="ExercisePriceRangePerShare082362Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare082362Member"/>
  <xs:element name="ExercisePriceRangePerShare082390Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare082390Member"/>
  <xs:element name="ExercisePriceRangePerShare082818Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare082818Member"/>
  <xs:element name="ExercisePriceRangePerShare082870Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare082870Member"/>
  <xs:element name="ExercisePriceRangePerShare085818Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare085818Member"/>
  <xs:element name="ExercisePriceRangePerShare235818Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare235818Member"/>
  <xs:element name="ExercisePriceRangePerShare268818Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare268818Member"/>
  <xs:element name="ExercisePriceRangePerShare514870Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare514870Member"/>
  <xs:element name="FirstAmendmentToLeaseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_FirstAmendmentToLeaseMember"/>
  <xs:element name="HousetonMethodistResearchInstituteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_HousetonMethodistResearchInstituteMember"/>
  <xs:element name="LabSuppliesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_LabSuppliesMember"/>
  <xs:element name="MayoClinicArizonaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MayoClinicArizonaMember"/>
  <xs:element name="MayoClinicJacksonvilleMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MayoClinicJacksonvilleMember"/>
  <xs:element name="MedicalPracticeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MedicalPracticeMember"/>
  <xs:element name="MountSinaiLicenseAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MountSinaiLicenseAgreementsMember"/>
  <xs:element name="OneDistributorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OneDistributorsMember"/>
  <xs:element name="OneVendorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OneVendorMember"/>
  <xs:element name="OtherMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OtherMember"/>
  <xs:element name="OverthecounterMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OverthecounterMember"/>
  <xs:element name="PhysiciansOfficeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PhysiciansOfficeMember"/>
  <xs:element name="PurchasedTechnologyRightsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PurchasedTechnologyRightsMember"/>
  <xs:element name="RangeOfExercisePrice082104Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RangeOfExercisePrice082104Member"/>
  <xs:element name="RangeOfExercisePrice120281Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RangeOfExercisePrice120281Member"/>
  <xs:element name="RangeOfExercisePrice362870Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RangeOfExercisePrice362870Member"/>
  <xs:element name="RegistrationRightsAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RegistrationRightsAgreementMember"/>
  <xs:element name="TelconAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TelconAgreementMember"/>
  <xs:element name="ThreeDistributorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ThreeDistributorsMember"/>
  <xs:element name="TwoDistributorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TwoDistributorsMember"/>
  <xs:element name="TwoVendorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TwoVendorsMember"/>
  <xs:element name="UCLicenseAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UCLicenseAgreementsMember"/>
  <xs:element name="UniversityOFBethIsraelDeaconessMedicalCenterMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember"/>
  <xs:element name="UniversityOFMichiganMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UniversityOFMichiganMember"/>
  <xs:element name="UniversityOFSouthernCaliforniaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UniversityOFSouthernCaliforniaMember"/>
  <xs:element name="UniversityOfTexasHealthScienceCenterMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UniversityOfTexasHealthScienceCenterMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>bmra-20210531_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 27 21:08:32 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_PropertyandequipmentnetTable" roleURI="http://www.biomerica.com/role/PropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_IntangibleassetsnetTable" roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ExpectedamortizationofintangibleassetsTable" roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_AccountspayableandaccruedexpensebalancesTable" roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_IncometaxexpenseTable" roleURI="http://www.biomerica.com/role/IncometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_DeferredTaxTable" roleURI="http://www.biomerica.com/role/DeferredTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ThematurityofleaseliabilitiesTable" roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Investments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionPlanExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseDecreaseInDeferredRentLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bmra_IncreaseDecreaseInDeferredRentLiability" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:href="bmra-20210531.xsd#bmra_OperatingLeaseRightofUseAssetAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bmra_OperatingLeaseRightofUseAssetAmortization" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bmra_IncreaseDecreaseInLeaseLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="14" weight="-1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavKWZZQpVGPQgLzjYAjvzt1lMb3ldQptVWNNbJwjkia1PUcr18sUX/6/CBQxCu0zoFpf9ty/fXA1UJHl1DDNUMKOhjgQRktncV0LGXCJAYv622TM2H9q43r] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="bmra_Equipment" xlink:href="bmra-20210531.xsd#bmra_Equipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="bmra_Equipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:href="bmra-20210531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovements"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovements" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IntangibleassetsnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedPatentsGross" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization" order="4" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DeferredTaxTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_DefferedTaxAssetsStockOptions" xlink:href="bmra-20210531.xsd#bmra_DefferedTaxAssetsStockOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bmra_DefferedTaxAssetsStockOptions" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>bmra-20210531_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 27 21:08:32 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ShareholdersEquityType2or3" roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ORGANIZATION" roleURI="http://www.biomerica.com/role/ORGANIZATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_PROPERTYANDEQUIPMENTNET" roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INTANGIBLEASSETSNET" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSES" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SHAREHOLDERSEQUITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INCOMETAXES" roleURI="http://www.biomerica.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_GEOGRAPHICINFORMATION" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUBSEQUENTEVENTS" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_AccountingPoliciesByPolicy" roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_PROPERTYANDEQUIPMENTNETTables" roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INTANGIBLEASSETSNETTables" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SHAREHOLDERSEQUITYTables" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INCOMETAXESTables" roleURI="http://www.biomerica.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_GEOGRAPHICINFORMATIONTables" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SharebasedcompensationassumptionsTable" roleURI="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_RevenuefromcontractswithcustomersTable" roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_PropertyandequipmentnetTable" roleURI="http://www.biomerica.com/role/PropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_IntangibleassetsnetTable" roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ExpectedamortizationofintangibleassetsTable" roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_AccountspayableandaccruedexpensebalancesTable" roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_OutstandingStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_NonvestedStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_StockOptionsSummaryTable" roleURI="http://www.biomerica.com/role/StockOptionsSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_IncometaxexpenseTable" roleURI="http://www.biomerica.com/role/IncometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_IncomeTaxRateReconciliationTable" roleURI="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_DeferredTaxTable" roleURI="http://www.biomerica.com/role/DeferredTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_GeographicinformationregardingnetsalesTable" roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ThematurityofleaseliabilitiesTable" roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SHAREHOLDERSEQUITYDetails" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INCOMETAXESDetails" roleURI="http://www.biomerica.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_GEOGRAPHICINFORMATIONDetails" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUBSEQUENTEVENTSDetails" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#DocumentAndEntityInformation" roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="bmra_A5ConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Investments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_CommitmentsAndContingencies" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="bmra_A5ConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PreferredStockUndesignatedShares" xlink:href="bmra-20210531.xsd#bmra_PreferredStockUndesignatedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_PreferredStockUndesignatedShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_GrossProfit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="bmra_A5ConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_StockIssuedDuringPeriodValuePreferredStock" xlink:href="bmra-20210531.xsd#bmra_StockIssuedDuringPeriodValuePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_StockIssuedDuringPeriodValuePreferredStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:href="bmra-20210531.xsd#bmra_StockIssuedDuringPeriodSharesPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_StockIssuedDuringPeriodSharesPreferredStock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseDecreaseInDeferredRentLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bmra_IncreaseDecreaseInDeferredRentLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:href="bmra-20210531.xsd#bmra_OperatingLeaseRightofUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bmra_OperatingLeaseRightofUseAssetAmortization" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bmra_IncreaseDecreaseInLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_CashPaidDuringTheYearForAbstract" xlink:href="bmra-20210531.xsd#bmra_CashPaidDuringTheYearForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="bmra_CashPaidDuringTheYearForAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_CashPaidDuringTheYearForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_CashPaidDuringTheYearForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseInRightOfUseAsset" xlink:href="bmra-20210531.xsd#bmra_IncreaseInRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_IncreaseInRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseInLeaseLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseInLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_IncreaseInLeaseLiability" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ORGANIZATION">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNET">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXES">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATION">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureTextBlock" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="bmra_GeographicInformationDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_MarketsAndMethodsOfDistributionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LiquidityPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_LiquidityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_LiquidityPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_PrepaidsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20210531.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="bmra_InventoriesAbstract" xlink:href="bmra-20210531.xsd#bmra_InventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable">
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalLabMember" xlink:href="bmra-20210531.xsd#bmra_ClinicalLabMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_ClinicalLabMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PhysiciansOfficeMember" xlink:href="bmra-20210531.xsd#bmra_PhysiciansOfficeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_PhysiciansOfficeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OverthecounterMember" xlink:href="bmra-20210531.xsd#bmra_OverthecounterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_OverthecounterMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractManufacturingMember" xlink:href="bmra-20210531.xsd#bmra_ContractManufacturingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_ContractManufacturingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LabSuppliesMember" xlink:href="bmra-20210531.xsd#bmra_LabSuppliesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_LabSuppliesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="bmra_PropertyAndEquipmentNetAbstract" xlink:href="bmra-20210531.xsd#bmra_PropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_Equipment" xlink:href="bmra-20210531.xsd#bmra_Equipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="bmra_Equipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:href="bmra-20210531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovements" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IntangibleassetsnetTable">
    <loc xlink:type="locator" xlink:label="bmra_IntangibleAssetsNetAbstract" xlink:href="bmra-20210531.xsd#bmra_IntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedPatentsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:href="bmra-20210531.xsd#bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable">
    <loc xlink:type="locator" xlink:label="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:href="bmra-20210531.xsd#bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082390Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082390Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare082390Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare268818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare268818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare268818Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare085818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare085818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare085818Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare082818Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare514870Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare514870Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare514870Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082362Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082362Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare082362Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare235818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare235818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare235818Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082870Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082870Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare082870Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="bmra_NonVestedStockOptionsActivityAbstract" xlink:href="bmra-20210531.xsd#bmra_NonVestedStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/StockOptionsSummaryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice082104Member" xlink:href="bmra-20210531.xsd#bmra_RangeOfExercisePrice082104Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_RangeOfExercisePrice082104Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice120281Member" xlink:href="bmra-20210531.xsd#bmra_RangeOfExercisePrice120281Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_RangeOfExercisePrice120281Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice362870Member" xlink:href="bmra-20210531.xsd#bmra_RangeOfExercisePrice362870Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_RangeOfExercisePrice362870Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="7" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavKWZZQpVGPQgLzjYAjvzt1lMb3ldQptVWNNbJwjkia1PUcr18sUX/6/CBQxCu0zoFpf9ty/fXA1UJHl1DDNUMKOhjgQRktncU+Luh9IUkPp2reBbkbl2NKHGEIZtIZzBg=] CSR-->
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxExpenseAbstract" xlink:href="bmra-20210531.xsd#bmra_IncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable">
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxRateReconciliationAbstract" xlink:href="bmra-20210531.xsd#bmra_IncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="bmra-20210531.xsd#bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DeferredTaxTable">
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAbstract" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAbstract" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DefferedTaxAssetsStockOptions" xlink:href="bmra-20210531.xsd#bmra_DefferedTaxAssetsStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DefferedTaxAssetsStockOptions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable">
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20210531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20210531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="srt_StatementGeographicalAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SouthAmericaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SouthAmericaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MiddleEastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_MiddleEastMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OtherMember" xlink:href="bmra-20210531.xsd#bmra_OtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="bmra_OtherMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueSegmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:href="bmra-20210531.xsd#bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20210531.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:href="bmra-20210531.xsd#bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoDistributorsMember" xlink:href="bmra-20210531.xsd#bmra_TwoDistributorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_TwoDistributorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ThreeDistributorsMember" xlink:href="bmra-20210531.xsd#bmra_ThreeDistributorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_ThreeDistributorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OneDistributorsMember" xlink:href="bmra-20210531.xsd#bmra_OneDistributorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_OneDistributorsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20210531.xsd#bmra_OneVendorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_OneVendorMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ATMAgreementMember" xlink:href="bmra-20210531.xsd#bmra_ATMAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_ATMAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DistributorsInChinaMember" xlink:href="bmra-20210531.xsd#bmra_DistributorsInChinaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_DistributorsInChinaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DistributionRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PurchasedTechnologyRightsMember" xlink:href="bmra-20210531.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bmra_PurchasedTechnologyRightsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="bmra_A5ConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MX" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_CostOfGoodsProductLineMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:href="bmra-20210531.xsd#bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashUninsuredAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryGross" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryLIFOReserve" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20210531.xsd#bmra_OneVendorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_OneVendorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoVendorsMember" xlink:href="bmra-20210531.xsd#bmra_TwoVendorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_TwoVendorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails">
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_TransactionTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="bmra_A5ConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2010PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2010PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2010PlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2014PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2014PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2014PlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2017PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2017PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2017PlanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2020PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2020PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2020PlanMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RegistrationRightsAgreementMember" xlink:href="bmra-20210531.xsd#bmra_RegistrationRightsAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="bmra_RegistrationRightsAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_AtMarketIssuanceSalesAgreementMember" xlink:href="bmra-20210531.xsd#bmra_AtMarketIssuanceSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bmra_AtMarketIssuanceSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESDetails">
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_INCOMETAXESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_INCOMETAXESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="bmra_INCOMETAXESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_CaliforniaStateIncomeTaxMember" xlink:href="bmra-20210531.xsd#bmra_CaliforniaStateIncomeTaxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="bmra_CaliforniaStateIncomeTaxMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails">
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20210531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_0" xlink:href="bmra-20210531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BuildingInIrvineCaliforniaMember" xlink:href="bmra-20210531.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="bmra_BuildingInIrvineCaliforniaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFSouthernCaliforniaMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOFSouthernCaliforniaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_UniversityOFSouthernCaliforniaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFMichiganMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOFMichiganMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_UniversityOFMichiganMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaHPStoolAntigenMember" xlink:href="bmra-20210531.xsd#bmra_BiomericaHPStoolAntigenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_BiomericaHPStoolAntigenMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaInFoodsMember" xlink:href="bmra-20210531.xsd#bmra_BiomericaInFoodsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_BiomericaInFoodsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MedicalPracticeMember" xlink:href="bmra-20210531.xsd#bmra_MedicalPracticeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_MedicalPracticeMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaHPyloriProductMember" xlink:href="bmra-20210531.xsd#bmra_BiomericaHPyloriProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_BiomericaHPyloriProductMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_HousetonMethodistResearchInstituteMember" xlink:href="bmra-20210531.xsd#bmra_HousetonMethodistResearchInstituteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_HousetonMethodistResearchInstituteMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MayoClinicArizonaMember" xlink:href="bmra-20210531.xsd#bmra_MayoClinicArizonaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_MayoClinicArizonaMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MayoClinicJacksonvilleMember" xlink:href="bmra-20210531.xsd#bmra_MayoClinicJacksonvilleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_MayoClinicJacksonvilleMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOfTexasHealthScienceCenterMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOfTexasHealthScienceCenterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_UniversityOfTexasHealthScienceCenterMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FirstAmendmentToLeaseMember" xlink:href="bmra-20210531.xsd#bmra_FirstAmendmentToLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_FirstAmendmentToLeaseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RoyaltyAgreementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TelconAgreementMember" xlink:href="bmra-20210531.xsd#bmra_TelconAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_TelconAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MountSinaiLicenseAgreementsMember" xlink:href="bmra-20210531.xsd#bmra_MountSinaiLicenseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_MountSinaiLicenseAgreementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UCLicenseAgreementsMember" xlink:href="bmra-20210531.xsd#bmra_UCLicenseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_UCLicenseAgreementsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MX" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeasesRentExpensesMinimumRentals" xlink:href="bmra-20210531.xsd#bmra_OperatingLeasesRentExpensesMinimumRentals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_OperatingLeasesRentExpensesMinimumRentals" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod" xlink:href="bmra-20210531.xsd#bmra_RentalExpenseIncreaseDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_RentalExpenseIncreaseDuringPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RentalExpenseIncreaseDuringThePeriodPercentage" xlink:href="bmra-20210531.xsd#bmra_RentalExpenseIncreaseDuringThePeriodPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_RentalExpenseIncreaseDuringThePeriodPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseDepositLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseDepositLiability" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseExpirationPeriod" xlink:href="bmra-20210531.xsd#bmra_LeaseExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_LeaseExpirationPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyExpensePercentageOfSales" xlink:href="bmra-20210531.xsd#bmra_RoyaltyExpensePercentageOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_RoyaltyExpensePercentageOfSales" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedFeesAndOtherRevenueReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyPercentage" xlink:href="bmra-20210531.xsd#bmra_RoyaltyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_RoyaltyPercentage" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_PaymentsForFees" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LicenseMaintenanceFeePayable" xlink:href="bmra-20210531.xsd#bmra_LicenseMaintenanceFeePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_LicenseMaintenanceFeePayable" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20210531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BilledCommitmentPercentage" xlink:href="bmra-20210531.xsd#bmra_BilledCommitmentPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_BilledCommitmentPercentage" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails">
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:href="bmra-20210531.xsd#bmra_SUBSEQUENTEVENTSDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="bmra_SUBSEQUENTEVENTSDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="18" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>bmra-20210531_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 27 21:08:32 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and cash equivalents at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and cash equivalents at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, less allowance for doubtful accounts of $837,415 and $70,981 as of May 31, 2021 and 2020, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $1,972,357 and $1,867,643 as of May 31, 2021 and 2020, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Net property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets, net of accumulated amortization of $469,077 and $231,489 as of May 31, 2021 and 2020, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization, Right of Use Assets (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization of $126,769 and $496,124 as of May 31, 2021 and 2020, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible asssets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization, Intangible Assets (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Notes 1 and 9)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" xml:lang="en-US">Equity Interest Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US">Preferred Stock, No Par Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PreferredStockUndesignatedShares" xlink:href="bmra-20210531.xsd#bmra_PreferredStockUndesignatedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PreferredStockUndesignatedShares_lbl" xml:lang="en-US">Preferred Stock, undesignated shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PreferredStockUndesignatedShares" xlink:to="bmra_PreferredStockUndesignatedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.08 par value, 25,000,000 shares authorized, 12,307,157 and 11,740,089 issued and outstanding at May 31, 2021 and 2020, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Dividend and interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Options exercised, number of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="bmra_StockIssuedDuringPeriodValuePreferredStock" xlink:href="bmra-20210531.xsd#bmra_StockIssuedDuringPeriodValuePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_StockIssuedDuringPeriodValuePreferredStock_lbl" xml:lang="en-US">Issuance of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodValuePreferredStock" xlink:to="bmra_StockIssuedDuringPeriodValuePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:href="bmra-20210531.xsd#bmra_StockIssuedDuringPeriodSharesPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl" xml:lang="en-US">Issuance of preferred stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:to="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of preferred to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of preferred to common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation expense in connection with options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Change in allowance on accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseDecreaseInDeferredRentLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability_lbl" xml:lang="en-US">Reduction in deferred rent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:to="bmra_IncreaseDecreaseInDeferredRentLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:href="bmra-20210531.xsd#bmra_OperatingLeaseRightofUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:to="bmra_OperatingLeaseRightofUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseDecreaseInLeaseLiability_lbl" xml:lang="en-US">Reduction in lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInLeaseLiability" xlink:to="bmra_IncreaseDecreaseInLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Increase in intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from sale of convertible preferred stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseInRightOfUseAsset" xlink:href="bmra-20210531.xsd#bmra_IncreaseInRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseInRightOfUseAsset_lbl" xml:lang="en-US">Increase in right of use asset due to lease extension or establishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseInRightOfUseAsset" xlink:to="bmra_IncreaseInRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseInLeaseLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseInLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseInLeaseLiability_lbl" xml:lang="en-US">Increase in lease liability due to lease extension or establishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseInLeaseLiability" xlink:to="bmra_IncreaseInLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_InventoriesAbstract" xlink:href="bmra-20210531.xsd#bmra_InventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_InventoriesAbstract_lbl" xml:lang="en-US">Inventories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_InventoriesAbstract" xlink:to="bmra_InventoriesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ShareBasedCompensationAssumptionsAbstract" xlink:href="bmra-20210531.xsd#bmra_ShareBasedCompensationAssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ShareBasedCompensationAssumptionsAbstract_lbl" xml:lang="en-US">Share based compensation assumptions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShareBasedCompensationAssumptionsAbstract" xlink:to="bmra_ShareBasedCompensationAssumptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RevenueFromContractsWithCustomersAbstract" xlink:href="bmra-20210531.xsd#bmra_RevenueFromContractsWithCustomersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RevenueFromContractsWithCustomersAbstract_lbl" xml:lang="en-US">Revenue from contracts with customers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RevenueFromContractsWithCustomersAbstract" xlink:to="bmra_RevenueFromContractsWithCustomersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue From Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertyAndEquipmentNetAbstract" xlink:href="bmra-20210531.xsd#bmra_PropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property and equipment, net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PropertyAndEquipmentNetAbstract" xlink:to="bmra_PropertyAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_Equipment" xlink:href="bmra-20210531.xsd#bmra_Equipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_Equipment_lbl" xml:lang="en-US">Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_Equipment" xlink:to="bmra_Equipment_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:href="bmra-20210531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements_lbl" xml:lang="en-US">Furniture, fixtures and leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IntangibleAssetsNetAbstract" xlink:href="bmra-20210531.xsd#bmra_IntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Intangible assets, net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="bmra_IntangibleAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross_lbl" xml:lang="en-US">Licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization-licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization-patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:href="bmra-20210531.xsd#bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Expected amortization of intangible assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:href="bmra-20210531.xsd#bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract_lbl" xml:lang="en-US">Accounts payable and accrued expense balances [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OutstandingStockOptionsActivityAbstract" xlink:href="bmra-20210531.xsd#bmra_OutstandingStockOptionsActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OutstandingStockOptionsActivityAbstract_lbl" xml:lang="en-US">Outstanding Stock Options Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OutstandingStockOptionsActivityAbstract" xlink:to="bmra_OutstandingStockOptionsActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, number of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Options outstanding, number of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options outstanding, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted, number of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Granted, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options granted, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercised, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options canceled or expired, number of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options canceled or expired, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_NonVestedStockOptionsActivityAbstract" xlink:href="bmra-20210531.xsd#bmra_NonVestedStockOptionsActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_NonVestedStockOptionsActivityAbstract_lbl" xml:lang="en-US">Non-vested Stock Options Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="bmra_NonVestedStockOptionsActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Non-vested shares, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Non-vested shares, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non-vested shares, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Non-vested shares, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Forfeited, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_StockOptionsSummaryAbstract" xlink:href="bmra-20210531.xsd#bmra_StockOptionsSummaryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_StockOptionsSummaryAbstract_lbl" xml:lang="en-US">Stock Options Summary [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockOptionsSummaryAbstract" xlink:to="bmra_StockOptionsSummaryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding, Number (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable, Number (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxExpenseAbstract" xlink:href="bmra-20210531.xsd#bmra_IncomeTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncomeTaxExpenseAbstract_lbl" xml:lang="en-US">Income tax expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="bmra_IncomeTaxExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign Taxes Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxRateReconciliationAbstract" xlink:href="bmra-20210531.xsd#bmra_IncomeTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncomeTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Income Tax Rate Reconciliation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="bmra_IncomeTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed &quot;expected&quot; tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Permanent tax differences and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign taxes of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAbstract" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAbstract_lbl" xml:lang="en-US">Deferred Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DeferredTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Accounts receivable, principally due to allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory valuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US">Compensated absences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US">Deferred rent expense/Capitalized leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DefferedTaxAssetsStockOptions" xlink:href="bmra-20210531.xsd#bmra_DefferedTaxAssetsStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DefferedTaxAssetsStockOptions_lbl" xml:lang="en-US">Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DefferedTaxAssetsStockOptions" xlink:to="bmra_DefferedTaxAssetsStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl" xml:lang="en-US">Losses of foreign subsidiaries &amp; Other, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:to="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationDisclosureAbstract_lbl" xml:lang="en-US">Geographic Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="bmra_GeographicInformationDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationRegardingNetSalesAbstract" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationRegardingNetSalesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationRegardingNetSalesAbstract_lbl" xml:lang="en-US">Geographic information regarding net sales [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationRegardingNetSalesAbstract" xlink:to="bmra_GeographicInformationRegardingNetSalesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Net Sales Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20210531.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Supplemental cash flow information related to leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:href="bmra-20210531.xsd#bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TheMaturityOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">The maturity of lease liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="bmra_TheMaturityOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&apos; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, none issued and outstanding at May 31, 2021 and 321,429 issued and outstanding at May 31, 2020 and Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding at May 31, 2021 and 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" xlink:href="bmra-20210531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of common and common equivalent shares:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss, net of tax:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" xlink:href="bmra-20210531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00" xlink:href="bmra-20210531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:href="bmra-20210531.xsd#bmra_SupplementalDisclosureOfCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SupplementalDisclosureOfCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Cash-Flow Information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="bmra_SupplementalDisclosureOfCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_CashPaidDuringTheYearForAbstract" xlink:href="bmra-20210531.xsd#bmra_CashPaidDuringTheYearForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_CashPaidDuringTheYearForAbstract_lbl" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringTheYearForAbstract" xlink:to="bmra_CashPaidDuringTheYearForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" xlink:href="bmra-20210531.xsd#bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl" xml:lang="en-US">The accompanying notes are an integral part of these statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A5ConvertiblePreferredStockMember_lbl" xml:lang="en-US">5% Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A5ConvertiblePreferredStockMember" xlink:to="bmra_A5ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="bmra-20210531.xsd#bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl" xml:lang="en-US">Increase (reduction) in income taxes resulting from:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAbstract" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="bmra_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureTextBlock" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl" xml:lang="en-US">Geographic Information Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:href="bmra-20210531.xsd#bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract_lbl" xml:lang="en-US">Revenues from sales to unaffiliated customers:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20210531.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl" xml:lang="en-US">Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalLabMember" xlink:href="bmra-20210531.xsd#bmra_ClinicalLabMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ClinicalLabMember_lbl" xml:lang="en-US">Clinical Lab [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalLabMember" xlink:to="bmra_ClinicalLabMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PhysiciansOfficeMember" xlink:href="bmra-20210531.xsd#bmra_PhysiciansOfficeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PhysiciansOfficeMember_lbl" xml:lang="en-US">Physicians Office [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PhysiciansOfficeMember" xlink:to="bmra_PhysiciansOfficeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OverthecounterMember" xlink:href="bmra-20210531.xsd#bmra_OverthecounterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OverthecounterMember_lbl" xml:lang="en-US">Over-the-counter [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OverthecounterMember" xlink:to="bmra_OverthecounterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractManufacturingMember" xlink:href="bmra-20210531.xsd#bmra_ContractManufacturingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ContractManufacturingMember_lbl" xml:lang="en-US">Contract Manufacturing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractManufacturingMember" xlink:to="bmra_ContractManufacturingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LabSuppliesMember" xlink:href="bmra-20210531.xsd#bmra_LabSuppliesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LabSuppliesMember_lbl" xml:lang="en-US">Lab Supplies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LabSuppliesMember" xlink:to="bmra_LabSuppliesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082390Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082390Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare082390Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.82 - $3.90 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082390Member" xlink:to="bmra_ExercisePriceRangePerShare082390Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare268818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare268818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare268818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $2.68 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare268818Member" xlink:to="bmra_ExercisePriceRangePerShare268818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare085818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare085818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare085818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.85 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare085818Member" xlink:to="bmra_ExercisePriceRangePerShare085818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare082818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.82 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082818Member" xlink:to="bmra_ExercisePriceRangePerShare082818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare514870Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare514870Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare514870Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $5.14 - $8.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare514870Member" xlink:to="bmra_ExercisePriceRangePerShare514870Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082362Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082362Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare082362Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.82 - $3.62 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082362Member" xlink:to="bmra_ExercisePriceRangePerShare082362Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare235818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare235818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare235818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $2.35 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare235818Member" xlink:to="bmra_ExercisePriceRangePerShare235818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082870Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082870Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare082870Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.82 - $8.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082870Member" xlink:to="bmra_ExercisePriceRangePerShare082870Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice082104Member" xlink:href="bmra-20210531.xsd#bmra_RangeOfExercisePrice082104Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RangeOfExercisePrice082104Member_lbl" xml:lang="en-US">Range Of Exercise Price $0.82 - $1.04 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice082104Member" xlink:to="bmra_RangeOfExercisePrice082104Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice120281Member" xlink:href="bmra-20210531.xsd#bmra_RangeOfExercisePrice120281Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RangeOfExercisePrice120281Member_lbl" xml:lang="en-US">Range Of Exercise Price $1.20 - $2.81 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice120281Member" xlink:to="bmra_RangeOfExercisePrice120281Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice362870Member" xlink:href="bmra-20210531.xsd#bmra_RangeOfExercisePrice362870Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RangeOfExercisePrice362870Member_lbl" xml:lang="en-US">Range Of Exercise Price $3.62 - $8.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice362870Member" xlink:to="bmra_RangeOfExercisePrice362870Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_AsiaMember_lbl" xml:lang="en-US">Asia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SouthAmericaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SouthAmericaMember_lbl" xml:lang="en-US">South America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SouthAmericaMember" xlink:to="srt_SouthAmericaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MiddleEastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MiddleEastMember_lbl" xml:lang="en-US">Middle East [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MiddleEastMember" xlink:to="us-gaap_MiddleEastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OtherMember" xlink:href="bmra-20210531.xsd#bmra_OtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OtherMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OtherMember" xlink:to="bmra_OtherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueSegmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueSegmentMember_lbl" xml:lang="en-US">Revenue, Segment Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueSegmentMember" xlink:to="us-gaap_SalesRevenueSegmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xml:lang="en-US">Geographic Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:href="bmra-20210531.xsd#bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl" xml:lang="en-US">Shelf Registration Statement, Maximum Authorized Common Stock Issuance, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US">Other Receivables, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl" xml:lang="en-US">Threshold Period Past Due for Write-off of Trade Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLIFOReserve_lbl" xml:lang="en-US">Inventory, LIFO Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReserve" xlink:to="us-gaap_InventoryLIFOReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavKWZZQpVGPQgLzjYAjvzt1lMb3ldQptVWNNbJwjkia1PUcr18sUX/6/CBQxCu0zoFpf9ty/fXA1UJHl1DDNUMKOhjgQRktncWh4iOUImBhOzxuE1jvruCbgfE0SvcfAbM=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of Stock, Shares Issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeasesRentExpensesMinimumRentals" xlink:href="bmra-20210531.xsd#bmra_OperatingLeasesRentExpensesMinimumRentals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OperatingLeasesRentExpensesMinimumRentals_lbl" xml:lang="en-US">Operating Leases Rent Expenses Minimum Rentals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeasesRentExpensesMinimumRentals" xlink:to="bmra_OperatingLeasesRentExpensesMinimumRentals_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod" xlink:href="bmra-20210531.xsd#bmra_RentalExpenseIncreaseDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod_lbl" xml:lang="en-US">Rental Expense, Increase During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RentalExpenseIncreaseDuringPeriod" xlink:to="bmra_RentalExpenseIncreaseDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RentalExpenseIncreaseDuringThePeriodPercentage" xlink:href="bmra-20210531.xsd#bmra_RentalExpenseIncreaseDuringThePeriodPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RentalExpenseIncreaseDuringThePeriodPercentage_lbl" xml:lang="en-US">Rental Expense, Increase During The Period, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RentalExpenseIncreaseDuringThePeriodPercentage" xlink:to="bmra_RentalExpenseIncreaseDuringThePeriodPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseDepositLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseDepositLiability_lbl" xml:lang="en-US">Lease Deposit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseDepositLiability" xlink:to="us-gaap_LeaseDepositLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseExpirationPeriod" xlink:href="bmra-20210531.xsd#bmra_LeaseExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LeaseExpirationPeriod_lbl" xml:lang="en-US">Lease Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseExpirationPeriod" xlink:to="bmra_LeaseExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyExpensePercentageOfSales" xlink:href="bmra-20210531.xsd#bmra_RoyaltyExpensePercentageOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RoyaltyExpensePercentageOfSales_lbl" xml:lang="en-US">Royalty Expense Percentage Of Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyExpensePercentageOfSales" xlink:to="bmra_RoyaltyExpensePercentageOfSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedFeesAndOtherRevenueReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl" xml:lang="en-US">Accrued Fees and Other Revenue Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Proceeds from Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyPercentage" xlink:href="bmra-20210531.xsd#bmra_RoyaltyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyPercentage" xlink:to="bmra_RoyaltyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LicenseMaintenanceFeePayable" xlink:href="bmra-20210531.xsd#bmra_LicenseMaintenanceFeePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LicenseMaintenanceFeePayable_lbl" xml:lang="en-US">License Maintenance Fee, Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LicenseMaintenanceFeePayable" xlink:to="bmra_LicenseMaintenanceFeePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20210531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl" xml:lang="en-US">Clinical Trial Agreement Maximum Budgeted Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BilledCommitmentPercentage" xlink:href="bmra-20210531.xsd#bmra_BilledCommitmentPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BilledCommitmentPercentage_lbl" xml:lang="en-US">Billed Commitment, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BilledCommitmentPercentage" xlink:to="bmra_BilledCommitmentPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_MarketsAndMethodsOfDistributionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl" xml:lang="en-US">Markets And Methods Of Distribution [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:to="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LiquidityPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_LiquidityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LiquidityPolicyTextBlock" xlink:to="bmra_LiquidityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl" xml:lang="en-US">Concentration Risk Geographic Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_PrepaidsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Prepaids Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PrepaidsPolicyPolicyTextBlock" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ATMAgreementMember" xlink:href="bmra-20210531.xsd#bmra_ATMAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ATMAgreementMember_lbl" xml:lang="en-US">ATM Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ATMAgreementMember" xlink:to="bmra_ATMAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoDistributorsMember" xlink:href="bmra-20210531.xsd#bmra_TwoDistributorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TwoDistributorsMember_lbl" xml:lang="en-US">Two Distributors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoDistributorsMember" xlink:to="bmra_TwoDistributorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ThreeDistributorsMember" xlink:href="bmra-20210531.xsd#bmra_ThreeDistributorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ThreeDistributorsMember_lbl" xml:lang="en-US">Three Distributors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ThreeDistributorsMember" xlink:to="bmra_ThreeDistributorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OneDistributorsMember" xlink:href="bmra-20210531.xsd#bmra_OneDistributorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OneDistributorsMember_lbl" xml:lang="en-US">One Distributors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneDistributorsMember" xlink:to="bmra_OneDistributorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DistributorsInChinaMember" xlink:href="bmra-20210531.xsd#bmra_DistributorsInChinaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_DistributorsInChinaMember_lbl" xml:lang="en-US">Distributors in China [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DistributorsInChinaMember" xlink:to="bmra_DistributorsInChinaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20210531.xsd#bmra_OneVendorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OneVendorMember_lbl" xml:lang="en-US">One Vendor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneVendorMember" xlink:to="bmra_OneVendorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_MX_lbl" xml:lang="en-US">MEXICO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MX" xlink:to="country_MX_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DistributionRightsMember_lbl" xml:lang="en-US">Distribution Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PurchasedTechnologyRightsMember" xlink:href="bmra-20210531.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PurchasedTechnologyRightsMember_lbl" xml:lang="en-US">Purchased Technology Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PurchasedTechnologyRightsMember" xlink:to="bmra_PurchasedTechnologyRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoVendorsMember" xlink:href="bmra-20210531.xsd#bmra_TwoVendorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TwoVendorsMember_lbl" xml:lang="en-US">Two Vendors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoVendorsMember" xlink:to="bmra_TwoVendorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2010PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2010PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2010PlanMember_lbl" xml:lang="en-US">2010 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2010PlanMember" xlink:to="bmra_A2010PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2014PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2014PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2014PlanMember_lbl" xml:lang="en-US">2014 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2014PlanMember" xlink:to="bmra_A2014PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2017PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2017PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2017PlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2017PlanMember" xlink:to="bmra_A2017PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2020PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2020PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2020PlanMember_lbl" xml:lang="en-US">2020 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2020PlanMember" xlink:to="bmra_A2020PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_AtMarketIssuanceSalesAgreementMember" xlink:href="bmra-20210531.xsd#bmra_AtMarketIssuanceSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_AtMarketIssuanceSalesAgreementMember_lbl" xml:lang="en-US">At Market Issuance Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AtMarketIssuanceSalesAgreementMember" xlink:to="bmra_AtMarketIssuanceSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RegistrationRightsAgreementMember" xlink:href="bmra-20210531.xsd#bmra_RegistrationRightsAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RegistrationRightsAgreementMember_lbl" xml:lang="en-US">Registration Rights Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RegistrationRightsAgreementMember" xlink:to="bmra_RegistrationRightsAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_CaliforniaStateIncomeTaxMember" xlink:href="bmra-20210531.xsd#bmra_CaliforniaStateIncomeTaxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_CaliforniaStateIncomeTaxMember_lbl" xml:lang="en-US">California State Income Tax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CaliforniaStateIncomeTaxMember" xlink:to="bmra_CaliforniaStateIncomeTaxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BuildingInIrvineCaliforniaMember" xlink:href="bmra-20210531.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BuildingInIrvineCaliforniaMember_lbl" xml:lang="en-US">Building In Irvine California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BuildingInIrvineCaliforniaMember" xlink:to="bmra_BuildingInIrvineCaliforniaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FirstAmendmentToLeaseMember" xlink:href="bmra-20210531.xsd#bmra_FirstAmendmentToLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_FirstAmendmentToLeaseMember_lbl" xml:lang="en-US">First Amendment To Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FirstAmendmentToLeaseMember" xlink:to="bmra_FirstAmendmentToLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl" xml:lang="en-US">Property Available for Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl" xml:lang="en-US">Royalty Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TelconAgreementMember" xlink:href="bmra-20210531.xsd#bmra_TelconAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TelconAgreementMember_lbl" xml:lang="en-US">Telcon Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TelconAgreementMember" xlink:to="bmra_TelconAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MountSinaiLicenseAgreementsMember" xlink:href="bmra-20210531.xsd#bmra_MountSinaiLicenseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MountSinaiLicenseAgreementsMember_lbl" xml:lang="en-US">Mount Sinai License Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MountSinaiLicenseAgreementsMember" xlink:to="bmra_MountSinaiLicenseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UCLicenseAgreementsMember" xlink:href="bmra-20210531.xsd#bmra_UCLicenseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UCLicenseAgreementsMember_lbl" xml:lang="en-US">UC License Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UCLicenseAgreementsMember" xlink:to="bmra_UCLicenseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFSouthernCaliforniaMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOFSouthernCaliforniaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UniversityOFSouthernCaliforniaMember_lbl" xml:lang="en-US">University OF Southern California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFSouthernCaliforniaMember" xlink:to="bmra_UniversityOFSouthernCaliforniaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFMichiganMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOFMichiganMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UniversityOFMichiganMember_lbl" xml:lang="en-US">University OF Michigan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFMichiganMember" xlink:to="bmra_UniversityOFMichiganMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember_lbl" xml:lang="en-US">University OF Beth Israel Deaconess Medical Center [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember" xlink:to="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaHPStoolAntigenMember" xlink:href="bmra-20210531.xsd#bmra_BiomericaHPStoolAntigenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BiomericaHPStoolAntigenMember_lbl" xml:lang="en-US">Biomerica HP Stool Antigen [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaHPStoolAntigenMember" xlink:to="bmra_BiomericaHPStoolAntigenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaInFoodsMember" xlink:href="bmra-20210531.xsd#bmra_BiomericaInFoodsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BiomericaInFoodsMember_lbl" xml:lang="en-US">Biomerica InFoods [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaInFoodsMember" xlink:to="bmra_BiomericaInFoodsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MedicalPracticeMember" xlink:href="bmra-20210531.xsd#bmra_MedicalPracticeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MedicalPracticeMember_lbl" xml:lang="en-US">Medical Practice [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MedicalPracticeMember" xlink:to="bmra_MedicalPracticeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaHPyloriProductMember" xlink:href="bmra-20210531.xsd#bmra_BiomericaHPyloriProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BiomericaHPyloriProductMember_lbl" xml:lang="en-US">Biomerica H. Pylori Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaHPyloriProductMember" xlink:to="bmra_BiomericaHPyloriProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_HousetonMethodistResearchInstituteMember" xlink:href="bmra-20210531.xsd#bmra_HousetonMethodistResearchInstituteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_HousetonMethodistResearchInstituteMember_lbl" xml:lang="en-US">Houseton Methodist Research Institute [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_HousetonMethodistResearchInstituteMember" xlink:to="bmra_HousetonMethodistResearchInstituteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MayoClinicArizonaMember" xlink:href="bmra-20210531.xsd#bmra_MayoClinicArizonaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MayoClinicArizonaMember_lbl" xml:lang="en-US">Mayo Clinic Arizona [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MayoClinicArizonaMember" xlink:to="bmra_MayoClinicArizonaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MayoClinicJacksonvilleMember" xlink:href="bmra-20210531.xsd#bmra_MayoClinicJacksonvilleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MayoClinicJacksonvilleMember_lbl" xml:lang="en-US">Mayo Clinic Jacksonville [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MayoClinicJacksonvilleMember" xlink:to="bmra_MayoClinicJacksonvilleMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOfTexasHealthScienceCenterMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOfTexasHealthScienceCenterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UniversityOfTexasHealthScienceCenterMember_lbl" xml:lang="en-US">University Of Texas Health Science Center [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOfTexasHealthScienceCenterMember" xlink:to="bmra_UniversityOfTexasHealthScienceCenterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - Outstanding Stock Options Activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20210531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20210531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Accounting Standards Update [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionDomain_lbl" xml:lang="en-US">Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsTable_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_INCOMETAXESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_INCOMETAXESDetailsTable_lbl" xml:lang="en-US">INCOME TAXES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="bmra_INCOMETAXESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_INCOMETAXESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_INCOMETAXESDetailsLineItems_lbl" xml:lang="en-US">INCOME TAXES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="bmra_INCOMETAXESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20210531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_lbl" xml:lang="en-US">PropertySubjectToOrAvailableForOperatingLease_ [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:href="bmra-20210531.xsd#bmra_SUBSEQUENTEVENTSDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUBSEQUENTEVENTSDetailsTable_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="bmra_SUBSEQUENTEVENTSDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUBSEQUENTEVENTSDetailsLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="bmra_SUBSEQUENTEVENTSDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_BilledCommitmentPercentage_lbl0" xml:lang="en-US">Percentage of the commitment billed during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BilledCommitmentPercentage" xlink:to="bmra_BilledCommitmentPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl0" xml:lang="en-US">The maximum budgeted costs related to clinical trial agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for the description of risks that arise due to concentrations of operating facilities, revenues, assets, customers, vendors or the like in a certain geographic area, either domestic or foreign. The description may address risks inherent in the geographic area, and, at a minimum, informs users of the general nature of the risk, but excludes &quot;Information about Geographic Areas&quot; that may be disclosed elsewhere.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accumulated depreciation and amortization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl0" xml:lang="en-US">Amount of deferred tax assets related with foreign subsidiaries and other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:to="bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_DefferedTaxAssetsStockOptions_lbl0" xml:lang="en-US">Amount of deferred tax assets related with stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DefferedTaxAssetsStockOptions" xlink:to="bmra_DefferedTaxAssetsStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_Equipment_lbl0" xml:lang="en-US">Amount before accumulated depletion of equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_Equipment" xlink:to="bmra_Equipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl0" xml:lang="en-US">Accumulated amount of amortization of licenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl0" xml:lang="en-US">Accumulated amount of amortization of patents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovements_lbl0" xml:lang="en-US">Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities and additions or improvements to assets held under a lease arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FurnitureFixturesAndLeaseholdImprovements" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl0" xml:lang="en-US">The entire disclosure for reporting segments according to the geographic areas.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability_lbl0" xml:lang="en-US">The increase (decrease) during the period in the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:to="bmra_IncreaseDecreaseInDeferredRentLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseDecreaseInLeaseLiability_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in LeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInLeaseLiability" xlink:to="bmra_IncreaseDecreaseInLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseInLeaseLiability_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in lease liability due to lease extension or establishment in noncash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseInLeaseLiability" xlink:to="bmra_IncreaseInLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseInRightOfUseAsset_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in right of use asset due to lease extension or establishment in noncash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseInRightOfUseAsset" xlink:to="bmra_IncreaseInRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_LeaseExpirationPeriod_lbl0" xml:lang="en-US">Represents the number of years in which the lease expires.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseExpirationPeriod" xlink:to="bmra_LeaseExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_LicenseMaintenanceFeePayable_lbl0" xml:lang="en-US">Amount of license maintenance fee payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LicenseMaintenanceFeePayable" xlink:to="bmra_LicenseMaintenanceFeePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_LiquidityPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for liquidity position during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LiquidityPolicyTextBlock" xlink:to="bmra_LiquidityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for Markets And Methods Of Distribution during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:to="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl0" xml:lang="en-US">Amount of accumulated amortization of right-of-use asset from operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization_lbl0" xml:lang="en-US">Amortization of Right of Use Asset for Operating Lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:to="bmra_OperatingLeaseRightofUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_OperatingLeasesRentExpensesMinimumRentals_lbl0" xml:lang="en-US">This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor&apos;s debt and the lessee&apos;s obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeasesRentExpensesMinimumRentals" xlink:to="bmra_OperatingLeasesRentExpensesMinimumRentals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_PreferredStockUndesignatedShares_lbl0" xml:lang="en-US">Number of preferred shares undesignated during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PreferredStockUndesignatedShares" xlink:to="bmra_PreferredStockUndesignatedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for prepaids.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PrepaidsPolicyPolicyTextBlock" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod_lbl0" xml:lang="en-US">Amount of rental expense increase during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RentalExpenseIncreaseDuringPeriod" xlink:to="bmra_RentalExpenseIncreaseDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_RentalExpenseIncreaseDuringThePeriodPercentage_lbl0" xml:lang="en-US">Percentage of rental expense increased during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RentalExpenseIncreaseDuringThePeriodPercentage" xlink:to="bmra_RentalExpenseIncreaseDuringThePeriodPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_RoyaltyExpensePercentageOfSales_lbl0" xml:lang="en-US">Royalty expenses expressed as a percentage of sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyExpensePercentageOfSales" xlink:to="bmra_RoyaltyExpensePercentageOfSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_RoyaltyPercentage_lbl0" xml:lang="en-US">Percentage of royalty to be received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyPercentage" xlink:to="bmra_RoyaltyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of supplemental cash flow information related to lease for the periods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl0" xml:lang="en-US">Amount related with Maximum Authorized Common Stock Issuance of Shelf Registration Statement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl0" xml:lang="en-US">Number of preferred stock issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:to="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_StockIssuedDuringPeriodValuePreferredStock_lbl0" xml:lang="en-US">Equity impact of the value of preferred stock issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodValuePreferredStock" xlink:to="bmra_StockIssuedDuringPeriodValuePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MedicalPracticeMember_lbl0" xml:lang="en-US">MedicalPracticeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MedicalPracticeMember" xlink:to="bmra_MedicalPracticeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare082362Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare082362Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082362Member" xlink:to="bmra_ExercisePriceRangePerShare082362Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UniversityOFSouthernCaliforniaMember_lbl0" xml:lang="en-US">UniversityOFSouthernCaliforniaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFSouthernCaliforniaMember" xlink:to="bmra_UniversityOFSouthernCaliforniaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RangeOfExercisePrice082104Member_lbl0" xml:lang="en-US">RangeOfExercisePrice082104Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice082104Member" xlink:to="bmra_RangeOfExercisePrice082104Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare082870Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare082870Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082870Member" xlink:to="bmra_ExercisePriceRangePerShare082870Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UCLicenseAgreementsMember_lbl0" xml:lang="en-US">UCLicenseAgreementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UCLicenseAgreementsMember" xlink:to="bmra_UCLicenseAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RoyaltyExpensePercentageOfSales_lbl1" xml:lang="en-US">RoyaltyExpensePercentageOfSales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyExpensePercentageOfSales" xlink:to="bmra_RoyaltyExpensePercentageOfSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UniversityOFMichiganMember_lbl0" xml:lang="en-US">UniversityOFMichiganMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFMichiganMember" xlink:to="bmra_UniversityOFMichiganMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_CashPaidDuringTheYearForAbstract_lbl0" xml:lang="en-US">CashPaidDuringTheYearForAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringTheYearForAbstract" xlink:to="bmra_CashPaidDuringTheYearForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare268818Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare268818Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare268818Member" xlink:to="bmra_ExercisePriceRangePerShare268818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BiomericaHPStoolAntigenMember_lbl0" xml:lang="en-US">BiomericaHPStoolAntigenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaHPStoolAntigenMember" xlink:to="bmra_BiomericaHPStoolAntigenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OtherMember_lbl0" xml:lang="en-US">OtherMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OtherMember" xlink:to="bmra_OtherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FirstAmendmentToLeaseMember_lbl0" xml:lang="en-US">FirstAmendmentToLeaseMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FirstAmendmentToLeaseMember" xlink:to="bmra_FirstAmendmentToLeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare514870Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare514870Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare514870Member" xlink:to="bmra_ExercisePriceRangePerShare514870Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="bmra_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl0" xml:lang="en-US">SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ThreeDistributorsMember_lbl0" xml:lang="en-US">ThreeDistributorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ThreeDistributorsMember" xlink:to="bmra_ThreeDistributorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl1" xml:lang="en-US">MarketsAndMethodsOfDistributionPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:to="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_AtMarketIssuanceSalesAgreementMember_lbl0" xml:lang="en-US">AtMarketIssuanceSalesAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AtMarketIssuanceSalesAgreementMember" xlink:to="bmra_AtMarketIssuanceSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BiomericaInFoodsMember_lbl0" xml:lang="en-US">BiomericaInFoodsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaInFoodsMember" xlink:to="bmra_BiomericaInFoodsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl1" xml:lang="en-US">GeographicInformationDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LabSuppliesMember_lbl0" xml:lang="en-US">LabSuppliesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LabSuppliesMember" xlink:to="bmra_LabSuppliesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ContractManufacturingMember_lbl0" xml:lang="en-US">ContractManufacturingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractManufacturingMember" xlink:to="bmra_ContractManufacturingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RangeOfExercisePrice362870Member_lbl0" xml:lang="en-US">RangeOfExercisePrice362870Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice362870Member" xlink:to="bmra_RangeOfExercisePrice362870Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SupplementalDisclosureOfCashFlowInformationAbstract_lbl0" xml:lang="en-US">SupplementalDisclosureOfCashFlowInformationAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="bmra_SupplementalDisclosureOfCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ATMAgreementMember_lbl0" xml:lang="en-US">ATMAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ATMAgreementMember" xlink:to="bmra_ATMAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PurchasedTechnologyRightsMember_lbl0" xml:lang="en-US">PurchasedTechnologyRightsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PurchasedTechnologyRightsMember" xlink:to="bmra_PurchasedTechnologyRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OneDistributorsMember_lbl0" xml:lang="en-US">OneDistributorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneDistributorsMember" xlink:to="bmra_OneDistributorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DistributorsInChinaMember_lbl0" xml:lang="en-US">DistributorsInChinaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DistributorsInChinaMember" xlink:to="bmra_DistributorsInChinaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl1" xml:lang="en-US">FiniteLivedPatentsAccumulatedAmortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2020PlanMember_lbl0" xml:lang="en-US">A2020PlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2020PlanMember" xlink:to="bmra_A2020PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LicenseMaintenanceFeePayable_lbl1" xml:lang="en-US">LicenseMaintenanceFeePayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LicenseMaintenanceFeePayable" xlink:to="bmra_LicenseMaintenanceFeePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2014PlanMember_lbl0" xml:lang="en-US">A2014PlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2014PlanMember" xlink:to="bmra_A2014PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A5ConvertiblePreferredStockMember_lbl0" xml:lang="en-US">A5ConvertiblePreferredStockMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A5ConvertiblePreferredStockMember" xlink:to="bmra_A5ConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OneVendorMember_lbl0" xml:lang="en-US">OneVendorMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneVendorMember" xlink:to="bmra_OneVendorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesPreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:to="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ClinicalLabMember_lbl0" xml:lang="en-US">ClinicalLabMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalLabMember" xlink:to="bmra_ClinicalLabMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OperatingLeasesRentExpensesMinimumRentals_lbl1" xml:lang="en-US">OperatingLeasesRentExpensesMinimumRentals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeasesRentExpensesMinimumRentals" xlink:to="bmra_OperatingLeasesRentExpensesMinimumRentals_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2017PlanMember_lbl0" xml:lang="en-US">A2017PlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2017PlanMember" xlink:to="bmra_A2017PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare082818Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare082818Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082818Member" xlink:to="bmra_ExercisePriceRangePerShare082818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl1" xml:lang="en-US">ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TelconAgreementMember_lbl0" xml:lang="en-US">TelconAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TelconAgreementMember" xlink:to="bmra_TelconAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare085818Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare085818Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare085818Member" xlink:to="bmra_ExercisePriceRangePerShare085818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_CaliforniaStateIncomeTaxMember_lbl0" xml:lang="en-US">CaliforniaStateIncomeTaxMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CaliforniaStateIncomeTaxMember" xlink:to="bmra_CaliforniaStateIncomeTaxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract_lbl0" xml:lang="en-US">RevenuesFromSalesToUnaffiliatedCustomersAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_HousetonMethodistResearchInstituteMember_lbl0" xml:lang="en-US">HousetonMethodistResearchInstituteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_HousetonMethodistResearchInstituteMember" xlink:to="bmra_HousetonMethodistResearchInstituteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RentalExpenseIncreaseDuringThePeriodPercentage_lbl1" xml:lang="en-US">RentalExpenseIncreaseDuringThePeriodPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RentalExpenseIncreaseDuringThePeriodPercentage" xlink:to="bmra_RentalExpenseIncreaseDuringThePeriodPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2010PlanMember_lbl0" xml:lang="en-US">A2010PlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2010PlanMember" xlink:to="bmra_A2010PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare082390Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare082390Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082390Member" xlink:to="bmra_ExercisePriceRangePerShare082390Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock_lbl1" xml:lang="en-US">PrepaidsPolicyPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PrepaidsPolicyPolicyTextBlock" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PhysiciansOfficeMember_lbl0" xml:lang="en-US">PhysiciansOfficeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PhysiciansOfficeMember" xlink:to="bmra_PhysiciansOfficeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember_lbl0" xml:lang="en-US">UniversityOFBethIsraelDeaconessMedicalCenterMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember" xlink:to="bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00_lbl0" xml:lang="en-US">SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MayoClinicArizonaMember_lbl0" xml:lang="en-US">MayoClinicArizonaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MayoClinicArizonaMember" xlink:to="bmra_MayoClinicArizonaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RoyaltyPercentage_lbl1" xml:lang="en-US">RoyaltyPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyPercentage" xlink:to="bmra_RoyaltyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TwoVendorsMember_lbl0" xml:lang="en-US">TwoVendorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoVendorsMember" xlink:to="bmra_TwoVendorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BiomericaHPyloriProductMember_lbl0" xml:lang="en-US">BiomericaHPyloriProductMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaHPyloriProductMember" xlink:to="bmra_BiomericaHPyloriProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod_lbl1" xml:lang="en-US">RentalExpenseIncreaseDuringPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RentalExpenseIncreaseDuringPeriod" xlink:to="bmra_RentalExpenseIncreaseDuringPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MountSinaiLicenseAgreementsMember_lbl0" xml:lang="en-US">MountSinaiLicenseAgreementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MountSinaiLicenseAgreementsMember" xlink:to="bmra_MountSinaiLicenseAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare235818Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare235818Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare235818Member" xlink:to="bmra_ExercisePriceRangePerShare235818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl1" xml:lang="en-US">FiniteLivedLicenseAccumulatedAmortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl0" xml:lang="en-US">TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MayoClinicJacksonvilleMember_lbl0" xml:lang="en-US">MayoClinicJacksonvilleMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MayoClinicJacksonvilleMember" xlink:to="bmra_MayoClinicJacksonvilleMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TwoDistributorsMember_lbl0" xml:lang="en-US">TwoDistributorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoDistributorsMember" xlink:to="bmra_TwoDistributorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BuildingInIrvineCaliforniaMember_lbl0" xml:lang="en-US">BuildingInIrvineCaliforniaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BuildingInIrvineCaliforniaMember" xlink:to="bmra_BuildingInIrvineCaliforniaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UniversityOfTexasHealthScienceCenterMember_lbl0" xml:lang="en-US">UniversityOfTexasHealthScienceCenterMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOfTexasHealthScienceCenterMember" xlink:to="bmra_UniversityOfTexasHealthScienceCenterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OverthecounterMember_lbl0" xml:lang="en-US">OverthecounterMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OverthecounterMember" xlink:to="bmra_OverthecounterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl1" xml:lang="en-US">ConcentrationRiskGeographicPolicyPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl0" xml:lang="en-US">IncreaseReductionInIncomeTaxesResultingFromAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LiquidityPolicyTextBlock_lbl1" xml:lang="en-US">LiquidityPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LiquidityPolicyTextBlock" xlink:to="bmra_LiquidityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RangeOfExercisePrice120281Member_lbl0" xml:lang="en-US">RangeOfExercisePrice120281Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice120281Member" xlink:to="bmra_RangeOfExercisePrice120281Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LeaseExpirationPeriod_lbl1" xml:lang="en-US">LeaseExpirationPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseExpirationPeriod" xlink:to="bmra_LeaseExpirationPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BilledCommitmentPercentage_lbl1" xml:lang="en-US">BilledCommitmentPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BilledCommitmentPercentage" xlink:to="bmra_BilledCommitmentPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl1" xml:lang="en-US">ClinicalTrialAgreementMaximumBudgetedCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl0" xml:lang="en-US">SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RegistrationRightsAgreementMember_lbl0" xml:lang="en-US">RegistrationRightsAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RegistrationRightsAgreementMember" xlink:to="bmra_RegistrationRightsAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl0" xml:lang="en-US">Property Available for Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueSegmentMember_lbl0" xml:lang="en-US">Revenue, Segment Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueSegmentMember" xlink:to="us-gaap_SalesRevenueSegmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MiddleEastMember_lbl0" xml:lang="en-US">Middle East [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MiddleEastMember" xlink:to="us-gaap_MiddleEastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl0" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl0" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl0" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SouthAmericaMember_lbl0" xml:lang="en-US">South America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SouthAmericaMember" xlink:to="srt_SouthAmericaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl0" xml:lang="en-US">Cash, Uninsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl0" xml:lang="en-US">Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl0" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl0" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLIFOReserve_lbl0" xml:lang="en-US">Inventory, LIFO Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReserve" xlink:to="us-gaap_InventoryLIFOReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl0" xml:lang="en-US">Geographic Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DistributionRightsMember_lbl0" xml:lang="en-US">Distribution Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaMember_lbl0" xml:lang="en-US">Asia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl0" xml:lang="en-US">Cost of Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl0" xml:lang="en-US">Accrued Fees and Other Revenue Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl0" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl0" xml:lang="en-US">Royalty Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl0" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseDepositLiability_lbl0" xml:lang="en-US">Lease Deposit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseDepositLiability" xlink:to="us-gaap_LeaseDepositLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl0" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_MX_lbl0" xml:lang="en-US">MEXICO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MX" xlink:to="country_MX_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl3" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl1" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl0" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl0" xml:lang="en-US">Other Receivables, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl0" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl0" xml:lang="en-US">Proceeds from Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl0" xml:lang="en-US">Threshold Period Past Due for Write-off of Trade Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>bmra-20210531_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 27 21:08:32 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ShareholdersEquityType2or3" roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ORGANIZATION" roleURI="http://www.biomerica.com/role/ORGANIZATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_PROPERTYANDEQUIPMENTNET" roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INTANGIBLEASSETSNET" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSES" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SHAREHOLDERSEQUITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INCOMETAXES" roleURI="http://www.biomerica.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_GEOGRAPHICINFORMATION" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUBSEQUENTEVENTS" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_AccountingPoliciesByPolicy" roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_PROPERTYANDEQUIPMENTNETTables" roleURI="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INTANGIBLEASSETSNETTables" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SHAREHOLDERSEQUITYTables" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INCOMETAXESTables" roleURI="http://www.biomerica.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_GEOGRAPHICINFORMATIONTables" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SharebasedcompensationassumptionsTable" roleURI="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_RevenuefromcontractswithcustomersTable" roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_PropertyandequipmentnetTable" roleURI="http://www.biomerica.com/role/PropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_IntangibleassetsnetTable" roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ExpectedamortizationofintangibleassetsTable" roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_AccountspayableandaccruedexpensebalancesTable" roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_OutstandingStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_NonvestedStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_StockOptionsSummaryTable" roleURI="http://www.biomerica.com/role/StockOptionsSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_IncometaxexpenseTable" roleURI="http://www.biomerica.com/role/IncometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_IncomeTaxRateReconciliationTable" roleURI="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_DeferredTaxTable" roleURI="http://www.biomerica.com/role/DeferredTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_GeographicinformationregardingnetsalesTable" roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ThematurityofleaseliabilitiesTable" roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SHAREHOLDERSEQUITYDetails" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_INCOMETAXESDetails" roleURI="http://www.biomerica.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_GEOGRAPHICINFORMATIONDetails" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#bmra_r_SUBSEQUENTEVENTSDetails" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20210531.xsd#DocumentAndEntityInformation" roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="A5ConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Investments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_CommitmentsAndContingencies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="A5ConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="OperatingLeaseRightOfUseAssetAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PreferredStockUndesignatedShares" xlink:href="bmra-20210531.xsd#bmra_PreferredStockUndesignatedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PreferredStockUndesignatedShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="A5ConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValuePreferredStock" xlink:href="bmra-20210531.xsd#bmra_StockIssuedDuringPeriodValuePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValuePreferredStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesPreferredStock" xlink:href="bmra-20210531.xsd#bmra_StockIssuedDuringPeriodSharesPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesPreferredStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInDeferredRentLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseDecreaseInDeferredRentLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInDeferredRentLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseRightofUseAssetAmortization" xlink:href="bmra-20210531.xsd#bmra_OperatingLeaseRightofUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightofUseAssetAmortization" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidDuringTheYearForAbstract" xlink:href="bmra-20210531.xsd#bmra_CashPaidDuringTheYearForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashPaidDuringTheYearForAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringTheYearForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringTheYearForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInRightOfUseAsset" xlink:href="bmra-20210531.xsd#bmra_IncreaseInRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="IncreaseInRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncreaseInLeaseLiability" xlink:href="bmra-20210531.xsd#bmra_IncreaseInLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="IncreaseInLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ORGANIZATION">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNET">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXES">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATION">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureTextBlock" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="GeographicInformationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_MarketsAndMethodsOfDistributionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="MarketsAndMethodsOfDistributionPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_LiquidityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConcentrationRiskGeographicPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidsPolicyPolicyTextBlock" xlink:href="bmra-20210531.xsd#bmra_PrepaidsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PrepaidsPolicyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20210531.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="InventoriesAbstract" xlink:href="bmra-20210531.xsd#bmra_InventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable">
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationAssumptionsAbstract" xlink:href="bmra-20210531.xsd#bmra_ShareBasedCompensationAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAssumptionsAbstract" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable">
    <loc xlink:type="locator" xlink:label="RevenueFromContractsWithCustomersAbstract" xlink:href="bmra-20210531.xsd#bmra_RevenueFromContractsWithCustomersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractsWithCustomersAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalLabMember" xlink:href="bmra-20210531.xsd#bmra_ClinicalLabMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ClinicalLabMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PhysiciansOfficeMember" xlink:href="bmra-20210531.xsd#bmra_PhysiciansOfficeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="PhysiciansOfficeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OverthecounterMember" xlink:href="bmra-20210531.xsd#bmra_OverthecounterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="OverthecounterMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractManufacturingMember" xlink:href="bmra-20210531.xsd#bmra_ContractManufacturingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ContractManufacturingMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabSuppliesMember" xlink:href="bmra-20210531.xsd#bmra_LabSuppliesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="LabSuppliesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/PropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="PropertyAndEquipmentNetAbstract" xlink:href="bmra-20210531.xsd#bmra_PropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="Equipment" xlink:href="bmra-20210531.xsd#bmra_Equipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="Equipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FurnitureFixturesAndLeaseholdImprovements" xlink:href="bmra-20210531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="FurnitureFixturesAndLeaseholdImprovements" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IntangibleassetsnetTable">
    <loc xlink:type="locator" xlink:label="IntangibleAssetsNetAbstract" xlink:href="bmra-20210531.xsd#bmra_IntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedPatentsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="FiniteLivedLicenseAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20210531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="FiniteLivedPatentsAccumulatedAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:href="bmra-20210531.xsd#bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable">
    <loc xlink:type="locator" xlink:label="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:href="bmra-20210531.xsd#bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="OutstandingStockOptionsActivityAbstract" xlink:href="bmra-20210531.xsd#bmra_OutstandingStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OutstandingStockOptionsActivityAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare082390Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082390Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare082390Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare268818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare268818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare268818Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare085818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare085818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare085818Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare082818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare082818Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare514870Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare514870Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare514870Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare082362Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082362Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare082362Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare235818Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare235818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare235818Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare082870Member" xlink:href="bmra-20210531.xsd#bmra_ExercisePriceRangePerShare082870Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare082870Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="NonVestedStockOptionsActivityAbstract" xlink:href="bmra-20210531.xsd#bmra_NonVestedStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMavKWZZQpVGPQgLzjYAjvzt1lMb3ldQptVWNNbJwjkia1PUcr18sUX/6/CBQxCu0zoFpf9ty/fXA1UJHl1DDNUMKOhjgQRktncXYHRWw/Vc9j6XqULqjyy4DX6Wfeix8fu4=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/StockOptionsSummaryTable">
    <loc xlink:type="locator" xlink:label="StockOptionsSummaryAbstract" xlink:href="bmra-20210531.xsd#bmra_StockOptionsSummaryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsSummaryAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePrice082104Member" xlink:href="bmra-20210531.xsd#bmra_RangeOfExercisePrice082104Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="RangeOfExercisePrice082104Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePrice120281Member" xlink:href="bmra-20210531.xsd#bmra_RangeOfExercisePrice120281Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="RangeOfExercisePrice120281Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePrice362870Member" xlink:href="bmra-20210531.xsd#bmra_RangeOfExercisePrice362870Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="RangeOfExercisePrice362870Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="IncomeTaxExpenseAbstract" xlink:href="bmra-20210531.xsd#bmra_IncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable">
    <loc xlink:type="locator" xlink:label="IncomeTaxRateReconciliationAbstract" xlink:href="bmra-20210531.xsd#bmra_IncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="bmra-20210531.xsd#bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="IncreaseReductionInIncomeTaxesResultingFromAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DeferredTaxTable">
    <loc xlink:type="locator" xlink:label="DeferredTaxAbstract" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DefferedTaxAssetsStockOptions" xlink:href="bmra-20210531.xsd#bmra_DefferedTaxAssetsStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="DefferedTaxAssetsStockOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20210531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:to="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable">
    <loc xlink:type="locator" xlink:label="GeographicInformationRegardingNetSalesAbstract" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationRegardingNetSalesAbstract"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20210531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20210531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationRegardingNetSalesAbstract" xlink:to="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_GeographicConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="srt_StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_EuropeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_AsiaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SouthAmericaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SouthAmericaMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MiddleEastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_MiddleEastMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherMember" xlink:href="bmra-20210531.xsd#bmra_OtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="OtherMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:href="bmra-20210531.xsd#bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="RevenuesFromSalesToUnaffiliatedCustomersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20210531.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="TheMaturityOfLeaseLiabilitiesAbstract" xlink:href="bmra-20210531.xsd#bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_MX" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="A5ConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DistributionRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasedTechnologyRightsMember" xlink:href="bmra-20210531.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="PurchasedTechnologyRightsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_CostOfGoodsProductLineMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ATMAgreementMember" xlink:href="bmra-20210531.xsd#bmra_ATMAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ATMAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DistributorsInChinaMember" xlink:href="bmra-20210531.xsd#bmra_DistributorsInChinaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DistributorsInChinaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoDistributorsMember" xlink:href="bmra-20210531.xsd#bmra_TwoDistributorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="TwoDistributorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThreeDistributorsMember" xlink:href="bmra-20210531.xsd#bmra_ThreeDistributorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ThreeDistributorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneDistributorsMember" xlink:href="bmra-20210531.xsd#bmra_OneDistributorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OneDistributorsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneVendorMember" xlink:href="bmra-20210531.xsd#bmra_OneVendorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OneVendorMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" order="11.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:href="bmra-20210531.xsd#bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashUninsuredAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryLIFOReserve" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OneVendorMember" xlink:href="bmra-20210531.xsd#bmra_OneVendorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OneVendorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoVendorsMember" xlink:href="bmra-20210531.xsd#bmra_TwoVendorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="TwoVendorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsTable" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_TransactionTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RegistrationRightsAgreementMember" xlink:href="bmra-20210531.xsd#bmra_RegistrationRightsAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="RegistrationRightsAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A2010PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2010PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2010PlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A2014PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2014PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2014PlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A2017PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2017PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2017PlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A2020PlanMember" xlink:href="bmra-20210531.xsd#bmra_A2020PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2020PlanMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A5ConvertiblePreferredStockMember" xlink:href="bmra-20210531.xsd#bmra_A5ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="A5ConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_CommonStockMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AtMarketIssuanceSalesAgreementMember" xlink:href="bmra-20210531.xsd#bmra_AtMarketIssuanceSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="AtMarketIssuanceSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_CostOfSalesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="SHAREHOLDERSEQUITYDetailsLineItems" order="10.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="INCOMETAXESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_INCOMETAXESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="INCOMETAXESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_INCOMETAXESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="INCOMETAXESDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CaliforniaStateIncomeTaxMember" xlink:href="bmra-20210531.xsd#bmra_CaliforniaStateIncomeTaxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="CaliforniaStateIncomeTaxMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="INCOMETAXESDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20210531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:href="bmra-20210531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="COMMITMENTSANDCONTINGENCIESDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_MX" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20210531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="PropertySubjectToOrAvailableForOperatingLease_Domain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BuildingInIrvineCaliforniaMember" xlink:href="bmra-20210531.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="BuildingInIrvineCaliforniaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstAmendmentToLeaseMember" xlink:href="bmra-20210531.xsd#bmra_FirstAmendmentToLeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="FirstAmendmentToLeaseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RoyaltyAgreementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TelconAgreementMember" xlink:href="bmra-20210531.xsd#bmra_TelconAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TelconAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MountSinaiLicenseAgreementsMember" xlink:href="bmra-20210531.xsd#bmra_MountSinaiLicenseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MountSinaiLicenseAgreementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UCLicenseAgreementsMember" xlink:href="bmra-20210531.xsd#bmra_UCLicenseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="UCLicenseAgreementsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniversityOFSouthernCaliforniaMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOFSouthernCaliforniaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniversityOFSouthernCaliforniaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniversityOFMichiganMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOFMichiganMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniversityOFMichiganMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniversityOFBethIsraelDeaconessMedicalCenterMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniversityOFBethIsraelDeaconessMedicalCenterMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BiomericaHPStoolAntigenMember" xlink:href="bmra-20210531.xsd#bmra_BiomericaHPStoolAntigenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BiomericaHPStoolAntigenMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BiomericaInFoodsMember" xlink:href="bmra-20210531.xsd#bmra_BiomericaInFoodsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BiomericaInFoodsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalPracticeMember" xlink:href="bmra-20210531.xsd#bmra_MedicalPracticeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MedicalPracticeMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BiomericaHPyloriProductMember" xlink:href="bmra-20210531.xsd#bmra_BiomericaHPyloriProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BiomericaHPyloriProductMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HousetonMethodistResearchInstituteMember" xlink:href="bmra-20210531.xsd#bmra_HousetonMethodistResearchInstituteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HousetonMethodistResearchInstituteMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MayoClinicArizonaMember" xlink:href="bmra-20210531.xsd#bmra_MayoClinicArizonaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MayoClinicArizonaMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MayoClinicJacksonvilleMember" xlink:href="bmra-20210531.xsd#bmra_MayoClinicJacksonvilleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MayoClinicJacksonvilleMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniversityOfTexasHealthScienceCenterMember" xlink:href="bmra-20210531.xsd#bmra_UniversityOfTexasHealthScienceCenterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniversityOfTexasHealthScienceCenterMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="COMMITMENTSANDCONTINGENCIESDetailsLineItems" order="7.0"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesRentExpensesMinimumRentals" xlink:href="bmra-20210531.xsd#bmra_OperatingLeasesRentExpensesMinimumRentals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="OperatingLeasesRentExpensesMinimumRentals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RentalExpenseIncreaseDuringPeriod" xlink:href="bmra-20210531.xsd#bmra_RentalExpenseIncreaseDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="RentalExpenseIncreaseDuringPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RentalExpenseIncreaseDuringThePeriodPercentage" xlink:href="bmra-20210531.xsd#bmra_RentalExpenseIncreaseDuringThePeriodPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="RentalExpenseIncreaseDuringThePeriodPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseDepositLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseDepositLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseExpirationPeriod" xlink:href="bmra-20210531.xsd#bmra_LeaseExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="LeaseExpirationPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyExpensePercentageOfSales" xlink:href="bmra-20210531.xsd#bmra_RoyaltyExpensePercentageOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="RoyaltyExpensePercentageOfSales" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedFeesAndOtherRevenueReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPercentage" xlink:href="bmra-20210531.xsd#bmra_RoyaltyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="RoyaltyPercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_PaymentsForFees" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseMaintenanceFeePayable" xlink:href="bmra-20210531.xsd#bmra_LicenseMaintenanceFeePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="LicenseMaintenanceFeePayable" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20210531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="ClinicalTrialAgreementMaximumBudgetedCosts" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BilledCommitmentPercentage" xlink:href="bmra-20210531.xsd#bmra_BilledCommitmentPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="BilledCommitmentPercentage" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsTable" xlink:href="bmra-20210531.xsd#bmra_SUBSEQUENTEVENTSDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsLineItems" xlink:href="bmra-20210531.xsd#bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SUBSEQUENTEVENTSDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="SUBSEQUENTEVENTSDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="bmra-20210531.xsd#bmra_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659601260760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Aug. 27, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOMERICA INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--05-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,510,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,938,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000073290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659600250824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,199,311<span></span>
</td>
<td class="nump">$ 8,641,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, less allowance for doubtful accounts of $837,415 and $70,981 as of May 31, 2021 and 2020, respectively</a></td>
<td class="nump">1,455,051<span></span>
</td>
<td class="nump">1,765,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">3,206,255<span></span>
</td>
<td class="nump">2,850,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">370,290<span></span>
</td>
<td class="nump">1,509,083<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,230,907<span></span>
</td>
<td class="nump">14,766,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $1,972,357 and $1,867,643 as of May 31, 2021 and 2020, respectively</a></td>
<td class="nump">310,520<span></span>
</td>
<td class="nump">279,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net of accumulated amortization of $469,077 and $231,489 as of May 31, 2021 and 2020, respectively</a></td>
<td class="nump">1,553,081<span></span>
</td>
<td class="nump">1,711,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">165,324<span></span>
</td>
<td class="nump">165,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $126,769 and $496,124 as of May 31, 2021 and 2020, respectively</a></td>
<td class="nump">294,830<span></span>
</td>
<td class="nump">168,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">264,151<span></span>
</td>
<td class="nump">168,193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">11,818,813<span></span>
</td>
<td class="nump">17,259,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">583,380<span></span>
</td>
<td class="nump">986,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">388,896<span></span>
</td>
<td class="nump">278,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">327,944<span></span>
</td>
<td class="nump">211,809<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,300,220<span></span>
</td>
<td class="nump">1,477,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">1,291,570<span></span>
</td>
<td class="nump">1,569,678<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,591,790<span></span>
</td>
<td class="nump">3,046,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 1 and 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, none issued and outstanding at May 31, 2021 and 321,429 issued and outstanding at May 31, 2020 and Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding at May 31, 2021 and 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.08 par value, 25,000,000 shares authorized, 12,307,157 and 11,740,089 issued and outstanding at May 31, 2021 and 2020, respectively</a></td>
<td class="nump">984,571<span></span>
</td>
<td class="nump">939,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">36,685,176<span></span>
</td>
<td class="nump">35,213,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(47,956)<span></span>
</td>
<td class="num">(39,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(28,394,768)<span></span>
</td>
<td class="num">(21,925,732)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity</a></td>
<td class="nump">9,227,023<span></span>
</td>
<td class="nump">14,213,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Equity</a></td>
<td class="nump">11,818,813<span></span>
</td>
<td class="nump">17,259,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5ConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, none issued and outstanding at May 31, 2021 and 321,429 issued and outstanding at May 31, 2020 and Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding at May 31, 2021 and 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, none issued and outstanding at May 31, 2021 and 321,429 issued and outstanding at May 31, 2020 and Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding at May 31, 2021 and 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659607692536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts (in Dollars)</a></td>
<td class="nump">$ 837,415<span></span>
</td>
<td class="nump">$ 70,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization (in Dollars)</a></td>
<td class="nump">1,972,357<span></span>
</td>
<td class="nump">1,867,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization, Right of Use Assets (in Dollars)</a></td>
<td class="nump">469,077<span></span>
</td>
<td class="nump">231,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, Intangible Assets (in Dollars)</a></td>
<td class="nump">$ 126,769<span></span>
</td>
<td class="nump">$ 496,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">12,307,157<span></span>
</td>
<td class="nump">11,740,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">12,307,157<span></span>
</td>
<td class="nump">11,740,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5ConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par Value (in Dollars per share)</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred Stock, No Par Value (in Dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_PreferredStockUndesignatedShares', window );">Preferred Stock, undesignated shares</a></td>
<td class="nump">4,428,571<span></span>
</td>
<td class="nump">4,428,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from operating lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_OperatingLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_PreferredStockUndesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred shares undesignated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_PreferredStockUndesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659600503272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 7,199,027<span></span>
</td>
<td class="nump">$ 6,692,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="num">(6,702,046)<span></span>
</td>
<td class="num">(4,910,935)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">496,981<span></span>
</td>
<td class="nump">1,781,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">4,608,950<span></span>
</td>
<td class="nump">2,274,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,410,506<span></span>
</td>
<td class="nump">1,910,209<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">7,019,456<span></span>
</td>
<td class="nump">4,184,624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,522,475)<span></span>
</td>
<td class="num">(2,402,848)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Dividend and interest income</a></td>
<td class="nump">66,863<span></span>
</td>
<td class="nump">71,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(367)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">66,496<span></span>
</td>
<td class="nump">71,184<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(6,455,979)<span></span>
</td>
<td class="num">(2,331,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(13,057)<span></span>
</td>
<td class="num">(7,390)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,469,036)<span></span>
</td>
<td class="num">$ (2,339,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in Dollars per share)</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in Dollars per share)</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common and common equivalent shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">11,928,941<span></span>
</td>
<td class="nump">10,166,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="nump">11,928,941<span></span>
</td>
<td class="nump">10,166,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,469,036)<span></span>
</td>
<td class="num">$ (2,339,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(8,115)<span></span>
</td>
<td class="num">(3,310)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (6,477,151)<span></span>
</td>
<td class="num">$ (2,342,364)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659600371816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY - USD ($)<br></strong></div></th>
<th class="th">
<div>Series A Preferred Stock [Member] </div>
<div>5% Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 774,173<span></span>
</td>
<td class="nump">$ 22,830,006<span></span>
</td>
<td class="num">$ (36,531)<span></span>
</td>
<td class="num">$ (19,586,678)<span></span>
</td>
<td class="nump">$ 3,980,970<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,677,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,037<span></span>
</td>
<td class="nump">212,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,995<span></span>
</td>
<td class="nump">10,098,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,232,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_StockIssuedDuringPeriodValuePreferredStock', window );">Issuance of preferred stock</a></td>
<td class="nump">$ 45,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,871,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,917,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_StockIssuedDuringPeriodSharesPreferredStock', window );">Issuance of preferred stock (in Shares)</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred to common stock</a></td>
<td class="num">$ (20,000)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred to common stock (in Shares)</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense in connection with options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,339,054)<span></span>
</td>
<td class="num">(2,339,054)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2020</a></td>
<td class="nump">$ 25,714<span></span>
</td>
<td class="nump">$ 939,205<span></span>
</td>
<td class="nump">35,213,707<span></span>
</td>
<td class="num">(39,841)<span></span>
</td>
<td class="num">(21,925,732)<span></span>
</td>
<td class="nump">14,213,053<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2020</a></td>
<td class="nump">321,429<span></span>
</td>
<td class="nump">11,740,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,940<span></span>
</td>
<td class="nump">95,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,712<span></span>
</td>
<td class="nump">998,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,011,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred to common stock</a></td>
<td class="num">$ (25,714)<span></span>
</td>
<td class="nump">$ 25,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred to common stock (in Shares)</a></td>
<td class="num">(321,429)<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense in connection with options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,469,036)<span></span>
</td>
<td class="num">(6,469,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 984,571<span></span>
</td>
<td class="nump">$ 36,685,176<span></span>
</td>
<td class="num">$ (47,956)<span></span>
</td>
<td class="num">$ (28,394,768)<span></span>
</td>
<td class="nump">$ 9,227,023<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,307,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_StockIssuedDuringPeriodSharesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_StockIssuedDuringPeriodSharesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_StockIssuedDuringPeriodValuePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of preferred stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_StockIssuedDuringPeriodValuePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659601285560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,469,036)<span></span>
</td>
<td class="num">$ (2,339,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">138,267<span></span>
</td>
<td class="nump">129,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Change in allowance on accounts receivable</a></td>
<td class="nump">766,434<span></span>
</td>
<td class="num">(2,129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Inventory reserve</a></td>
<td class="nump">1,550,594<span></span>
</td>
<td class="nump">17,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="nump">377,391<span></span>
</td>
<td class="nump">200,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncreaseDecreaseInDeferredRentLiability', window );">Reduction in deferred rent liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(37,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_OperatingLeaseRightofUseAssetAmortization', window );">Amortization of right-of-use asset</a></td>
<td class="nump">237,588<span></span>
</td>
<td class="nump">269,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(455,614)<span></span>
</td>
<td class="num">(309,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,906,013)<span></span>
</td>
<td class="num">(717,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,138,793<span></span>
</td>
<td class="num">(1,306,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncreaseDecreaseInLeaseLiability', window );">Reduction in lease liability</a></td>
<td class="num">(241,132)<span></span>
</td>
<td class="num">(199,483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(95,958)<span></span>
</td>
<td class="num">(41,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(403,331)<span></span>
</td>
<td class="num">(12,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">110,269<span></span>
</td>
<td class="nump">51,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,251,748)<span></span>
</td>
<td class="num">(4,297,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Increase in intangibles</a></td>
<td class="num">(159,727)<span></span>
</td>
<td class="num">(85,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(135,856)<span></span>
</td>
<td class="num">(33,608)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(295,583)<span></span>
</td>
<td class="num">(118,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="nump">1,011,475<span></span>
</td>
<td class="nump">10,232,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from sale of convertible preferred stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,917,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">102,255<span></span>
</td>
<td class="nump">223,534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,113,730<span></span>
</td>
<td class="nump">12,373,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes in cash</a></td>
<td class="num">(8,115)<span></span>
</td>
<td class="num">(3,310)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(4,441,716)<span></span>
</td>
<td class="nump">7,954,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">8,641,027<span></span>
</td>
<td class="nump">686,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">4,199,311<span></span>
</td>
<td class="nump">8,641,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_CashPaidDuringTheYearForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">27,171<span></span>
</td>
<td class="nump">7,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncreaseInRightOfUseAsset', window );">Increase in right of use asset due to lease extension or establishment</a></td>
<td class="nump">79,159<span></span>
</td>
<td class="nump">1,942,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncreaseInLeaseLiability', window );">Increase in lease liability due to lease extension or establishment</a></td>
<td class="nump">$ 79,159<span></span>
</td>
<td class="nump">$ 1,980,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_CashPaidDuringTheYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_CashPaidDuringTheYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseDecreaseInDeferredRentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseDecreaseInDeferredRentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in LeaseLiability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in lease liability due to lease extension or establishment in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseInRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in right of use asset due to lease extension or establishment in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseInRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_OperatingLeaseRightofUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of Right of Use Asset for Operating Lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_OperatingLeaseRightofUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606415704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 1: &#xa0;&#xa0;&#xa0;ORGANIZATION </font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">Biomerica Inc. and Subsidiaries (collectively the &#x201c;Company&#x201d;, &#x201c;Biomerica&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, or &#x201c;our&#x201d;) develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </font><font style="FONT-SIZE:10pt; COLOR:black">(physicians' offices and over-the-counter through drugstores and online)</font><font style="FONT-SIZE:10pt">and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. </font><font style="FONT-SIZE:10pt; COLOR:black">Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</font><font style="FONT-SIZE:10pt">Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research and development of revolutionary, patented, diagnostic-guided therapy (&#x201c;DGT&#x201d;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Our medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient&#x2019;s body, stools, or blood, often in extremely small concentrations.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic, in March 2020 we began redirecting and focusing a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. During fiscal 2021, we sold 2 primary types of Covid 19 tests; 1) antibody diagnostic tests that use a patient&#x2019;s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body&#x2019;s immune response to a COVID-19 infection, even if the infection was asymptomatic, and 2) antigen tests that use a patient&#x2019;s nasal fluid sample to detect if a patient is currently infected with the virus. </font><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Aside from the COVID-19 products we offer, the other products we sell are primarily focused on gastrointestinal diseases, food intolerances, diabetes and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#x2019;s regulatory agency.&#xa0; In addition, some products are cleared for sale in the U.S. by the FDA.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606239592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 2: &#xa0;&#xa0;&#xa0;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">PRINCIPLES OF CONSOLIDATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The enclosed consolidated financial statements for the years ended May 31, 2021 and 2020 include the accounts of Biomerica, Inc. ("Biomerica") as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTING ESTIMATES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">MARKETS AND METHODS OF DISTRIBUTION</font></b></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt;">Due to </font><font style="font-size: 10pt;">the Coronavirus global pandemic, the Company&#x2019;s operations have been negatively impacted. <font style="color: black;">The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, loss of contracts and/or customers, closure of the Company&#x2019;s manufacturing or distribution facilities or of the facilities of the Company&#x2019;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&#x2019;s operations and financial performance and may continue to have significant material negative impacts on the Company.&#xa0;&#xa0; </font></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $28.4 million as of May 31, 2021.&#xa0; Management expects to continue to incur significant costs as it advances its trials and development activities.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020 and declared effective by the SEC on September 30, 2020 and an ATM Agreement. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Under an ATM Agreement, sales of the Placement Shares are deemed to be &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act.&#xa0; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0cm"><font style="FONT-SIZE:10pt">During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement (</font><font style="FONT-SIZE:10pt; COLOR:black">File No. 333-239980) </font><font style="FONT-SIZE:10pt">and ATM Agreement which resulted in gross proceeds of $1,177,394 and net proceeds to the Company of $1,011,475 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.</font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 12pt 0cm 0cm;"><font style="font-size: 10pt;">As a result of cash and cash equivalents on hand at May 31, 2021, management believes the Company has sufficient funds to operate through August 2022 and the ability to raise additional funds through the ATM noted above.<br/></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">FAIR VALUE OF FINANCIAL INSTRUMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&#xa0;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">CONCENTRATION OF CREDIT RISK</font></b></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&#xa0; As of May 31, 2021, the Company had approximately $3,767,000 of uninsured cash. </font><font style="font-size: 10pt; color: black;">The Company does not believe it is exposed to any significant credit risks.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&#xa0; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. </font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">For the years ended May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 60% and 57% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2021 and 2020 one of the distributors mentioned above accounted for 33% and 26%, respectively, of net consolidated sales.&#xa0; At May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 73% and 80%, respectively, of gross accounts receivable. <a name="_Hlk48558057"></a>Of the 73% as of May 31, 2021, 41% was owed by a distributor in China. Total gross receivables at May 31, 2021 and 2020 were </font><font style="font-size: 10pt;">$2,292,466 </font><font style="font-size: 10pt; color: black;">and $1,836,852, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2021, one vendor accounted for 58% of the purchases of raw materials. For the year ended May 31, 2020, one vendor accounted for a total of 59% of the purchases of raw materials.</font><font style="FONT-SIZE:10pt">&#xa0;</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">GEOGRAPHIC CONCENTRATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2021 and 2020, approximately $803,000 and $613,000 of Biomerica's gross inventory and approximately $25,000 and $31,000, of Biomerica's property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.</font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><strong><font style="font-size: 10pt;">CASH AND </font></strong><font style="font-size: 10pt;"><strong><font style="color: black;">CASH EQUIVALENTS</font></strong></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTS RECEIVABLE</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. &#xa0;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &#xa0;Based on various criteria,&#xa0;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &#xa0;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &#xa0;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &#xa0; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt">The Company has established a reserve of $837,415 for doubtful accounts as of May 31, 2021. The majority of this reserve has been established to cover 100% of outstanding accounts receivable from an international distributor.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><b><font style="FONT-SIZE:10pt">PREPAIDS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt">The Company occasionally prepays for items such as inventory, insurance and other items.&#xa0; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt">As of May 31, 2021, the prepaids were approximately $370,000, composed of prepayments to insurance and various other suppliers. As of May 31, 2020, approximately $1 million of the prepaids was an advance payment to one of our suppliers, which was subsequently refunded by the supplier when the Company determined it no longer needed the materials that had been ordered.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">INVENTORIES, NET</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Inventories approximate the following at May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Raw materials</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,583,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,635,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Work in progress</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,006,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">988,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Finished products</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">617,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">228,000 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">3,206,000 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">2,851,000 </font></b></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2021 and 2020, inventory reserves were approximately $1,617,000 and $67,000, respectively. </font><font style="FONT-SIZE:9pt">Of the inventory reserve, </font><font style="FONT-SIZE:9pt">$1,502,675 was related to a market downturn in our COVID-19 antibody test and materials, as the market shifted to&#xa0; COVID-19 PCR viral tests and antigen tests.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">PROPERTY AND EQUIPMENT, NET</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $104,715 and $105,299 for the years ended May 31, 2021 and 2020, respectively. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">INTANGIBLE ASSETS, NET</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $33,552 and $23,873 for the years ended May 31, 2021 and 2020, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2021 or 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately-held companies. &#xa0;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&#x2019;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&#x2019;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &#xa0;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">SHARE-BASED COMPENSATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of the accounting provisions of ASC 718<a name="_Hlk17621381">, </a>Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">In applying the Black-Scholes options-pricing model, assumptions used were as follows: &#xa0;</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Dividend yield</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Expected volatility</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;71.19-107.53% </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;55.52-72.62% </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Risk free interest rate</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;0.34-1.18% </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;0.43-1.80% </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Expected Term</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;5.50-6.25 Years </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;3.75-6.25 Years </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">REVENUE RECOGNITION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#xa0; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2021 and 2020 and does not believe that any additional discounts will be given through the end of the contract periods. </font><font style="FONT-SIZE:10pt">Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. <font style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &#xa0;Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </font><a name="_Hlk49511094"></a></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Year Ended</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Clinical lab</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3,077,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,922,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Physician's office</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,801,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,195,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Over-the-counter</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">766,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,270,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Contract manufacturing</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">552,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">306,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Lab supplies</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">7,199,000 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">6,693,000 </font></b></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">See Note 8 for additional information regarding revenue concentrations.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">SHIPPING AND HANDLING FEES </font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Research and development costs are expensed as incurred. The Company expensed $2,410,506 and $1,910,209 of research and development costs during the years ended May 31, 2021 and 2020, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">INCOME TAXES</font></b></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2021 and 2020, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&#xa0;&#xa0; During the fiscal year ended May 31, 2021, this valuation allowance was increased to $5,590,000, which fully covers the tax asset of $5,590,000</font><font style="font-size: 9pt; color: black;">.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#x201c;Interest expense&#x201d; line and penalties related to liabilities for income taxes within the &#x201c;Other expense&#x201d; line of the consolidated statements of operations and comprehensive loss. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <font style="BACKGROUND:white">$10,070</font> and $<font style="BACKGROUND:white">174</font> for the years ended May 31, 2021 and 2020, respectively. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">FOREIGN CURRENCY TRANSLATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2021 and 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.<font style="COLOR:black">&#xa0;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&#xa0; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.</font></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&#xa0; Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#xa0; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#xa0; Leases are classified as financing or operating which will drive the expense recognition pattern.&#xa0; The Company has elected to exclude short-term leases.&#xa0; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&#xa0; An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#xa0; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&#x2019;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not book the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&#xa0; Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#xa0; The leases do not include the options to purchase the leased property.&#xa0; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NET LOSS PER SHARE </font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2021 and 2020 were 2,081,366 and 1,789,251, respectively. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company also had 0 and 321,429 of Series A 5% Convertible Preferred Stock outstanding for the years ended May 31, 2021 and 2020, respectively. &#xa0;The 321,429 shares outstanding at May 31, 2020 were converted to common stock during the year ended May 31, 2021.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">SEGMENT REPORTING</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">ASC 280, Segment Reporting (&#x201c;ASC 280&#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">REPORTING COMPREHENSIVE LOSS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#x2019; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">RECENT ACCOUNTING PRONOUNCEMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 7.2pt 0cm 0cm"><font style="FONT-SIZE:10pt; COLOR:black">Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#x2019;s present or future consolidated financial statements. </font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659610206136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 3: &#xa0;&#xa0;&#xa0;PROPERTY AND EQUIPMENT, NET</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Property and equipment, net of accumulated depreciation, consist of the following at May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Equipment </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,849,888 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,921,833 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Furniture, fixtures and leasehold improvements</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">432,989 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">225,189 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated depreciation</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(1,972,357)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(1,867,643)</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Net property and equipment</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">310,520 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">279,379 </font></b></p></td></tr></table><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659610279432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 4: &#xa0;&#xa0;&#xa0;INTANGIBLE ASSETS, NET</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets, net of accumulated amortization, consist of the following at May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Licenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">182,176 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">551,397 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Patents</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">239,423 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">113,382 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-licenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(107,194)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(487,989)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-patents</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(19,575)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(8,135)</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Intangible asssets, net</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">294,830 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">168,655 </font></b></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Expected amortization of intangible assets for the years ending May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">21,846 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">20,058 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">20,058 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">19,071 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2026</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">18,975 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">194,822 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">294,830 </font></b></p></td></tr></table><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606341400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 5:&#xa0;&#xa0;&#xa0; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company&#x2019;s accounts payable and accrued expense balances consist of the following at May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Accounts payable</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">431,621 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">833,412 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Accrued expense</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">151,759 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">153,299 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">583,380 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">986,711 </font></b></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt">As of May 31, 2021 and 2020 the Company had one vendor and two vendors which accounted for 17% and 27%, respectively, of accounts payable.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606497560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 6: &#xa0;&#xa0;&#xa0;SHAREHOLDERS' EQUITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On February 24, 2020, the Company filed with the Secretary of State of Delaware a certificate of designation to authorize for issuance 571,429 shares of Series A 5% Convertible Preferred Stock.&#xa0; On February 26, 2020, the Company filed with the Secretary of State of Delaware a certificate of correction, correcting certain language defects in the previously filed certificate of designation.&#xa0; Please see below a description of the Series A 5% Convertible Preferred Stock shares that were issued in February 2020, and subsequently converted into registered common shares.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">STOCK OPTION AND RESTRICTED STOCK PLANS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">In August 2010, the Company adopted a stock option and restricted stock plan (the "2010 Plan") which provided that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock could be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2010. &#xa0;The 2010 Plan expired in December 2020. Options granted under the 2010 Plan were granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2014. &#xa0;The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">In December 2017, the Company adopted a stock option and restricted stock plan (the &#x201c;2017 Plan&#x201d;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company&#x2019;s unissued common stock may be granted to affiliates, employees or consultants of the Company.&#xa0; This plan was approved by shareholders in December 2017.&#xa0; The 2017 Plan expires in December 2027.&#xa0; Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;) and on December 11, 2020 the shareholders of the Company approved The Plan. The 2020 Plan authorizes the issuance of an </font><font style="font-size: 10pt; color: black;">aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000. &#xa0;The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">Stock option expense during fiscal 2021 was $377,391.&#xa0; This included, by department, $64,491 for research and development, $221,052 for administrative, $18,035 for sales and marketing and $73,813 for production.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">Stock option expense during fiscal 2020 was $200,470. This included, by department, $17,892 for research and development, $156,750 in administrative, $2,933 in sales and marketing and $22,895 for production.&#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Activity as to aggregate stock options outstanding is as follows: </font></p><br/><table width="734" style="WIDTH:550.7pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER OF STOCK OPTIONS</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">EXCERCISE PRICE <br/>RANGE PER SHARE</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:79.4pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED AVERAGE EXERCISE <br/>PRICE</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2019</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">1,476,209 </font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><b><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">2.07 </font></b></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">517,500 </font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$2.68-$8.18</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.47 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options excercised</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(137,958)</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1.64 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(66,500)</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.85-$8.18</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.43 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2020</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">1,789,251 </font></b></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><b><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$8.18</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">2.75 </font></b></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">430,616 </font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$5.14-$8.70</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.73 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options excercised</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(86,750)</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.62</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1.20 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(51,751)</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$2.35-$8.18</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.77 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2021</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">2,081,366 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><b><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$8.70</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">$1.20 - $6.73</font></b></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The weighted average fair value of options granted during 2021 and 2020 was $6.73 and $4.47, respectively. The aggregate intrinsic value of options exercised during 2021 and 2020 was approximately $501,000 and $589,000, respectively. The aggregate intrinsic value of options outstanding at May 31, 2021 and 2020 was approximately $2,132,000 and $6,923,000, respectively. The aggregate intrinsic value of options vested and exercisable at May 31, 2021 and 2020 was approximately $1,872,000 and $4,442,000, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt">The number of non-vested stock options included in the table above is as follows:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:54.75pt"> <td style="HEIGHT:54.75pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Number of<br/>&#xa0;shares</font></p></td> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Stock options<br/>weighted<br/>average grant <br/>date fair value</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2020 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">822,584 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.78 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Granted </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">430,616 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.73</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Vested&#xa0; </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(409,459)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.36</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Forfeited </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(50,500)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.80</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2021 </font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">793,241 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">5.54 </font></b></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2021, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $1,208,000. The weighted-average period over which this amount is expected to be recognized is 2.59 years. The weighted average remaining contractual term of options that were exercisable at May 31, 2021 was 6.07 years.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The following summarizes information about all of the Company's stock options outstanding at May 31, 2021. These options are comprised of those granted under the 2010, 2014, 2017 and 2020 plans.</font></p><br/><table width="733" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">RANGE OF <br/>EXERCISE PRICES</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER <br/>OUTSTANDING <br/>MAY 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED <br/>AVERAGE <br/>REMAINING <br/>CONTRACTUAL <br/>LIFE IN YEARS</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>&#xa0;AVERAGE <br/>EXERCISE PRICE</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER <br/>EXCERCISABLE <br/>AT MAY 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED <br/>AVERAGE <br/>EXERCISE PRICE</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$1.04</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">216,000</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">3.75</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">216,000</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$1.20-$2.81</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">1,024,500</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">6.45</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$2.17 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">795,250</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$2.02 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$3.62-$8.70</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">840,866</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">8.00</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$6.03 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">276,875</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$4.54 </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">COMMON STOCK ACTIVITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><a name="_Hlk17185589"><font style="FONT-SIZE:10pt">During the year ended May 31, 2020, options to purchase 137,958 shares of common stock were exercised at prices ranging from $0.82 to $3.90.&#xa0; Total net proceeds to the Company were $223,534.</font></a></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On December 1, 2017, the Company entered into an At Market Issuance Sales Agreement (or &#x201c;ATM Agreement&#x201d;) with an agent, and filed a prospectus supplement with the SEC pursuant under which the Company could offer and sell from time to time up to an aggregate of $7,000,000 of shares of the Company&#x2019;s common stock, par value $0.08 per share (the &#x201c;Placement Shares&#x201d;), through the agent. From December 1, 2017 to March 19, 2020, the Company sold common stock resulting in $6,997,935 of gross proceeds under this ATM Agreement, of which $3,771,048 were sold during the year ended May 31, 2020. </font><font style="FONT-SIZE:10pt">This At Market Issuance Agreement expired on July 20, 2020 upon the expiration of the Company&#x2019;s Form S-3 registration statement base prospectus dated July 20, 2017. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 12pt"><font style="FONT-SIZE:10pt; COLOR:black">The Placement Shares sold and issued under this ATM Agreement have been registered under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), pursuant to the Registration Statement on Form S-3 (File No. 333-219130) (the &#x201c;Registration Statement&#x201d;), which was originally filed with the SEC on June 30, 2017 and declared effective by the SEC on July 20, 2017, the base prospectus contained within the Registration Statement, and the prospectus supplement related to the sale of shares under the ATM Agreement was filed with the SEC on December 1, 2017.&#xa0;</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On March 20, 2020, the Company filed a new prospectus supplement to the S-3 registration statement base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the ATM Agreement. </font><a name="_Hlk47966232"><font style="FONT-SIZE:10pt">This ATM Agreement expired on July 20, 2020 upon the expiration of the Company&#x2019;s Form S-3 registration statement base prospectus dated July 20, 2017. Gross proceeds for the year ended May 31, 2020 were $6,817,330. There were no proceeds for the year ended May 31, 2021, for this July 20, 2017 Form S-3 registration statement.</font></a></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Combined Placement Shares sold under the ATM Agreements during the year ended May 31, 2020 under the two prospectus supplements dated December 1, 2017 and March 20, 2020 totaled 1,674,943 shares. Total net proceeds from the sale of Placement Shares under the two prospectus supplements during the year ended May 31, 2020 were $10,232,857 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&#xa0; These shares were sold at prices ranging from $2.33 to $9.08 per share. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On September 11, 2020, the Company filed a Pre-Effective Amendment No. 1 to the Form S-3 to register 571,429 shares of Biomerica common stock in connection with the Stock Purchase Agreement dated February 21, 2020, wherein the Company entered into a registration rights agreement with the selling stockholder, pursuant to which we agreed to file a registration statement registering the resale of the shares of our common stock issuable upon conversion of our Series A Preferred Stock issued to the selling stockholder under the Stock Purchase Agreement.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><a name="_Hlk79676889"><font style="FONT-SIZE:10pt; COLOR:black">On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for the Form S-3 &#x201c;shelf&#x201d; </font></a><font style="FONT-SIZE:10pt; COLOR:black">Registration Statement filed on July 21, 2020 and amended on September 11, 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">During the year ended May 31, 2020, 250,000 shares of common stock were converted from Preferred Stock as described below in &#x201c;Preferred Stock Activity&#x201d;.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">During the year ended May 31, 2021, options to purchase 86,750 shares of common stock were exercised at prices ranging from $0.82 to $3.62.&#xa0; Total net proceeds to the Company were $102,255.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020 and declared effective by the SEC on September 30, and an ATM Agreement. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On May 21, 2021, in conjunction with the Company&#x2019;s 2020 Stock Incentive Plan, that was approved by shareholders at the Company&#x2019;s annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to 900,000 shares of the Company&#x2019;s common stock that could be issued under this Plan.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Under an ATM Agreements, sales of the Placement Shares are deemed to be &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act.&#xa0; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">During the year ended May 31, 2021, 321,429 shares of common stock were converted from Preferred Stock as described below in &#x201c;Preferred Stock Activity&#x201d;.</font><a name="_Hlk49188299"></a></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0cm"><font style="FONT-SIZE:10pt">During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement <a name="_Aci_Pg1">(</a></font><font style="FONT-SIZE:10pt; COLOR:black">File No. 333-239980</font><font style="FONT-SIZE:10pt; COLOR:black">) </font><font style="FONT-SIZE:10pt">and ATM Agreement which resulted in gross proceeds of $1,177,394 and net proceeds to the Company of $1,011,475 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt">PREFERRED STOCK ACTIVITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with </font><font style="FONT-SIZE:10pt">Palm Global Small Cap Master Fund LP (&#x201c;Palm&#x201d;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&#x2019;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#x2019;s common stock, subject to certain adjustments. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay such accruing dividends. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered 571,429 common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. <font style="COLOR:black">On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares.&#xa0; On January 21, 2021 Palm Converted their remaining 321,429 Convertible Preferred Shares into registered common shares. At May 30, 2021, the Company had no shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative Dividends were paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past cumulative dividends. </font></font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606421864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 7: &#xa0;&#xa0;&#xa0;INCOME TAXES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Provision for income taxes for the years ended May 31 consists of the following:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;Years ended May 31,</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Current:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Foreign Taxes Subsidiaries</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(12,257)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(6,590)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total current</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">(13,057)</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></b></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Deferred:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal&#xa0;</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Total deferred</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">(13,057)</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></b></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Provision for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (</font><font style="FONT-SIZE:10pt">21<font style="COLOR:black">% for 2021 and 2020) to pretax income as a result of the following:</font></font></p><br/><table style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto; height: 135px;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Years ended May 31,</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 101.383px; white-space: nowrap; padding: 0cm;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0cm;"><font style="font-size: 10pt; color: black;">2021</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 101.383px; white-space: nowrap; padding: 0cm;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0cm;"><font style="font-size: 10pt; color: black;">2020</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Computed "expected" tax benefit </font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">1,355,756 </font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">489,651 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Increase (reduction) in income taxes resulting from:</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Change in valuation allowance</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(2,102,000)</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(1,029,000)</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">State income taxes, net of federal benefit</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">190,233 </font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">154,254 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Research and development tax credits</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">456,388 </font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">49,770 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Permanent tax differences and other</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">98,823 </font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">334,525 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Foreign taxes of subsidiaries</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 14.6333px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(12,257)</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 14.6333px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(6,590)</font></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">Income tax expense</font></strong></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 14.6333px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">$</font></strong></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">(13,057)</font></strong></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 14.6333px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">$</font></strong></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">(7,390)</font></strong></p>
</td>
</tr>
</table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The tax effect of significant temporary differences&#xa0;is presented below:</font></p><br/><table style="width: 550.1pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">As of May 31,</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0cm;"><font style="font-size: 10pt; color: black;">2021</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0cm;"><font style="font-size: 10pt; color: black;">2020</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Deferred tax assets:</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm 0cm 0cm 10.8pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Accounts receivable, principally due to allowance for doubtful accounts</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">200,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">17,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Inventory valuation&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">387,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">16,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Compensated absences</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">85,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">64,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Net operating loss carryforwards&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">3,195,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">2,286,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Tax credit carryforwards</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">1,055,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">599,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Deferred rent expense/Capitalized leases</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">14,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">17,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Stock Options</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">299,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">181,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Losses of foreign subsidiaries &amp; Other, net</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">370,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">303,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm 0cm 0cm 10.8pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Accumulated depreciation and amortization</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(15,000)</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">5,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Total deferred tax assets&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">5,590,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">3,488,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Less valuation allowance</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(5,590,000)</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(3,488,000)</font></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">Net deferred tax asset</font></strong></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">$</font></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">&#xa0;- </font></strong></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">$</font></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">&#xa0;- </font></strong></p>
</td>
</tr>
</table><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">The Company has provided a valuation allowance of approximately $5,590,000 and $3,488,000 as of May 31, 2021 and 2020, respectively. The net change in the valuation allowance for the years ended May 31, 2021 and 2020 was an increase of $2,102,000 and $1,029,000, respectively.</font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">The Company increased the deferred tax asset and the valuation allowance by $313,000 as of May 31, 2020 based on the outstanding stock options as of May 31, 2020. This change had no impact on the Company&#x2019;s consolidated financial statements as our deferred tax asset is fully offset by our valuation allowance. </font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">At May 31, 2021, the Company has Federal income tax net operating loss carryforwards of approximately $12,957,000. &#xa0;At May 31, 2021, the Company has California state income tax net operating loss carryforwards of approximately $6,768,000. For tax reporting purposes, operating loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in 2022 and 2037 for federal and state purposes, respectively.&#xa0; Federal net operating losses beginning in 2018 have no expiration date. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2021, the Company has Federal research and development tax credit carryforward of approximately $715,000. &#xa0;The Federal credits begin to expire in 2027. &#xa0;The Company also had similar credit carryforwards for state purposes of $341,000 at May 31, 2021, which don&#x2019;t expire.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, annual use of the Company's net operating loss ("NOL") and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company's NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2021, the Company did an analysis of its ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740. Should such position be identified in the future and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal year 2017.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659610129752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureTextBlock', window );">Geographic Information Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 8: &#xa0;&#xa0;&#xa0;GEOGRAPHIC INFORMATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company operates as one segment. Geographic information regarding net sales is approximately as follows: </font></p><br/><table width="733" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="7" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Year Ended</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Revenues from sales to unaffiliated customers:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Europe</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4,301,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">60%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,434,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">36%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Asia</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,908,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">26%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,867,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">28%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">United States</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">548,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">8%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">445,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">7%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">South America</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">250,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,615,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">24%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Middle East</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">192,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">314,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Other</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">18,000 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">7,199,000 </font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">100%</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">6,693,000 </font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">100%</font></b></p></td></tr></table><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments according to the geographic areas.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606249272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 9: &#xa0;&#xa0;&#xa0;COMMITMENTS AND CONTINGENCIES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">OPERATING LEASES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. </font><font style="FONT-SIZE:10pt">&#xa0;On November 30, 2015, the Company entered into the First Amendment to Lease wherein it exercised its option to extend its lease until August 31, 2021. The initial base rent for the lease extension was $21,000 per month, increasing to $23,637 through August 31, 2021. On April 9, 2021 the Company exercised its second option to extend its lease for an additional five years through August 2026.&#xa0; The Company was also granted an additional five years lease extension option through August 2031. The rent is currently $23,637 per month and will increase on September 1, 2021 to $25,970 per month and be increased 3% each year thereafter. The security deposit of $22,080 remains the same.<font style="COLOR:black">&#xa0;</font></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">In November 2016, the Company&#x2019;s subsidiary, Biomerica de Mexico, entered into a ten-year lease for approximately 8,104 square feet at a monthly rent of $2,926. The Company has one 10-year option to renew at the end of the initial lease period. The yearly rate is subject to an annual adjustment for inflation according to the United States Bureau of Labor Statistics Consumer Price Index for All Urban Consumers. The monthly rate is currently $3,262. &#xa0;Biomerica, Inc. is not a guarantor of such lease. &#xa0;Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Total gross rent expense in the U.S. for fiscal 2021 was $294,759 and 2020 was $300,267.&#xa0; Rent expense for the Mexico facility for fiscal 2021 and 2020 was $25,351 and $43,481, respectively. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 0.9pt 0cm 0cm"><font style="FONT-SIZE:10pt">For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#x2019;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&#xa0; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred.&#xa0; </font></p><br/><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Courier New&quot;; MARGIN:0cm"><font style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">Supplemental cash flow information related to leases for the year ended May 31: </font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Operating cash flows from operating leases&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">320,606 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">311,742 </font></p></td></tr> <tr style="HEIGHT:14.4pt"> <td style="HEIGHT:14.4pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Right-of-use assets obtained in exchange for<br/>&#xa0;&#xa0;&#xa0; &#xa0;new operating lease liabilities</font></p></td> <td style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">79,159 </font></p></td> <td style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Weighted average remaining lease term (in years)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5.27</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.27</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Weighted average discount rate</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.50%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.50%</font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Future minimum lease payments under the operating lease as of May 31, 2021 are as follows:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">337,630 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">350,311 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">360,769 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">371,539 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2026</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">382,631 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">103,927 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Total undiscounted lease payments</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,906,807 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Less imputed interest</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">287,293 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Total operating lease liabilities</font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,619,514 </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company also has various insignificant leases for office equipment.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">RETIREMENT SAVINGS PLAN</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan's inception.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">LITIGATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. There were no legal proceedings pending as of May 31, 2021.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt">On July 2, 2020, we received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena requested information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also requested information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. In addition, on December 15, 2020, the SEC sent a second subpoena related to this investigation to Zack Irani, the Company&#x2019;s CEO, requesting documents held by Mr. Irani concerning his past purchases of Company stock, his past communications with certain persons and entities, and other personal and Company documents. The Company and Mr. Irani have cooperated fully with the SEC&#x2019;s investigation and provided information as requested. At this time, the Company is unable to predict the duration, scope or outcome of these investigations.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">CONTRACTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt">Contracts and Licensing Agreements</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $11,000 and $15,000 is included in cost of sales for the agreement for each of the years ended May 31, 2021 and 2020, respectively. Sales of products manufactured under these agreements comprise approximately 1.5% and 1.8% of total sales for the years ended May 31, 2021 and 2020, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business.&#xa0; The Company has other royalty agreements, however they are not considered material.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (&#x201c;Telcon Agreement&#x201d;) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (&#x201c;Telcon&#x201d;), a medical company in South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica&#x2019;s new InFoods&#xae; IBS products (&#x201c;IBS Products&#x201d;) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. We are working with Telcon management to extend the term of the Telcon Agreement. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica&#x2019;s starting clinical trials in the United States, receipt of U.S. FDA clearance and Telcon&#x2019;s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common stock in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt">Additionally, the Telcon Agreement provides for&#xa0;a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.&#xa0; In order to retain the exclusivity within South Korea, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon&#x2019;s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019.<b> </b>&#xa0;&#xa0;In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. &#xa0;During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On May 29, 2019, the Company entered into an exclusive distribution agreement which contained certain annual minimum sales requirements, with MaxHealth Medical International Limited (a Chinese company) for the distribution of the Company&#x2019;s EZ Detect Product in China.&#xa0; On March 15, 2021, the Company terminated this agreement due to MaxHealth&#x2019;s failure to meet the minimum sales requirements.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the &#x201c;Mount Sinai License Agreements&#x201d;) with the Mount Sinai Icahn School of Medicine in New York (&#x201c;Mount Sinai&#x201d;) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&#xa0; This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States.&#xa0; The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for Emergency Use Authorization with the FDA based on this on this technology. The Company purchased materials in the amount of $5,100 during fiscal 2020 and subsequently to that another $2,850.&#xa0; No royalty fees have been paid yet on these agreements.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On May 7, 2020, the Company entered into an exclusive license agreement (the &#x201c;UC License Agreements&#x201d;) with The Regents of the University of California (&#x201c;UC&#x201d;) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at the University by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus.&#xa0;If this technology development is successful, the Company will work with the University to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated and cleared with regulatory agencies for commercial sale into the market.&#xa0; The exclusive UC License Agreements provide for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $5,000 with the execution of the agreement. An additional $5,000 was paid in September 2020.&#xa0; No royalties have been paid yet on this agreement. A license maintenance fee of $10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 16.2pt 0cm 0cm"><b><font style="FONT-SIZE:10pt">Clinical Trial Agreements</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.&#xa0; The initial budget was estimated to be $82,472. The work started in October 2017 with charges for work performed being invoiced and paid monthly.&#xa0; This study ended in February 2020. The Company incurred $2,200 in fiscal 2020 and $12,567 in expenses previously invoiced for a total of $14,767. In addition, $17,064 in fees has been accrued for unbilled charges as of May 31, 2021.</font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">In November 2017, the Company entered into a Clinical Trial Agreement with the University of Michigan to perform an InFoods</font><font style="font-size: 10pt;">&#xae; <font style="color: black;">24 Endpoint Determination Study.&#xa0; The Company will be invoiced monthly for work performed the previous month. The maximum budget for the study is $181,015. The Company incurred $20,550 and $30,900 in expenses for this study during fiscal 2021 and 2020, respectively. This commitment is approximately 56% billed.&#xa0; The Company has accrued $2,050 in charges as of May 31, 2021.</font></font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">In January 2018, the Company entered into a Clinical Trial Agreement with Beth Israel Deaconess Medical Center for the purposes of conducting an Antibody Guided Restriction Trial Using Biomerica InFoods</font><font style="font-size: 10pt;">&#xae; <font style="color: black;">24G Test in patients with a previous diagnosis of Irritable Bowel Syndrome.&#xa0; The study began in the first quarter of fiscal 2019. The Company was invoiced monthly for work performed the previous month.&#xa0; The total cost of the study was initially estimated to be $142,000, however the study was expanded and total costs of the trial was approximately $305,000. The Company incurred $0 and $141,640 in expenses for this study during fiscal 2021 and 2020, respectively. This study was closed in February 2020 and no additional costs are expected.</font></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">On July 12, 2019, the Company entered into a Clinical Trial Agreement with a research management institution for the purpose of conducting a clinical trial of the Biomerica HP Stool Antigen test.&#xa0; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&#xa0; The maximum budgeted costs were approximately $117,200.&#xa0; During fiscal 2021 and 2020, $13,111 and $13,355 in charges were billed, respectively. This study is now closed so no further charges will be incurred.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">On July 22, 2019, the Company entered into a Clinical Trial Agreement with a research institution, for the purpose of conducting a clinical trial of the Biomerica InFoods&#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000.&#xa0; The Company incurred $20,875 in charges during fiscal 2020. This commitment is approximately 31% billed. In addition, the Company was billed $12,675 in fiscal 2021 and accrued $19,600 in unbilled charges as of May 31, 2021.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">On September 25, 2019, the Company entered into a Clinical Trial Agreement with a medical practice for the purpose of conducting a clinical trial of the Biomerica InFoods&#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $136,000. During fiscal 2021 and 2020, the Company was invoiced $11,725 and $45,250 respectively in expenses. This commitment is approximately 42% billed. In addition, the Company accrued $5,975 in unbilled charges as of May 31, 2020. No charges were accrued at May 31, 2021.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">On September 25, 2019, the Company entered into a Clinical Trial Agreement with a research institution for the purpose of conducting a clinical trial of the Biomerica H. pylori product.&#xa0; The term of the agreement shall be until completion of the work outlined and the charges were invoiced monthly for work performed in the previous month.&#xa0; The maximum budgeted costs will be approximately $57,800. The Company was invoiced $41,845 in charges during the year ended May 31, 2020. At May 31, 2020, the commitment was approximately 72% billed and the study was closed so no further charges will be incurred.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">In December 2019, the Company entered into a Clinical Trial Agreement with Houston Methodist Research Institute for the purpose of conducting a clinical trial of the Biomerica InFoods&#xae; product.&#xa0; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&#xa0; The maximum budgeted costs will be approximately $133,000. During the years ended May 31, 2021 and 2020, the Company was invoiced $0 and $4,000 in charges, respectively. This commitment is approximately 3% billed. The Company accrued $3,550 in charges at May 31, 2021.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Arizona for the purpose of participating in the ongoing end point clinical trial of the Biomerica InFoods&#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. &#xa0;At May 31, 2021 and 2020, $0 and $17,390 had been invoiced to the Company. The Company has accrued $3,750 in expenses as of May 31, 2021. This commitment is approximately 13% billed.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Jacksonville for the purpose of participating in the ongoing end point clinical trial of the Biomerica InFoods&#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. The Company has not received any billings as of May 31, 2020, however accrued $17,390 in charges as of that date. The Company received $22,827 in billings in fiscal 2021 and did not accrue any charges as of May 31, 2021. As of May 31, 2021, approximately 17% of the commitment had been invoiced.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt">On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica InFoods&#xae; product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850. As of May 31, 2021, $4,850 had been billed and $3,750 in accruals remained. As of May 31, 2021, approximately 4% of the commitment had been invoiced.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">The addition of both Mayo Clinic sites and other major medical centers were brought into the InFoods&#xae; IBS clinicals studies in order to accelerate patient enrollment.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606445224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 16.2pt 0cm 0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NOTE 10:&#xa0;&#xa0;&#xa0; SUBSEQUENT EVENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">Subsequent to May 31, 2021, options to purchase 1,500 shares of Biomerica common stock were exercised at the exercise price of $2.68 per share.&#xa0; Proceeds to the Company were approximately $4,000.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">Subsequent to May 31, 2021, the Company sold 201,553 shares of its common stock under its Form S-3 &#x201c;shelf&#x201d; Registration statement. The average sale price was $4.16 per share. Net proceeds to the Company were approximately $824,000.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On June 21, 2021, the Company signed an exclusive distribution and marketing agreement in Canada for its Helicobacter Pylori (H. Pylori) test.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">In June 2021, the Company received a patent in Japan (#6902526) for the System and Method for a Digital Health System Providing a Food Recommendation Based on Food Sensitivity Testing. This technology is designed to allow for easier implementation of the dietary restrictions that result from InFoods&#xae; diagnostic testing. This method describes using a smartphone or similar technology to identify prepared or packaged foods that contain restricted food ingredients, using barcodes or product labels.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">In August 2021, the Company received a notice of allowance for a patent in Japan whose claims cover the use of the InFoods&#xae; technology to diagnose and treat depression, and covers the compositions, devices and methods of depression sensitivity testing.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659602423512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">PRINCIPLES OF CONSOLIDATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The enclosed consolidated financial statements for the years ended May 31, 2021 and 2020 include the accounts of Biomerica, Inc. ("Biomerica") as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTING ESTIMATES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_MarketsAndMethodsOfDistributionPolicyTextBlock', window );">Markets And Methods Of Distribution [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">MARKETS AND METHODS OF DISTRIBUTION</font></b></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt;">Due to </font><font style="font-size: 10pt;">the Coronavirus global pandemic, the Company&#x2019;s operations have been negatively impacted. <font style="color: black;">The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, loss of contracts and/or customers, closure of the Company&#x2019;s manufacturing or distribution facilities or of the facilities of the Company&#x2019;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company&#x2019;s operations and financial performance and may continue to have significant material negative impacts on the Company.</font></font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_LiquidityPolicyTextBlock', window );">Liquidity [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $28.4 million as of May 31, 2021.&#xa0; Management expects to continue to incur significant costs as it advances its trials and development activities.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $15,000,000 to the base prospectus filed with the SEC on July 21, 2020 and declared effective by the SEC on September 30, 2020 and an ATM Agreement. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Under an ATM Agreement, sales of the Placement Shares are deemed to be &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act.&#xa0; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0cm"><font style="FONT-SIZE:10pt">During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $7.06 to $7.79 under its Form S-3 Registration Statement (</font><font style="FONT-SIZE:10pt; COLOR:black">File No. 333-239980) </font><font style="FONT-SIZE:10pt">and ATM Agreement which resulted in gross proceeds of $1,177,394 and net proceeds to the Company of $1,011,475 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.</font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 12pt 0cm 0cm;"><font style="font-size: 10pt;">As a result of cash and cash equivalents on hand at May 31, 2021, management believes the Company has sufficient funds to operate through August 2022 and the ability to raise additional funds through the ATM noted above.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">FAIR VALUE OF FINANCIAL INSTRUMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&#xa0;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">CONCENTRATION OF CREDIT RISK</font></b></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&#xa0; As of May 31, 2021, the Company had approximately $3,767,000 of uninsured cash. </font><font style="font-size: 10pt; color: black;">The Company does not believe it is exposed to any significant credit risks.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&#xa0; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. </font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">For the years ended May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 60% and 57% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2021 and 2020 one of the distributors mentioned above accounted for 33% and 26%, respectively, of net consolidated sales.&#xa0; At May 31, 2021 and 2020, the Company had two distributors and three distributors which accounted for a total of 73% and 80%, respectively, of gross accounts receivable. <a name="_Hlk48558057"></a>Of the 73% as of May 31, 2021, 41% was owed by a distributor in China. Total gross receivables at May 31, 2021 and 2020 were </font><font style="font-size: 10pt;">$2,292,466 </font><font style="font-size: 10pt; color: black;">and $1,836,852, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2021, one vendor accounted for 58% of the purchases of raw materials. For the year ended May 31, 2020, one vendor accounted for a total of 59% of the purchases of raw materials.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock', window );">Concentration Risk Geographic Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">GEOGRAPHIC CONCENTRATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2021 and 2020, approximately $803,000 and $613,000 of Biomerica's gross inventory and approximately $25,000 and $31,000, of Biomerica's property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><strong><font style="font-size: 10pt;">CASH AND </font></strong><font style="font-size: 10pt;"><strong><font style="color: black;">CASH EQUIVALENTS</font></strong></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTS RECEIVABLE</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. &#xa0;International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &#xa0;Based on various criteria,&#xa0;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. &#xa0;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &#xa0;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &#xa0; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt">The Company has established a reserve of $837,415 for doubtful accounts as of May 31, 2021. The majority of this reserve has been established to cover 100% of outstanding accounts receivable from an international distributor.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_PrepaidsPolicyPolicyTextBlock', window );">Prepaids Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><b><font style="FONT-SIZE:10pt">PREPAIDS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt">The Company occasionally prepays for items such as inventory, insurance and other items.&#xa0; These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 2.7pt 0cm 0cm"><font style="FONT-SIZE:10pt">As of May 31, 2021, the prepaids were approximately $370,000, composed of prepayments to insurance and various other suppliers. As of May 31, 2020, approximately $1 million of the prepaids was an advance payment to one of our suppliers, which was subsequently refunded by the supplier when the Company determined it no longer needed the materials that had been ordered.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">INVENTORIES, NET</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Inventories approximate the following at May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Raw materials</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,583,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,635,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Work in progress</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,006,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">988,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Finished products</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">617,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">228,000 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">3,206,000 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">2,851,000 </font></b></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2021 and 2020, inventory reserves were approximately $1,617,000 and $67,000, respectively. </font><font style="FONT-SIZE:9pt">Of the inventory reserve, </font><font style="FONT-SIZE:9pt">$1,502,675 was related to a market downturn in our COVID-19 antibody test and materials, as the market shifted to&#xa0; COVID-19 PCR viral tests and antigen tests.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">PROPERTY AND EQUIPMENT, NET</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $104,715 and $105,299 for the years ended May 31, 2021 and 2020, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">INTANGIBLE ASSETS, NET</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $33,552 and $23,873 for the years ended May 31, 2021 and 2020, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2021 or 2020.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately-held companies. &#xa0;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&#x2019;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&#x2019;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &#xa0;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">SHARE-BASED COMPENSATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of the accounting provisions of ASC 718<a name="_Hlk17621381">, </a>Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">In applying the Black-Scholes options-pricing model, assumptions used were as follows: &#xa0;</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Dividend yield</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Expected volatility</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;71.19-107.53% </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;55.52-72.62% </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Risk free interest rate</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;0.34-1.18% </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;0.43-1.80% </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Expected Term</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;5.50-6.25 Years </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;3.75-6.25 Years </font></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">REVENUE RECOGNITION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#xa0; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2021 and 2020 and does not believe that any additional discounts will be given through the end of the contract periods. </font><font style="FONT-SIZE:10pt">Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. <font style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &#xa0;Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </font><a name="_Hlk49511094"></a></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Year Ended</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Clinical lab</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3,077,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,922,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Physician's office</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,801,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,195,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Over-the-counter</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">766,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,270,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Contract manufacturing</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">552,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">306,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Lab supplies</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">7,199,000 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">6,693,000 </font></b></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">See Note 8 for additional information regarding revenue concentrations.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">SHIPPING AND HANDLING FEES </font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Research and development costs are expensed as incurred. The Company expensed $2,410,506 and $1,910,209 of research and development costs during the years ended May 31, 2021 and 2020, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">INCOME TAXES</font></b></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0cm;"><font style="font-size: 10pt; color: black;">The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2021 and 2020, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&#xa0;&#xa0; During the fiscal year ended May 31, 2021, this valuation allowance was increased to $5,590,000, which fully covers the tax asset of $5,590,000</font><font style="font-size: 9pt; color: black;">.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#x201c;Interest expense&#x201d; line and penalties related to liabilities for income taxes within the &#x201c;Other expense&#x201d; line of the consolidated statements of operations and comprehensive loss.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Cost [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <font style="BACKGROUND:white">$10,070</font> and $<font style="BACKGROUND:white">174</font> for the years ended May 31, 2021 and 2020, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">FOREIGN CURRENCY TRANSLATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2021 and 2020.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.<font style="COLOR:black">&#xa0;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&#xa0; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.</font></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt">In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&#xa0; Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#xa0; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#xa0; Leases are classified as financing or operating which will drive the expense recognition pattern.&#xa0; The Company has elected to exclude short-term leases.&#xa0; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&#xa0; An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#xa0; As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company&#x2019;s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not book the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&#xa0; Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#xa0; The leases do not include the options to purchase the leased property.&#xa0; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">NET LOSS PER SHARE </font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2021 and 2020 were 2,081,366 and 1,789,251, respectively. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">The Company also had 0 and 321,429 of Series A 5% Convertible Preferred Stock outstanding for the years ended May 31, 2021 and 2020, respectively. &#xa0;The 321,429 shares outstanding at May 31, 2020 were converted to common stock during the year ended May 31, 2021.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">SEGMENT REPORTING</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">ASC 280, Segment Reporting (&#x201c;ASC 280&#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">REPORTING COMPREHENSIVE LOSS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#x2019; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,serif; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">RECENT ACCOUNTING PRONOUNCEMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0cm 7.2pt 0cm 0cm"><font style="FONT-SIZE:10pt; COLOR:black">Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#x2019;s present or future consolidated financial statements.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the description of risks that arise due to concentrations of operating facilities, revenues, assets, customers, vendors or the like in a certain geographic area, either domestic or foreign. The description may address risks inherent in the geographic area, and, at a minimum, informs users of the general nature of the risk, but excludes "Information about Geographic Areas" that may be disclosed elsewhere.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity position during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_MarketsAndMethodsOfDistributionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Markets And Methods Of Distribution during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_MarketsAndMethodsOfDistributionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_PrepaidsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for prepaids.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_PrepaidsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606430984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Raw materials</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,583,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,635,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Work in progress</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,006,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">988,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:89.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Finished products</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">617,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">228,000 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:89.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">3,206,000 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">2,851,000 </font></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Dividend yield</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Expected volatility</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;71.19-107.53% </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;55.52-72.62% </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Risk free interest rate</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;0.34-1.18% </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;0.43-1.80% </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:107.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Expected Term</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;5.50-6.25 Years </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;3.75-6.25 Years </font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Year Ended</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Clinical lab</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3,077,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,922,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Physician's office</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,801,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,195,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Over-the-counter</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">766,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,270,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Contract manufacturing</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">552,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">306,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:115.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Lab supplies</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:115.9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">7,199,000 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">6,693,000 </font></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606455816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Equipment </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,849,888 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,921,833 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Furniture, fixtures and leasehold improvements</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">432,989 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">225,189 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:234pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated depreciation</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(1,972,357)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(1,867,643)</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:234pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Net property and equipment</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">310,520 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">279,379 </font></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606509432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Licenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">182,176 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">551,397 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Patents</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">239,423 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">113,382 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-licenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(107,194)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(487,989)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:72%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-patents</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(19,575)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(8,135)</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Intangible asssets, net</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">294,830 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">168,655 </font></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">21,846 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">20,058 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">20,058 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">19,071 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2026</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">18,975 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:110.15pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">194,822 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:110.15pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">294,830 </font></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659621727560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Accounts payable</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">431,621 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">833,412 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:131.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Accrued expense</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">151,759 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">153,299 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:131.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">583,380 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">986,711 </font></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606285704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table width="734" style="WIDTH:550.7pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER OF STOCK OPTIONS</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">EXCERCISE PRICE <br/>RANGE PER SHARE</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:79.4pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED AVERAGE EXERCISE <br/>PRICE</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2019</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">1,476,209 </font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><b><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.6pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">2.07 </font></b></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">517,500 </font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$2.68-$8.18</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.47 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options excercised</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(137,958)</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1.64 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(66,500)</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.85-$8.18</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.43 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2020</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">1,789,251 </font></b></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><b><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$8.18</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">2.75 </font></b></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">430,616 </font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$5.14-$8.70</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.73 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options excercised</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(86,750)</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:66.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.62</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:67.2pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1.20 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:300.25pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(51,751)</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$2.35-$8.18</font></p></td> <td style="HEIGHT:15pt; WIDTH:12.6pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.77 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:300.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2021</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">2,081,366 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66.05pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><b><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$8.70</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:12.6pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:67.2pt; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">$1.20 - $6.73</font></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:54.75pt"> <td style="HEIGHT:54.75pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Number of<br/>&#xa0;shares</font></p></td> <td style="HEIGHT:54.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:54.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Stock options<br/>weighted<br/>average grant <br/>date fair value</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2020 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">822,584 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.78 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Granted </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">430,616 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.73</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Vested&#xa0; </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(409,459)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.36</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:172.8pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Forfeited </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(50,500)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.80</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:172.8pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2021 </font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">793,241 </font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">5.54 </font></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">RANGE OF <br/>EXERCISE PRICES</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER <br/>OUTSTANDING <br/>MAY 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED <br/>AVERAGE <br/>REMAINING <br/>CONTRACTUAL <br/>LIFE IN YEARS</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED<br/>&#xa0;AVERAGE <br/>EXERCISE PRICE</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER <br/>EXCERCISABLE <br/>AT MAY 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED <br/>AVERAGE <br/>EXERCISE PRICE</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$1.04</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">216,000</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">3.75</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">216,000</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15.14%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$1.20-$2.81</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">1,024,500</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">6.45</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$2.17 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">795,250</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15.04%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$2.02 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:15.14%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$3.62-$8.70</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">840,866</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">8.00</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$6.03 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">276,875</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15.04%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">$4.54 </font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659607592808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;Years ended May 31,</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Current:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Foreign Taxes Subsidiaries</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(12,257)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(6,590)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total current</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">(13,057)</font></b></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></b></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Deferred:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal&#xa0;</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:149.75pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Total deferred</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:149.75pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:21.6pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">(13,057)</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><table style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto; height: 135px;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Years ended May 31,</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 101.383px; white-space: nowrap; padding: 0cm;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0cm;"><font style="font-size: 10pt; color: black;">2021</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 101.383px; white-space: nowrap; padding: 0cm;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0cm;"><font style="font-size: 10pt; color: black;">2020</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Computed "expected" tax benefit </font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">1,355,756 </font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">489,651 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Increase (reduction) in income taxes resulting from:</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Change in valuation allowance</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(2,102,000)</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(1,029,000)</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">State income taxes, net of federal benefit</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">190,233 </font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">154,254 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Research and development tax credits</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">456,388 </font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15px; width: 82.8833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">49,770 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Permanent tax differences and other</font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">98,823 </font></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15px; width: 82.8833px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">334,525 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15px; width: 496.833px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Foreign taxes of subsidiaries</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 14.6333px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(12,257)</font></p>
</td>
<td style="height: 15px; width: 13.5167px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 14.6333px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none solid; border-width: 0px 0px 1pt; height: 15px; width: 86.75px; background: #b8cce4 none repeat scroll 0% 0%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(6,590)</font></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15px; width: 496.833px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">Income tax expense</font></strong></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 14.6333px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">$</font></strong></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">(13,057)</font></strong></p>
</td>
<td style="height: 15px; width: 13.5167px; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 14.6333px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">$</font></strong></p>
</td>
<td style="border-color: currentcolor currentcolor windowtext; border-style: none none double; border-width: 0px 0px 2.25pt; height: 15px; width: 86.75px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">(7,390)</font></strong></p>
</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><table style="width: 550.1pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">As of May 31,</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0cm;"><font style="font-size: 10pt; color: black;">2021</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0cm;"><font style="font-size: 10pt; color: black;">2020</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Deferred tax assets:</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm 0cm 0cm 10.8pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Accounts receivable, principally due to allowance for doubtful accounts</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">200,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">17,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Inventory valuation&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">387,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">16,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Compensated absences</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">85,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">64,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Net operating loss carryforwards&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">3,195,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">2,286,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Tax credit carryforwards</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">1,055,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">599,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Deferred rent expense/Capitalized leases</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">14,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">17,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Stock Options</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">299,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">181,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Losses of foreign subsidiaries &amp; Other, net</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">370,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">303,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm 0cm 0cm 10.8pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Accumulated depreciation and amortization</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(15,000)</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">5,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Total deferred tax assets&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">5,590,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #b8cce4; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">3,488,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 68%; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><font style="font-size: 10pt; color: black;">Less valuation allowance</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(5,590,000)</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0cm;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><font style="font-size: 10pt; color: black;">(3,488,000)</font></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 68%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">Net deferred tax asset</font></strong></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">$</font></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">&#xa0;- </font></strong></p>
</td>
<td style="height: 15.75pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">$</font></strong></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0cm 2.9pt 0cm 0cm;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0cm;"><strong><font style="font-size: 10pt; color: black;">&#xa0;- </font></strong></p>
</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606456376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550.1pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="7" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Year Ended</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Revenues from sales to unaffiliated customers:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Europe</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4,301,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">60%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,434,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">36%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Asia</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,908,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">26%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,867,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">28%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">United States</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">548,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">8%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">445,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">7%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">South America</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">250,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,615,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">24%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Middle East</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">192,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">314,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:229.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Other</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">18,000 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:229.7pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:10.8pt; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">Total</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">7,199,000 </font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">100%</font></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b></b>&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><b><font style="FONT-SIZE:10pt; COLOR:black">$</font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">6,693,000 </font></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><b><font style="FONT-SIZE:10pt; COLOR:black">100%</font></b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659606565992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock', window );">Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0cm; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Operating cash flows from operating leases&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">320,606 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">311,742 </font></p></td></tr> <tr style="HEIGHT:14.4pt"> <td style="HEIGHT:14.4pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Right-of-use assets obtained in exchange for<br/>&#xa0;&#xa0;&#xa0; &#xa0;new operating lease liabilities</font></p></td> <td style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">79,159 </font></p></td> <td style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:14.4pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:14.4pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:297.35pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Weighted average remaining lease term (in years)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5.27</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.27</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:297.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Weighted average discount rate</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.50%</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6.50%</font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">337,630 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">350,311 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">360,769 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">371,539 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">2026</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">382,631 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">103,927 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Total undiscounted lease payments</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,906,807 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:203.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Less imputed interest</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">287,293 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:203.05pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">Total operating lease liabilities</font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0cm"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0cm; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,619,514 </font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to lease for the periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659530384984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Jan. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (28,394,768)<span></span>
</td>
<td class="num">$ (21,925,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue', window );">Shelf Registration Statement, Maximum Authorized Common Stock Issuance, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in Shares)</a></td>
<td class="nump">158,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 1,011,475<span></span>
</td>
<td class="nump">10,232,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="nump">102,255<span></span>
</td>
<td class="nump">223,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="nump">$ 3,767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other Receivables, Gross, Current</a></td>
<td class="nump">$ 2,292,466<span></span>
</td>
<td class="nump">1,836,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 310,520<span></span>
</td>
<td class="nump">279,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable', window );">Threshold Period Past Due for Write-off of Trade Accounts Receivable</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Accounts Receivable, Credit Loss Expense (Reversal)</a></td>
<td class="nump">$ 766,434<span></span>
</td>
<td class="num">(2,129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidSupplies', window );">Increase (Decrease) in Prepaid Supplies</a></td>
<td class="nump">370,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">1,617,000<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Inventory, LIFO Reserve</a></td>
<td class="nump">1,502,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">104,715<span></span>
</td>
<td class="nump">105,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 33,552<span></span>
</td>
<td class="nump">23,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 2,410,506<span></span>
</td>
<td class="nump">1,910,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">5,590,000<span></span>
</td>
<td class="nump">3,488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">5,590,000<span></span>
</td>
<td class="nump">3,488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="nump">10,070<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">1,553,081<span></span>
</td>
<td class="nump">$ 1,711,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 1,619,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</a></td>
<td class="nump">2,081,366<span></span>
</td>
<td class="nump">1,789,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 1,177,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="nump">$ 1,011,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)</a></td>
<td class="nump">321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Accounts Receivable, Credit Loss Expense (Reversal)</a></td>
<td class="nump">$ 837,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember', window );">Purchased Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="nump">$ 7.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="nump">$ 28,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=bmra_A5ConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">$ 803,000<span></span>
</td>
<td class="nump">$ 613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Distributors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Distributors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Distributors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Distributors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Distributors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Distributors in China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Cost of Goods and Service, Product and Service Benchmark [Member] | One Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 1,942,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 1,980,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related with Maximum Authorized Common Stock Issuance of Shelf Registration Statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period past due for trade accounts receivable to write off as uncollectible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bmra_A5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bmra_A5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_ThreeDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_ThreeDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_DistributorsInChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_DistributorsInChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659610136216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,583,000<span></span>
</td>
<td class="nump">$ 1,635,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">1,006,000<span></span>
</td>
<td class="nump">988,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished products</a></td>
<td class="nump">617,000<span></span>
</td>
<td class="nump">228,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 3,206,255<span></span>
</td>
<td class="nump">$ 2,850,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659601319752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.19%<span></span>
</td>
<td class="nump">55.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">0.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">107.53%<span></span>
</td>
<td class="nump">72.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.18%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659600359784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">$ 7,199,000<span></span>
</td>
<td class="nump">$ 6,693,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember', window );">Clinical Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">3,077,000<span></span>
</td>
<td class="nump">2,922,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember', window );">Physicians Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">2,801,000<span></span>
</td>
<td class="nump">2,195,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_OverthecounterMember', window );">Over-the-counter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">766,000<span></span>
</td>
<td class="nump">1,270,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember', window );">Contract Manufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">552,000<span></span>
</td>
<td class="nump">$ 306,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_LabSuppliesMember', window );">Lab Supplies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_OverthecounterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_OverthecounterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_LabSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_LabSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659610150392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_PropertyAndEquipmentNetAbstract', window );"><strong>Property and equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_Equipment', window );">Equipment</a></td>
<td class="nump">$ 1,849,888<span></span>
</td>
<td class="nump">$ 1,921,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_FurnitureFixturesAndLeaseholdImprovements', window );">Furniture, fixtures and leasehold improvements</a></td>
<td class="nump">432,989<span></span>
</td>
<td class="nump">225,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(1,972,357)<span></span>
</td>
<td class="num">(1,867,643)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">$ 310,520<span></span>
</td>
<td class="nump">$ 279,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_Equipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of equipment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_Equipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FurnitureFixturesAndLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities and additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FurnitureFixturesAndLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_PropertyAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_PropertyAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659600470472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details) - Intangible assets, net - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedLicenseAgreementsGross', window );">Licenses</a></td>
<td class="nump">$ 182,176<span></span>
</td>
<td class="nump">$ 551,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">239,423<span></span>
</td>
<td class="nump">113,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_FiniteLivedLicenseAccumulatedAmortization', window );">Less accumulated amortization-licenses</a></td>
<td class="num">(107,194)<span></span>
</td>
<td class="num">(487,989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_FiniteLivedPatentsAccumulatedAmortization', window );">Less accumulated amortization-patents</a></td>
<td class="num">(19,575)<span></span>
</td>
<td class="num">(8,135)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible asssets, net</a></td>
<td class="nump">$ 294,830<span></span>
</td>
<td class="nump">$ 168,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FiniteLivedLicenseAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of licenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FiniteLivedLicenseAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FiniteLivedPatentsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FiniteLivedPatentsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedLicenseAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedLicenseAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659605075832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets<br></strong></div></th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ExpectedAmortizationOfIntangibleAssetsAbstract', window );"><strong>Expected amortization of intangible assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 21,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">20,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">20,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">19,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">18,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">194,822<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 294,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ExpectedAmortizationOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ExpectedAmortizationOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659607767864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Customer Concentration Risk [Member] - Accounts Payable [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">One Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Two Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659607543288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_AccountsPayableAndAccruedExpenseBalancesAbstract', window );"><strong>Accounts payable and accrued expense balances [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 431,621<span></span>
</td>
<td class="nump">$ 833,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expense</a></td>
<td class="nump">151,759<span></span>
</td>
<td class="nump">153,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 583,380<span></span>
</td>
<td class="nump">$ 986,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_AccountsPayableAndAccruedExpenseBalancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_AccountsPayableAndAccruedExpenseBalancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659524604456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">28 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 22, 2021</div></th>
<th class="th"><div>Jan. 21, 2021</div></th>
<th class="th"><div>Jul. 21, 2020</div></th>
<th class="th"><div>Mar. 20, 2020</div></th>
<th class="th"><div>Feb. 24, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Aug. 31, 2010</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 19, 2020</div></th>
<th class="th"><div>May 21, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Feb. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,255<span></span>
</td>
<td class="nump">$ 223,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011,475<span></span>
</td>
<td class="nump">10,232,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,255<span></span>
</td>
<td class="nump">223,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 377,391<span></span>
</td>
<td class="nump">$ 200,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501,000<span></span>
</td>
<td class="nump">$ 589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,132,000<span></span>
</td>
<td class="nump">6,923,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,872,000<span></span>
</td>
<td class="nump">4,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 215 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,491<span></span>
</td>
<td class="nump">17,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,052<span></span>
</td>
<td class="nump">156,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,035<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,813<span></span>
</td>
<td class="nump">$ 22,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5ConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred Stock, Dividends Per Share, Declared (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,177,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,011,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | At Market Issuance Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,232,857<span></span>
</td>
<td class="nump">$ 6,997,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,771,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Common Stock [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Common Stock [Member] | At Market Issuance Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Common Stock [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Common Stock [Member] | At Market Issuance Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,750<span></span>
</td>
<td class="nump">137,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,940<span></span>
</td>
<td class="nump">$ 11,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,429<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Stock, Amount Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Stock Issued During Period, Shares, Conversion of Units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bmra_A2010PlanMember', window );">2010 Plan [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bmra_A2014PlanMember', window );">2014 Plan [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bmra_A2017PlanMember', window );">2017 Plan [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bmra_A2020PlanMember', window );">2020 Plan [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=bmra_RegistrationRightsAgreementMember', window );">Registration Rights Agreement [Member] | Common Stock [Member] | At Market Issuance Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,817,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=bmra_RegistrationRightsAgreementMember', window );">Registration Rights Agreement [Member] | Maximum [Member] | Common Stock [Member] | At Market Issuance Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SHAREHOLDERSEQUITYDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bmra_AtMarketIssuanceSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bmra_AtMarketIssuanceSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2010PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2010PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2017PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2017PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=bmra_RegistrationRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=bmra_RegistrationRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659602174744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082390Member', window );">Exercise Price Range Per Share $0.82 - $3.90 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,476,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, number of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137,958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare268818Member', window );">Exercise Price Range Per Share $2.68 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, number of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare085818Member', window );">Exercise Price Range Per Share $0.85 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired, number of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082818Member', window );">Exercise Price Range Per Share $0.82 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options (in Shares)</a></td>
<td class="nump">1,789,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,789,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare514870Member', window );">Exercise Price Range Per Share $5.14 - $8.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, number of stock options (in Shares)</a></td>
<td class="nump">430,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price</a></td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082362Member', window );">Exercise Price Range Per Share $0.82 - $3.62 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, number of stock options (in Shares)</a></td>
<td class="num">(86,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare235818Member', window );">Exercise Price Range Per Share $2.35 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired, number of stock options (in Shares)</a></td>
<td class="num">(51,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired, weighted average exercise price</a></td>
<td class="nump">$ 4.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082870Member', window );">Exercise Price Range Per Share $0.82 - $8.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options (in Shares)</a></td>
<td class="nump">2,081,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082870Member', window );">Exercise Price Range Per Share $0.82 - $8.70 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082870Member', window );">Exercise Price Range Per Share $0.82 - $8.70 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082390Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082390Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare268818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare268818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare085818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare085818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare514870Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare514870Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082362Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082362Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare235818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare235818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082870Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082870Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659613768328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_NonVestedStockOptionsActivityAbstract', window );"><strong>Non-vested Stock Options Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested shares, number of shares | shares</a></td>
<td class="nump">822,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested shares, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 3.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, number of shares | shares</a></td>
<td class="nump">430,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 6.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested, number of shares | shares</a></td>
<td class="num">(409,459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 3.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited, number of shares | shares</a></td>
<td class="num">(50,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested shares, number of shares | shares</a></td>
<td class="nump">793,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested shares, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 5.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_NonVestedStockOptionsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_NonVestedStockOptionsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659601227768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - Stock Options Summary<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice082104Member', window );">Range Of Exercise Price $0.82 - $1.04 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Minimum</a></td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Maximum</a></td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number (in Shares) | shares</a></td>
<td class="nump">216,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number (in Shares) | shares</a></td>
<td class="nump">216,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice120281Member', window );">Range Of Exercise Price $1.20 - $2.81 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Minimum</a></td>
<td class="nump">1.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Maximum</a></td>
<td class="nump">$ 2.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number (in Shares) | shares</a></td>
<td class="nump">1,024,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 164 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number (in Shares) | shares</a></td>
<td class="nump">795,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice362870Member', window );">Range Of Exercise Price $3.62 - $8.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Minimum</a></td>
<td class="nump">3.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Maximum</a></td>
<td class="nump">$ 8.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number (in Shares) | shares</a></td>
<td class="nump">840,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number (in Shares) | shares</a></td>
<td class="nump">276,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice082104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice082104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice120281Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice120281Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice362870Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice362870Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659601247944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">$ 5,590,000<span></span>
</td>
<td class="nump">$ 3,488,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">2,102,000<span></span>
</td>
<td class="nump">1,029,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">12,957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=bmra_CaliforniaStateIncomeTaxMember', window );">California State Income Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">6,768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 341,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_INCOMETAXESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_INCOMETAXESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=bmra_CaliforniaStateIncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=bmra_CaliforniaStateIncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659601404072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - Income tax expense - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign Taxes Subsidiaries</a></td>
<td class="num">(12,257)<span></span>
</td>
<td class="num">(6,590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(800)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(13,057)<span></span>
</td>
<td class="num">(7,390)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (13,057)<span></span>
</td>
<td class="num">$ (7,390)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659600296248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - Income Tax Rate Reconciliation - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncomeTaxRateReconciliationAbstract', window );"><strong>Income Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed "expected" tax benefit</a></td>
<td class="nump">$ 1,355,756<span></span>
</td>
<td class="nump">$ 489,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract', window );"><strong>Increase (reduction) in income taxes resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(2,102,000)<span></span>
</td>
<td class="num">(1,029,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">190,233<span></span>
</td>
<td class="nump">154,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">456,388<span></span>
</td>
<td class="nump">49,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent tax differences and other</a></td>
<td class="nump">98,823<span></span>
</td>
<td class="nump">334,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign taxes of subsidiaries</a></td>
<td class="num">(12,257)<span></span>
</td>
<td class="num">(6,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (13,057)<span></span>
</td>
<td class="num">$ (7,390)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncomeTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncomeTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659607718936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - Deferred Tax - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Accounts receivable, principally due to allowance for doubtful accounts</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory valuation</a></td>
<td class="nump">387,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Compensated absences</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">3,195,000<span></span>
</td>
<td class="nump">2,286,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">1,055,000<span></span>
</td>
<td class="nump">599,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent expense/Capitalized leases</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_DefferedTaxAssetsStockOptions', window );">Stock Options</a></td>
<td class="nump">299,000<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet', window );">Losses of foreign subsidiaries &amp; Other, net</a></td>
<td class="nump">370,000<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">5,590,000<span></span>
</td>
<td class="nump">3,488,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(5,590,000)<span></span>
</td>
<td class="num">(3,488,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accumulated depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets related with foreign subsidiaries and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DefferedTaxAssetsStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets related with stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DefferedTaxAssetsStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659613366520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659602263208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 7,199,027<span></span>
</td>
<td class="nump">$ 6,692,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 4,301,000<span></span>
</td>
<td class="nump">2,434,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">1,908,000<span></span>
</td>
<td class="nump">1,867,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">548,000<span></span>
</td>
<td class="nump">445,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember', window );">South America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">1,615,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember', window );">Middle East [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">192,000<span></span>
</td>
<td class="nump">314,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bmra_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenue, Segment Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Europe [Member] | Revenue, Segment Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Asia [Member] | Revenue, Segment Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | UNITED STATES | Revenue, Segment Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | South America [Member] | Revenue, Segment Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Middle East [Member] | Revenue, Segment Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Other [Member] | Revenue, Segment Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net Sales Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_SouthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_MiddleEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bmra_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bmra_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659525951480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 01, 2021</div></th>
<th class="th"><div>May 07, 2020</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>May 25, 2016</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Aug. 26, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Jun. 25, 2020</div></th>
<th class="th"><div>May 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 25, 2019</div></th>
<th class="th"><div>Jul. 22, 2019</div></th>
<th class="th"><div>Jul. 12, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,410,506<span></span>
</td>
<td class="nump">$ 1,910,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,759<span></span>
</td>
<td class="nump">153,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFSouthernCaliforniaMember', window );">University OF Southern California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFMichiganMember', window );">University OF Michigan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,550<span></span>
</td>
<td class="nump">30,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember', window );">University OF Beth Israel Deaconess Medical Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">141,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPStoolAntigenMember', window );">Biomerica HP Stool Antigen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,111<span></span>
</td>
<td class="nump">13,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInFoodsMember', window );">Biomerica InFoods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,675<span></span>
</td>
<td class="nump">20,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MedicalPracticeMember', window );">Medical Practice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,725<span></span>
</td>
<td class="nump">45,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPyloriProductMember', window );">Biomerica H. Pylori Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_HousetonMethodistResearchInstituteMember', window );">Houseton Methodist Research Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicArizonaMember', window );">Mayo Clinic Arizona [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicJacksonvilleMember', window );">Mayo Clinic Jacksonville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOfTexasHealthScienceCenterMember', window );">University Of Texas Health Science Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember', window );">Telcon Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedFeesAndOtherRevenueReceivable', window );">Accrued Fees and Other Revenue Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Proceeds from Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RoyaltyPercentage', window );">Royalty Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_MountSinaiLicenseAgreementsMember', window );">Mount Sinai License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related Party Transaction, Purchases from Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_MountSinaiLicenseAgreementsMember', window );">Mount Sinai License Agreements [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related Party Transaction, Purchases from Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember', window );">UC License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_LicenseMaintenanceFeePayable', window );">License Maintenance Fee, Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember', window );">UC License Agreements [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember', window );">Building In Irvine California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember', window );">Building In Irvine California [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RentalExpenseIncreaseDuringPeriod', window );">Rental Expense, Increase During Period</a></td>
<td class="nump">$ 25,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RentalExpenseIncreaseDuringThePeriodPercentage', window );">Rental Expense, Increase During The Period, Percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseDepositLiability', window );">Lease Deposit Liability</a></td>
<td class="nump">$ 22,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember', window );">Building In Irvine California [Member] | First Amendment To Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_OperatingLeasesRentExpensesMinimumRentals', window );">Operating Leases Rent Expenses Minimum Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RentalExpenseIncreaseDuringPeriod', window );">Rental Expense, Increase During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RoyaltyExpensePercentageOfSales', window );">Royalty Expense Percentage Of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,351<span></span>
</td>
<td class="nump">$ 43,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">MEXICO | Property Available for Operating Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_OperatingLeasesRentExpensesMinimumRentals', window );">Operating Leases Rent Expenses Minimum Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_LeaseExpirationPeriod', window );">Lease Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,759<span></span>
</td>
<td class="nump">$ 300,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_BilledCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the commitment billed during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_BilledCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum budgeted costs related to clinical trial agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ClinicalTrialAgreementMaximumBudgetedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of years in which the lease expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LicenseMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of license maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LicenseMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_OperatingLeasesRentExpensesMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_OperatingLeasesRentExpensesMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RentalExpenseIncreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rental expense increase during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RentalExpenseIncreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RentalExpenseIncreaseDuringThePeriodPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of rental expense increased during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RentalExpenseIncreaseDuringThePeriodPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RoyaltyExpensePercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty expenses expressed as a percentage of sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RoyaltyExpensePercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedFeesAndOtherRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount of fees and other revenue, excluding investment income receivable, earned but not yet received, which were recognized in conformity with revenue recognition criteria based on estimates or specific contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedFeesAndOtherRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919106-209958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFSouthernCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFSouthernCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFMichiganMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFMichiganMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFBethIsraelDeaconessMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPStoolAntigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPStoolAntigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInFoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInFoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MedicalPracticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MedicalPracticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPyloriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPyloriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_HousetonMethodistResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_HousetonMethodistResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicArizonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicArizonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicJacksonvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicJacksonvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOfTexasHealthScienceCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOfTexasHealthScienceCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_MountSinaiLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_MountSinaiLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_FirstAmendmentToLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_FirstAmendmentToLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659607491896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract', window );"><strong>Supplemental cash flow information related to leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 320,606<span></span>
</td>
<td class="nump">$ 311,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 79,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">5 years 98 days<span></span>
</td>
<td class="text">6 years 98 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659600502728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - The maturity of lease liabilities<br></strong></div></th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_TheMaturityOfLeaseLiabilitiesAbstract', window );"><strong>The maturity of lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 337,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">350,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">360,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">371,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">382,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">103,927<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,906,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">287,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,619,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_TheMaturityOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_TheMaturityOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140659601259576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised | $</a></td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="nump">201,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 4.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="nump">$ 824,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SUBSEQUENTEVENTSDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SUBSEQUENTEVENTSDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M9?PX=+!SOK&.=WNE;[BCP8'LZ(:J;X>5@)%;LD1Q0E,9\Q0)NATZ8_QIYAN
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M$S.T4FO9Y.:7ZN%GU2^H!9A6N6[_HX?>%L]0VFA3%?U@0%!D9?<IO_6!V!M
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MN+^NH*OJO]BWB;NWQY=_ U!+ P04    " #TBAM3M,6$OP@$  #F#P  &
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)V7:V_B.!2&_XH5[4H=J=O$N6<$
M2!2ZFDK3#AJFLQ]6^\$D!JPF-FL[,#/:'[_.I2'@$"C]4'(YY_AY$Q^_\6#'
M^*M88RS!CRRE8FBLI=Q\-$T1KW&&Q!W;8*KN+!G/D%2G?&6*#<<H*9.RU+0M
MRS<S1*@Q&I379GPT8+E,"<4S#D2>98C_O,<IVPT-:+Q=^$I6:UE<,$>##5KA
M.98OFQE79V93)2$9IH(P"CA>#HTQ_#B!49%01GPG>"=:QZ"0LF#LM3AY3(:&
M51#A%,>R*('4SQ9/<)H6E13'OW51HQFS2&P?OU7_LQ2OQ"R0P!.6_D42N1X:
MH0$2O$1Y*K^RW2=<"_**>C%+1?D?[*K8P#= G O)LCI9$62$5K_H1_T@6@G0
M.9%@UPGVI0E.G>"40BNR4M84230:<+8#O(A6U8J#\MF4V4H-H<5KG$NN[A*5
M)T>3+\_S+Y\?I^-O#U-P/_X\?IX\@/FGAX=O<W S0QQ3N<:2Q"@5'\ ?X&4^
M!3>_?1B84HU=5##C>IS[:AS[Q#A/Z"=PX"VP+1MV9$\NSK8.LTVEMQ%M-Z+M
MLIQ[HMPX5;,7T1@#U0<@8?E"+O-43:F8Y50*<$,HF+(T15QT2JVJ^V7UHD^V
MH] )7.@-S&U;DQX66%$(FZ@#=J=A=_K9XSC/\A1)G*CIJEHW)JAJ")H E#$N
MR:_JPCD5U3A>"P]&@>UXP9&,CKC0#WS7Z1;B-D+<BX6TN6]!N98 M@0O H.Q
M$/B"5^)JD*X?6<&Q%CW,=J ;1MU2O$:*=Z641RH179%%>K$03YLTT%9/.SH2
MHH>YD0]MMUN(WPCQ>X5,6):IF:-6G?@5;! '6Y3FN,T,-EB9P%HM#)WT5?F@
MA67=6>$1^YF@ _*@(0\N)K^M  5 N5PS3G[AI(LUT.>"9Y5_1[P7!!XPAPUS
M^'YF(D3>S1OJ?6@[5@"UANT(A(%K6:>F>=3P1N_G59\&0LWQA-!5%W1T*71'
M8"\TM/8.9_5B>[^#":-;K-JRZ,.9^D[ G*M6G9?3_.\GG"TP_P?\!^:8$R5I
M?#*FQWM@RW%A+\]1\5N@;!9\?V>CU6.<Z;1S48<*]O8)^_U34W!1O]5%VZ_8
M"Z!K'R]MY^,.L??."?NM\Q3VZ9:#NO<=+PX=(8[=0[NW1]COCZ=HSS0<U"U.
M0]9#>I'W-@C[??":MME;$^SWIBO>GG_^4?2%'(+NG0CV6]&U+TZW&8VV+^20
M=N]!L-^$--IG=MV"%&I?)!I^7\@A_MZ28+\G:?@Y3; @*UI^C%5/OA-7]QO7
MM4.UT!Q#GP^LT,W6)JS8 3\AOB)4@!0O5:9U%Z@2O-I45B>2;<I]V8))M<LK
M#]=J(XYY$:#N+QF3;R?%5J_9VH_^!U!+ P04    " #TBAM33:KYL%T%  ![
M$P  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*U836_;.!#]*X2QAR[0
MUB+U'3@&$MO=!DCB($[;PV(/C$7;0B71)6DG_?<=48KD2!23PQX2B]3,\,UP
M^&;$R1,7/^6.,86>\ZR0YZ.=4ONS\5BN=RRG\C/?LP+>;+C(J8*AV([E7C":
M:*4\&Q/'"<8Y38O1=*+G[L1TP@\J2PMV)Y \Y#D5OR]9QI_.1WCT,G&?;G>J
MG!A/)WNZ92NFONWO!(S&C94DS5DA4UX@P3;GHPM\-B-AJ: EOJ?L29X\H]*5
M1\Y_EH.KY'SDE(A8QM:J-$'AY\AF+,M*2X#C5VUTU*Q9*IX^OUC_HIT'9QZI
M9#.>_4@3M3L?12.4L T]9.J>/WUEM4-^:6_-,ZG_HZ=*-H05UP>I>%XKPSA/
MB^J7/M>!.%' P8 "J15(5\$=4'!K!5<[6B'3;LVIHM.)X$](E-)@K7S0L=':
MX$U:E-NX4@+>IJ"GIK/E[6IY?36_>%C,T>H!?FX6MP\KM/R"EG>+^XN'*Q!
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MP"1II0/2UBSBOZ.G@-3:"[8KKR6.3 /^J,\5)" PK37!VL)#[(7G"U2<=%O
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MU4%U(T)W>#".'-_!M _1(!G@8-QG'05ASPKQ0;!-G*6O:6[&Z0VK#)3Z(!K
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MX_ V&#</LAH<#]:LMVAJ-HVZ[[NL9M!BSF+(X0!"B*QG/F\Q40+HRU_0XBP
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MW?-:JAT$,.I 4QGZ@9X&P[I*GTQ#A81,3K@,=TEPT(K$0B53  0I9) HPJX
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M(%FG%5=!K;P%!Z"$B*Q2"JG'<VVMFEC7,G%,C@HP.%@X%^2HP'0)Y+*LCB5
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M=OIA=/5O!^.A$/C;\^2QVCVD>6'_$V TQ7\X]$UGT5D_\G61![IU-CD4_4B
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M=1YG:YW'\S!0XW3>4C^\L9^\^5&%A7J 4X?_QO#\)PV'*04U,"OB* 9-H'Z
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M+I&_.4L\3XQ$PV#S*JE/[<T## U_@D4!>^"CK<IFP&9=S$&?:7\8^^XFS_X
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MLWN=IR3[(.&;C!0QF@]0@>5V@\J+'(J4M@[>GN%)@@,&2J/X+A83M&N.-#\
MC[5/-ADRRSH(1A)V@D!K1=6\]/B\JM KFH>;N(1)X&&0EB)+4YT8\R-#!CR
MOW;\P%L_T6M%!<:6V4B;F.?4/-=17-(J6%C$I"L-6YZ!%*/:"]>T&222Z,:D
MRXP< 1%T8!FK15\VT6OSU,.>A#]W.) 69U'A<])%:-6,2+/%YJ-(1\EW_\S4
M=F*9MD"M[4W=I)L&5C<-&E7&50S>2X16Y(4:Z)GAQG__.KX<W_V^IP' RJ/F
MCF!1)8F,N YVC?.P6*D%:  YV#O\Q#%"C('GU5HL&82N$/*4).L;D)!'4MFP
M2V^[IZUCB#63A,)FDB _'FC!;]970]\%>0L[X>\*T5O;EGE6H Y!\5=A=(_[
MR4>A)-O,?AEX14FVH8$I7!?ANTG57T&7H$GK=IF(FHH%<4G0 5"W>58@/:"2
MIZ@GF$9TAC95OLGD:.=A3,:PVB"I;SO]H-UNX_^-:D<CB(?&C,7#D\^#?YZ.
M+E"6_EH!L[K,E+;0/T]"W"5-KBGN"X32WBM3])37,SA]O;;W'NS,\.Z+&BYS
M3137+0 >YS0B%J-[@L.A% !]<ZTCJ\C!]<C0$./*<,7F.,\S6#GZ(98'@3B-
M\&1 J\HJ$"J(@4KQ.(HP$?E:D_$E'6KW _5^G)(F+4H811X5)>-O8H#JCU^&
M<U+$5B$9%\OH4AJ4EBOFH- @/V8VT8GD)D?D5HIYPV4BZ$.>C3R5(D]:$(5$
MP.5=QIJEB6VY3< VDHA,5R$&(>CL1?AHA-P&7TI"%M' S W+9@EB4*CQ,*4<
M TVJ1*OC3A\9 F=M28>M(G)($NS*T+'BG0Z7(O%T0(3[])E[#]>!:ZY0B(%7
MH,+GK&#1W(-EFL&T('<0-9"HH*W9T7A6V<XTN %LXI[B!,9EX,991H 7'HF+
M%Z_9!\)_1;RM:<*P",PL#D3'!0]XBNH[0:L<&6/,2[3A1("$KBMT,S&@Q-V"
M>76^1E++!_232L<F":N,&M_3E2FXTK,D7G+H:UB!?WUJL74N>])B# X&7/ ^
M+;FH"I1#E@)Y-T"918()1M@?J06.HPWM$&<Y +/4-1KQN],_#4Y/S\"1(3*!
M?++TL/FP,(ZX0E0$%)+E8;JDLX^;]';0:I^0=ANT!F>R0'P9H4PU/>JIB49_
M2/"!J0E;U0_J(R@[=9VU5*_7.^KVSLY.VXS(U%8DT1$'!2SXRQQ=&:N6@-JW
MG: S& 2]LV,Q5I[6LEXTKY>?;G<ZP?&@#Z$],!,.%7DM>+AAR7'!D1(>>AW"
MW"A$$M$M0W#W/*#"A4<+3<+,)D_F!'5.#BE+@^$(!#IPZF1%Y/FB2277$G]
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M4YYX'N;YE@Z @YK*%Q#D.8#X/'"+6$:\:@SBSZSLG#V'A,]U:M3-A&*."PY
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M0,%Q10)^SPV>[1@^?GD")TNMZJN1B!P"UAIKL4-LK\<4=D_>U6D(<+##Q(+
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M-0'<Y&/6\H&Q&KKJ+-C]A@"_[=%>SQ_%X3+-J-3Q>]Q\WT#7-6ETFYLT+FI
MZ%@*%UXI8\U3.-G"5HS)Z//H>CK^-F*#<;$'Q+JPW3,0?-O"UF+.@7<+RE[_
M"ZKP0"YXQV]6"Z2<3)0B*?3:R%[(;LMN"86JH<BD-="0@RB9,EJ,$=$/&+X
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M]79R-');&0G/& E">)2YV6JXSU-,_P1H$^.:=OA.^S:\B/C(#A %#0C],+@
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M?S 6%_F<B86+@?/]'=_Q%/,4#AQ%"OZ5_;M_*ZA5$>N=%$1+<'. ;M *^LW
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MLA?H?"VE>5]8 _4/C=%_4$L#!!0    ( /2*&U-9[!*IG (  &,%   9
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M)4$?)N?A8%7KI]5:69I]7MS1SP:U4Z#WC5+V=' .^M_7]&]02P,$%     @
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ML5WIO+EVMTRL]>,"VY;O"UG=P,W7YOTRK*[M5_/J\7,3BW6&"LW9"ET)9FB
MJ!X4U43RG;[$EUSBDT /-_@&8T(9X/J*XQU63U2 YE4W^ =02P,$%     @
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M="V%$"-<9'"P!1EJI(BZE>+U=7=M>"O,,.=TT!)FU&@.=6O.JRMJVA2>W;6
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M6WU1^;)Z>>LN5Z IU<>YB&(A=0/X?9;GZOF+OL'ZA<&3_P-02P,$%     @
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M\X)^/N-<[3IF@N+;HO,'4$L#!!0    ( /2*&U,\N%BL7 ,  %L,   9
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;+67T8[:.A"&7\6*>M%*9YLX60*I
M (G-=END94%+M]51=2Y,F!"K2<RQ'>B^?6TG)&P#B NX =N9^6?F,PQ#?\OX
M+Y$ 2/0[2W,QL!(IUY]L6T0)9$1\9&O(U9.8\8Q(M>4K6ZPYD*5QRE+;=1S?
MS@C-K6'?G,WXL,\*F=(<9AR)(LL(?[V#E&T'%K9V!\]TE4A]8 _[:[*".<B7
M]8RKG5VK+&D&N: L1QSB@37"GT(<: =C\9W"5NRMD2YEP=@OO1DO!Y:C,X(4
M(JDEB'K;0 AIJI54'O]7HE8=4SONKW?J#Z9X5<R"" A9^H,N93*P>A9:0DR*
M5#ZS[5>H"NIHO8BEPKRB;67K6"@JA&19Y:PRR&A>OI/?%8@]!^P?<7 K!_=O
M!^^(@U<Y>*;0,C-3UCV19-CG;(NXME9J>F'8&&]5#<WU-<XE5T^I\I/#^<MD
M,GK^%TT?T'S\Y6G\, Y'3]_0* RG+T_?QD]?T&SZ. ['G^?H_3U(0E/Q =V@
M9]A 7@"*.<M0Q'+)U7T(E;M,JJR!"V7W,K]'[]]]Z-M2Y:HCVE&5UUV9EWLD
M+^RBB9)-!/J<+V'Y5L!61=:5NKM*[]R3BA/RBCS\#W(=%Q_()SS;VSF1C%=C
M]XR<=T3NG@JR6G%8$?-A9G%-].>C,D5C"9GX[T2@VSK0K0ET>R303O9!7U2X
MNYE#]U'J^$9'?_DWPRX. L=1Y6[V.;7M?#_P]NW>)-JI$^V<3#14!S0B*7HD
M"_1S MD"^"D ?JWK7Y=TMP[4O1#I4J>S1]!SNMTVZ;:=&[CN4=*].M'>R41G
MR:N@$26Y0-,XIA&<@SNHQ8/KXL9.T[F<"P&OA-Z0[#FX3?R0(0XZ1Y'CO3:+
M3R8[W0"_D0G<1*S()?!SF&.W47>O3+UI7-B[%'6O!;/K^P>@M^VPJ[\.QZ W
MO0^?;GYA]<.$)B0O8K4H.,U79Z%OVA;N7!E]T\FP?RGT?@MII^,>0.^WFKGG
M^,?)-[T0GVZ&NHG/B_4ZI2#.XMTT+]R[,N^FE>'@4KR# QQ;%.V],4TIK<ST
M*I#I".4<4Y_6$_+(S(5_G=_IR=F,?XU,.79/"%]1U=A3B)6D\[&K/@*\G&3+
MC61K,PPNF%3EF&6BIG_@VD ]CQF3NXT.4/^?&/X!4$L#!!0    ( /2*&U,K
M$=2PH@(  )D&   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;(U5;6_:
M,!#^*U:T#ZU$&^*0%RI :H%JDU;&:+MIFO;!)(983>+4=J#]]SL[$(424+\D
M?GF>N^?.Y_-@R\6+3"A5Z"U+<SFT$J6*&]N644(S(J]Y07/867&1$053L;9E
M(2B)#2E+;=SM^G9&6&Z-!F9M+D8#7JJ4Y70ND"RSC(CW.YKR[=!RK/W"@JT3
MI1?LT: @:_I(U7,Q%S"S:RLQRV@N&<^1H*NA=>O<C'V--X!?C&YE8XQT)$O.
M7_3D6SRTNEH036FDM 4"OPT=TS35AD#&Z\ZF5;O4Q.9X;_W>Q ZQ+(FD8Y[^
M9K%*AE9HH9BN2)FJ!=]^I;MX/&TOXJDT7[2ML & HU(JGNW(H"!C>?4G;[L\
M- B.>X* =P3\68*[([@FT$J9"6M"%!D-!-\BH=%@30],;@P;HF&Y/L5')6"7
M 4^-YHL?\^GBZ0^ZG4W0].?SM_G#=/;40;/I$[J84$58*B_1%9H+*!RAWA')
M8T1?2U; 4:H.RJ'0KM#SXP1=?+D<V HD:<-VM'-_5[G')]P_D'?D.AV$N]AI
M88\_S>X>LFU(0YT+7.<"&W/NJ5R<B?'O[5(J 47W[XPCMW;D&D>]$XZF>]MM
M":NHOJ'J.[@9.6&O'X;AP-XT4]."ZV,G=-T:=Z"M5VOKG=5V7XJ<J5+0#EJQ
M-SV0)A\IA<N2\#1&+"L$WU"M7[8%4-GW&L)Z+NZ'_0_ZCV$8>TX#=B#?J^5[
M9^5_IQ+T1E&9E2E1-(8K#=TM8D0WC3:UWI&,*Z<?8-<+/NAM X9^X/=.)-RO
M%?MG%<^@NHK6RFN3ZQ^=NNMT/5W^!V*/83CHN\''Y-J-QJ&;]@,1:Y9+..P5
M$+O7 80KJD98310O3"]9<@6=R0P3>#NHT #87W&N]A/=GNK7:/0?4$L#!!0
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MWF6D"Q7U05Q/%*_L63;C2I^,=KC2=Q<11J"_+SA7[Q-S/+:W8?8/4$L#!!0
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M7%PBCZAOE3I0O#*#N>0*Q]PL-W@1@] )>+[B7.T#/>OMU1[]!5!+ P04
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M\/)6]' %>KA]H(<KT,/]>="#BU+7KS50[!== 1YN3^#!Y_$;X$%4_-4.XW6
MAZ'Y;1<\7 $>;A_@X0KP<'\>\."BD(;%N@KP< 5XN!W@86X2VP$/(L"#] $>
M1( '60L\-MWI79#VH34"-;4+(N"#='3'MQ1?+O@\'>T!R2A?V1X@ I>(ONFQ
M+N(1@4"DCQ8W$?&>F+>X^Z^V7Y%V^[M9ZN%JE#33-45Y(N"$=/7)W]Y;NR+M
MT]H6EG02)>-T/3A2.];=T3+9:OF-3]8LWM@ME;1'(00MQ=E>(@"-Z %-%;K[
M:8P3@3K$[\%1/0$EGK[PM0U+/>9S=%GJF62<M(=N^+R19)S.\CT!>-Z:QP6V
MU'T^X_.:]94] 7_>!KW\ZN M]U\I,[C= =3!L2> S#,X1;VH4+X!CL^\=A_>
M&BBJO9Y 0T^_'],9/0]W'><>O'831FMY CB]#N#4Q-R*GWW09/];'+)47,_O
MB==&.MTI$D\@G:='NN*6)1A'0;RC+9(GT,KK8XODU6X@O7V+M+,NX$?.7"/#
MT1F@ "#/_-3PAF*-Y^GD(5CNY%::*.61^@F57@GXV,&<QX(E_$5WHTL G[_S
MBU&G+X\AWP15+BJ3J(,-YCWE47B=3 *V?#UL%3>F=^F,O@ DOX_KN[X ''_G
MUW8V=\9+OWT?1^>,O@ J?^<G#39WQLL.YKJ=4:">O_/MHHDS7G:P8>*, AG]
M3F0D.W5&@8Q^'\CH"V3T?V!D//?;R*@['^/7+@'_P,AXWL%<IS,B6+\S_$-@
MXWD7'P;^B&#M>B_L@D>\TUP5P=HM6]@'0")8N]@*?V"(_++@SM0M$:S=685Z
M(+JF]_Q^6%&.+MH*LLK[SNOW"-;NIT*G%_77+HK"CK-TVZGAGR[F:=[:=;2J
MK-WAA/J2X^;GL!9/;M07/40L2\E6[>8FU".:L87UWC1"L'8?%/916T3U'Y_H
M^O6)[1C=A\4\#:-SI+6J8>W'R(I?)61K?!_&&8CH'2.%@Z+FGU:_\U>]R9/'
M\O?);I,\3V;ERP<:,"Z+ >S[NR3)%V^*GSQ;_MSBX?\!4$L#!!0    ( /2*
M&U/-UT:I\00  (P=   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;,V9
M;6^C.!#'OXH5K72[TA:P38!4::32]K25MFJON;W3:74OW. FJ(!SQFE:Z3[\
MV4!PLCP<"=TJ;UH@S,S?]OC'V!ZO&7]*%Y0*\!)'27HV6 BQ/#7-=+:@,4D-
MMJ2)_.61\9@(><OG9KKDE 2941R9R+(<,R9A,IB,LV=W?#)F*Q&%";WC(%W%
M,>&O/HW8^FP !YL']^%\(=0#<S)>DCF=4O%M><?EG5EZ"<*8)FG($L#IX]G@
M')Y>V(XRR-[X(Z3K=.L:J*8\,/:D;JZ#LX&E%-&(SH1R0>2_9WI!HTAYDCK^
M*9P.RIC*</MZX_W7K/&R,0\DI1<L^C,,Q.)LX U 0!_)*A+W;/V%%@T:*G\S
M%J797[ NWK4&8+9*!8L+8ZD@#I/\/WDI.F++ #H-!J@P0#\:X 8#7!C@K*&Y
MLJQ9ET20R9BS->#J;>E-761]DUG+UH2)&L:IX/+74-J)R?3+^?W5E]NOEU?W
MTU_ U6_?KG__"WR\I(*$4?H)G(#;E4@%28(PF8.I8+,G<+M4 Y""<S4"H7B5
M+WT )D@7A--T; JI2ODV9X4"/U> &A1 !&Y8(A8IN$H"&NPZ,&5SRC:A39M\
MU.KQAKP"##\#9"%8H^>BL[75(@:7'8PS=W:#NZL7RF=A2L$=#V<4W)-D+J\I
M!U/57^"#97A(]2 V1A;X?D/C!\K_;HEKEW'M+"[^B0/[_:MT"JX%C=,V2<-2
MTK"U*S;^F8[\&20KU6+ 'D&:B6#%2Q_#).^B]%/=&.:1AEDDA:KG";1=!UFC
ML?E<(]$I)3K[2UQG+* !(,^42[8!NAG3I1K3.GEY%'=+'C(LMUZ;6VIS.VG;
M1 \.[CRWTGDG$+NCH5<OT"L%>OL*/*#KO$K70<.QZY6-2F6C7I,0&8ZG)J%G
M0*_+)(26QJMU+-,0;C$?=AJH.2>)Z)%'19CM1!I"=VA9]:,%D1:(]A-X0!X5
M(;83R3;LACD(-<YA;YX/]THE#71X-$2'&NFP&]-G))G)VBP C,NQ68:\3UI5
MX7[B.,UII>$.N]&]5NPA*5;%/#9LW"!3<QZV@[YKR= YQ33 H7<T*:;9#=OA
M_89E@U^$VJD;7&^$AK!^T) &/;+>HW+PBS"[I8,[;)"GD8^Z(?\M:B]4Q7Y[
M)VKNHV[<[UM^H2K[6SI1LQ_U8__0@'8^,=U.M3S2[$='PWZDV8^ZL;]G&>&C
M*N]M;#G0:1@OS7O4C?<]R@@?51GO&&X#XY%F/'H;QF/#09U223,>'0WCD68\
MZL;XWFL;'U4)?^(YLBBM'S&L 8^[ ;[7ZL;'5;Q# S5HTW3'[73___4-WJLH
MQ9K8&!U+-N&M+9=V3O^$HM0O0N[DE5KL-'SSL$8[MM^S*/6+<+OK'K=AW8,U
M['$[[+L7I=V^?5A3'#M'DV*:W[C;9DR_>FHWN$8X[K;1\A85<1%J.Z^1Y4'L
M-'Q]L68Z[K?I4ILQX%]P$R9AO(H[;89J>MM'LP]C:VS;!Q3E>TWYW<":VO:[
MU-F^7:VS&[]FML:W_39;YI7$(2^=$V=K&_UH*F];P]@^8">]1^)H%MOOLC_N
MVYVJ:G/K7"NF?)X=]\DO)5LE(C\.*I^61XKGV4':#\]]>'J1'PQJ-_DYY0WA
M\U V***/TJ4E%XD#P/.CO_Q&L&5V>O; A&!Q=KF@)*!<O2!_?V1,;&Y4@/(
M=O(?4$L#!!0    ( /2*&U-*O.8$!@,  #$*   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;,66;V_:,!#&OXH53=HFM>0_@2H@0<O62NO:P=IIFO;"
MD NQFL3,-M!*^_"SG1#2-= B==J;)'9\S_WN2>)<N*;LCB<  MUG:<Y[1B+$
MXL0T^2R!#/,674 N[\2495C((9N;?,$ 1SHH2TW'LMIFADEN]$,]=\WZ(5V*
ME.1PS1!?9AEF#T-(Z;IGV,9F8DSFB5 39C]<X#E,0-PLKID<F95*1#+(.:$Y
M8A#WC(%],K1=%:!7W!)8\]HU4J5,*;U3@XNH9UB*"%*8"26!Y6D%IY"F2DER
M_"I%C2JG"JQ?;]0_Z.)E,5/,X92FWT@DDI[1,5 $,5ZF8DS7YU 6Y"N]&4VY
M/J)UL3:0&6=++FA6!LMQ1O+BC.]+(VH!3G='@%,&.)J[2*0IS[# _9#1-6)J
MM513%[I4'2WA2*Z>RD0P>9?(.-&?G _&H_.K3V>C\>0M&GVYN?CZ';T[ X%)
MRM^C8_29YL<KX (B-!%T=H>N%LI.C@;*3R(>0E-(#J5FSLJ<PR*GLR.G[:!+
MFHN$HU$>0?18P)0%5%4XFRJ&SE[%2_R 7/L(.99COT$FX@EFP(OC'GFW,LG5
M\NX.^6<]0#\&4RZ8?,5^[DGG5>D\G<Y[/EU1PA'*E]D4&*)Q.8-^HZ;J"J\*
M=5^KJZ]RU>\XCM_Q0G/50.575/ZA5&O]SLL)O (FOV$T9S@7*,("4(P)0RN<
M+D&R;I])$V^1-ZCQNJV@TTS;KFC;>VD_*A*(#G2N_<0YS[7:=KN9):A8@I>Q
MO))?P1._VJW ;6;L5(R=O8RW^LD>:%?GB5W'GM7U_&XS2[=BZ;Z(Y97LZC:\
M7NZ.1VI;VWW3V@LI_PDQD,,]*V4?F>9;OF7M *IMY/9+@5[)N#)AW3FOM>.[
MM)TMI_-/=[=2OFY@T'4=S]X!MMWD;?<_;7!EXKJ1?LO_>S\V:W_Q#-A<]RH<
MS>@R%\4/O9JM^J%!T05LEQ?-U"5F<R+_3RG$,M1J!=(M5O0GQ4#0A>X)IE3(
M#D-?)K*G Z86R/LQI6(S4 FJ+K'_!U!+ P04    " #TBAM3&PY[$48$  ")
M$P  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6S%F&%OXC@0AO_*"%6Z
M/8E-8@,AK ")MIQ:J5PYN+W5:74?##$0-8DYVY0BW8\_.PD)%)(-*=+R 9S$
MGGD],WX<W-TR_B)6E$IX"_Q0]&HK*==?3%/,5S0@PF!K&JHG"\8#(M4E7YIB
MS2EQHT&!;V++LLV >&&MWXWNC7F_RS;2]T(ZYB V04#X[I;Z;-NKH=K^QL1;
MKJ2^8?:[:[*D4RJ_KL=<79FI%=<+:"@\%@*GBUYM@+[<XHX>$/7XRZ-;<= &
M/9498R_ZXM'MU2RMB/IT+K4)HGY>Z1WU?6U)Z?@W,5I+?>J!A^V]]=^BR:O)
MS(B@=\S_YKERU:LY-7#I@FQ\.6';!YI,J*7MS9DOHF_8QGW;K1K,-T*R(!FL
M% 1>&/^2MR00!P/41,\/P,D '.F.'44J[XDD_2YG6^"ZM[*F&]%4H]%*G!?J
MK$PE5T\]-4[VIP^#R?#A^>E^.)G^ L,_OC[^^3=\NJ>2>+[X%3[#5++Y"SRO
M=0P%3./D=4VI?&L+YCSQ<QO[P3E^$(81"^5*P#!TJ7MLP%2B4^5XK_P6%UH<
MD1TT4!VPA=$-F"!6A%,1?Q>8;Z2!:43FFSGF)R1<4GA>P/"-\KDG*(RY-Z=P
M8QD.5G&Y08;5A.\C&LPH_Z? 83-UV(P<-O(RH95_UA7FPICL5.5+&'"N9>AV
M/<E!_;V@6.CW)V4.'B4-1)&85BJF56+V[/WLZS#R0B_8!.<*(+;8CBQJ&+SV
M=:BZYNL9'7:JPZZH@[SEZ;!/=.A4G=?13G6T"W7LZ_]Y(X4DH>N%RSK\OM&Y
MAT]>"%'RU'KY#\X58*PK]M ZT(61;5G6>65.JLRY7-FW"$:JD :OE"NXPH1J
M0JMG<*=6(5<LW! ?GKP%/:>TV&,#=I1P 1T(HA5=4&Z==!*=*TSBN ;.">]<
M4(+(RA!IE5*7^"<SGUZ<_,1%V>RC WZCR\55"%WBIF3L<"8/5\,H,K"E,8H-
M!Y7!*,K C1H_'Z0HPSIJ7AVEB<G.$</R<I$Q'56%>CY,T2G5=<9RI&181\5<
MOP9/$Q>'2PI9N-G*75,9[%$%VG^0J3]P:2=017837+(K@BK*M@9TC;VA!!N<
M,T6 VCEASJ"/RE'_0USMG!1!N]/"K9P:P!GT<07H5XA=XN8X=E;.6L89]G$Q
M]G.YVC#LZ/74,=I6&:[B#.48_WRNX@SSN,P+^F5<34P><E7'*R<9&>)Q5<3G
M@S4Q>5@7CF%WCCXYNC+@XV+@7X.RB8O#!>8T+<>V<\1E6P"NL 5\$+(_<.G$
MD"TJOVR/P-?8(TKPH7U2![9A-7*BFZ$?ET/_1]B:N#AZ9VW;3KN5(RX#/ZX
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MGD,,ZG%Y)_3(+5E2D@&3A#,D8#9PKOS>R \,P$;\)K"1>^_(6)ER_F0&M^G
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MRLGF_M ,M-C:%KP6&ANZ?2WPS@72&.#W7 A]&)@ W2UN_B]02P,$%     @
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MH=99_V+:,Z/V/95;5BJL=!NT'+R?8,!D.[VV"RVJ9@!<"XWC9'.YPXD?I!'
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MIZ5]^Z!=@MT_*H7GP!'T?Y/T#U!+ P04    " #TBAM3,Y,#6-D$  !$&P
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M8J36'*.VK?KO?ED5=ND\0I6Z3H]I!%BR72RS_?OB:7$4-$X/0-X]OX*7D^Q
M1X?)SI=FA*^#6("0KE1(YZ*KIA*>'=ED-Y)MTU./9R85WNGEAA*?\L1 O5\Q
M)M]ND@&*@[/1OU!+ P04    " #TBAM3-/LBLV<+  #E1@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6R]G&U3XS@2@#_O_0H5M5<U6\422[+\LL50
M!0D,80ED"7-W55OW03@B<8UCL[8#P];]^),=)W)BO3C F ^0!'>KK>Y^U)*E
M'+\DZ;=LSE@.OB^B./M\,,_SI]]ZO2R8LP7-CI(G%O/_/";I@N;\;3KK94\I
MH]-2:!'UD&4YO04-XX.3X_*S<7IRG"SS*(S9. 79<K&@Z>L9BY*7SP?P8/W!
M73B;Y\4'O9/C)SIC$Y9_?1JG_%UOHV4:+EB<A4D,4O;X^> 4_G8'H5U(E)?\
M*V0O6>TU*.[E(4F^%6^&T\\'5F$2BUB0%SHH__/,^BR*"E7<D+\JK0>;1@O!
M^NNU]HOR[OG=/-",]9/HW^$TGW\^\ [ E#W2993?)2^7K+HC4N@+DB@K?X.7
MU;4N.0#!,LN3127,+5B$\>HO_5[U1$V WZA< %4":%< *P1P)8#;MF!7 G9;
M 5()D+8F.96 LRO@* 3<2L!M:Y)7"7AM3?(K ;^M +36GK/:&@4WSFYX6]G*
MVMVPX6]E*VN'P]8>AVN7P]8^AVNGPX;7E2)KM\.&WY4B:\?#UIZ':]?#TO>]
M52J6>3R@.3TY3I,7D!;7<WW%BQ(&I3Q/WS NP#7)4_[?D,OE)_W;T6AX/SJ_
MN9^ TYL!Z-_>W ]OOIS?](?G$_!IP'(:1MDOX%?P=3( GW[^Y;B7\V8+X5Y0
M-7&V:@(IFIBPIR-@P4. + 0EXGV]^(B^ LLMI2V)]*!%X]@JQ*$K$3_7B]\D
MSQMQ1R)^8;8=$:7TE_:-$XGXI5[\=#D[ LA1]OO0;#M6>^VJM;3,:[_KI:^6
M\5'5<5+QZQ;=[BFE1WKI 0N.*MNA+Q&_:1%QE=-EXK>F6X^X.%**CUN(0[7X
M'P9Q&F_NW9.(W[6/V)ULZW$P;>B$-G1"I3[\3CK]><T%P3!GB^R_FF;QIEE<
M-FLKFKUC&:-I, <TGH(!>^;EW1,OUG)P_IT7C!F3)=-*HU-J+*K%YQ-D0XM8
M/.^?ZVG3O [ZD,>IO[ENRV1[8[*M-?DT"-(EFX+KD#Z$49B'+#L$_66:<K-E
MYJZTD;H9!+K$W[%6=AE&OL)8LC&6:(W]&O-:-<W"_!7<7H )KZ?G+(U!GT8A
M+\7CD((_1VSQP%*=,YU-8TZ7,>1NFG6U]]CG'X0!C<!]&O+?I[.4L3*&1O1[
MN%@NP-ER.F,Y=UD_R?),-K*YC5#QD.TB>=][&[N\CX[M@=>, D0<=R=6FE<A
M/GV26^MOK/6UUMX6D;$V3=I)?C.?;+=FVU:ST!)ED?6A^52IV^HCUW)LA1VU
M\@SND2JC,)B',QJWR0\H( L[I2P4F(5ZSKX_1^Z@A*<>+.LE:<<+GD(]4-\R
M!L F+I%%B+63*)++L.6K4@4*JD(]5O>.6=(<LRRB,D/P%CI:,\["*"I=MEB$
M>=%EAV#,TH"_H#-YM^GU$>?(LOZI"SC!9*B'\G8VG;%\#H992EG$/4R#)&99
M!D9L6L9DGQO,V=,FTP1[H==II@F,0CU'WY]I0]@D+>;18NU$]Q^2ZZ"-+%5X
M(X%DI$?R6S(2-;&\FXV22Z -'5MEKT WTJ/[+$P6+.6]#B['8)(G?'9_&N?A
MC+7"-ZK5R)WB&PE\HQ^-[S&2X!NZRK(!"7RCC\<WDE2[&$*X&S"RRS!1C#A(
MX!OI\2WB91A?),DT:Q4F LNHTSH8">BB'UT)WZ)F*0PM5\T4 63TX=7P$,G*
M8<<ENV$BJ8<MSU6%B4 YTJ-\WU$>27CL.ZJNPP+'6(_CO8=Y@SX,#<,\%N3%
M>O*NA_!Q6CP6"5B;1,*"M[C;18G:JL2/YNT-EO 6.\I$PH*W^.-Y6ZG<A?]N
M(N$F;VV"5'4J%KS%'UHN7U7JZG807Y7/6' 9?W"Y;-!G(U,>"7)C/;EK%<P1
M&+]&21KRG$JFRR!OE5("P[C3NA@+F.(?71??X"9?B>NI,LH6?+4_O-R]JE36
M;;&A9RMBU!9 M4VE['XQ>F70YYIBU!8TMI%6U66RS%B>Q'S>EL^3:9CE8--S
MPSC+PWR9MQH ;,%A&W<9K79MC5</V?='Z\B6,!=CY0!@"YK:>IJ^90"PFPL0
MN[,SR26VVEH!75L/R;V7RYWFD@U1#4&V *QM NR^>:77ATUI)8ALZPOC$7U-
MP"K>P&D:_IW$K1;E;4%>V^\RB8C@*M%S]?U)=$6:F(4\'%2+CD1PENBY^)8D
MJE3JEC@DET 7^XKP)8*]1,_>?;.H4K>UA.2JLH@('A-]7;QW!670!TUI1 2Q
MB9[8]32ZHL&W+(F?"VO;Y!*I/4XCG>:2P"C18_3]N71=M= ZEP1;B9Z%^Y;W
ME;JV22)(2O0DW3\Z]?J@:XI.P6"BKW[O6$0+YXQIFK]R'](XH^5VPD-PNDB6
M<9Z!Y+'^N=3<9OV+D(<43^ <P6E'S^GZ6CTW@GVG&;AD-,KG8!*$+.;3^O9+
M](Y L .[S"5'P-31P_3]N?2[T^0KQ+ZG(JPC".M\_(:(2N76M%UMBB"J\[$;
M'9QFP:L><QR!7,>T6+MG5AOTV8:D=FK;'?1,ODM>>9*\B@!JM8[L"*XZ;J<)
M(D#J&-9JJQO3Q9PG65%J/**Z<B0KN$0YJW $3QT]3^]9%/"9J$C=%AWO"B"Z
M5J<;600277U5NDZY"\:RD@"K71EWG /QDO&_ 0N?Z4,D<\E%I7O+):CH;$5O
MNP*8KAZ8DSP)OH%AEA6V#99I&,^*' R3Z2&8S&E:@&%EZ:<PKCZ1;5^]J-JI
MAX.'^8_"0$%-5T_-<9H$C$TS\)@FBU7OK?J*3:5F2+:0Z3I*(-,UK,U6B:,%
MU(5!"20&0KF"G:Z>=:.BM "3,*8AQWA0)/.>M'(%#=UN=W_5MG_IRT]-;35>
M\J&49JP*C*TK996IVWSZ1: R+ 1/7<,4OYT;P/_ 9/F0L;^6Y8#_W)9K@IIN
MIRL!G@"J9UIA_2@777K-%0&D+'8\05[/L/NK_\8$\01%O4Z?9GF"CIZ!CO1U
M=3N/25IQND"D[(" UR2C>KCV!!<]/=+673NB(9]'Q+284G 3N/?IJV(XZWN2
M]5,UHSW!1,^P)5;KZ3?FH"<PZ76*24]@TM-CLGT47'H2#*I[OK8?UC _7X;1
MM*@=AC$8IL_%_>VW$=D3I/,Z)9TO2.?K27?[Q%*:%S=YS3C5#G4UM"]!&7:P
M8C[O"Y;YAF=(K?KYC9'N"][YG?+.%[SS37-H7GI%ZYX_Y-T0I(4SMDM7V?$J
M7U88^JYJ:[7@GV]Z9J^WZ'[.-@6UMG8\,S1D6D_U!29]/2:O5_:QIR0+\\T:
M@&Q(/O,ENUN1Y:EZ3:#2-SRO;QO'%V&:Y>"4XVU:3@;ODU7VM8IG 5"_T^FX
M+[CIZ[FYPY1B;B,6A#(P"N-RU6H59#*@?_&;LW4$E43W:V<&3,N:;\RT+[YD
M+5/-/F[KQJ3BM3EPN4EAT6E)# :\H)0>"30H*D_U87CXCY]^:I[,VS&O=LK
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M%     @ ](H;4Y>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M!&GY((,@*Q_D$.3E@X80-"P?-(*@4?F@%PAZ*1_T"D&OY8/&$#0N'R0#E'%
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #TBAM3F?^FA^X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #T
MBAM3F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( /2*&U/+A@I'"@0  "D/   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #T
MBAM3:B=F3Q '  !)'@  &               @(%-#   >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ ](H;4[3%A+\(!   Y@\  !@
M         ("!DQ,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( /2*&U--JOFP704  'L3   8              " @=$7  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #TBAM31VWMM!8&  "0&@
M&               @(%D'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ ](H;4P5 /\(K!P  AAP  !@              ("!L",  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /2*&U/L8-#/-0<
M !P2   8              " @1$K  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " #TBAM3?0G*$@$E   %9P  &               @(%\
M,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ](H;4[V9
M>1G' @  WP4  !@              ("!LU<  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( /2*&U/0^V56#0,  (8&   9
M  " @;!:  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M](H;4P@H'XG= @  #08  !D              ("!]%T  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " #TBAM33[]'^>00  "1.   &0
M            @($(80  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( /2*&U/5VZ[!? @  "<5   9              " @2-R  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ](H;4R$(!7WY @
M0@8  !D              ("!UGH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " #TBAM3F#0V4*(9  !Q4   &0              @($&
M?@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /2*&U,C
MQWQ]> 0  *<)   9              " @=^7  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ ](H;4_L<MHY9)P  \78  !D
M     ("!CIP  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /2*&U._WK *(@0  .$)   9              "
M@=;0  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ ](H;
M4[\1U.'V!   6@L  !D              ("!+]4  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " #TBAM3"N$C*>8"  #M!0  &0
M        @(%<V@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( /2*&U/^A-!Z9@,  $('   9              " @7G=  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ](H;4[DH?2]B"@  /#@
M !D              ("!%N$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " #TBAM33U*O$7D"  !,!@  &0              @(&OZP
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /2*&U.]51G]
M+ ,  &<,   9              " @5_N  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ ](H;4SRX6*Q< P  6PP  !D
M ("!PO$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #T
MBAM3*Q'4L*("  "9!@  &0              @(%5]0  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( /2*&U/% $7KF0(  !D'   9
M          " @2[X  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#
M%     @ ](H;4X@SUJ9G @  C 8  !D              ("!_OH  'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #TBAM3/[F*NGT"   ?
M!P  &0              @(&<_0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+ 0(4 Q0    ( /2*&U,MTH3J7@(  .8%   9              " @5
M 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ](H;4T06
MNG=?"P  >E$  !D              ("!Y0(! 'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6Q02P$"% ,4    " #TBAM3S==&J?$$  ",'0  &0
M    @(%[#@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M /2*&U-*O.8$!@,  #$*   9              " @:,3 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ ](H;4QL.>Q%&!   B1,  !D
M             ("!X!8! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " #TBAM3WD8\E\ #   @#@  &0              @(%=&P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( /2*&U/$"*M!^P(
M *\*   9              " @50? 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ ](H;4_A0BBA[ P  T0D  !D              ("!
MAB(! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #TBAM3
MS;B79;X#  !/#   &0              @($X)@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( /2*&U/^**(P& (  %D$   9
M      " @2TJ 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ ](H;4S.3 UC9!   1!L  !D              ("!?"P! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #TBAM3-/LBLV<+  #E1@
M&0              @(&,,0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( /2*&U.[#G+T[0(  .X'   9              " @2H] 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ](H;4S.KY7ZZ
M @  M0<  !D              ("!3D ! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " #TBAM3K_V7;Q #  #X!P  &0
M@($_0P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( /2*
M&U/"[$U>#P,  # 1   -              "  89& 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ ](H;4Y>*NQS     $P(   L              ( !P$D!
M %]R96QS+RYR96QS4$L! A0#%     @ ](H;4]@S72@'!   8"    \
M         ( !J4H! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /2*&U.2
M+*"6N $  .<<   :              "  =U. 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( /2*&U.,3^J/N@$  .X<   3
M      "  <U0 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     X #@ /P\
' +A2 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>226</ContextCount>
  <ElementCount>389</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>88</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedCashFlow</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INTANGIBLEASSETSNET</Role>
      <ShortName>INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITY</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATION</Role>
      <ShortName>GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNET</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INTANGIBLEASSETSNETTables</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INTANGIBLEASSETSNET</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITY</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/InventoriesTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SharebasedcompensationassumptionsTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/PropertyandequipmentnetTable</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details) - Property and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/PROPERTYANDEQUIPMENTNETTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Intangible assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/IntangibleassetsnetTable</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details) - Intangible assets, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INTANGIBLEASSETSNETTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INTANGIBLEASSETSNETTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - SHAREHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/OutstandingStockOptionsActivityTable</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/NonvestedStockOptionsActivityTable</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Stock Options Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/StockOptionsSummaryTable</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - Stock Options Summary</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - INCOME TAXES (Details) - Income tax expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/IncometaxexpenseTable</Role>
      <ShortName>INCOME TAXES (Details) - Income tax expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - INCOME TAXES (Details) - Income Tax Rate Reconciliation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/IncomeTaxRateReconciliationTable</Role>
      <ShortName>INCOME TAXES (Details) - Income Tax Rate Reconciliation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - INCOME TAXES (Details) - Deferred Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/DeferredTaxTable</Role>
      <ShortName>INCOME TAXES (Details) - Deferred Tax</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - GEOGRAPHIC INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - The maturity of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details) - The maturity of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bmra-20210531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bmra-20210531.xml</File>
    <File>bmra-20210531.xsd</File>
    <File>bmra-20210531_cal.xml</File>
    <File>bmra-20210531_def.xml</File>
    <File>bmra-20210531_lab.xml</File>
    <File>bmra-20210531_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001513162-21-000112-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001513162-21-000112-xbrl.zip
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MWHT_%A(D.8+0>AE&*2/XZW$QL*9ZHFDK<C%_=#LN%@W@2I?A.U0@V:HA;=N
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MMFO-%6>]]=A$M\R+;Q-J4>^8-]@:MNO[+/ +H*9:JTJ:;8WIB@9Q*5,VJAU
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M/@>ZLUU*B"\4L5I=K3:J39F_%\PY:VIL". :! E\J,F90FL!&*>'B-^+$L4
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M6(_L.M5&?34 HC!0=*3R4?<M8Z73G#504CV5P9D[Y0RQ; [8&JBJGLIQJ,T
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MYP7$K H^=ZM672JJY@"PJIA=$_9U#KT ]$YKN9S- S[=U' P8$9P,[CX9HS
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M4@*C%4 < Z5X((F5 4A7I!N+'#K  FZV&-SR<55/P!-NZ,?+J  F7$18X-I
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M\75%\AA#!:#0E$<V!#,0M!<)+MQ_)!V2X?0'[-&?P"3!%#<?_"J4Z/ /L@%
M(21ZA2B\ F1(@0V@8I^QK_#H$.OD4.SI$V#9)S2F78^+-A^4Z5R6)KEH.4BU
M 5.L 1(&\WS0^R,0AX^,=GW I2Q0\=G-[[WS$[5SJO#6"LK \@W"BJ96<(4D
M'K18/073"2.>.<-3*P50A[ #=ZL_1_0[S?*N  H8-Y=*D2@5'[ZS&4<,LA-"
M3\81?X468# /B_(D7L'GHU7PB9X9V@VHP1CI@(GND<:$L2R/."(]NS4>APXI
MVXF+:<PH7)(A.;8LU"EXOW<$5/RU\@Q3Z/YT/ F C@,D$R$0!0^OB -']W&#
M;5#9<S$1OX;&@4%],P*2TF(SGRVPLQ R(MK"7$$IB',4HB!GF5T?E1^I"L1A
MO/LQ7P$K@ )CP'[X.Q?)\H_$D*B?$@5*8H!A^&"1)37CZY(%]PC[SO501/$@
M.%!C"):*S*>LFDR\B\"R+5"/1-RN[ON@+!(7YU2Y@I<BH92R!\XNN,HW(^5%
M$H!<B&0NI./G$>.>]I3> W&%6L_C<H7I("5)N7L9;I/%VA![OYPF)*;T'#36
M+,YN/KI *=@,&\QAQJ$!;F&1-G\X[9_BK/CY\KR[HM9Z:UI/^%GJ5E-PI'FV
M*!Z<)-3_F+[&TY&QG0U,8X DV]\ -:YB+YB[B!BUMBQ&W7^X@OG_4&XNE3Y
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M\(RDQ'(QE)RC1F%T"[-F'T,NJ74C4G(8!!=+D;Y<,#+!;A$@&/T#RT $4Q(
M 7+8AHKBCZS))(K<VBX&,<1YB;3B(1Y8."2%HC A5^2@C"@D6N$&L:/SYFO*
M(\HT/'/R+/^KL&(P&(* QX&3>"/1I(B1B)$D;L1'L8\$XSSMP.!-W1 M/+;K
M,#LR!,20%3Z O';\0EH_P1L3#9[(\ME(KD?/81C5M ):!2<;868I##;?!09
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M\E-!F167F/AZ[9XJM5KM1*MU.NWJSVMG;:1K#%)$(X*$/#;&1<W00S\R5G>
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MOT)&Q<:X..W'@4CFH09RT%:UT0\QTWDP<<RN@M".0XSE8/P6M]$4=:=R/:?
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M];6AXB$W(\ES!\K')A,+WN"JX2\'&-!4,.B_FQ$X',==3V\KI8(M6;-P 1!
MI62:LG!G!>%EA*X\_T^0&)BMWT[IP$L#EM;F[GK*);?,C2?,L\2?2=5S_/8E
M.]7XM95FK[KVU<*BMT(W,3IE[.+"E53G_2Z5H*+]=*ZVE/+7-8D']PX4&7L2
M'(>[]F":^RK.55:/3]^Z&P[N^M>7QQ#F7SG+]G@Y3]5HIG^2XGMQV;_$\RK3
M4-ND=A!7J6\A.A(:#Y,Q:!N>N%!D0&?!."XS?1W9K/X?XAR\F-'/GUX#\+ 2
M78TU/O;BYPK60#4\/"KIO=MLR5L4S!S#EX:D+88SFPIUC9-2_<1 F7(1IP&M
M#L-#-[9>*)23@F&MY6#J9?^^FE2LB0.?DK6QVC>TU$RB84%&*HV(A*A+KCI9
MVN 7:BA#<0$W)(@!":AIU?;X#<A2R10PP,R9YM>3/I*0XP_*+)@("$W0A)5L
M8$%8U"*$\$>B8! ];C4Z+;CT5[+Q'#\ZM<8N$?WOM<O>9]>(*^5H*7E$ K:4
M!0?[&Y,N>I>V6F6OZ!XUDV3;@80Z98-U%MQ+U%Y^-L7Y=7WS=7!S?SN\'HQD
MZ69P?P22=$TC^4/_XG\_#F^_W%R^QZPH1"5\832CB[^T9 V:O9>XN5T02K]P
MC(D6LB5M5!YL-ZET#;>*D.F!WPPE>P*1X4FCSCA'?VK[07AF0V]3\@G2&FA3
MN>!7D)IPNXGI!\M%8C:0M;5XDYD68T[D[;.-7OBUDY(.-.WFGP@:TB45I_DR
MQID14^</]P8K8" GTAV(DE838&6ET?B)5D2:LM[&%JUE'##;??QD0=T7O%PH
M0!G$I8'C*J$DJ!O/-K;GQ%^55&ADSOTI*;])(V\R7:3 ;H\++V%K,"GRR%(/
M8[,37%7$3<573"9J$N(*&^>V,I_'!DJF8Q_! CAE$J0O]1]8_@J76VA/G*2B
MYRO7R6?JD\Z),@&I0ZMP!&P[6%3"$I/2C8O-PH,4"N3D"5P?49!@%#C@TFZP
MM"MX6OJ2^->>$!:1=I!M+1ZGWUCX/!*['?&OIK5)FU)MK(@M,O(AI))-^^1K
MS<8I!>_+ 2,D%/QB3\(GMAA3U^F'S!+_O+Z\_^.]85#^=3N\' S/\#(_]>]&
M@_?@Z;3F 8KO0,\<- W?2U84>LE7I'0X^XZ-/T:.,X?R'^XCFT7A?H%^OTN_
M$$E'UNUGEO?'X/KC'_?O58/7:>F#DZ('?Y?HIKJ]E@Y_W?4O+Z]O/IY]N+V_
MO_T,QY9^=W][E_WBT^#J/OO-D Q,OB),_8PT+'Z/4?C%M^;QGI_)K3%;S(,7
M8G:RD'@23M98N_9SI>L&-'@OP: 5;@%C!QXG?D'+02Z&3V2Q\Q^_2YF-LA_9
M,N%GNG45ELE^9%O'%##Q7D KDU1L$9&<I8WAPX:F7\"TQ0!3MX&8M ^>!.XA
M:#^0LJ1L$ /[O0H^Q=N0JXP<@><"SQN"Y\K;>$X_^KN47YQ5\9\/W?$8M>L@
MTW9W[-6J5T,^<:Y2OK7C<]F>E^WYB!+'K@!L37#_767XKN[M7.HOBXC%4RR*
MZ,]5')\J&UT:[2[XEN!;QP=8P;<.?S"'X5L=W2C)M_:@/PM=N>S!_>GY?X.W
M>>Y[CSX*JE67:\4)3W(+ZD[V(!@?Q_@4I5.]PG;D:-> +0C*V3'E]+K=^B@,
MPN&VS5%>V2X-LXXOSH7Q6BOC=:/+BB+0U^/^0IQ7_N52;0],2+[DS8YJ"A=?
M0ZBNWD0GSDMPR6/EDII6M7W0,LN;".19X5;<.@*<U$M>/L*<L.\R(B]S*L?F
M9"CD5VQ7*T5,$7?26AI^F>3-.DB(E(JQ-^=6:CW,W?3,5T>*[?W0&RF6ML0-
M7=8*/;^"O0GV)MB;8&]'S-XTN6NH:[,W3A6G'R$G)5G1T2?N#&FR5UR)*4Z"
MXU/=DH0JTK,.VH8CR(ZS?-HG%_HB(_9"R">VXQ\17O.,)*?E9>61''<O2?KC
M:Q61Y>2-^<12"^/40ZAFPAK\3NP \KPE;YJ3L<V79DV'\^/=YR60JW+LUJ)%
M6TV:3IYMA+.$2BN.H<?;:JQ[R]):Y,V'Q"LV%$WNF 9)'^<:35MQ63_,D-PP
M\B$OC^2=7]Q^O;X\4WLDD?#!FV (XS-C9;58O+',,A+C,8(G>TK'Y<H@) /=
M70RE9QO:DL%(K-H5'OP1LM3AF_7*S!1E."_G;+/GOL:IB0EF;UP)7<7GGU^J
M=6F2%:G9:RUH=1GTSCK+R5W,I^NK6_;0%G#!6-;A6\'F#;^XA,):KG5/76]$
MVOK=\/9N,+S_1NJU0I74.VCWVM ,]GP(Y!;#)K(M" F?A(:,7A"VI &D'4]L
MS">97(R[P,?U!O\%LG)&B@:R3J<^M$J=VZ%%R[%(0RC<D-0G)$**5/]@6<L^
M8DG(D[0S/1T?,M%)NC(>Y$^H[)%?Q)NNVW,F((]"4AP2!"84+GF!OO5,%D+-
M$UHJ)18&) >;]7O-K?X-XU@SSP^QI*9Y]T3ZSTB!1%)#C*1,LVI3-)/]D;2W
MQ"\Z7@"E%LEC2=\X6!X#$Y2<)2N+P0F ($49Z08XH& P>#-4W\(V5>#D)0]W
M<BB+@&>-'R>TR"- /E6IH@!!73G'?D9)[<OXF"U\#G ZON4^0N8U.1$#X*HJ
MM%>?S&HPD%HRH6^!OGWFV"YBQ11:TB<H0@*ETY9QG:V37Q=4E:3%'@I6.4W:
M_Y'%Q06.H"1$_(,#,[:DU6!A10$@";^(-F:L+1G>[CM5:<NF:E =3E4,6>OU
MRG<MW*34_;H2KWS)]R\$EI\ E-D*<\5MIC[;KCV+9JRLW/F=\:W$ M-YSK==
MF5Z\,NM'9F6JLO;2,FOCL09_QH8#_H!?[?/(4T%Y(8Q0)E^,K\R\2T>\[6)+
M51DBBS4POF^Y6&C] E5-\7/7;@@<!9MP?<)AZJZ\-:;JT'W_YN/UAT\#J3\:
M#>Z;6GNHH+9(C'-,K,5%9:00*G>"58JE65S0ACB.\-^DNH[G>(^O["O"TZ%2
M3J*V$$F6Z6&9E'=AU31!0(Z@J*KE3P+IPINDY8A^8<8OIK_Q[_W11?KGY/=?
M97Q,%Y)N*%*Z^$!*']%_EV*B(BLA1527AH0!,L.V\'#4!>*C1[PD<&4LPH85
M=(/Z/5BL3:'L-LJJ"K!MUPLY(?X04842['.J"(,D!CW1I?6+IU3AQ2HMK0[L
M2S.H!#SUD_)T]E2"%G]AP-0X]Y&5W.;[.9-2WV-:%X;Y<:@N,(,3BFL;V;3\
M=),5OV64!O _(%(D)SF6U0I:JGIQ*I9,3A8\;S_&" ^A=IF. R=(_3=D#JJ(
MT\J_@,TQU<3:(7D^[MTZX8D)3Y8\3;4D_@U*7BTI(\<R^IBNRX:A475,T^6N
MJ>]"&SM^%.'KJP&.$,.*JOBD[K/U0&MD4=492I NX=1#6@L2#OWE"27E1S,:
M-:^6Q[VC6,5PBF0VJ20-=BR,0U3YL>4"O;+%D+*2I,D\\.%_(5*>+,+$'B3<
M-0)SFO8DF3K>"ZLU%N\P@MV14OEX4[0>.MUT7"LSJ1W';P,/2*MKOG+<J27=
M>#RSHC7,R$?J%67-%);+< /K C1;3\TOKQTM:JQ7A#E_@G*O"V\6JM/%W4<O
M.7(>$OI,->LNIUF7F?1\VV4:A<N\BWG*?<)2%E>KK+W:K<%:W/SSCG*T9'7:
M)JO+KH_GC;?319RII *J;O#-,E=/>%[1XLJ:))K>Y5O9KK,X\#-34JZ[W=$0
MJ^/K8'3_.;^;5B--C2OBW\3K. N]LZ1/3B*E9M;?K,PIQ<* YAG;S^3&\.P)
M.1-2;=IR[6S'#E[4)9(LR$CD*997<2%5:,Y([C97383B0J-$V<<DYI#*J@\(
M2U<8$0\WMGS_%40VO6Z%2M$(Y+DUP?_&*L/:&GMR"\P6"A5)0>%\X-02!V$S
M)=.)AS8>F]!^/:^TA"A;+XAV_++'P "=Q-!L[OEPN?S+PV);H:DUAEXG,C,
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M-PA),B<\/7>B6*^!AEMPJ&R0S.F'&6R9T/:7<'3@1X73"; JYT6T<C^X^C+
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M4*S0P-,8D?'(,5D3KI,H$5196,=QL\+=LN#UOXWQACQ,5*?;*5:<J%6PX@+
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MK3CA26Y!M![?.>-32C<?/QVT:\ 6!.7LF')ZW6Y]% ;A<-OF**]L%^+3)DD
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MZH;<Z_S.^-;YO "0G2QP*<]^;[ HRY3.[SK?](;#HBRO.;_3O_6:#8O2+.2
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M@'\.I5<$;XR]1]?^-WD)#PI9D(N)C9K2A4Q&FD\9)Q2<Q6D$<PP%;R)Y^$_
MX_&3%#Y!FM_,B_!>;4@RA?1'NJH'Q,^(?]1:1@\OQ/*#[/!)AJR/9I;M0H;H
M&,/.M\9AA+<>(G_&)W"&3UC#?D$^6IF_"6F;G99BL@E7*.''CS, 3)IG"; +
MHMG,\C'0(3USZODSBC36@Q>%DN4X $O(U;S *&6YK__/FGO![\%"8N>*=%UR
M> %*'L5&#T%/GR07D\&] "6)S9$[P=@"$VJ*JL 0:IO\VTQS;.>.Y98]H[53
M1%MJK9-$-[NL@+Y-U;H7ZRR6]IA<->S??!Q(MU=\LM3@K\'PXGHTD.Z&UQ>#
M464.8K75Z3;\$'=X2VNT%$$".TFH_?+YPV#($\#ME_O1??\& ,9__;G_;47Q
MOZ;<F@CB$,21OODG ?;@DJ>#_M?!L(^E!O?5</"Y?WVS0"\7>()A_^+^2_\3
M__6GZZN!='TC?1OTA]4)%T%'@HZ.@(YX[3XYLAR"RNI@@DH$E9P"E2RK8H._
M+@@A]#]\RM!'_UX2ZI@@D%,CD)+JV+K2HVSTQ1:NFU,+NSAH'T05TU_5;IM3
M.\#=L\=3@^AA2$)3.W#%4ZF&(,(?!%D<.5GH+=,0-"%H0M#$@O8D4J4%50BJ
M$ J4( M!%E4(BSWX5L3A5GZXT.GC[)W6ZE;G6JY-^(MPZ-8'T519T=J0A]O<
M&PR!;O5!MTZK7:W5+S!-8%I1KW:U3&MD@6L"U[;%-;-GR)HA1*A MOTP-J4F
M=I\P]/=RX'JK4]B\5MRI"]_7Z9%$MZW(W4Z) G;")2S(XH3(HB6N201-")K(
M:$^=EJ*+.W5!%8(J^#MULR-W10"6( M!%AEAT<XOCU.KHC@[JB1U<?OY\^V-
M-+J_O?A?J7]Q?_WU^O[;,BAR*@75J:*+);G6+)[_^Q_.WZJI=@VCVUL+/=*'
M+R,?:K) /16H;",A=X(FF3:O<EHIQY/FD3]^L@(DJ;HI]XQN7*32FT+-EIGG
MLKHO?#T=J,@32G/?'N,'?<M]A FGOC>3:(@''O:=WNHIK92C2/>D2I&+X#UO
MC-"$S,Z5F:$SO-,T73;T=DZM%ZO>Y[@9#M^ZTB4:(]*@7*55;^0,5 BK@/)(
M+@:7Y4JD_)/_-X;C=1!$ECM&TLAR\#;ZCSY",_RX](OG2PSR>+SQ[_W[S^FO
MZ0^3WW_%,BI\@E&M1_R33.KM3&U2]PF.*8!:35$@!=%\[M"QR0NPOM'@ G '
MEA"R$CYQP:=T\6,O<J#BSQ3_"F,'R'$HHH08] 0!X+_17**;LQ[Q,A^A\S1&
MOW<F!-'!/_!7BI:9TD3Q9GJ_!QE\E:6YQ5I7 U(J72A-10>1?H$1> #=X3.A
MVQO19O \C. X?"]ZI#LC@&I)5["'Q8.#3>"SP3!0>S&E\= (/&>2)2H\5^2$
M0#VV*[WKR+T>ID'=@%T^8O '*:W$19)L?-#\<<KP+ 7\.UTV3556VEU*2F2Z
MR9O<H+4L/4KSFGNRGF6,3'$1_9C;@+YXR_\3.:^2IK!6T]$<?P7+(D_0"E2K
M#O?*\V?2Z$S','NT@Y"]$8086<A$#\##.)R=D-IGW)RJF;/3NK 2"?Z!\:O@
M*5#M:Q&E*38 #=KXD+BJ6XL()3U9STAZ0,AED";<)ZW1-4)CC%*A#1QG',*1
MJ3U=QZP#JKQ1[%JBK^P["]25,!$F#H;\^8Z2\\5_)"CPRQ7F4=*-UY)T73_3
MU)ZJ*[\N3YL_TL+TE':@&)SGVUB060[&&,H#,[R.(+"+)%WA:I--T-BQ #X(
ML[AQ: /D7K.O</A'N<$BHD(E.\MVV7RVNP((E$'#[_G,F:OX!P\%6"YPK#,]
MP^R!P][S-[S(X%H+%D(=*:DBH4SY>,RMLGP\EI N7F/^0; #V(Y=25,LQS%U
MS+V "C[?L@-@YE1<OE,UB((C\G%9I"Y2%=1(3*1GYOQSN.*22MHV>YV.IFL;
MJJ3WRURF7G+A8U;8 N!72$RFJ7;D+J9I7:>U,'U$OW:]LN/@?],','"R!__&
MGDY%-\;G_4 88[XP*^!G00F=AWLW?/'RB3A&E24M#WAPECTDU5)5N6.VY5Y;
M9SRWE6?V4&+E^//2]LJM[NU=4CQ5%1F3KMPU\-*GF ]@J36)QB&MHCJ;87V
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M[C$^#".L0+=5 ]C"+'(>K6Q;B*S[>,&<I#<RV$@%4R%@RZ;?91T$P! B8%*
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M&>F$W\@N8=G_RT,C=00S788%0L W,!;55,@ZTD<3=T3B'4S4M&7W>:&NF+B
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M? ,[TJE4A2I5FO8_%NQ0Q>9&_+$2P;R^\6%LZT,X<!2VJK P[&TQ96^!V L
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M!8H<T<;E?E'C\L4'W^QPKBM*2R-_-[F?^0X[Q&NMCH!>*>@QPB'0F/_X7<I
MD_W(X  _4_AVS);&_<[ ^V*[$^\%*%U2YR'4G[8G&Y\!&YI^ 3-G#T5K]6 !
M]3L6K@CCF!3(Y4_J=PF@<T96]EYBOU=1G//FR^</@Z%T>\5J%=_>W5_?WHQ6
ME&JK&B5BDCL<2@@Z7:;33DLQQ*G4ADP'?UT,AA?7HX%T-[R^&$A<S<1A_^8C
M_AH3\>B/_G @*/?P.+(%Y6+U$^\D7K*6H[]N=%1FK]461U4;<OZ3G-G@4NI_
M'0S[F'P'?S'RY@B;4/K;Y$P_^KNU)C[T+_[WX_#VR\WE^_]\Z(['J'V".O(:
MS2"*6B.P-#>N1C#4,T];L:B]4DTB-C-JQ"$N'"(#[;YMGYQCR/+E#/L\/?.'
MN%>*^3#]N5*ZA"XX'5E3>CD%J]<CO^T4J4-BAB#B]0PC<5:5*U-;4C'IJGOV
M#O+W!!G7##5J1L;XJ XOBX_UJ#:DSH/09"V4KIH>]$%5+JVEF&MI6WNQ<T_1
M'-K.E'V$BFMHLIG;L=8W<.NO/68VE:R]H9;:9MAFJ*9L*,JJ)FDGA&:Q#7+X
MQ=?7EMA02<%HT3U[UVVI78%JG)Y\^+4?BUS,47,WQ)M*I4E-87\(60+E:$L(
M$G&O4GM:BW50]&/,<@TK9]KB@#9RRJQ@9Z<&T4.PN%]4W91[1O=700_UI8=5
M-PE-!NF!-/M5EP."*&I"%*O\\B<'T1K9(*=V'H<0VFJKTZZ+7=+DL]V-#3*&
MG&X'323/Q_;(W/9/T2=^I#DA-474@U@.G0XXVJLW'!J*NR)/HG9:OG&J_OOM
M(F$$ M=0)1<"]=@%JMYJZW71ZD_-BCM4%H>V=?RI<#;M(7+T$/Z.AD;U;)U_
M879[LF:H6^=?",(Y$.&(VXQ#YCSD&SR"=(Z!=,2=1[44L0,Z$-<@!\D0, V1
M(5 'BA09 AOYXT2&P#ZC.G5%[J@=D2$@,@1V>\-@M-0V*-QF]7%$AS^MS;77
MPZ_]6.2BR!"HNRSIM$SALV\$K8D,@2,*_A16]A[C?+H=V31V$.=S:H<G$@2:
MHMC'"0(=31!%;8E".,OK:8*<VGD<)D% *U,!0[C!:T5K(D% Q#,VB G]8JC8
M<%!%@H!($#A*+5]KZ2)!0"0(U$Y-$ D"-3C2PY0C,JLL1]0RRROVY%EQY7"P
M- %U^=@W#%7+G*3P.A6<8_4UIAG<MZ\^S#%?C9"A-/&B!P?MB@$W-'9HVY!#
M6>FJLM[)"R,2E-DHRBS?QV'?I%G3,ZQ+HD->W)6@S2;19OGF#$=%FB>G8]04
MX0^J8;PCESAGTCN(,5N'D7'V'_T([<[A+ZY3_=8-UQ>ZU^</T_=]RWU$,\SD
M/[RFC]Q9K_!5_\7R)VR2V]3RN8F@Q?Q;W>XUY7L_N)VRSNYJ[_O@!PW;NO/M
M,1K"M'?()W,J74WO*06=Z]6VV=$4KG5]Y3LYWQ6@_D2 =&C2?T:^]8@R $C!
M%P43#(C= A$Z=.P$@JNVB#&P4LA^A.23X-K%.[:]R4??"X(WD5#]?N5[,_5_
M(A? =^\Q2&*X%D-2ZW2[:K< DH9J&HI2'2QS-@5P6P]PP5J35("6E8,5"GFO
M =3J-KQ _,!6KX,@0I/+R,?X30<@<P4\SXW'F+R)@=H&H%K-$'6S9W0Y8*V]
MYK4)\RUPQR-7B6+5PZW5:5>(8FOMN6)A?.7Y4V2'$89;WYT,( *!C)"LY4VL
MU#>"KE%,P)U.I6SQS1U6*[3?G*X"A*X<Y%".:(\0WR-^KZ]LMGD]Z2T>40Q2
MU>SV-$,]466S(B!"LO=)*IL&1^&:DE*XN@*2AMKNFD4BJZTK';5SZLIFY6 %
M>[V9RF9G U"!TM31"D#5[6!S9TM=L_:J9N50 \>04#49=,T-H*OI*_0>,,$K
M%-$-5#4K!SD$M@A5DP*WF]&2WN 1Q4)(4[JJWJE0N!^5JME; .)GV[5GT8S"
M:E.0KLEV*U,\:PMF75D$L_5C>S"OJ3[M!LS)_<B-YSZC +]%9LF_"\F"12GB
MCC^=D[L\>%5ZL2?A$[L-,G6=77/Q=T3TRLXP%.Y&[^+VTZ?^W6CP?NPYCC4/
MT._2S/(?;??,0=/PO61%H9=\1:ZDV'=L_#%RG+DU 6"P613N%[AY6_KEC2A"
MHUT^BI ]F]S=FEJK>Q3!T/GKUWZN=.F $.\E&'2_M\;)KHKOV'\^?/POA0XL
MI38WPGM,16"J@S<EU\K^;]DH"\J<M\I1.$+4QBP0CQ._H.5P4('P1XOPQ-:7
M/"K".:1_82*<^\JBTIS6#I2X'R96B*2I9?L N@@=-!LVD74B9&PK/NBY9U0;
MDRC36RRF7UU-/\(#=GM8V[/%XRS+L$O(QL'J*?NL(7 /D3O4U339Z);I&B@(
MY+ $(@![^%S)O?.M1:6OA@=SF)9(9O>P=4QJY*4X%IK[2*MX5RMJ:L7]-N0>
M0L/9:79TU66]&X!V#=A"=90C9&QA">-ZB%CA'-GF'+\2QTAJ@PA3K_:FGK I
M#E&6K*WTY+;1JZXNF: /X0HY+L *QG,09X;>J8>B)92JLF?&8@E/V9NQ82G
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MI]6NUNH7F"8P+5^":BW5/-WB7@+7]HAK9L^0-4.(4(%L^V%L2DWL/F'H[^7
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M>WQW1:&=GU];4[\X/,=COD8TS\*-VU/F&;+UT^Z;>-Y]=4O%B;7$$131K]R
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M@S&JK'<Z<J_3+;<IPJH(JR*LBK J*S"FW1_(W8ZZ4IRRPS#TC55&+ES3)T9
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M79Q*(*#7M]^']Q?75_.EKX=\U8O"YW^,?^Z4+NN1XWY,),PD#?>%=VV T8U
M\EPB!>1Q @%>2TKE4[)3 95\\@CQ.W9Y<$$5 L.!5VUX>SKUO5^@WB%Q7O!;
M(P]U-C@N6^$X0S5:$V3E7HY)3]=YQ36+WS\OSNZ_'4-VU%(1O<_7MV?GMT>
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M@Y#:ZOQ&1U);_=_28D,>^)5!S+(5DR*'2CB)#7@,-WZ>F&/7<[S'E]B+\U0
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MS]>E]<Z$F6Q]"Q+N?4=6(42WF/,?V2C>\;RF-9-I\%E-PV65U_>:W.\H65&
M>#YF:!K+)W$\C>K94HR<Y3AX>XL^O[?4VA86'%,/-V=>?YQ6LZHH$K?DD6I7
MNC: &BB6.IP:C@UBZ-I&WIC^."VUH9A43$&HL",;FZF9LN"#UU[B4"31F5FC
M^X,NQ<@)+V:V#X1.3),GXH#YLN*5BQEX07UQ*BFM5HY($'@^,V#L@\9$@GC$
ML?_";YW>7MS=W,[H"#P&]@-L.$;.;#"Z1$<"0XS1*0U4Z-1Z99-],9I5QOC+
M:=9NXF3'*'+R0D S!JQ"Y59>Q/BBTD%.$HRXR<E\/Y?[/--E2/2[#&-F*^)R
M+ELI15@=[H$DJ5Y":IGN=6!KH9@O@%P(?E.8?/(8.<RQ&6BH;#Z%E+&ZM&;(
MH@:ZW!6+Y+->(A7O0MG-.0:ZS)252Q <'M/&\@?6A:6LQJP'B5/>#&@^KMN)
ML)K"H8/1N4(P@UD$#2M?\NF_(+,N'R?KZ0/9D)$% VDM:XZ_,>EI^)E,51J1
MRZ8+C0('EK7VI$B39JP]6M@,U3*DXG8>2S&)B)%?Q,Q%[4;JMX:Y<G_\IA&P
M,>Q\9JH5>P![@?G/1NXP6@(JK0\3EV7@'&Q5B:=B,<1G8N#$2@S_-W&U!6L3
M93S"^Z"O(+AT"CF! ]],%B3/NT Z1\*C"P30)9D"8$+W9"ZYL=Y*4KLMK:P<
MM<92AC@:I!7-M[>"H: "DU5K7NV W#BFTQU?N)?:D"*##C)%2U^0:&<];VP3
M(&B;>FR! C.'N8)WO#80G\9\9&8I/2O%QG/H?+Y]MEI.-\RX<VLD>#EA9EE3
MZAUGC7EL9QXBZY&P A N8YK$DSW@9-[W-;G=TYB=HAZ.EO#9:HIK,_1BRO)E
M8F,#PF &('V:UZSIJFFVAOO)LTWNH*A)F0!GQV .9E.G((RL%UZ^@K&^D <_
MPE4&K.:56VONTJ7'%D:S&AH:=RX(?J]J<J?;8Q,:=-8/715YPCU)SDL*%9M[
M9<LLJ.EJR[UN;V;]WWN0(Z7;IN.P$#E@)M(P33_B7XG<!YO.X,4DJ6GQ,#Y^
M%-A_$=SYB()/+XP,\%POQQ);%SVG>7@QUKKLUL-$[5@+O6.T.<MV(F8!H)IG
M@B?SCR6J>I]RNG?E/96I7CYLELH,59GZ?0<YMQ\-.F?-10P=9SQ;/TO7I4C,
M[Z@FK+H[]V8)MEI;.G>MJ0?XT"(9*W*A;[Y#.2Y; Q.7FA,!Y-I0I$!,TYG,
MLN>8&L3[DK@6QU:(Z0\HTGNUK\J*VBE5&D7N=+B:Z(H\8!J4J G[7J*0<UGF
MHH5&-IM.M\,X@,ZO;^IT?Y.8EBQ:(Q1K%6BWTJ&PK:12!ZQ??Q@N-XEJ?P/U
M^DS@7Q>!;Q '9-<P,?P-DH+R*?W6K'/C%9O$48'R#=W0?O! 1+Y&=!7N+<&Z
M,DO"V+@_@MS4\*NJZU>V_!Z7'X*>T@2 $L-(=<RRC4?7"VPVB^S[/$;][#T#
MH>Y>7 NR8#(KN4Q+'L@CVV1'%\W1^>AX0H9&JUQY<,%%SAP8P;JF8 8,YL+B
MY8ZI/6 C4+?OO,Q[>[6M8:R>6WZ7>1.,@D$=,IW33H9(BA(T/*%/SJS,U!6:
M@929H-A)MU6YVZ[5_*2PFXX7%(02]'77RV9+#"5<6()0F+AP?&.STKR0>7Z7
MCZHMG]-:8DIPGT- Z/1/9@$.IG1V&.56%F2"Y*P9F0EU8\%*;<:W&_"H.)F
MYN:1L/K.G/07KJUC:R0>XFE4G AS2#9_IEH&@;U#Y^+B=1NQMUG%5W/-7ZRC
M><>-H2(5/+9]979E<P]#V^P7SA9IPGM5EU55Y6JERWJGDW6<= CF>1=HC8VK
MS9YCQ0EP,5]2=)HG"M/EYJ;6FVZ!JU4Y,AHA;ZP2\VM4>4*X:*'IJRO#0A7@
M7Y_5 J5'O4A)L)@+:?N]G,3/3XY4B$]U-8E/\QE@...S>:J'66:7C3NKEDD0
M"Q+491'VMC+$AFM3IB#3J4&EXI7B4]RR8V?6_0AMFM4F< 1=%H4M]!VSPIT
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MO:-6]#8;0-0NI=(<1&V]W5\5(G[68250.J7$X5])MWT4RKK*@K[BH>?CGU5
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M1,0ZBWP8\0;8ZUEWU,G2F]<L2#I/8ITDI6">>":KT+1V-K17,;0'-N+/GS-
M?2>3!^+/YQT0@&4061G N2.WZ+,/:)!0?(#(U("P+PPCX(0/"8+U X.'S =O
M'"/]Z WZ_UL\F8Y?P3(<'WCF$+#<*VHN 0/02VC6X;E894IID$E"9)FATRLB
MF<\ X[@6I6")!,TGI1N)C_+NI*UDA6<I*/.)]$)Y WM(;P5;5P*(3R'8K:@&
M"5BSRHUW*8NV*(88#\^((1URMC*:Y05"BX;Z>G1*X_<['KYO32P@Z"X5C$)@
MD))_^_CKP7<H'O\?4$L#!!0    ( /2*&U-/DME'N1,   _5   1    8FUR
M82TR,#(Q,#4S,2YX<V3M75EWVSBR?N]?@>N7VW.F'2VVL_C$F2-KL=6M+5J<
M9<Z<7)J$)"04H0"D;?G7#P"2$BD2("4K'G@N7SIN$BA\A0]+5:$(O?_'P\(&
M=Y!0A)V+H\JK\A& CHDMY,PNCB:CX]JHWFX?_>,# +^]_Y_C8W %'4@,%UK@
M=@7J>+$<F0B,B>'0*28+\+N[^!LX!G/779Z72O?W]Z],5H::B$"*/6)"RA^
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M8L%G?]?[O5&_TV[4QLT&N*QU:KUZ$XRNF\WQZ'UINWJ*<(]"J^]\$']O#]]
M0%!$634^0K8KJIO=8F*K<DA&*<9&8D(=BJ9O X.P/IA#EQ6W:2[6MNMDDEC-
M3R+X/2[\;RFL%I0F*&TS.V\!UWTLI7&[7*IF,>Y.5-R-QNR?;K/'>.NW0'_0
M'-;&;58 U'H-5K([&#:OF[U1^Z8).OU1Z@PMR,PBLV:[Y;R$BK(?DOK],DH!
M:Q$2APD#Y6(!5A \FK-U;8YMB_EGS9\><E>\=A63DQBWBF)9M)[FIW5T76,T
M]CN-YG#T?Z#Y<=(>?RG8RSD]ZP:=MVQ\+YV3ZP*)K2K&UUE^ONJUT35H=?J?
M"B-'Q5)_>%7KM;^*!2O&3NQ%]I[WFK'10-2T,?4(9/\3K9_.0$%!L,Q-NMW:
M\$N_-6I?]=JM=KW6&]?J]?ZD-V[WK@9L?-?;S5%\R<M7)=E1,<[>;',6B!7+
MW48PV$@&H>B"416C@R$W L9?V/[/-XH!7Y1ZS7&,0EF9#,[>;G,6RA'&QEK2
M'X#)*DA2D=1F4Z9WU;[L-&NC$7.CM@E*>Y_IMKW;IF<C!?AB"F8RF0G6F]&@
M]J7&N[_78$^&DV:C^7G [.BMM3"[M'I*5<K;G(4202!23*U * BE%A0J][2(
MM>S;RO']*_DZ@Z1*8J^*B/A?E3U>,!(L=\P3;8YKG[>F3_1YAKM4J297-UX9
MB-K%A%!U_U6S?S6L#:Z9]=1K]8?=I,&=7B*+DI-M2C9B0$1.08[25>UWN^VQ
M<!W94L^<2F[K-GL)LUM5+M-%JIQN4Q41%X2*(@*+P)_"8;KDNP;KM^8-[[PM
MUVCK9=8,.DMZ0:$$X(LH)H_26C--[#DN<F8#;",307JY$G^MXF::O%@60XG8
MPD86"(7]P1,R?'G@]_!AVDE(0=QN<8>Q<6M#ND?T(:B8Y3)5GA"% +_[C10\
M[Q&-2"%673*3R5UB$P5U>\8H4FB3EU)&TRLY@Q4%50<)6J00E[=.ULRK[A?"
M*(C=+Y21MB7*"F52ERNPH62JX&D[P)&Z1FZ_S738JLIP1S%Y]@Y[I-"C*I=-
M5,X@2$'9$X,A*<1EEU8'=JN[1454%!;\[>#6-:!K('L?ORZLJ;0MJRE1E?Q>
M7="$9)X61 <;GG/'5,4$02HF17R_VWZ9$62I)H(L^Q#&]\A-P\4RFY7<QE/*
M+?Z)$'2H:-^@U%LL^5\IG.:LDK'@/BG>$B%:H $"#HCB 1% Q0A0C( A9#/%
M@U."%R9V7&*8+KU'[MSTJ,L+IXR G%4R1D B3K/G" C0  X'K/$ #@BL$15K
MN#(VYW^ALC(<"_[TT)+G-3K033*O+)C!=R+.HXS+10@.&P6L5;!N]@_ &BYH
M56_-KN',$..&+8;0I:F42@MEQ0Q.$N$>6> NMB^'K0&_N8+&3!J;#TMHNM R
M%IBXZ%&TCID.<=Z2S.Y23SUW3Q+AH1Q4A\V#:/L 3P':'@,%_4\*Z:8Y4;DK
M*?VGDT3L*6=$MW"==CBSIDMCQ2<AV]X,TR0>M. #MV.9D2T^W4N9VKO55'.<
M"%OMR/'F))R" (_8J0-$(( $0DQ%>MPN4?[4"(FTE)KI1) K/<BOG+S_142)
M>R_^^:E[<_:O?WXVE][#%^?LG?7XYF[V9>5,&M[]U1OR[LU?U>^3\8K:;^[,
MQ[+]I_OWRLW/D\?Y?&)/&W!0&GZ</$Z^HGFC_];JN!])]VNW!T_=U\L:NAN4
MC8>IU?JZI!UK:-9?W_Q]VC7N_OKT]>O'Y<W5X..L\_C]2^W[W:-;L;NW)[;U
M<>G>?.KU;O^\__X#&97!Q"25MW3RN?2Z5+_\^%#WRH^XM9R^<U>EZ>=:9?+G
MM5UI-'J3[E_]^??9Q^$/US$G<-9^<"[+$-W_K'^ZJA-<;DW&Y/JUTT/UUOBO
M[L6_0'TT]&_R>,I8[7LNOP*"7U(R<K'YH^\[VS7317?\Z[?$HI6K0D: Z"09
MT5..8?X)T*99(-H%0<,@;+G8I50\][!S!RDSY/*QG*-XIF>1C )FD<Q:/?:;
MW8GC@F)_VXE0-?(6"X.D$"LME$EG,M:716><PZ"UXM0YSZESFL&0\CK#X4L$
MY^*'SH5]GR_^PC_Q=XV'P 1."[ZDE<C: U,RIM+($>$6+A^P!D(SO#BQ5+,U
M-AZ&A@N'T,2.B6PD0,B(4Q3.3!<X30F?J5EDK0'>'(BW]]]NIC^%TP:<0D*@
MQ;HNR6'B9<:\.TV)@DD8"T5SSHHU<N?4G+0]3%E0O9N=)L)8LLR<8E_+Q1G$
M,V(LY\CD%_N1A6B>P)E!N)/E0)<:=EK4:I=Z&8SFSK6*3,I-\R#2/E@#X"<1
M0$ HZ-\S-2MMXN8HGN5!G.Z:GJ6:QP6+OL_G+9?^;:RL=8/.IS:^CTU+F]^(
MXV)^3I0VF?>IG[7!)H([.6GF'F,$#N!X  >T-=$%).!BX(,J1H=T=(SY5;.N
M1Y"[PE/16\S:O&4FIYN:YY6C>.8<3P1]\I//F@=A^_R$42  $0B%C9S_.];T
MG,ST,AF[=$J2U]9'K87)E=.1P:8GK@ETK*;CLF'>WBQL/E/*$IG>:%EXHX&(
MZ)],'/#E@8C _P<KY_M2[.YJ_M!_%+OE6CQF3]%BB8D+G-0[R"4W9P/_#O4.
M-H4X117^?\=AO6/^Z+A2/3ZIO'J@5G@1\(XHN-+^3<2[H0CK[8-"?05Z&@X:
MWFP>K3HSC*6H68*V2]?"CC?"UHAV[)G4^]!EN+)JBO^G$2B96-+O<,_)3UB!
M$W.V:34W)^E7Z^<CA=6-$+*6E,9(KCZ@T'PUPW<EBDPA-P/'=G'^AV@[;#5H
M-/CU ='JQ5$D1;QV2T76Z!'P+P(7E]^?LV?,*VR[<,$7AB-@!*4NCESB\2N\
M1:DE6ZFQ-1;U+(\$*[*#;)N;/6%9ZK'*R/7XVRN"O678"&+B(UMM&JA(M\4U
M$+G/ESSUN1[)?*YM$I_UT2L_5!E=09IOB^!%/4SR_83<>3U,\=5'V?Q09<J&
M*:]\,P\37GO0U4?%+(#R21?F_M5$ZI]62JG 11?3N$IAGF,MDN;8GV[+TD?+
M'?'*F QSO@9^RA<;"#4_X:OI'S0%]\YKI/C.B./;=ES]C&06?;3."U2ZR_2P
M<R--Z-!'SWPPY=,X);U!'^54X.0JK0\I@P&NCSY29-)1J#APU5 M!<B86Q+7
M,7(@J8].::"D+&V.6"+!@DT$2!^M\@+=3=-A>)3$+(<1/TC27&$Y7MFN'PVS
MA[?EQP2*$/L8=T2 71_U]\0MI7\\A]T@X-R?BDJ=3;19'[7SP51LBA!RJVFQ
M-)P5'R;8A72,HS^9T$(.,YJ08:]_$$$C]9\&7SH'GB*U_,)[I?RK1DOYQ?=,
M6>DP1%>@S4;3GZ:L1AI-H#U RZ8-KS,PD-7PN!YL9?H"#=+"1!]M,Q'*ASXK
MG!@Y-69'.,ROAFSCM0<&<?M35HQ"'5?*)^)7^B $BI\LM#R3HV@[:RL9TB&D
MGLUO4.6Q,GUZ8Q_0LF$?M9\UBP3)H2F<E""X2;GRPF8<XXEC3*?"T8&6ON'8
M_(B5<9\E_^5EIH.PIH9H-F?38D+]J!F;0M["$Z9D-+H6[X(%=J#+'/BT3I@:
M-DWM!?_PSPU?!=]27ARQ<6HA]PG1H7W4D<_V 0F&E A83!P+4C3COS%GB0,
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M5JKXJ5]]KMW.A9*K*'Y6U_^!3[&__1M02P,$%     @ ](H;4VSO&<Q4#P
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MD,CWMFGD-H+3125I286>Q];S;;/89R*4. ,&3+8\S".=3R2LVU- 7ES]%=6
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M')!9B9^#[H1[(3+IEG\A))\F/SSQJ2^#<!9.;QI,](2VSD*\_P-02P,$%
M  @ ](H;4Y0KY@.P2P  3] $ !4   !B;7)A+3(P,C$P-3,Q7V1E9BYX;6SM
M?>MSXS:R[_?[5\R=\^7>.C691S:OK>2<DB79T:XM*9*<9'+J5HHF(8D9BE1
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MIC<>_=%;C";CUXIJ-(OXHK7& L^UP7/PZ\FI'@03O++\+)?F4"0E36&>$I.
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M C]:P]A+RLR82GB4@KFX<=3%#E1N6Y2AC\C"BZ? */PY#^;L:'#<]V(6\=6
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MRY?2B-TKC7@I8]'4_RXF2:'>VZV]/LU_[LV&/T]N!\/9?/C+_6CQL>%S4^V
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MT:R2U(LC8"[;R+>##=HK]5OZ82HK*+W)HM>]=U2F](":6M70!-2;;(J&5:;
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MJ^;J/%#,I^;"=8"S7]'/P6C#EJ?0.0W9-L3Y0@4HA:M/UQ_=L6:(2IX8'/V
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ML8>R.+@!#>,#AK5175)W+0<VKAU:KP0;Y@?YQ98$/:'PZ1)Z";Q%3^MTL7K
M!SABMX^B/,4C#FY<B0QK(2L<!4=;$;,W2V!Q!&.:U1TK^OWW/\P./Q0V]#ML
M,+__^(.!!>WD.U!"21/<\I4=P4LCW?ND7+'T4]4)T%XS0/L=1*L#W!/0KJXM
MZN'%<]C8;93TR>,F]L1D&_JNJ=?:.H:0H8KC\+M";9@3MJ)*C-E3L)^:*J2
M'=$6%>QX=S\6$=A;[ 25_=:PK4BT+X&2E&RBR6AW0"5]F[%[C7$%]S]%"Z>!
M& P)[%]8-"=B?IZ\"%,\?_08Y(!*\!'U[&499"0<_%,4^5]0$(R$ 86![8)#
MSA 7-657+<OGZ-WWLP_?_Y!;/N]_^'YV].[]:[%\='#31J[B*H_@ I#?9JKQ
MQK*&VA"H,.#: AI;3(=]MIES%*(47F(T^_OC*1E% VDB S8L7Z7J<ZAM137P
M*[*A'$#8'"5-0!LNH;'[H+[DO<93'/%VECV2S8V3R0$'@+3M)&YHA1)JG0FY
MT^OAQ:?D1KRM'QP BO?TP@OZ^03$WE[Y[HU\7\$607DWWHY$Y!%?Y7(99]"_
M1-XC"E"*X+BQ&AKC.PAA5F!+%M&\S4GD]R8YD2I0R+6U92!]5CBRZBK9OW#7
MY% E'/"W+Z?#'OKD;+,-HAV$MY#:)Y:TB'Q4B[I#R@Q?8U#E0)ZC8^VP?VWF
M ';*PFR"36WZQL%C;?=B27TW)KHD0UH^6XFYX6"+M@5!V7A6Q1YNR?FAB3/G
MMQX\D?*O/9AK8'H0LJ2QQE=1TKU163&UHU6#NIM;[:2FCBSIG[$/S=)1+6YP
M4F94E5#A<WX%NDARXE9:$&/(-2 \MBZR?PQO#"Y4/Y<35#L2?=,W=42TV:#\
MSHR\5(Y"@C 8+L>"@6@\RVDB^)SPDD/4/?(WZ\T^X.OK*,7_R2^F?G!SP:XA
MU=8[=<E2:$9W5$;Z+QE64!=A"K'LTHLDP0>/14S^2PZ(Q[M[3&/^@L8!FO+@
MEBUK5;XX&,R[@[(_(,W!3Z3#/YTB3E?6K<.<SI*8FMQ5&IZ3P$N2Q>HNC9:?
M1T,??S3+<.,RPM-QI!FQEVC#?62Y3+O$DQLSUQ)SMCV>KZX@-K%\2N[&BQ<Q
M'<BG^3MN8'RW]N)Q\BLI#FWU>9D*1_PWK'GG'%XS@/L#VK%YL0JPI0L20L;M
M+JHG][WGK:J+-+R[6OX8294YEJ>:*<(H!CF)0IB8"*!4I&+]K<JUCWN[/0HE
MF<RS=!W%Z-<ZO>&(>J8SI/U'\@)N5'4+A1JVU*N.CN]7U,3*AQMS'08_2NMI
M#Q9/2EHC[PCJGE13Y+^=DM8?1DR'?=ZQ=XGG)K(U15 ,9S-ZAL^&YM>/:"?'
M&3(D I1AJ3'Q83>519:2W,TD?-$:F)ICND94@Q=-6$5USZEABR%4&<#VU\')
M"WDI6SK[2J,K>V.9S-;27UR]HHW;]*\C;-..ERV8.YC5=YP\+E15P'6D?FQU
M#K*N1/GHVEL* U31MUEMH@^A#Q/T%))34@[?-K0X;_BD1.R]UY.QHHJ;K-&S
MV$=<A>9IR:EZ=*>T$#UT$;F&B$)*?,2,Y?N#V#1"]@<77#1%(4ARW/SN\,WA
M1[#%*N>9])F!=]_-#@\/R?]WS[@S</1N]NWAA]E1D8#IZ&CVX3UN_/&'PA;.
M\\8U]D<OU7Q8Y>I&BX6-_6NLSNKVNQHMR%GU^:J,:]DAH\"2 I1K#,O=@JY!
MIN,55%T=T_N'!GTKSD#1>/;OZ#F<**E.D0O0+;Y4_$JRV1M>RW?(CNA.XHUE
M\<**PX(.?O:<2.ZUD\R+))JSL2>R0W1L]Y%P0)<(DON-F#!B.8VF@B6)&T*Z
M!.8U 7R?ED+R@AL/^1?AB;=%J3=.=@7>6#;??+%9X+W6J%H#DB[Y (4'R[R#
MZ[="8JFUW@4)9FR.FOIU,GV)2BHPQG -PP0?5B["9;2!EU%"'N@O5O?>RSAH
MTN3!KNFDR9W"TWB::YP^'*KH@ "3</QTU0P)G-QZRDME:'O=PM1#(?3/O)@4
MIVJ^LC^%*[1$XT3V*PQKU04KYT<I82AMZ19^Z@)M(DYQ_BZRWJFQQKJ+*7N"
MLBOXNBFNHK?K.Y@Q!::=!Z^.6\2&U3H*?"R=/!IV%#7 &,;V>[ N"\('&=38
M+)K_WMM&R1]!WLLQBO@":X>C,B<[N*I5K+;(9H?U*1][ :FKY'AK[[/(8Z1Y
M5RJ'R&:'E>"]L\BO;(G[)&QO/&":A[XE]2<=U$%V-1E/JL_5Z*W-5+6EJK0Y
M3]SX"V.XW>8V??588-12W;RQ+/H<."QPTS:2UJ NR\TLP.TH;Y]0;NU4??PY
M&WL=;N$S#+.17D96Q"TBHQR3 P52%2;Q N@VZ^O^JK?M\L8$[#^E: [/*ZMS
MUU[ *:]@GT<+)U&2+E8%M9&N YHCC%/?0B3LUOA<OW]"LPTD[H7.%$C;I[\_
M'V/%^"F.DN0FCE8C^:^:]*TG#V@,SI$Z;0'R)FZ%SA!$4^3[4S'_W.]@$)"L
MMS"$L1>09%_^!H6([+(D7J@H[#B.%T-M:(O;J!I''/ 4G6?@*>^>Y_!K$7!\
M#-<2=>O<J+XN/6RR!.+)K#'U4ZS*@HB6N1D3?^(1+?O1!:SP2M(4?2C._+J7
M:Q-%08QMNT4V=3?><PE7;,=Y0R*-;J#HY]CZ'EHPQE[R*@-206R<<UAW% =N
MH0X30C]05!4=@ON(<?,U<R7%3&C5FF-?;-3WM>.BHS&._8RS#"YXZ="(94J$
M4X(D"A/'WD"!J)CPV)OC(!5\<IIERAFBJM S\F$X3A2DRKB6([H56.(@JOPS
MW:U0F8<(42JNJZ\HBY==-DB\%*;AVR6],6W2_3&&1).ZAV2/"WY=H!PSW<W*
M"6B8TMDK^]*9EBD8KJ,P:BNV,6'!'VT,XUBV:W&Y$1LW-.QL"OI%*KLF:,23
M-=<EY5YXCEG+,_5E>(1%M;D?PU44%U%K]]X+3,Y>\'$[BGT4>O'N(H4;6K #
M]\33#BAS.;I'O/T:AU_KCL 1)R.RWAXIT>(+ "DAZ]J^MP##[F7>> O?IU!@
M,6+Q<1_#$([E!.>-9?\FA,,)]R%T](P24MX/RX@-8V<0YDJN"S_V=(<[^VD6
M6A<PQ:[$5RX[RT?P:M>_SXWE-4Q'=A:T1[ =:MD:77##WXKA=V%6L>30,J4Z
M$['J9.\,S[OI;S^&>!4KV:L*3Q$+7;YQ/O82M!SE.V*/9#-Q Y,#SC=%_T;+
M#A! T.?MR^(YH%I*3#<)G$72;&5KYB[%<% Z14&6CO0DF3>6S>)-;!:X#C?Z
MUUZ(F@"@]F0J@E1S/8POAO\&255XZ,^?\2'A"5YGFT<8+U:=YZOCJ2T]#BP[
M@+68$VJZJ23N-!)X$X;Z2V+JQN&,5.#>SNMZ71[L/E_5Y$ZB.ED0G0Y"96)7
MP*AP74RO5#EO8<^C&#,1YH6NEKO[V L3;TG<,//0I_\*J%/FDX="8F?.8WSZ
M#Y].LQC_[PU]0S/JNVP;?%L]@%B8$.?[*48HBF<M=R"MJ;JMH&4/FYVJUQ8D
MT2^)WCYWHWYMHO$<!,X(V.&G:N$G-'"5G$4FPKW<+,(I&[])+M[.%&546J^O
M1GTRI3:R77M$B2=>A&_UE*JLJ\-ZH\=Z9^7D1:B&V)FU=Z0K9 K(L9.5=;+=
MNWFE+4]25KX<YJ2V=H$:24(R5A8R^T^S]Y@0O7R?S*E6=V4/>U1(PU]M3JAI
MF- \EO1OBRV]:SU[@?$2)6-]A-I<6+7%M=GCU?$K_DX?B]'DJ-%V"L&9QB#H
MY O07B07\?I&G++T1EXN+Z<$<E(@IS7+,\7/BHIZ!4%049Q C@TG\NZ7+*<[
M6JX(G2LJ$1L30KB 35V--9VMTA@8"F"6+=A@MY'J83AFG+*T5ZF48-EP!D+J
M6?RWL+FJ:]CO^!G&C]$87S(K\Q#M<O#HX2: > ]@F%#W%)C',6Z7GU4?=Z#9
M[L;;T5_/OW@QAD<QU*S:QQ* @9%SQ*NX\S\-)D=C1(?),WQI\_G./D2F:>5:
M0<4[\RMMD9UU#;_0OXQ5SUIE9-LN.06>!'%OVSA:0N@7S^/F]U?3M<0[PE6U
MOMOK,(;![01W^T,/'5K9RZ@VPMY4KJCU9*VL#3LXG);UU&)/]WB?DY@!3"1O
MP?/+_E;E.6BNS0$,G19S3/M72YJ3W!8&%:!))D]:$4ZT];2KQ;5W!T[1/PUR
M]LK_J3/%>^^*^Y([!7*6WE9% >FIVH6F-Q1<5050<SU,JT@*T3L<MICT;/KI
M=)G3!]D$=B-3B<I QUT@\U)K(;8ER&.UXA9[OHFR,,U_G4+_:*08&MFH5JL=
M29CAQM&4_=H83*,J6+VE\MQ$UBB*MQU?H[(@/<IJ[9'/06T;<IU1;9^II!SU
MP]T$M*"VQ(4H9"Z/BY.5$F>L0U5;<G=YK;2B@'O5>TK.Y/$$U^<=WMS_.<OS
MUR3W$:?:5OE2"_I-9V[31WD+?\E0@E)X!^-GM(3Y!GL+E]%32"F.HH9L\6ZU
MPIN5*0FB62M???'2F[C=,;I#2".2P1>4KJOKO*?8"U/700B6$=RN3F=/6CW\
M_D5H91Y,2;B(0L+R_ 6-Y7<5C6@YXDK "B]6(8^HK=N"GTCK?[IVY2B(D1E2
MRYUZCX<"C7C=$R]9GP?1E\166'=W0)O9F@5\J$1PDTZ ]F*6QG ;L\T5)2=4
MF[T"QIKJ%&(#?(F\XND+/BG%*?K5&\U^$(UG]S92P GO<6*C1Y[TN]''Y1V0
M@A";:)+-W/#6L4H;=![%IU'VF*ZR8+Y<DJ/W.'N><$"+^DG$!\_J6Y.8#&+G
M>0'^F'-'(/Y'T0M@^4#T[#T&SC,#JTBU"2[I8M@O^B)CB774+?\.;BM)S,!)
M#+&]"6B2MR*U$?B:U..($R]P?M@=6E)]CK@D16N(_[R[O#A?W,($6]F%C8V1
M'S^-E5-5,JC=#4;&#C?;:M$-*P':QWG>+S51[F?HE4Z]3W!+?HR[P0LW:N$2
M]E .HJ8Z3'#MWCKTMYLWSM5M.%=:G=MO]CPUD4(OH"["90R]!)["_+\7X6GA
M:+[%T"R+%>[5K>1<1:K2LI'@2H<A;D$1/\L]2]C^\$OW>TQ.2T'9U0EH3 17
MW3CJK(EA]$25X?Z2#'!+$GM$JX<$SI,$IORC$P=5ZM0LV+)Z'/&*O3>:D(-W
M3"@<1*N##!M*'B'B#E;:LJN I;<JQB?Q+GY+8ZPV04<RFQ0&=O!:1H4O'A!%
MYR@WN5.59;N72%5M"7HE1-X;HC3>T$@APN(1Q\K/JX>T!D<2,QTY+K:J)#\Q
MIO8GVZM@RS[QFQAN/>2/6TM#,N@8T:X&H&ISQ4V^31N5QKOSW#:J$A5#C#'U
M88QZNB?WM>;WB-@+596QHF+ !Z3'- UWMG $%CMC]H,J(YH.K++GJ %G:X]C
M#NVD$H "8QS<T::Y(3^U34\D6;%JXLY_!$O^QML1DXU<NBR7<89%56#=GJVE
MQ(I]'[T9HS+S?YOWS2_K\M[=C742^-5!B-H)0;IN@VK6L\TVB'80WL* JB#K
MN!8P, 4T\]GC8YC"==F(8')^$Z O=3%6):O2 Z'7,"61$O2.RX?^\>XA@3Y6
M]I6>Q_;3\WCXU!C>0<Y-=>X$+V*7)*HF(VD$L!%:%[3UJKZ.T:J/@+W"&SI+
M9!HRD2=@()&,RU\R1 IBI7B=$=';XQFG\E'MVZ52GKANF%R7$!"BJHOC)Z#*
M8FU=QRNM@+%1VB&/H8W!G.[(91LIG4I"%FGE;SN8XP_OQ%NCSA_/;X.96GLD
M9PI]U))WIH8G+'LZ5HCZ"!#"4[Q A@J1HW;SBK_.MFW6\-/9MAG<J6[;J.PZ
M^6U;@ "%;9NW1.:1CC09""EN6;[C7:Q.Z.,UQ@/GX<(=):/:C7D4,\.O+=G(
MHY)X 7T W7SW-R-UDYQZEY3%NQ=-I[ @3H(?Y7RQ(B#;DFH^5\\[Y^__?J."
MZA/[R!N /A\DYIPH&<+(NH+'@]V0-DWN-%5)164_KT);LTP(KQ)DJ*!7M'0#
M['+VLO3*1W6TR^FDWFU#$\I3ASL&HW(&1;4%<;O+:272;4M*EO'[-R6FGJ68
M67;V.0JQ0G)V3F,-/YUS&H,[V3EM6Y @B5M797?V66TZ1S4!"!2.:KQ5,MS$
MSE8KN$P7J[.7)7UR=>NE<!&2@>>A3_Y#W!;/V'88ZY&:%@-6WVGK<,9[MDU)
MD'T-%D1 C*F _&>:/IC@V"U,32#0*G:KNTY]BL%A<GLD;V&2QFB90K\8LOV+
M1LO\A4WWEFT99*2T9)/_?$ZC -[R%,9(_2:M66=UBH)-XFN_Z/X-_M3JBQ"Z
M=Q#7,_T!UF.[S>7E!-NMS#[VY6::U^XBQ#8O9H7D-<&2'BF(HCV&Y8+6>\-S
M+_CR5F[W$(XXVM$-W>F82Y\4A;SW7F!"R(T50M,:P[KT6\/SKW=Q*Y"29JXC
M#ED2V0MOZ<Q(%P"MN-B+D#XV6E2/C=HXD(0W=WO;<?*)F5"XQJ>OQHA-6;T:
M WX&27K /-09OJ2D="IY8A8#_,%YCP%*UNT+5E>QSUR1=8*>V2O3)RB^5S \
M,PC>,E248M^;2-D+?=>'B4.<*,;&"V+BC5(/YL&A)!]O%* E/ER/FD%*,)P-
M?,G9$ <0TS3S18^)5/N5"["5+$\\<<-GT(WW8FST<'5-MY]%-=,97/ZRCYDO
MS('2X*YW0U^PIS= "I=;[\L5/M3$R L26J>\2.@Q5F2W=%BK7C(Y/[Q'6MX7
ML"D[.+9=527)S.$BGGBO5P3%"'^+XL_DC6"TA(E-B G&M7X:DK+$@1GI0&RA
M;1P]8:X</VM1%B@3:9+)FY^F"_KG*,0F(/0_19%O$V>"<5WAC,\2!V=E!P(T
M\OIT(BI-+E(FTB33-SJVL[,.X[-=MLEO7[6,)75JMK+#*'/$RTU%^H.\\F3S
M51,YXY<DV :7@](GNK*L"Y]HK9)YAFGV,'6MS^-=W:2(W:9E/L\]%-/2/PV6
MR+-\XO$^1>0J-O2)#WL4C3@^UY9SLXT]'UXFVJ()V"$8. U/L8;#5JHX*\MN
MFI]P#.9^C ),ACB 7M>WN<>WW3STXT^(%Q91- ;/56O'B>SM87+T[Y0A@3Y)
M]8=D\18EG\]C",NKP-?QK3*Y?L7[*&L^/!\-;@I6N"UY.TH;T_@EUSF7K(%R
MM(^5*X,^F^JCG+E''4UR#^/-.,7:1F37LL-@O)G(]D[2: *[YJB@ZWQ_XZVT
MKDLCB=-_W9*A54L6X0Z-#P3_:__C:%.T<?'3&E%0*08E*5IZ ;B"7I+%>=V8
M3OTAJQ!DKCY!2W=*1KXJ4K0@S"!Y'W 2A=0?D?P-I>N3+$FC#8SU?%7JU&SY
MJI0YXF;8H_WS5R'+DD)>B6U9TG!\)6PFR,I1I;=$_4NA'6<)"F&2W,&GS7X-
MK7'*5C%'=%,*C<4*3R$531@:R&6E*I'XF*6JN%/N<5IC8+8)V;.7(AB7!%3A
M__/OO9=1(&;"A\V %P/^)(J0D *5:G!KE_5 01.IIHO4ZV4X.V7*J$%8\E'M
MOJ@5,\-_44O[S0#M25\W5'V=A^EH"WCOL:;"DFAOP'23+VDWR5Y##MXXUIV,
MABV;3L*'!#CM5$PT%< 4[#=% 556F\HBF$&%D_^+ XIVNBXK\I=EX*K^[O3F
MF)E$B\&_8>SE>1:'*,6'U'/T0OZ38"#0".%U%/@7&_)@F%I?B9(4U:G9^LB5
M.>*%J93]9V!54*!??E#2 *A!Q)%Q;2;)"DAZ:V1\<B.Q,5]0$&#J^ZD(3U&R
M#"+B*QG5<M'CP+)G5(LY#EI+&A2B-160DP$UG:D4+C;"1-/8T5\UPR=4;=JZ
M-H^HO\WR$%PN^*\E2PSE:?JYAHZ#*':I2!K1[.*)]W AD,B_%%ZB9Y)N>DDR
MP<^?8ICKRT]QE(SCDY*/:O$,)F6& ZZBL=,08V7Q-96.VH2--\H&^1LOM0:D
MUEANX--D@7?^RINXOE*7R(B#EL[\S(Y6#/PME]DFHTGOM>M&JE.SE\9;CS&>
M?H%)0LITE%V U^AS$.QK'P<FNZX<:Y-=:VEZHZS [4 HDU!SAS(Q8T8HV^ZK
M*X<84Y,B"V,*"V/H)"KB"IKD%JM]<TW+U-8D:<L1H<>6+)C%VZN,B_;M]"GX
M(LV$6_NW]%=L").K,T!C^*+>X#5\2>^_P. 97D5ANA[=,C-AR6[ 93]F.6C'
M"_-N(F>#'J#@F(*FRV08\*@W\C^@%]]_B2: ZY(3-^<1=0;Y$/[6J8.ME]S-
MH=M<%4M*F0Z)D3I.A+PI+Y:=R(9L\M'[WG&\4$\,]$1PM3:F3\7UQSS'>)@(
M@BDK5N/;S'CDH_<[M^$;_:3?#[O5P@SCVU8=%;>="GH)*U-'+V[+1^_WKPZ]
M#>GW1&^Y,-;0.U^E,)X0A-O\3!C'+48Y8+Y?PQAZI.&K,B>8F# '=G>EQD'W
M6/E])4.ZR)PM9HF'1D)U0A=( ODI@JUO?N"BMG=2%O?V@G'S.(K&LUPZBL\)
M]P(R[T%C;,H^G#PS+D*&Y:+<*\,IG+]) EENQ?A"#QY[ 2DSI>?6UR9JZ>1M
MQ)PX36@"MCD="C&O*-P.<U+@L: U!0^_J:0K'[_1PIEJN;W!3K(X[H0G#YNH
M=G\HN[J-S80B]MR>/<2B8J2D94W2T%5>(+!,D8Q@,C)2.*-9=AUR&>$#IJF7
M7-M34JGM@48PUZ%?($BKS0G98569*]>^T6,&BCZ.[8_AY'#8YY%PM/Q,HM?Q
MRI-G$NGN.DK'C2V7#&D[S8:0&V[J@KK3[[UME/P1Y'T!Z3R1A.5JHFV_():N
MA5%,^")+$WP,(T\ZFS41BSIS.RWK5I66M<=1B@QQD-3HO5<#LR0P!>M54X"5
MT:JS-N:/>]GYD^AODWF6KJ,8_0K]AQ##NL$%>?29'._*PIPW,5I"K;0K^HIO
M!#XMWO:/P#XW>*LHVTM; ]K<<5H8"UB3IP3KO];VL]X6GWQ#$UQGFT<XSLWM
M\%P.O8UL:2V[N]2+4Y&=._A$>-M/L=E$=?L9"&F/3LUL\#4*00[!;R:0'FP,
M, Z2E4\H@N']&CFBSD)FW/:HDV&=M_H#ZM]XTA*!BPRL78[^!DE)->C/GV'L
M/<'6#C1U32_D?6#[RK[Z%\U.9U/X4M !7DX(P-)(VQ)2KS(3NAF.1_JHI8(:
M/++!]LXAFZ'R?J**Q4F=$7YK>#P<_,2NSN8GW#!-+L*\,O1X;W['X-/YB;T7
M^Y(MXXGT@+[N&>)5?J8"$ [Y2?*$,/AV(+U\&6DF++7_B8$CBAK723E?-69&
M5=F)%D_3.S ,R/_PA_S^W^9PTU/= EZ[E38\H+4^\8$%-E9-)1F;)2>O^,O7
MF\(8P;VC?_U:4Y0H@/(S_Q^@ HS /:@6T!?<T#<:>)S':&KP9-F4=(2#O IF
MDP_09 0\[D"S8<$,H-S,RLOY&:@X(A6 <YYFH.0*%&Q5K8J+3'+X.8V"P(L3
ML,56+35IIW\.^@U^!7TBIGK:YN=1O(*HS!YZ]K)%,:50\3Y)3X:<ZP&-7GD^
M(FO3DNQU2Q)S'> O/HI)>">*]7T?4_SBAX+PD&=:-5'9+AVJRMSTK-Y19S1)
M(WC,&9OHB==N'=OX)JQJ$!W;63WZ]3H*?X0))ML[]E6-DKTLR4K\<+X,W/?@
MF7;6B'NUGQ102WA5W*OZPO0-WS I6UCP@YG,!9"'DRQ6N6TRWFXT J]CA5.I
M16@,/R'YQY)?@P@O1EY3P4XU+ Y2K5-AY4>)]E$)L!AG/BPOB!:4_HTDXY4W
M?7H[&%-[Q@R]+CC%Y^FJ:.VT%;V<?9>AV59FJ+X9=$X2]!(.^)@:6&%RX)G0
MF\+=N55DC_*QJXG-99RWM5DJ[B_:Z/PW.$<6F\.@<>&UM<U-RN(<;!:@M3PW
M7GDM;A#(5+]]^Y >+^#+U19E.8+0>(]2N0E6O0C.61+> M,F@' &"&N \B:]
M#/[WAV -(0Z=<#^^%@\<D]'A7,V:5[X#3X2SB^5-Q4'(K]%8%8%N2+.4N]3.
M/[C7Z1Q1Y=WV$Y/QIR3Y0/]'^#\TD3O\AZQA5CKU?+:O>U_%[JK*N[V*;Y9G
MQBLJ7K;^K=Y2J&%U%%^1@D"F]RV_SHV[QW3L)D)U-U&Y M#<Y']+6L&M4]E,
MEB;YL)OA,G?99N/%>@%2HO[VPJ($7(CR25814$6?*23^4Q!(%?0DF_;@EP[Y
M1B5)A]9-AG89?8%Q_A/:H)%RG([)L(,M8:2I<#X'VH!8>NWW,S-PA4*TR393
M.,B-C,:!D@&J26#0H'E#OAZVV]?U5>XS_(J_RKVI:'^5WLMO[:ODH'&TKY(E
M@2E\E>69L)$7J-CAI_^!"GAWGH-G\"E)WI\LFNFS<BH3S[XX&F!'^X8EPAG8
MEV+(9)>YO=/<+=QXV,H*GTZBD-KNF1?<PWCSSJ)CQ?[<;!<=F,:T=91&)ZJA
MH@H:9,$E6DWSGL79]R)WR;B1^[ !ZF/-H=7E&#ZAD$RH*'9U]!O029()_J85
MDWCNO;13^XSBWKZ9R)JZ5TH*,N^EF8:VYHJ_D(IIK^[DP^#]M9]\NE.2J(E&
MA_\9)Q\^8$<_^7"$,XV33Y<YD69Z!::%[H2L5D9W.5,=C:!J.+QVN\$0_:/9
M"28B=994QN&D9<\7JF<)];5^^3AAMI]^CO(P,\/_OS^ *6#!\$K@(EQ&&WCO
MO9RB9!E$21:/6^%3-)[=:S(!)YQ=(N\!<!=0]YE.T7H%438A*YN_29!.1;.H
M/*X5H</M;*U>)X\#,1Y2C(>RKCP;#-9C<V1RJ )SA#,VSPA?%" ^AUC?>4%-
M_AB&<#72#;YL3)LO;26\</#T\.;N#2CZN'WVJBB_ICI1F7)_0$4QW@E#NX#B
MC>D"4!Q>^!&RI#G9L2")'7Q,D(^\&#F.D%<4)@M=HOGW1M==ZJ5P'OJ7N+%=
MI249V:YAI,03-UJ5A%Q[H0_(B@=3@)F:5!E@4U@ 0Z.[&&!_\[4 --Z08YR?
MH]0+1.=G,4L<@-T3JF"9=YW$)BF1(@-8HAF;7G"<PA7$Q/UB_[4)+<6A![Y>
MD+IGU-C2,\6<X$Q/M$V\:2R!L2.^'*.E+5W 3XD!^Y71=-C3W52=PE%'X"Q0
M*B](C\<AY5@N\"B"H-5]5L*0<*/UB[Y3T8$&.)-#R]S-=8LA? L)_RA ^1LZ
M(X^7@(X=VU^5';EGE/0%[<[32->M(;2N>TRR(GV=[VW2',3.2^<*T9P9IKIK
ML3>NNWX0#ATY^(?@G0-\<MN3D3NRW_^21>D?B1MXB?^9_XMZAA]S\FZ/*J,
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M17+8=X)+ T2TD:J[9D9^I;MLNPVHG>X%)UZR/@^B+ZUC'KW4O(\N:;R4E@/
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M'JY]U,-(H,^C!))W"/Z2X?WL[)F&8XX9Q\L=S&IL#X\+;O!CV1SD[9EW< [
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MR2,H\.]CDJK@%.;_'5^A]F/+NK.@/\]"K;QL4@8!)CJCE9OQ9Y%Z+U/0UH/
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M9FF)#^+C?G"*0]M^?*C&%L\A4W<&=6]0=I\.T/7DWO+1J*^/\6/"N^4:^ED
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MAWG=I5*H%*1XGIHG,4KQ$XR>8F^[1LM&YG>I(Y<#"&5BMO&ARA@'+G7W9B4
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M!T)EGB!O8-DV2%J,[VB/S*M5@ALP/W'+<NVN>BG5O2GHAVG3P(]X]R\\7;Y
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MRJ@>Y"2M)D7C0*O--HAV$-[!^!DM(5L+7T<T@@;ZE*&$VDW-OY]$27H=I?^
MZ2U<1D\A<9Q31UO!^SA!6E8XMQ_@96-:IGZ!:MSV=SX#9$#\UQ3L8 KJ,6?[
MR1(<?>I64=X*0[,F3?,[JM%XS$]9YU%<_(JT&V?'MSP%%U: W2D.IB"XBJ%X
M4TZ>DC<&=AMPZN1#L*(N^$*V?O_5M6?^!M'3FLSG&<;>$[R%&P^14+&3B)0
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M+-K9C]37;L@]N/E]6-J#VT-.8@]NL:2S![?-Q$D]A90)6;@9=Q?$>#,N2T5
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MO!AZ,P 1;A@#'Q,@I?9(3\PX1$_A&W"_Q_W&VP'/][%4DF(:*,2=B>;!I,F
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M63< VU3UKL$ ,[^EL%I'$HO:K"<QBE2&XC19B876+ZS2>*[*NXN6/X3WJAK
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MN#T[93>WR]NSFQ2;H9^BS<_=B1-?&BH/ @G&=UP1HCT3'>*B!!)="BA-CBO
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MR7.11GAO.FVPD<82K]EZOLAML61/,ENG3\7Q!K6?P"NO;J0F_K7,W7!:,2D
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MQNQQ:\X>>'TG9O&QKI[;^[@27J8/4YVP8EY)@'I06G;/L"#9U!+0)N$O_!$
M,,H[F?3NO#L,1I(VC7>]%*) L@O$1PHN 1_9E)A>:XFAU\CL.N]M8K4<7RAI
MXF9WIXX=0RX":57S4_%0:-I\=:(<?_XX(=-8U>Q2=>G!IS"+$"&4$O0IZR:9
M.!SHE#_6?*6P-<3?"ZXSJVW(';=AHN^[8%UO:9BP^R?5K6((Q*T-L8PAEMAE
M558FXE:]L@.'D]VA2PW0?=ZD?D<ZJ<%D$B"=5!W65:8,9FXC2_@$TC1-U:VN
MDZY2A.1LI@CX]E"$22/,@=3ILA,<U!;N%O;0F$4";:0_&B4^$93V=?8R 4=;
MMYY'6524!%2+<M.:*/_AO*JA%EXPVV%3U;H2(#1/_*[>F3S&:92^Q+$5.]('
M#4%5(XRH_><(N!CM!ZE0Z1*.LZD7N!\KXJ(SXIE*^!R4]]MU77FBTF03IMHD
MWD[6;#&>CXBA/JKJ:L7YNCD7DX:]K/0(%7>!AUNJ]@RH5'5,39>DMX2+#O3X
M\M),N))[Z#:P;E4EG*D S(D&'D['TNL'5="F[@C-&</F3>8,ZKTZE-%IK%V
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M1="!X5%$9K5?UMME@TD\]1.752%-Q/I=6Q#%CX3N@$4<>>+G)PQVL;VQ4S=
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M#308I9QY95F0)#RC0= UM/6DL[18])4 RGGNV9TGF7UB@?'ID>=88,LH=T$
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MZ%WS[LW;-V0\GL8UI>]H-NQU:%U,38^)(6Q\)X#P=V8@_%T%PAWWG2%L_"B
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M6V+W\[RPQY79Y%9+09/<F-3U)*UZ?-KT0[*3*]G?[SY2< Z _<W&/[Q./YQ
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MA"&2Q4G^]7]02P$"% ,4    " #TBAM37C2VB+0G 0 &/A  $0
M    @ $     8FUR82TR,#(Q,#4S,2YX;6Q02P$"% ,4    " #TBAM33Y+9
M1[D3   /U0  $0              @ 'C)P$ 8FUR82TR,#(Q,#4S,2YX<V10
M2P$"% ,4    " #TBAM3;.\9S%0/  !\QP  %0              @ '+.P$
M8FUR82TR,#(Q,#4S,5]C86PN>&UL4$L! A0#%     @ ](H;4Y0KY@.P2P
M3] $ !4              ( !4DL! &)M<F$M,C R,3 U,S%?9&5F+GAM;%!+
M 0(4 Q0    ( /2*&U/AY5Y1%I@  (&_!P 5              "  367 0!B
M;7)A+3(P,C$P-3,Q7VQA8BYX;6Q02P$"% ,4    " #TBAM3,JT;]A9+  #=
MX00 %0              @ %^+P( 8FUR82TR,#(Q,#4S,5]P<F4N>&UL4$L%
3!@     &  8 B@$  ,=Z @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
